fludarabine profile

ID Source	ID
PubMed CID	657237
CHEMBL ID	1568
CHEBI ID	94701
SCHEMBL ID	3510
MeSH ID	M0082555

Synonym
adenine, 9-beta-d-arabinofuranosyl-2-fluoro-
ccris 3382
fludarabinum [latin]
9-beta-d-arabinofuranosyl-2-fluoroadenine
fludarabina [spanish]
2-fluoro-9-beta-d-arabinofuranosyladenine
einecs 244-525-5
nsc 118218h
f-ara-a
nsc 118218
fludarabine [inn]
9h-purin-6-amine, 9-beta-d-arabinofuranosyl-2-fluoro-
hsdb 6964
fludarabine (fludara) ,
AB00383071-11
fludarabine
smr000058874
2-f-ara-a
faraa
2-fluoro ara-a
nsc118218
2-fluoroadenine arabinoside
nsc-118218
21679-14-1
2-fluoroadenine-9-beta-d-arabinofuranoside, dna synthesis and methylation inhibitor
2-f-araa
DB01073
MLS000028687 ,
9-beta-d-arabinofuranosyl-2-fluoro-9h-purin-6-amine
fludarabine (inn)
D07966
fluradosa (tn)
CHEMBL1568
2-fluoro-ara-a
fluradosa
2-fluorovidarabine
(2r,3s,4s,5r)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
HMS3259F09
EN300-52641
tox21_113419
tox21_112795
dtxsid4039657 ,
dtxcid2019657
cas-21679-14-1
(2r,3s,4s,5r)-2-(6-amino-2-fluoro-9h-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
HMS2232K13
unii-p2k93u8740
p2k93u8740 ,
fludarabinum
fludarabina
BCP9000693
(2r,3s,4s,5r)-2-(6-amino-2-fluoro-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
BCPP000227
NCGC00181336-03
2-fluoroadenine-9-beta-d-arabinofuranoside
AM20090199
2-fluoro-9-.beta.-d-arabinofuranosyladenine
fludarabine [mi]
fludarabine [hsdb]
9-.beta.-d-arabinofuranosyl-2-fluoroadenine
fludarabine [who-dd]
fludarabine phosphate impurity, 2-fluoro-ara-adenine- [usp impurity]
9-.beta.-d-arabinofuranosyl-2-fluoro-9h-purin-6-amine
fludarabine phosphate impurity e [ep impurity]
fludarabine [vandf]
S1491
AKOS015916481
AKOS015854911
HG1007
9-\|a-d-arabinofuranosyl-2-fluoro-9h-purin-6-amine
gtpl4802
HBUBKKRHXORPQB-FJFJXFQQSA-N
CCG-221147
HY-B0069
MLS006011578
NC00633
SCHEMBL3510
tox21_113419_1
NCGC00182047-03
9-?-d-arabinofuranosyl-2-fluoro-9h-purin-6-amine
DS-1271
2-fluoro-9-arabinoadenine
(2r,3s,4s,5r)-2-(6-amino-2-fluoro-purin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol
bdbm68391
(2r,3s,4s,5r)-2-(6-azanyl-2-fluoranyl-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2r,3s,4s,5r)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol
cid_657237
9-(?-d-arabinofuranosyl)-2-fluoro-9h-purin-6-amine
AB00383071_13
mfcd00132942
fludarabine free base
C21550
2f-ara-a
EX-A833
sr-01000000270
SR-01000000270-2
CHEBI:94701
NCGC00021920-04
HMS3715F15
HMS3677N14
9-b-d-arabinofuranosyl-2-fluoroadenine
BCP01383
HMS3413N14
9-ss-d-arabinofuranosyl-2-fluoroadenine
f-ara-a;nsc 118218
BP-25389
2-fluoro-9-beta-arabinofuranosyladenine
fludarabinum (latin)
l01bb05
F0658
Z756440078
BP-55389

Excerpt	Reference	Relevance
" In addition, case records from National Cancer Institute (NCI) Group C protocols were reviewed for fludarabine in chronic lymphocytic leukemia (CLL), and cladribine and pentostatin in hairy cell leukemia (HCL), as well as adverse drug reactions reported to the NCI from January 1980 through September 1993."	( Neurotoxicity of purine analogs: a review. Cheson, BD; Foss, FM; Sorensen, JM; Vena, DA, 1994)	0.29
" In the FAMP group, a direct correlation was found between the LD50 values of both FAMP and Mitox and the number of synergistic interactions, while the Pearson correlation coefficient was not significant in the Pento group."	( The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Brugiatelli, M; Callea, I; Console, G; Filangeri, M; Iacopino, P; Morabito, F; Musolino, C; Oliva, B; Sculli, G; Stelitano, C, )	0.13
" As intravenous Campath-1H is almost invariably associated with reactions, sometimes of WHO grade 3-4, we adopted the subcutaneous route of administration, which proved to induce rare and mild adverse reactions but had comparable efficacy."	( Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Brando, B; Cafro, AM; Cairoli, R; Montillo, M; Morra, E; Oreste, P; Pungolino, E; Rossi, V; Tedeschi, A; Veronese, S, 2002)	0.31
"Subcutaneous Campath-1H administered to CLL patients with residual BM disease after FAMP proved to be safe and effective."	( Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Brando, B; Cafro, AM; Cairoli, R; Montillo, M; Morra, E; Oreste, P; Pungolino, E; Rossi, V; Tedeschi, A; Veronese, S, 2002)	0.31
" In summary, the combination of treosulfan and fludarabine is a safe and efficient conditioning regimen."	( Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D, 2004)	0.32
" The synergistic toxic effect of the two drugs led to a total elimination of the neoplastic population."	( The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Bolognesi, A; Farini, V; Lubelli, C; Polito, L; Ricci, F; Stirpe, F; Tazzari, PL; Zinzani, PL, 2004)	0.32
" These results suggest that CD34 selection of reduced-intensity PBSC allografts may cause adverse effects upon specific antimicrobial immunity which can lead to fatal infections, particularly in high-risk patients."	( Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality. Hartwig, UF; Herr, W; Huber, C; Kolbe, K; Kreiter, S; Meyer, RG; Schneider, PM; Ullmann, AJ; Wehler, T; Winkelmann, N, 2005)	0.33
" Reduced-intensity allogeneic SCT may offer a less toxic approach to patients with AML."	( Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" The safe dose of fludarabine in this context remains controversial."	( Clinical and imaging features of fludarabine neurotoxicity. Brace, JR; Lee, MS; McKinney, AM; Santacruz, K, 2010)	0.36
" This is a relatively safe drug for clinical use but may cause side effects, some of which may be life-threatening."	( Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab. Disel, U; Karakoc, E; Paydas, S; Yavuz, S, 2010)	0.36
"Cytoreduction with 4 courses of R-FM was safe and highly efficient in patients with recurrent/refractory follicular lymphoma who had high tumor burden; however, better consolidation than FM is needed to further improve outcome."	( Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H, 2010)	0.36
" In search of less toxic alternatives, we hypothesized that combination of busulfan (Bu), fludarabine (Flu) and clofarabine (Clo) would provide superior efficacy."	( The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC, 2011)	0.37
" Only a few studies have evaluated the long-term adverse effects of purine analogs on the immune system or stem cell toxicity, and most of these are not very recent."	( Purine analog toxicity in patients with hairy cell leukemia. Tadmor, T, 2011)	0.37
" Patients were evaluated for engraftment, adverse events, graft-versus-host disease, non-relapse mortality, relapse incidence, overall survival and disease-free survival."	( Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011)	0.37
" Non-hematologic adverse events of grade III-IV in severity included mainly infections and gastrointestinal symptoms (80% and 22% of the patients, respectively)."	( Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011)	0.37
" The most common adverse effects were hematologic, with 2 patients experiencing treatment-related myelodysplastic syndrome (MDS), evolving to acute myelogenous leukemia (AML) in 1 patient."	( Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P, 2011)	0.37
" Multivariate analysis (MVA) identified comorbidity score (HCT-CI) >2 and advanced disease as adverse factors with no independent impact of regimen."	( Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R, 2012)	0.38
"Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia."	( Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Adams, RH; Anderlini, P; Antin, JH; Arai, S; Carter, SL; Confer, DL; Deeg, HJ; Difronzo, NL; Eapen, M; Ewell, M; Gersten, ID; Horowitz, MM; Horwitz, M; Leifer, ES; McCarty, JM; Nakamura, R; Pulsipher, MA; Tolar, J, 2012)	0.38
" This treosulfan-based preparation proved to be safe and effective for thalassemia patients given allogeneic HSCT."	( Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M, 2012)	0.38
"Patients with class 3 thalassemia with high-risk features for adverse events after high-dose chemotherapy with hematopoietic stem cell transplantation (HSCT) are difficult to treat, tending to either suffer serious toxicity or fail to establish stable graft function."	( Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Pakakasama, S; Rujkijyanont, P; Sirachainan, N; Sirireung, S; Songdej, D; Srisala, S; Sruamsiri, R; Ungkanont, A, 2013)	0.39
" We conclude that FBM-A is an effective and safe conditioning regimen for adults up to age 69 with hematologic malignancies who have low-, intermediate-, or high-risk scores according to the DRI."	( Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO, 2013)	0.39
" Our data indicate that Flu (160 mg/m(2)) with targeted myeloablative Bu (90 mg·h/L) is less toxic than and equally effective as BuCy (Mel) in patients with similar indications for allo-HCT."	( Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B, 2014)	0.4
" In an effort to minimize these adverse effects, we conducted bone marrow transplantation (BMT) from unrelated volunteer donors using a conditioning regimen without BU or TBI."	( Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014)	0.4
"This conditioning regimen of FLAG combined with L-PAM (which did not contain BU and TBI) was associated with good outcomes and minimal late adverse effects in children with acute leukemia who have undergone allogeneic BMT from unrelated volunteer donors."	( Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014)	0.4
"Modified Bu/Flu as a new RIC regimen is well tolerated and safe for patients who need allogeneic hematopoietic stem cell transplantation, especially in older patients and/or patients with severe comorbidities."	( [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP, 2013)	0.39
" The FB3-ATG2 regimen is safe and efficient in both lymphoid and myeloid disorders."	( Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience. Chantepie, SP; Gac, AC; Reman, O, 2014)	0.4
" There was a slightly increased incidence of adverse events with lumiliximab but these increases did not appear to lead to differences in eventual outcomes."	( A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch Awan, FT; Byrd, JC; Flinn, IW; Hellmann, A; Hillmen, P; Hughes, SG; Robak, T; Shannon, M; Trone, D, 2014)	0.4
" Our RTMAC regimen would be less toxic and offers a high probability of survival for children with hematological malignancies."	( Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies. Hirabayashi, K; Koike, K; Kurata, T; Nakazawa, Y; Saito, S; Sakashita, K; Tanaka, M; Yanagisawa, R; Yoshikawa, K, 2014)	0.4
" Moreover, it appears to be safe with a low NRM rate among high-risk patients."	( The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ, 2016)	0.43
" The therapeutic efficacy of patients in 2 groups was analyzed according to the peripheral hemogram indexes, symptom and sign disappeared time as well as adverse reaction incidence."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
"application of rituximab combined with fludarabine and cyclophosphamide in the treatment of CLL shows the higher curative effect, can effectively improve the symptoms and reduce the incidence of adverse reactions."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
" In the safety analysis, the proportion of patients reporting adverse events was similar between the subcutaneous and intravenous groups (all grades: 82 [96%] of 85 patients and 81 [91%] of 89 patients; serious adverse events: 25 [29%] and 29 [33%] patients; grade ≥3: 59 [69%] and 63 [71%] patients, respectively)."	( Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Assouline, S; Badoux, X; Berthillon, N; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Li, S; McIntyre, C; Sayyed, P; Trneny, M, 2016)	0.43
" Odds ratio (OR) with 95% confidence interval (CI) were utilized to express the complete response, overall response and adverse events outcomes."	( Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis. Chen, B; Gao, C; Ge, Z; Liu, R; Zhang, X, 2017)	0.46
" Grade ≥3 adverse events occurred in 80."	( Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S, 2018)	0.48
" The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL; however, this combination is toxic for older patients."	( Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. Aviv, A; Bairey, O; Braester, A; Fineman, R; Herishanu, Y; Levi, I; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T; Yuklea, M, 2019)	0.51
" TBC combined with thiotepa is highly toxic to the skin with various cutaneous manifestations."	( Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation. Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I, 2020)	0.56
" At the final analysis, no new safety signals were observed [Grade ≥ 3 adverse events (AEs): 1L 82·7%, R/R 84·5%; serious AEs: 1L 58·1%, R/R 62·5%]."	( Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M, 2021)	0.62
" Trends toward improved survival were seen in patients transplanted for myeloid disease using bone marrow as stem cell source who achieved a busulfan AUC > 4000 μmol*min/day with two-year relapse-free survival approaching 80% CONCLUSIONS: This conditioning regimen is safe and effective in patients with high-risk leukemias, particularly myeloid disease."	( Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT, 2021)	0.62
" In this study, we aimed to investigate the side effect of Bu/Cy and Bu/Flu regimens on our patients who underwent allogeneic bone marrow transplantation."	( Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation. Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S, 2021)	0.62
"The therapeutic-related adverse effects of the two conditioning regimens in patients who underwent allogeneic bone marrow transplant were almost similar."	( Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation. Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S, 2021)	0.62
" Grade 3 adverse events included mucositis, diarrhea, and liver transaminitis (n = 3 each)."	( Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM, 2021)	0.62
"We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity."	( Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB, 2022)	0.72
" Her clinical course was complicated by high-grade pulmonary toxic effects 55 days after treatment that resulted in death."	( Pulmonary Toxic Effects After Myeloablative Conditioning With Total Body Irradiation Delivered via Volumetric Modulated Arc Therapy With Fludarabine. Abdul-Hay, M; Al-Homsi, AS; Byun, D; Galavis, P; Gerber, NK; Karp, JM; Modrek, AS; Teruel, J; Yuan, Y, )	0.13
" The prediction of transplantation-related mortality (TRM) using the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score and an arbitrary upper age limit of 55 years for administering myeloablative conditioning (MAC) are common strategies to ensure a safe procedure."	( Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H, 2023)	0.91

Excerpt	Reference	Relevance
" Concurrent with the phase I evaluation of 2-F-ara-AMP administered as a single intravenous (IV) bolus every 21 days to patients with advanced malignancy, plasma pharmacokinetic profiles of 2-F-ara-A were determined in 30 patients following the rapid infusion (2 to 5 minutes) of doses of 2-F-ara-AMP ranging from 80 to 260 mg/m2."	( Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Grever, MR; Malspeis, L; Staubus, AE; Young, D, 1990)	0.28
" Pharmacokinetic and pharmacodynamic studies were performed on specimens from 20 patients."	( Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S, 1998)	0.3
"Serial plasma samples were collected for pharmacokinetic analysis on day 2 of the first cycle of therapy."	( The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. Boumpas, DT; Davis, JC; Fessler, B; Knebel, W; Pucino, F; Sanders, WD; Yarboro, C, )	0.13
"Fludarabine pharmacokinetics in patients with RA are characterized by an intermediate-length distribution phase (approximately 40 min), terminal half-life of 10."	( The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. Boumpas, DT; Davis, JC; Fessler, B; Knebel, W; Pucino, F; Sanders, WD; Yarboro, C, )	0.13
" Plasma and cellular pharmacokinetic measurements were conducted during the first 5 days."	( Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. Ayres, M; Du, M; Gandhi, V; Hodge, JP; Keating, MJ; O'Brien, S; Plunkett, W; Ramakrishna, P; Rodriguez, CO; Rosner, GL; Weller, S, 2001)	0.31
" Pharmacokinetic studies were done using 11 samples with the first and fourth doses of Bu."	( Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Andersson, BS; Brown, C; Chaudhry, A; Duggan, P; Glick, S; Gyonyor, E; Morris, D; Quinlan, D; Ruether, JD; Russell, JA; Stewart, D; Tran, HT, 2002)	0.31
" Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters."	( Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X, 2004)	0.32
"Fludarabine, carboplatin, topotecan regimen is a promising treatment based on potential pharmacodynamic interactions, which merits additional study in poor prognosis, acute leukemia patients."	( A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ, 2004)	0.32
" The pharmacokinetic (PK) properties of F-ara-A (9-beta-D-arabinosyl-2-fluoradenine) before and after application of busulfan were prospectively investigated in 16 patients with hematological malignancies."	( F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bergeman, T; Bonin, M; Bornhauser, M; Ehninger, G; Illmer, T; Leopold, T; Pursche, S; Schleyer, E, 2007)	0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" We now report full pharmacokinetic (PK) data, correlations of PK with clinical outcomes, and final response and progression-free survival (PFS)."	( Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blum, KA; Brooker-McEldowney, M; Byrd, JC; Dalton, JT; Farley, KL; Fischer, B; Grever, MR; Heerema, NA; Hurh, E; Jarjoura, D; Johnson, AJ; Lin, TS; Mitchell, SM; Moran, ME; Phelps, MA; Rozewski, DM; Schaaf, LJ; Wu, D, 2009)	0.35
" Mean (+/-SD) elimination half-life did not differ significantly between IV and oral dosage groups (11."	( Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Greenblatt, DJ; Karyagina, EV; Lister-James, J; Lundberg, AS; Yin, W, 2010)	0.36
" Forodesine has biologic activity in CLL; pharmacodynamic parameters suggest that an alternate dosing schedule and/or higher doses to achieve greater intracellular dGTP may be beneficial in this patient population."	( Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Balakrishnan, K; Bantia, S; Bickel, S; Chen, Y; Gandhi, V; Kantarjian, H; Keating, MJ; Kilpatrick, JM; O'Brien, S; Ravandi, F; Tyler, BF; Verma, D, 2010)	0.36
" The elimination half-life at steady state of rituximab in all patients was estimated to be 19."	( Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L, 2010)	0.36
" Pharmacokinetic studies were fitted to a linear, 2-compartment model in which dose reduction led to incomplete saturation of CD52 binding sites and greater antibody clearance."	( Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Bloor, A; Chakraverty, R; Clark, A; Clark, R; Collin, M; Crawley, C; Fielding, A; Hale, G; Johnson, P; Kottaridis, P; Mackinnon, S; Milligan, D; Morris, E; Orti, G; Parker, A; Peggs, K; Pettengell, R; Pettitt, A; Roughton, M; Shen, J; Snowden, J; Thomson, K, 2010)	0.36
" We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive AML patients treated with pharmacokinetic targeted IV busulfan (AUC < 6000 μM/L*min per day × 4 days) and fludarabine (40 mg/m2 × 4 days) - (t-IV Bu/Flu)."	( Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Perez, L; Perkins, J; Pidala, J, 2010)	0.36
") busulfan can produce a more consistent pharmacokinetic profile than oral formulations can, but nonetheless, significant interpatient variability is evident."	( Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Bae, KS; Choi, Y; Han, SB; Hur, EH; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lim, HS; Lim, SN; Noh, GJ; Yun, SC, 2011)	0.37
"Busulfan has a narrow therapeutic range, and in children, pharmacokinetic variability has been found to be high even after the use of intravenous (i."	( Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ, 2012)	0.38
" Marked differences were observed compared to pharmacokinetic parameters for non-Hodgkin lymphoma (NHL) obtained previously: in CLL, time-varying clearance at time zero (CL(2)) was faster, volumes of distribution (V(1) and V(2)) were larger, and rate of change (K(des)) from the targetmediated clearance pathway to catabolic elimination was lower than NHL."	( Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. Dmoszynska, A; Joshi, A; Li, J; Mangat, R; Robak, T; Valente, N; Visich, J; Wenger, M; Zhi, J, 2012)	0.38
" The median half-life of rituximab during cycle 1 was 27 hours, compared to 199 hours during cycle 4 (P<0."	( Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Beum, PV; Lee, E; Lindorfer, MA; Marti, G; Mo, CC; Njuguna, N; Taylor, RP; Vire, B; Wiestner, A; Wilson, WH, 2013)	0.39
" Plasma busulfan concentrations were determined by HPLC-UV and the pharmacokinetic parameters were calculated using the WinNonlin program."	( Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. Colturato, VA; de Castro, FA; Lanchote, VL; Simões, BP; Voltarelli, JC, 2013)	0.39
" A detailed in vitro structure-activity relationship of 1a in CLL compared to that of 22 synthetic analogues is described along with preliminary in vivo pharmacokinetic and metabolism studies on the most potent compounds."	( Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies. Castro, JE; Choi, MY; Molinski, TF; Stout, EP, 2014)	0.4
" Pharmacokinetic treatment with targeted intravenous busulfan combined with fludarabine (BuFlu) was developed as a preparative regimen for acute leukemia and myelodysplasia."	( Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B, 2015)	0.42
"Considerable interpatient variability exists in pharmacokinetic and fludarabine-based biomarkers, but these biomarkers are not associated with clinical outcomes in fludarabine/TBI-conditioned patients."	( Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. Bemer, MJ; Heimfeld, S; Mager, DE; McCune, JS; Sandmaier, BM; Storer, BE, 2015)	0.42
" This regimen was associated with durable donor engraftment and relatively low rates of regimen related toxicity (RRT); future alemtuzumab pharmacokinetic studies may improve outcomes, by allowing targeted alemtuzumab clearance to reduce graft rejection and promote more rapid immune reconstitution."	( Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q, 2015)	0.42
" Pharmacokinetic parameters were determined in six children who received intravenous treosulfan (dose range 12-24 g/m(2)) in combination with fludarabine prior to blood or marrow transplantation."	( Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies. Byrne, JA; Earl, JW; Fraser, CJ; Koyyalamudi, SR; Kuzhiumparambil, U; Nath, CE; O'Brien, TA; Shaw, PJ, 2016)	0.43
" In part two of the study, we aimed to confirm the pharmacokinetic non-inferiority of subcutaneous rituximab, and investigate its safety and efficacy."	( Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Assouline, S; Badoux, X; Berthillon, N; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Li, S; McIntyre, C; Sayyed, P; Trneny, M, 2016)	0.43
" We did the primary analysis in patients in the intention-to-treat population with complete pharmacokinetic data (pharmacokinetic population)."	( Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Assouline, S; Badoux, X; Berthillon, N; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Li, S; McIntyre, C; Sayyed, P; Trneny, M, 2016)	0.43
"Between Aug 20, 2012, and June 17, 2013, we randomly assigned 176 patients to receive subcutaneous rituximab (n=88) or intravenous rituximab (n=88); 134 (76%) patients comprised the pharmacokinetic population."	( Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Assouline, S; Badoux, X; Berthillon, N; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Li, S; McIntyre, C; Sayyed, P; Trneny, M, 2016)	0.43
" Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants."	( Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC, 2016)	0.43
" As no definitive pharmacokinetic (PK) basis for HCT dosing for the wide age and weight range in HCT is available, linear body surface area (BSA)-based dosing is still used."	( Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Boelens, JJ; Dorlo, TPC; Huitema, ADR; Kuball, J; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM, 2019)	0.51
" This multi-institutional prospective study compared pharmacokinetic (PK) parameters of Bu between BuFlu and BuCy."	( Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. Hino, Y; Kato, J; Kikuchi, T; Koda, Y; Matsumoto, K; Mishina, T; Mori, T; Morita, K; Nagao, Y; Ohwada, C; Okamoto, S; Onizuka, M; Onoda, M; Sakaida, E; Shimizu, H; Shono, K; Takeda, Y; Yokota, A; Yokoyama, H, 2021)	0.62
"Busulfan (Bu) is a common component of conditioning regimens before hematopoietic stem cell transplantation (HSCT) and is known for high interpatient pharmacokinetic (PK) variability."	( Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. Ansari, M; Ben Hassine, K; Bittencourt, H; Bredius, RGM; Daali, Y; Kassir, N; Krajinovic, M; Lewis, V; Nath, CE; Nava, T; Shaw, PJ; Théoret, Y; Uppugunduri, CRS, 2021)	0.62

Excerpt	Reference	Relevance
"The Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in children with relapsed or refractory leukemia."	( Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S, 1997)	0.3
"A dose of idarubicin 12 mg/m2/d for 3 days given in combination with fludarabine and cytarabine was tolerated."	( Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S, 1997)	0.3
"Combinations of nucleoside analog drugs, such as F-araA and ara-C, combined with Topoisomerase II inhibitors, such as anthracyclines, are synergistic against human leukemic T-cells and induce apoptotic cell death."	( Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Avramis, VI; Cohen, LJ; Danenberg, P; Kwock, R; Mukherjee, SK; Nandy, P; Solorzano, MM, )	0.13
" These results support that fludarabine in combination with cyclophosphamide and/or mitoxantrone can be highly effective in the treatment of B-CLL."	( In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N, 1999)	0.3
" In conclusion, fludarabine combined with cyclophosphamide and dexamethasone is an effective therapy for recurrent indolent lymphoma."	( The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Arcaini, L; Astori, C; Baldanti, F; Bernasconi, C; Furione, M; Gerna, G; Lazzarino, M; Orlandi, E; Pagnucco, G; Paulli, M; Viglio, A, 1999)	0.3
" Among these agents, cytarabine may be the best agent for the combination with fludarabine phosphate."	( In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S, 2000)	0.31
" Because its toxicities are minimal and do not overlap with the toxicities of standard chemotherapy, it is an appealing agent to use in combination with chemotherapy."	( Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 2000)	0.31
" Two groups of infected mice were treated as follows: one group was treated by alternating the administration of Fludarabine and AZT (treatment A), while the other group received the same treatment plus GSH-loaded erythrocytes given with AZT (treatment A + L-RBC)."	( New drug combinations for the treatment of murine AIDS and macrophage protection. Brandi, G; Casabianca, A; Chiarantini, L; Fraternale, A; Magnani, M; Tonelli, A, 2001)	0.31
"Fludarabine, 9-beta-D-arabinofuranosyl-2-fluoroadenine, is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models."	( A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. Ang, KK; Beauduin, M; Garden, AS; Grégoire, V; Hamoir, M; Hittelman, WN; Humblet, Y; Khuri, FR; Milas, L; Mitine, C; Rosier, JF; Scalliet, P, 2002)	0.31
" The aim of study was to evaluate the activity and toxicity of FLU in combination with CY, the FLU-CY schedule, in patients with previously untreated B-CLL."	( Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia. Fricová, M; Guman, T; Kafková, A; Stecová, N; Tóthová, E, 2003)	0.32
" Although fludarabine was administered, the platelet count did not decrease when combined with rituximab."	( Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine. Asaka, M; Ehira, N; Fukushima, A; Imamura, M; Kanamori, H; Masauzi, N; Minami, H; Musashi, M; Obara, S; Ogura, N; Tanaka, J; Tsutsumi, Y; Yamato, H, 2005)	0.33
" The aim of this study was to evaluate the cytotoxicity of SDX-101 combined with agents proven to be effective as first-line treatment of B-CLL: the purine nucleoside analogs, fludarabine (FA) and cladribine (2-CdA), and the monoclonal antibodies, anti-CD52 (alemtuzumab; ALT) and anti-CD20 (rituximab; RIT)."	( Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P, 2006)	0.33
" In this study, Cloretazine was evaluated both as a monotherapy and in combination with fludarabine in murine tumor and human tumor xenograft models."	( Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models. King, I; Li, Z; Liu, L; Song, BL; Zheng, LM, 2007)	0.34
"The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL)."	( Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D, 2007)	0.34
" In conclusion, the individualized protocol of fludarabine combined with rituximab and amifostine showed the safety and effectiveness for treatment of aged patient with CLL."	( [Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia]. Li, SX; Liu, Y; Lu, XC; Zhu, HL, 2007)	0.34
"This study was aimed to investigate the feasibility of low dose of fludarabine, cyclophosphamide combined with donor derived alloreactive NK cells as a new nonmyeloablative conditioning regimen in the haploidentical hematopoietic stem cell transplantation (haploidentical HSCT)."	( [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice]. An, XM; Cao, S; Qi, J; Ren, XB; Xin, N; Yu, JP, 2007)	0.34
" Fourteen patients were treated with three cycles of rituximab (375 mg/m(2) weekly for 4 weeks) in combination with HDMP (1 gm/m(2) daily for 5 days)."	( Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Bole, J; Castro, JE; Kipps, TJ; Rassenti, L; Sandoval-Sus, JD, 2008)	0.35
" Furthermore, local tumor irradiation combined with intratumoral dendritic cell administration significantly enhanced the therapeutic efficacy of tumor-reactive T cell adoptive transfer in this lymphodepleted liver tumor model."	( Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. Chang, AE; Davis, MA; Hoff, J; Li, M; Li, Q; Teitz-Tennenbaum, S; Wilder-Romans, K, )	0.13
"The aim of study was to evaluate the clinical efficacy and toxicity of fludarabine combined with cytarabine (FA) regimen in the treatment of patients with refractory and/or relapsed acute myeloid leukemia (AML)."	( [Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia]. Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF, 2009)	0.35
" To assess the efficacy and toxicity of oral fludarabine in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin lymphoma (B-NHL), we conducted a multicenter phase II study."	( Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Ando, K; Hayashi, M; Hotta, T; Ishizawa, K; Itoh, K; Matsusako, M; Morishima, Y; Nakata, M; Nawano, S; Ogura, M; Taniwaki, M; Terauchi, T; Tobinai, K; Uchida, T; Watanabe, T; Yamamoto, J, 2009)	0.35
"Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab."	( Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Byrd, JC; Castro, J; Flinn, IW; Harris, S; Heerema, N; Hughes, S; Kipps, TJ; Leigh, B; Lin, TS; Molina, A; O'Brien, S; Tangri, S; Wierda, W; Woodworth, J; Wynne, D, 2010)	0.36
" To evaluate this effect in vivo, we performed a phase I study of chlorambucil combined with imatinib in relapsed CLL patients."	( A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Aloyz, R; Amrein, L; Assouline, S; Caplan, S; Desjardins, P; Egorin, MJ; Hebb, J; Panasci, L; Rousseau, C, 2011)	0.37
"To describe the clinical studies that led to the FDA approval of rituximab in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with chronic lymphocytic leukemia (CLL)."	( U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Casak, SJ; Davis, G; Jarral, V; Keegan, P; Khandelwal, A; Lemery, SJ; Pazdur, R; Rothmann, MD; Shen, YL; Zhao, H, 2011)	0.37
"The results of two multinational, randomized trials in CLL patients comparing rituximab combined with fludarabine and cyclophosphamide versus FC were reviewed."	( U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Casak, SJ; Davis, G; Jarral, V; Keegan, P; Khandelwal, A; Lemery, SJ; Pazdur, R; Rothmann, MD; Shen, YL; Zhao, H, 2011)	0.37
"On the basis of the demonstration of clinically meaningful prolongation of PFS, the FDA granted regular approval to rituximab in combination with FC for the treatment of patients with CLL."	( U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Casak, SJ; Davis, G; Jarral, V; Keegan, P; Khandelwal, A; Lemery, SJ; Pazdur, R; Rothmann, MD; Shen, YL; Zhao, H, 2011)	0.37
" The purpose of this phase II study was to determine the overall response rate, response duration and toxicity of cenersen administered in combination with FCR."	( Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Cook, H; Datto, M; Daugherty, FJ; Davis, PH; DeCastro, CM; Diehl, LF; Friedman, DR; Gockerman, JP; Lanasa, MC; Li, Z; Matta, KM; Moore, JO; Rehder, C; Rizzieri, D; Weinberg, JB, 2012)	0.38
"The objective of this trial was to evaluate safety and efficacy of bendamustine combined with rituximab (BR) in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)."	( Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D, 2011)	0.37
" Bendamustine was administered at a dose of 70 mg/m(2) on days 1 and 2 combined with rituximab 375 mg/m(2) on day 0 of the first course and 500 mg/m(2) on day 1 during subsequent courses for up to six courses."	( Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D, 2011)	0.37
" busulfan combined with fludarabine and analyzed the outcomes."	( Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ, 2012)	0.38
" Of 178 patients enrolled in the study, 165 were randomly assigned to receive 6 courses of oral fludarabine and cyclophosphamide (FC) in combination with rituximab (FCR; 375 mg/m(2) in cycle one, 500 mg/m(2) in all subsequent cycles) or alemtuzumab (FCCam; 30 mg subcutaneously injected on cycle days 1-3); each cycle was 28 days."	( Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Aurran, T; Béné, MC; Casasnovas, O; Cazin, B; Chevret, S; Corront, B; Cymbalista, F; Delépine, R; Delmer, A; Feugier, P; Leblond, V; Lepretre, S; Letestu, R; Mahé, B; Maisonneuve, H; Royer, B; Tournilhac, O; Van Den Neste, E; Vaudaux, S, 2012)	0.38
"Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models."	( Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. Christiansen, H; Griesinger, F; Lederer, K; Nitsche, M; Pradier, O; Schmidberger, H, 2012)	0.38
" However, AUY922 in combination with fludarabine was significantly more effective at inducing apoptosis in cells in co-culture than either drug alone, an effect that was irrespective of ATM/TP53 dysfunction."	( Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Best, OG; Mulligan, SP, 2012)	0.38
"Cladribine (C) and fludarabine (F) combined with cyclophosphamide/mafosfamide in vivo, as well as ex vivo trigger apoptosis in CLL cells."	( In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent. Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Kotkowska, A; Robak, T; Rogalińska, M; Smolewski, P; Wawrzyniak, E; Żołnierczyk, JD, 2013)	0.39
" Thus, we examined in vivo the antitumor activity of galiximab used alone and in combination with chemotherapeutic agents in SCID mice bearing human lymphoma xenografts."	( Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. Berquist, L; Bonavida, B; Chu, P; Clanton, D; Hariharan, K; Ho, SN; Molina, A; Murphy, T; Vega, MI, 2013)	0.39
" Together, our data suggest the potential for proteasome inhibitor based therapy in CLL and the rationale design of drug combination strategies based on CLL biology."	( The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Advani, P; Akhtar, D; Chanan-Khan, A; Chitta, K; Colon-Otero, G; Foran, J; Khan, AN; Masood, A; Miller, KC; Paulus, A; Rivera, C; Roy, V, 2014)	0.4
" In conclusion, we provide evidence that Notch is a therapeutic target in CLL cases with NOTCH1-activating mutations, supporting the use of Notch pathway inhibitors in combination with chemotherapy as a promising approach for the treatment of these high-risk CLL patients."	( The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; López-Otín, C; Matas-Céspedes, A; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S, 2015)	0.42
" Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyclophosphamide and rituximab (FCR) established its potential efficacy and tolerability."	( A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch Awan, FT; Byrd, JC; Flinn, IW; Hellmann, A; Hillmen, P; Hughes, SG; Robak, T; Shannon, M; Trone, D, 2014)	0.4
"This retrospective study compared efficacy and safety of fludarabine combined with intermediate-dose cytarabine (FA regimen) versus high-dose cytarabine (HiDAC regimen) as consolidation therapy in acute myeloid leukemia (AML) patients who achieved complete remission."	( Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia. Chen, C; Chen, Y; Ding, Y; Fu, J; Liang, A; Lu, H; Wang, W; Wu, H; Zhang, W; Zou, S, 2014)	0.4
"This study was aimed to investigate the morphological, immunophenotype, cytogenetic characteristics, clinical and therapy features in one elderly patient with chronic lymphocytic leukemia (CLL) combined with invasive aspergillose infection(IAI)."	( [Elderly chronic lymphocytic leukemia combined with invasive aspergillosis infection in one case]. Li, BL; Li, J; Li, SX; Liu, Y; Wang, HT; Wang, TM; Zhai, B; Zhu, HL, 2015)	0.42
" It is concluded that obatoclax can be safely administered to relapsed CLL patients in combination with FR and shows promising clinical activity."	( Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L, 2015)	0.42
" Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed by fludarabine 150 mg/m(2) and busulfan 8 mg/kg combined with either 75 mg (n = 26) or 50 mg (n = 32) alemtuzumab."	( Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G, 2015)	0.42
" We performed a phase 2 study of alemtuzumab in combination with fludarabine in patients with relapsed disease."	( A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Brown, JR; Cohen, JB; Flowers, CR; Jaye, DL; Katzen, HI; Lakhanpal, S; Leis, JF; Rosenthal, H; Sinha, R; Stock, W; Waller, EK, 2015)	0.42
" These patients may benefit from rituximab combined with intensive chemotherapy."	( [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement]. Li, H; Li, Z; Liu, H; Liu, W; Lü, R; Qiu, L; Xiong, W; Yi, S; Zou, D, 2015)	0.42
"To explore the clinical efficacy and safety of rituximab combined with fludarabine and cyclophosphamide for the treatment of the chronic lymphocytic leukemia (CLL)."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
" The patients in control group were treated with CHOP chemotherapy, the patients in observation group were treated with rituximab combined with fludarabine, cyclophosphamide treatment."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
"application of rituximab combined with fludarabine and cyclophosphamide in the treatment of CLL shows the higher curative effect, can effectively improve the symptoms and reduce the incidence of adverse reactions."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
" We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL."	( Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH, 2016)	0.43
"To investigate the efficacy and safety of haploidentical allo-HSCT in combination of reduced intensity preconditioning combined with cyclophosphamid (CTX)-induced immune tolerance after transplanitation for treatment of severe aplastic anemia (SAA)."	( [Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia]. Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y, 2016)	0.43
"A total of 15 patients with SAA received the haploidentical allo-HSCT of reduced intensity preconditioning combined with CTX-induced immune tolerance after transplartation in the General hospital of Beijing military command of chinese PLA from June 2012 to December 2014."	( [Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia]. Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y, 2016)	0.43
"The haploidentical allo-HSCT of reduced intensity preconditioning combined with CTX-induced immune tolerance after transplantation is safet and effective for SAA patients, that may be applied to clinical therapy."	( [Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia]. Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y, 2016)	0.43
" Here, we conducted a single-arm, phase II trial to examine the efficacy and safety of lower-dose fludarabine and cyclophosphamide combined with a standard dose of rituximab (LD-FCR) in elderly patients with previously untreated CLL."	( Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. Aviv, A; Bairey, O; Braester, A; Fineman, R; Herishanu, Y; Levi, I; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T; Yuklea, M, 2019)	0.51
" Subsequently, we demonstrated Entinostat (HDAC1 inhibitor) combination with Fludarabine significantly induced apoptosis in TP53 mutations CLL cells."	( Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway. Chen, B; Fang, Q; He, Z; Li, P; Ma, D; Ren, M; Wang, J; Zhe, N; Zhong, Q; Zhou, Z, 2019)	0.51
" For this particular group we evaluated the efficacy and safety of fludarabine, cytarabine, granulocyte colony-stimulating factor (FLAG) in combination with etoposide (FLAG-Eto) in 36 patients."	( Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J, 2020)	0.56
" Additional drugs reported in combination with the Treo-Flu backbone are thiotepa and melphalan."	( Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation. Ussowicz, M, 2020)	0.56
" This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in ND-AML and R/R-AML."	( Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M, 2021)	0.62
"This study aimed to identify the maximum-tolerated dose (MTD) of cyclophosphamide when combined with bortezomib and fludarabine (B-FC) in a phase 1b trial, and to assess the efficacy and safety of this combination in a phase 2 trial in patients with relapsed or refractory MCL (rrMCL)."	( Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study. Cai, QQ; Cao, JN; Feng, JF; Gao, Y; Huang, HQ; Jiang, WQ; Jin, J; Li, ZM; Wang, HQ; Wang, XX; Zhang, HL, 2021)	0.62
" We treated 174 consecutive patients with newly diagnosed CBF-AML in a prospective clinical trial of FLAG-based induction/consolidation in combination with gemtuzumab ozogamicin (FLAG-GO; N = 65) or in combination with idarubicin (FLAG-IDA; N = 109)."	( Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X, 2022)	0.72
"Total body irradiation (TBI) at a dose of 12 Gy combined with cyclophosphamide (CyTBI12Gy) is one of the standard myeloablative regimens for patients with acute myeloid leukemia (AML) treated with allogeneic hematopoietic cell transplantation (allo-HCT)."	( Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R, 2023)	0.91
"In this registry-based study we retrospectively compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) for adult patients with acute lymphoblastic leukemia (ALL) following conditioning with total body irradiation (TBI) combined with either cyclophosphamide (Cy) or fludarabine (Flu)."	( Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Aljurf, M; Arat, M; Bourhis, JH; Brissot, E; Forcade, E; Giebel, S; Helbig, G; Huynh, A; Kröger, N; Labopin, M; Labussière-Wallet, H; Lioure, B; Mohty, M; Nagler, A; Peric, Z; Reményi, P; Salmenniemi, U; Savani, BN; Socié, G; Spirydonidis, A; Srour, M; Tbakhi, A; Zahrani, MA, 2023)	0.91
"In conclusion, ATG and PTCy combined with Flu-based increased intensity conditioning regimen is effective for acute leukemia in children."	( Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ, 2023)	0.91

Excerpt	Reference	Relevance
" Bioavailability of F-ara-A after subcutaneous dosing was approximately 105% of the bioavailability after intravenous administration."	( Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. Boumpas, DT; Burstein, AH; Illei, GG; Kuo, GM; Pucino, F; Yarboro, C, 2001)	0.31
" Although intracellular events involved in the pharmacologic action of these compounds have been extensively studied, the role of plasma membrane transporters in nucleoside-derived drug bioavailability and action in leukemia cells has not been comprehensively addressed."	( Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M, 2003)	0.32
" Pharmacokinetic studies evaluating the bioavailability of oral fludarabine indicate that an oral dose of 40 mg/m2/day would provide similar systemic drug exposure to the standard intravenous dose of 25 mg/m2/day."	( Oral fludarabine. Figgitt, DP; Plosker, GL, 2003)	0.32
" Pharmacokinetic studies suggest decreased bioavailability with successive cycles, probably due to accelerated metabolism."	( High dose chlorambucil in the treatment of lymphoid malignancies. Nicolle, A; Proctor, SJ; Summerfield, GP, 2004)	0.32
" We have analyzed the role of plasma membrane transporters in nucleoside-derived drug bioavailability and action in CLL cells."	( Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Huber-Ruano, I; Marcé, S; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M; Villamor, N, 2005)	0.33
"This study determined the oral bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil, in patients undergoing nonmyeloablative hematopoietic cell transplantation."	( Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. Brunstein, C; DeFor, T; Ebeling, B; Green, K; Jacobson, P; McGlave, P; Rogosheske, J; Weisdorf, D, 2007)	0.34
"The pharmacokinetics, bioavailability and effects on electrocardiographic (ECG) parameters of fludarabine phosphate (2F-ara-AMP) were evaluated in adult patients with B-cell chronic lymphocytic leukemia."	( Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Greenblatt, DJ; Karyagina, EV; Lister-James, J; Lundberg, AS; Yin, W, 2010)	0.36
" P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases."	( The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. Baker, D; Betz, A; Burke, R; Coffey, G; DeGuzman, F; Druker, BJ; Fletcher, LB; Hollenbach, SJ; Loriaux, MM; Pak, Y; Pandey, A; Sinha, U; Spurgeon, SE; Tyner, JW, 2013)	0.39
" In this context, we reviewed the sometimes paradoxical antioxidant properties of quercetin and the functional role of its glucuronide and/or sulfate conjugates to discuss the low bioavailability of the molecule measured in vivo."	( The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia. Russo, GL; Russo, M; Spagnuolo, C, 2014)	0.4
" The oral bioavailability of F-ara-A from 1,2-dimyristoylglycerophosphate derivative 29 was similar to its oral bioavailability from fludarabine phosphate."	( Phospholipid derivatives of cladribine and fludarabine: synthesis and biological properties. Baranovsky, A; Bogushevich, S; Golubeva, M; Kalinichenko, E; Kulak, T; Kuzmitsky, B; Tsybulskaya, I, 2015)	0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The parent drug was almost quantitatively converted to 2-F-ara-A by apparent first-pass metabolism, with maximum levels of 2-F-ara-A and very low levels (less than 1 fmol/L) of 2-F-ara-AMP observed only in the plasma samples obtained shortly after dosing (2 to 4 minutes)."	( Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Grever, MR; Malspeis, L; Staubus, AE; Young, D, 1990)	0.28
" All patients were treated at a dosage of 25 mg/m2 per day for 5 consecutive days for a total of six courses."	( Fludarabine treatment in resistant Waldenstrom's macroglobulinemia. Aitini, E; Bendandi, M; Gherlinzoni, F; Salvucci, M; Tura, S; Zaccaria, A; Zinzani, PL, 1995)	0.29
" Fludarabine was administered at a dosage of 25 mg/m2 daily for 5 days as a 30-minute intravenous infusion."	( Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Bergmann, L; Fenchel, K; Hoelzer, D; Jahn, B; Mitrou, PS, 1993)	0.29
" Twenty-one patients were treated at a dosage of 25 mg/m2 per day for 5 consecutive days."	( Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Bendandi, M; Benfenati, D; Bocchia, M; Fanin, R; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL, 1993)	0.29
" FAMP was administered at a dosage of 25 mg/m2 daily for 5 days as 30 minute infusion every fifth week."	( Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Bergmann, L; Diehl, V; Engert, A; Fenchel, K; Hoelzer, D; Mitrou, PS; Pralle, H; Wijermans, P, 1995)	0.29
" With this agent, a dosage regimen of 25-30 mg/m2 daily over 5 days seems to be the most effective to date."	( Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. Kantarjian, H; Keating, MJ; O'Brien, S, 1996)	0.29
" Other adverse effects such as nausea and vomiting or neurotoxicity are of mild to moderate severity when the recommended dosage is used."	( [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine]. Hájek, R; Krahulcová, E; Mayer, J; Penka, M; Vásová, I, 1997)	0.3
"Previously untreated patients with low-grade lymphoma were entered onto dosing cohorts of four patients each."	( Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group. Bennett, JM; Cassileth, PA; Gordon, LI; Hochster, HS; Oken, MM; Raphael, BG; Winter, JN, 2000)	0.31
" However, further studies are required to optimize the CdA schedule and dosage in order to ameliorate its toxic profile while maintaining antitumor activity."	( Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P, 2000)	0.31
" All four patients obtained no clinical benefit from the treatment; moreover, inflammation indices worsened and the prednisone dosage was increased during the trial, in spite of a significant fall in CD4+ T cells."	( Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis. Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A, 2000)	0.31
" Bioavailability of F-ara-A after subcutaneous dosing was approximately 105% of the bioavailability after intravenous administration."	( Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. Boumpas, DT; Burstein, AH; Illei, GG; Kuo, GM; Pucino, F; Yarboro, C, 2001)	0.31
" They have shown a dose-response relationship and a higher response rate than previously seen in the lower-dose studies."	( Emerging information on the use of rituximab in chronic lymphocytic leukemia. Albitar, M; Keating, MJ; O'Brien, S, 2002)	0.31
" The sensitivity of CLL cells to nine drugs (2'-chlorodeoxyadenosine, cisplatin, chlorambucil, cyclosporin A, doxorubicin, fludarabine, prednisolone, verapamil and vincristine) and two types of irradiation (gamma and UV-irradiation) was determined from dose-response curves of 4-day cultures ex vivo."	( CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia. Hulkkonen, J; Hurme, M; Kivekäs, I; Vilpo, J; Vilpo, L, 2002)	0.31
" Dosage was increased gradually (target 30 mg, 3 times weekly, for a maximum of 12 weeks)."	( Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B, 2002)	0.31
" Granulocyte colony-stimulating factor (G-CSF), at the dosage of 5-10 microg/kg/die, or intermediate-dose Ara-C (800 mg/m(2)/q 12h x 6 doses), was administered to obtain peripheral blood stem cell (PBSC) mobilization."	( Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Brando, B; Cafro, AM; Cairoli, R; Montillo, M; Morra, E; Oreste, P; Pungolino, E; Rossi, V; Tedeschi, A; Veronese, S, 2002)	0.31
" form of busulfan (Bu) has prompted investigation of administration schedules other than the 4-times-daily dosage commonly used with oral Bu."	( Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Andersson, BS; Brown, C; Chaudhry, A; Duggan, P; Glick, S; Gyonyor, E; Morris, D; Quinlan, D; Ruether, JD; Russell, JA; Stewart, D; Tran, HT, 2002)	0.31
" Although increased dosing intensity and frequency leads to higher response rates than seen in patients treated with standard dose rituximab, responses are almost always partial remissions and the doses used are not feasible in routine clinical practice."	( Advancing therapy for chronic lymphocytic leukemia--the role of rituximab. Hillmen, P, 2004)	0.32
") dosage regimen is 25 mg/m2 daily for 5 consecutive days, with treatment cycles repeated every 28 days."	( Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Leporrier, M, 2004)	0.32
" Administration of cyclophosphamide at a lower dosage (< or =300 mg) appears to reduce the risk of myelosuppression without compromising efficacy."	( Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Eichhorst, BF; Hallek, M, 2004)	0.32
" The optimum dose of chlorambucil has not been defined and there are numerous different dosing schedules available."	( High dose chlorambucil in the treatment of lymphoid malignancies. Nicolle, A; Proctor, SJ; Summerfield, GP, 2004)	0.32
" In order to decrease the toxicity of the procedure, the dosage of total body irradiation was reduced from 12 to 8 Gy and subsequently the dose of cyclophosphamide from 120 to 80 mg/kg."	( Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Kolb, HJ; Ledderose, G; Rolf, B; Schleuning, M; Schnittger, S; Schoch, C; Schwerdtfeger, R; Weisser, M, 2004)	0.32
" According to MMF pharmacokinetic studies, which showed a short half-life of its active metabolite, mycophenolic acid, we increased MMF dosing from 15 mg/kg twice daily to 15 mg/kg 3 times daily to increase immunosuppression and reduce the incidence of both graft rejection and acute GVHD."	( Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Agura, E; Blume, KG; Bruno, B; Chauncey, TR; Kliem, C; Langston, AA; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Pulsipher, M; Sandmaier, BM; Shizuru, JA; Storb, R; Storer, BE; Wade, J, 2006)	0.33
" Intravenous dosing resulted in a median area under the curve (AUC) of 28."	( Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. Brunstein, C; DeFor, T; Ebeling, B; Green, K; Jacobson, P; McGlave, P; Rogosheske, J; Weisdorf, D, 2007)	0.34
" The comparative effect of different dosage schemes, the role of possible response-prediction factors such as the endogenous erythropoietin level and the results achieved using darbopoietin alpha are reviewed."	( [Anemia in chronic lymphatic leukemia: is erythropoietin the solution?]. Bendandi, M; de Gaona, ER; Iglesias, R; Panizo, C; Pérez-Calvo, J; Rifón, J, )	0.13
" Nine patients were enrolled at increasing dosage levels of ara-C (8, 12, and 16 g/m2 per dose level)."	( Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N, 2007)	0.34
" Pharmacokinetic assays of mycophenolic acid (MPA) showed a therapeutic area under the curve (AUC) at the dosage of 3 g daily, although a large inter- and intraindividual variations of MPA plasma levels were found."	( Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D, 2008)	0.35
" However, with MTD dosing this drug ratio is not optimal to produce synergy and future studies using ratiometric dosing are required to confirm these findings."	( Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR, 2008)	0.35
" Body surface area-based dosing in the FLU/MEL regimen led to a wide range of MEL doses administered per kilogram body weight (2."	( Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Karas, M; Koza, V; Steinerova, K; Vokurka, S, 2009)	0.35
" Mean (+/-SD) elimination half-life did not differ significantly between IV and oral dosage groups (11."	( Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Greenblatt, DJ; Karyagina, EV; Lister-James, J; Lundberg, AS; Yin, W, 2010)	0.36
" These data suggest that clinical strategies are needed to optimize dosing of fludarabine to prevent overexposure and toxicity in HCT."	( High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Brunstein, CG; Cao, Q; Green, KG; Jacobson, PA; Long-Boyle, JR; McGlave, PB; Miller, JS; Rogosheske, J; Wagner, JE; Weisdorf, DJ, 2011)	0.37
" Forodesine has biologic activity in CLL; pharmacodynamic parameters suggest that an alternate dosing schedule and/or higher doses to achieve greater intracellular dGTP may be beneficial in this patient population."	( Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Balakrishnan, K; Bantia, S; Bickel, S; Chen, Y; Gandhi, V; Kantarjian, H; Keating, MJ; Kilpatrick, JM; O'Brien, S; Ravandi, F; Tyler, BF; Verma, D, 2010)	0.36
" Bu in different dosing protocols, (2) compare intrasubject variability of Bu PK over repeated administrations; (3) examine the effect of concomitant administration of fludarabine on Bu PK, and (4) examine the effect of plasma concentrations of glutathione (GSH), the cosubstrate in Bu metabolism, on Bu clearance."	( Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Almog, S; Gopher, A; Halkin, H; Hassoun, E; Kurnik, D; Loebstein, R; Nagler, A; Shimoni, A, 2011)	0.37
" A dose-response relationship between busulfan exposure and outcome is known."	( Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K, 2010)	0.36
" In the remaining 53 patients, the first-dose AUC was within the target range and no dosing adjustments were required."	( Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C, 2011)	0.37
" busulfan dosage scheme."	( Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Bae, KS; Choi, Y; Han, SB; Hur, EH; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lim, HS; Lim, SN; Noh, GJ; Yun, SC, 2011)	0.37
"Because of the less graft-facilitating effect by bone marrow (BM), we need to assess a dosage of conditioning more accurately particularly in combination with reduced-intensity conditioning."	( A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. Atsuta, Y; Imahashi, N; Ito, T; Kato, T; Miyamura, K; Morishita, Y; Murata, M; Naoe, T; Nishiwaki, S; Ohashi, H; Sawa, M; Suzuki, R; Terakura, S; Yasuda, T, 2011)	0.37
" Although alemtuzumab in relapsed/refractory CLL may be beneficial, the optimal dosage and risk of infection related to its use remain thus far deeply controversial issues."	( Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Argentieri, D; Bartomioli, M; Bezares, RF; Diaz, A; Garay, G; Milone, G; Ryser, R; Stemelin, G; Zubiaur, EL, 2011)	0.37
" Busulfan clearance was not associated with sex or age, but was associated with the day of dosing and conditioning regimen (P = ."	( Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Blough, DK; Deeg, HJ; McCune, JS; McDonald, GB; O'Donnell, PV; Pawlikowski, MA; Rezvani, A; Yeh, RF, 2012)	0.38
" Therefore, mAb therapies that rely substantially on effector mechanisms subject to exhaustion, including complement, may benefit from lower, more frequent dosing schemes optimized to sustain and maximize killing by cytotoxic immune effector systems."	( Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. Beum, PV; Beurskens, FJ; Engelberts, P; Farooqui, M; Lindorfer, MA; Mackus, WJ; Parren, PW; Taylor, RP; Wiestner, A, 2012)	0.38
" We aimed to provide a rationale for optimal dosing and scheduling of this anti-CD20 antibody based on pharmacokinetics."	( Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012)	0.38
"The results of this pilot trial suggest that more differentiated dosing schedules based on gender and bone marrow infiltration should be explored for rituximab therapy for lymphoma."	( Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012)	0.38
" This study shows that, in routine clinical practice, there is low adherence to the original MD Anderson Cancer Center fludarabine-cyclophosphamide-rituximab schedule, and that the decision to modify dosage was mostly taken by the individual physician and was based on anticipated toxicity."	( Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Borel, C; Bouvet, E; Cazin, B; Compaci, G; Laurent, G; Michallet, AS; Obéric, L; Ysebaert, L, 2013)	0.39
" Oral dosing in mice prevented BCR-mediated splenomegaly and significantly inhibited NHL tumor growth in a xenograft model."	( The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. Baker, D; Betz, A; Burke, R; Coffey, G; DeGuzman, F; Druker, BJ; Fletcher, LB; Hollenbach, SJ; Loriaux, MM; Pak, Y; Pandey, A; Sinha, U; Spurgeon, SE; Tyner, JW, 2013)	0.39
" More frequent dosing of rituximab may be required to prevent autoimmune complications in at-risk patients (clinicaltrials."	( Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Beum, PV; Lee, E; Lindorfer, MA; Marti, G; Mo, CC; Njuguna, N; Taylor, RP; Vire, B; Wiestner, A; Wilson, WH, 2013)	0.39
" As a RIC regimen for CBT, 140 mg/m(2) melphalan with fludarabine and anti-lymphocyte globulin or anti-thymocyte globulin may be feasible, but further dosage optimization should be performed in controlled clinical trials."	( Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan. Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishii, E; Kato, K; Kawa, K; Koike, K; Ohga, S; Okada, K; Sawada, A; Suzuki, N; Suzuki, R; Yabe, H; Yasutomo, K, 2013)	0.39
"We utilized a new reduced intensity conditioning (RIC) containing of new dosage of intravenous Bu (9."	( [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP, 2013)	0.39
" Overall, patients dosed by DBW were more likely to undershoot goal AUC (-12."	( Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S, 2015)	0.42
" B-cell depletion was observed along with complement consumption; median C2 and CH50 levels appeared lower during monthly dosing in patients who responded."	( An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Butler, AC; Chan, G; Fang, L; Jewell, RC; Kipps, TJ; Laubscher, KH; Lewis, E; Lindeman, R; Patton, WN; Sedoti, D; Witman, P; Zhou, YY, 2015)	0.42
" Precision dosing trials are warranted."	( Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Davies, SM; Filipovich, AH; Jodele, S; Lane, A; Marsh, RA; Mehta, PA; Neumeier, L, 2016)	0.43
" We sought to develop a model for fludarabine dosing in adult HCT recipients that would allow for precise dose targeting and predict adverse clinical outcomes."	( Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Brundage, R; Brunstein, CG; Cao, Q; Jacobson, PA; Jensen, K; Kirstein, MN; Kurtzweil, A; Long-Boyle, J; Rogosheske, J; Sanghavi, K; Wagner, J; Warlick, ED; Weisdorf, DJ; Wiseman, A, 2016)	0.43
" Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants."	( Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC, 2016)	0.43
" We previously suggested an optimal day 0 targeted range of alemtuzumab, but there are no pediatric data regarding the pharmacokinetics (PK) of subcutaneous alemtuzumab to guide precision dosing trials."	( Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. Chandra, S; Emoto, C; Fukuda, T; Khandelwal, P; Marsh, RA; Mehta, PA; Neumeier, L; Teusink-Cross, A; Vinks, AA, 2017)	0.46
" These results suggest that individualized model-based dosing of fludarabine in infants and young children may reduce morbidity and mortality through improved rates of disease-free survival and limiting drug-related toxicity."	( Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Aweeka, F; Chan, D; Cowan, MJ; Dvorak, CC; Huang, L; Ivaturi, V; Jennissen, C; Liu, T; Long-Boyle, J; Orchard, PJ; Pai, SY; Stricherz, M; Tolar, J; Wahlstrom, J, 2017)	0.46
"Unintentional passive diffusion of conventional small molecular weight pharmaceuticals across intact membranes of normal healthy cells in tissues and organ systems induces sequelae that limit therapeutic dosage and duration of administration."	( Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen. Coyne, CP; Narayanan, L, 2018)	0.48
" As no definitive pharmacokinetic (PK) basis for HCT dosing for the wide age and weight range in HCT is available, linear body surface area (BSA)-based dosing is still used."	( Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Boelens, JJ; Dorlo, TPC; Huitema, ADR; Kuball, J; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM, 2019)	0.51
" Therefore, current linear BSA-based dosing leads to highly variable exposure, which may lead to variable treatment outcome."	( Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Boelens, JJ; Dorlo, TPC; Huitema, ADR; Kuball, J; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM, 2019)	0.51
" The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure."	( Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M, 2019)	0.51
" A randomized controlled trial (RCT) comparing alternative fludarabine dosing strategies to current practice may be warranted, but should be sufficiently powered for a relevant end point, while still feasible to enroll."	( Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation. Boelens, JJ; de Witte, MA; Dorlo, TPC; Huitema, ADR; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM, 2020)	0.56
" Personalized PK-directed dosing to achieve optimal fludarabine exposure should be tested in prospective trials and, based on this analysis, may reduce disease relapse after CAR T-cell therapy."	( Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Baggott, C; Boelens, JJ; Brown, PA; Chinnabhandar, V; Curran, KJ; Egeler, E; Fabrizio, VA; Goksenin, AY; Hermiston, M; Karras, NA; Keating, AK; Krupski, C; Kunicki, M; Laetsch, TW; Mackall, CL; Margossian, SP; Mauguen, A; Mavroukakis, S; Moskop, A; Myers, GD; Pacenta, H; Phillips, CL; Prabhu, S; Qayed, M; Rabik, CA; Rossoff, J; Satwani, P; Schultz, LM; Stefanski, HE; Talano, JA; Verneris, MR; Wilcox, R, 2022)	0.72
" Fludarabine exposure, previously shown to be highly variable when dosing is based on body surface area (BSA), is a predictor for survival in allogeneic hematopoietic cell transplantation (allo-HCT)."	( Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Admiraal, R; Bierings, M; Blok, H; Calkoen, FG; De Koning, C; Dekker, L; Hoogerbrugge, P; Huitema, ADR; Jiang, Y; Lindemans, CA; Nierkens, S; Nijstad, AL; Pieters, R; Spoon, M; Van Der Elst, KCM; Van Der Vlugt, M; Van Tinteren, H; Veldkamp, SR; Visscher, H; Vormoor, B; Vormoor, HJ, 2022)	0.72
" Measured GFR (mGFR) may better predict drug dosing to mitigate toxicity and increase the chances of successful engraftment."	( Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Alkhateeb, HB; Barreto, EF; Bartoo, GT; Hogan, WJ; Kutzke, JL; Leung, N; Litzow, MR; Mangaonkar, AA; Mara, KC; Merten, JA; Pawlenty, AG; Shah, MV, 2022)	0.72
" These findings suggest that PK-directed fludarabine dosing to achieve an optimal AUC may result in improved outcomes for patients receiving axi-cel."	( Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Bachanova, V; Bishop, MR; Brower, J; Chen, AI; Devlin, SM; Flynn, JR; Gonen, M; Ip, A; Leslie, LA; Maakaron, J; Maziarz, RT; McGuirk, JP; Nastoupil, LJ; Oluwole, OO; Parascondola, A; Perales, MA; Porter, DL; Riedell, PA; Schuster, SJ; Scordo, M; Shouval, R; Tomas, AA, 2023)	0.91

Class	Description
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	112.2020	0.0447	17.8581	100.0000	AID485294
Fumarate hydratase	Homo sapiens (human)	Potency	2.0931	0.0030	8.7949	48.0869	AID1347053
TDP1 protein	Homo sapiens (human)	Potency	0.3801	0.0008	11.3822	44.6684	AID686978; AID686979
AR protein	Homo sapiens (human)	Potency	16.3430	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035
Smad3	Homo sapiens (human)	Potency	0.3820	0.0052	7.8098	29.0929	AID588855; AID720534; AID720537
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	6.3096	0.0013	7.7625	44.6684	AID914; AID915
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	5.2081	0.0010	22.6508	76.6163	AID1224838; AID1224893
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.6879	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	2.0931	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	5.1209	0.0001	8.4406	100.0000	AID720579; AID720580
IDH1	Homo sapiens (human)	Potency	2.5929	0.0052	10.8652	35.4813	AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	11.8832	0.0017	23.8393	78.1014	AID743083
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	11.0824	0.0041	9.9848	25.9290	AID504444; AID720524
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	19.4081	0.0003	23.4451	159.6830	AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	13.5929	0.0006	27.2152	1,122.0200	AID743202; AID743219
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	8.9125	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	8.9125	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	8.9125	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	7.3078	0.0046	11.3741	33.4983	AID624296
lamin isoform A-delta10	Homo sapiens (human)	Potency	35.4813	0.8913	12.0676	28.1838	AID1487
Cellular tumor antigen p53	Homo sapiens (human)	Potency	12.4003	0.0023	19.5956	74.0614	AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
corticotropin-releasing hormone receptor 2	Homo sapiens (human)	IC50 (µMol)	47.1000	0.3680	7.0955	18.0000	AID602180
corticotropin releasing factor-binding protein	Homo sapiens (human)	IC50 (µMol)	47.1000	0.3680	7.0955	18.0000	AID602180
5'-nucleotidase	Homo sapiens (human)	Ki	700.0000	0.0884	0.1656	0.5100	AID1589305; AID1589306
Adenosine receptor A3	Rattus norvegicus (Norway rat)	Ki	10.4000	0.0003	0.9196	9.0000	AID33337
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
corticotropin-releasing hormone receptor 2	Homo sapiens (human)	EC50 (µMol)	53.0000	1.1200	11.5617	36.8000	AID602473
corticotropin releasing factor-binding protein	Homo sapiens (human)	EC50 (µMol)	53.0000	1.1200	11.5617	36.8000	AID602473
glycogen synthase kinase-3 beta isoform 1	Homo sapiens (human)	EC50 (µMol)	300.0000	0.2125	22.1562	83.9400	AID434954
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
DNA metabolic process	5'-nucleotidase	Homo sapiens (human)
leukocyte cell-cell adhesion	5'-nucleotidase	Homo sapiens (human)
response to inorganic substance	5'-nucleotidase	Homo sapiens (human)
response to ATP	5'-nucleotidase	Homo sapiens (human)
ADP catabolic process	5'-nucleotidase	Homo sapiens (human)
ATP metabolic process	5'-nucleotidase	Homo sapiens (human)
adenosine biosynthetic process	5'-nucleotidase	Homo sapiens (human)
negative regulation of inflammatory response	5'-nucleotidase	Homo sapiens (human)
calcium ion homeostasis	5'-nucleotidase	Homo sapiens (human)
inhibition of non-skeletal tissue mineralization	5'-nucleotidase	Homo sapiens (human)
AMP catabolic process	5'-nucleotidase	Homo sapiens (human)
adenosine catabolic process	Adenosine deaminase	Bos taurus (cattle)
cell adhesion	Adenosine deaminase	Bos taurus (cattle)
nucleotide metabolic process	Adenosine deaminase	Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic process	Adenosine deaminase	Bos taurus (cattle)
inosine biosynthetic process	Adenosine deaminase	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide binding	5'-nucleotidase	Homo sapiens (human)
5'-deoxynucleotidase activity	5'-nucleotidase	Homo sapiens (human)
protein binding	5'-nucleotidase	Homo sapiens (human)
5'-nucleotidase activity	5'-nucleotidase	Homo sapiens (human)
zinc ion binding	5'-nucleotidase	Homo sapiens (human)
identical protein binding	5'-nucleotidase	Homo sapiens (human)
thymidylate 5'-phosphatase activity	5'-nucleotidase	Homo sapiens (human)
IMP 5'-nucleotidase activity	5'-nucleotidase	Homo sapiens (human)
GMP 5'-nucleotidase activity	5'-nucleotidase	Homo sapiens (human)
XMP 5'-nucleosidase activity	5'-nucleotidase	Homo sapiens (human)
adenosine deaminase activity	Adenosine deaminase	Bos taurus (cattle)
protein binding	Adenosine deaminase	Bos taurus (cattle)
zinc ion binding	Adenosine deaminase	Bos taurus (cattle)
2'-deoxyadenosine deaminase activity	Adenosine deaminase	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	5'-nucleotidase	Homo sapiens (human)
nucleoplasm	5'-nucleotidase	Homo sapiens (human)
cytosol	5'-nucleotidase	Homo sapiens (human)
plasma membrane	5'-nucleotidase	Homo sapiens (human)
external side of plasma membrane	5'-nucleotidase	Homo sapiens (human)
cell surface	5'-nucleotidase	Homo sapiens (human)
membrane	5'-nucleotidase	Homo sapiens (human)
extracellular exosome	5'-nucleotidase	Homo sapiens (human)
lysosome	Adenosine deaminase	Bos taurus (cattle)
cytoplasmic vesicle lumen	Adenosine deaminase	Bos taurus (cattle)
anchoring junction	Adenosine deaminase	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1346136	Human ribonucleotide reductase regulatory subunit M2 (Nucleoside synthesis and metabolism)	1982	Molecular pharmacology, Mar, Volume: 21, Issue:2	In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
AID1346042	Human ribonucleotide reductase catalytic subunit M1 (Nucleoside synthesis and metabolism)	1982	Molecular pharmacology, Mar, Volume: 21, Issue:2	In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1223762	Antitumor activity against CLL1 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID341996	Antimicrobial activity against Streptococcus sp. 07941-1 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID33337	Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat adenosine A3 receptor	1995	Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7	Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1196587	Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID1196581	Cytotoxicity against human HL60 cells after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID1196584	Cytotoxicity against human SUDHL9 cells after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1196585	Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID1196583	Cytotoxicity against human SU-DHL6 cells after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID1222933	Apparent volume of distribution at steady state in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in presence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1370965	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
AID510575	Cell cycle arrest in human CEM cells assessed as accumulation at G2/M phase using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1223763	Antitumor activity against CLL2 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1222920	Tmax in CD-1 mouse brain at 60 mg/kg, iv administered as bolus dose in presence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID477295	Octanol-water partition coefficient, log P of the compound	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID96165	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay	2003	Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5	Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines.
AID1223766	Antitumor activity against CLL3 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1197746	Stimulation of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID342000	Antimicrobial activity against Staphylococcus aureus CCM 885 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID634635	Activity of Escherichia coli PNP assessed per mg of protein at 100 uM by UV spectrometric analysis	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID510579	Inhibition of DNA synthesis in human CEM cells assessed as BrDU incorporation using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID229569	Ratio of kinetic parameters Vmax to the of Km.	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1174818	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID766997	Inhibition of spliceosome-mediated splicing of DNAJB1 gene in human B-CLL cells at 10 uM after 4 hrs by RT-PCR analysis	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Stabilized cyclopropane analogs of the splicing inhibitor FD-895.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1370962	Antiproliferative activity against human HuH7 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
AID510576	Inhibition of RNA synthesis in human CEM cells assessed as BrU incorporation using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1370967	Antiproliferative activity against human FOCUS cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
AID1370964	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510566	Cytotoxicity against human K562 cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1222939	Elimination half life in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in absence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID1222924	Cmax in CD-1 mouse brain at 60 mg/kg, iv administered as bolus dose in presence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID1160916	Cytotoxicity against human primary CLL cells	2014	Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18	Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1222936	Apparent total clearance in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in presence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID1222913	Drug transport in human CCRF-CEM cells assessed as ENT1-mediated uptake at 10 uM after 1 to 60 mins by liquid scintillation counting analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID31885	Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.	1995	Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7	Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID510577	Inhibition of RNA synthesis in human CEM cells assessed as BrU incorporation using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510574	Cell cycle arrest in human CEM cells assessed as accumulation at G2/M phase using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1222926	AUC (0 to 4 hrs) in CD-1 mouse brain at 60 mg/kg, iv administered as bolus dose in absence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID33838	Kinetic parameter was determined against adenosine deaminase expressed as Vmax	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.
AID96168	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay	2003	Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5	Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines.
AID341999	Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1589305	Competitive type of inhibition of human 5'-nucleotidase using IMP as substrate assessed as inhibitor constant for free enzyme by Lineweaver-Burk plot analysis	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Lead optimization and biological evaluation of fragment-based cN-II inhibitors.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID510573	Cell cycle arrest in human CEM cells assessed as accumulation at S phase using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1222923	Cmax in CD-1 mouse brain at 60 mg/kg, iv administered as bolus dose in absence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1222935	Apparent total clearance in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in absence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID510581	Induction of mitotic arrest in human CEM cells assessed as pH3Ser10 positive cells at 5 times IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID94831	Compound was tested for cytotoxicity against K562 cell lines	1992	Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2	Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.
AID1589306	Non-competitive type of inhibition of human 5'-nucleotidase using IMP as substrate assessed as inhibitor constant for enzyme substrate complex by Lineweaver-Burk plot analysis	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Lead optimization and biological evaluation of fragment-based cN-II inhibitors.
AID510565	Cytotoxicity against human CEM-DNR-B cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID341995	Antimicrobial activity against Escherichia coli ATCC 25922 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID510563	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1196579	Cytotoxicity against human CCRF-CEM cells after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1223765	Antitumor activity against human HeLa cells assessed as cell viability by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1222932	Apparent volume of distribution at steady state in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in absence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID1222919	Tmax in CD-1 mouse brain at 60 mg/kg, iv administered as bolus dose in absence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID33816	Kinetic parameter was determined against adenosine deaminase expressed as Km	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.
AID1222943	AUC (0 to infinity) in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in absence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1370963	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
AID1223764	Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID81745	Compound was tested for cytotoxicity against HEp-2 cell lines	1992	Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2	Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.
AID1174817	Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.
AID96710	Compound was tested for cytotoxicity against L1210 cell lines	1992	Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2	Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1370966	Antiproliferative activity against human Mahlavu cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
AID96327	Percent inhibition of [3H]-thymidine incorporation was determined in human chronic myelogenous leukemic K-562 cell line at 10 ug/mL after 48 hr	2003	Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5	Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines.
AID1222928	AUC (0 to 4 hrs) in CD-1 mouse brain at 60 mg/kg, iv administered as bolus dose in presence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID1222940	Elimination half life in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in presence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID44000	Compound was tested for cytotoxicity against CCRF-CEM cell lines	1992	Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2	Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510578	Inhibition of DNA synthesis in human CEM cells assessed as BrDU incorporation using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID510568	Induction of apoptosis in human CEM cells using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510572	Cell cycle arrest in human CEM cells assessed as accumulation at S phase using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID510567	Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID341997	Antimicrobial activity against Streptococcus sp. 07706-1 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID510570	Cell cycle arrest in human CEM cells assessed as accumulation at G0/G1 phase using propidium iodide staining at IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1196582	Cytotoxicity against human K562 cells after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID1223768	Antitumor activity against CLL5 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID341998	Antimicrobial activity against Streptococcus sp. 07686-2 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID510580	Induction of mitotic arrest in human CEM cells assessed as pH3Ser10 positive cells at IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510571	Cell cycle arrest in human CEM cells assessed as accumulation at G0/G1 phase using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1223769	Antitumor activity against CLL6 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID510569	Induction of apoptosis in human CEM cells using propidium iodide staining at 5 times IC50 concentration after 24 hrs by flow cytometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID510564	Cytotoxicity against human CEM cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.
AID1196586	Cytotoxicity against healthy human PBMC after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID342001	Antimicrobial activity against Streptococcus pyogenes AP1 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1223767	Antitumor activity against CLL4 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1196580	Cytotoxicity against human Jurkat cells after 48 hrs by CellTitre-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells.
AID33792	Binding affinity to adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand	1995	Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7	Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID1222944	AUC (0 to infinity) in CD-1 mouse at 60 mg/kg, iv administered as bolus dose in presence of ENT1 inhibitor NBMPR-P	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.
AID1174819	Cytotoxicity against human T47D cells after 72 hrs by SRB assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347137	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	25 (0.74)	18.7374
1990's	434 (12.92)	18.2507
2000's	1337 (39.80)	29.6817
2010's	1302 (38.76)	24.3611
2020's	261 (7.77)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	812 (23.52%)	5.53%
Reviews	330 (9.56%)	6.00%
Case Studies	578 (16.74%)	4.05%
Observational	16 (0.46%)	0.25%
Other	1,716 (49.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1439)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma [NCT00958854]	Phase 2	37 participants (Anticipated)	Interventional	2006-01-31	Recruiting
A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma [NCT05155215]	Phase 1/Phase 2	68 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma [NCT05182073]	Phase 1	168 participants (Anticipated)	Interventional	2021-11-24	Recruiting
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) [NCT01088724]	Phase 4	4 participants (Actual)	Interventional	2002-02-28	Completed
A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus [NCT00076752]	Phase 2	9 participants (Actual)	Interventional	2004-01-30	Completed
A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Subjects With Relapsed/Refractory Multiple Myeloma [NCT03943472]	Early Phase 1	10 participants (Anticipated)	Interventional	2019-07-08	Recruiting
A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia [NCT03937544]	Phase 2/Phase 3	10 participants (Anticipated)	Interventional	2019-03-19	Recruiting
A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia [NCT00086580]	Phase 3	335 participants (Actual)	Interventional	2004-07-31	Completed
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome [NCT00074490]	Phase 2	442 participants (Actual)	Interventional	2004-01-01	Terminated(stopped due to Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2)
Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma [NCT03448978]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2018-02-26	Completed
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy [NCT00303719]	Phase 2	342 participants (Actual)	Interventional	2002-03-26	Terminated(stopped due to IRB Study Closure)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301) [NCT00326417]	Phase 1/Phase 2	97 participants (Actual)	Interventional	2006-01-31	Completed
A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML [NCT06158828]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies [NCT05694364]	Phase 1	88 participants (Anticipated)	Interventional	2023-01-25	Recruiting
A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations [NCT05521087]	Phase 1	80 participants (Anticipated)	Interventional	2024-05-29	Not yet recruiting
A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma [NCT05347485]	Phase 2	86 participants (Actual)	Interventional	2022-05-13	Active, not recruiting
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) [NCT04923893]	Phase 3	650 participants (Anticipated)	Interventional	2021-08-19	Recruiting
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies [NCT04904588]	Phase 2	300 participants (Anticipated)	Interventional	2021-09-30	Recruiting
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL) [NCT02048813]	Phase 3	529 participants (Actual)	Interventional	2014-02-20	Active, not recruiting
Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma [NCT01124526]	Phase 4	75 participants (Actual)	Interventional	2004-09-30	Completed
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases [NCT05805605]	Phase 2	56 participants (Anticipated)	Interventional	2023-05-01	Recruiting
A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors [NCT05678205]	Phase 1/Phase 2	133 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and Thiotepa [NCT03980769]	Phase 2	40 participants (Anticipated)	Interventional	2021-05-05	Recruiting
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) [NCT01027000]	Phase 2	68 participants (Actual)	Interventional	2010-02-28	Completed
Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION) [NCT05352828]	Phase 1	15 participants (Actual)	Interventional	2022-07-25	Active, not recruiting
Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia [NCT01145976]	Phase 3	98 participants (Anticipated)	Interventional	2010-03-31	Recruiting
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study [NCT04375631]	Phase 1	120 participants (Anticipated)	Interventional	2020-12-03	Recruiting
Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma [NCT01156350]	Phase 2	10 participants (Anticipated)	Interventional	2011-09-30	Not yet recruiting
COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation [NCT02431988]	Phase 1	10 participants (Actual)	Interventional	2016-06-30	Completed
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies [NCT02333162]	Phase 1	30 participants (Anticipated)	Interventional	2014-12-05	Recruiting
Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP) (BMT CTN 1502) [NCT02918292]	Phase 2	32 participants (Actual)	Interventional	2017-07-03	Completed
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen [NCT02722668]	Phase 2	16 participants (Actual)	Interventional	2017-05-15	Active, not recruiting
A Multicenter, Prospective, Non-randomized, Phase I-II Trial to Assess the Efficacy and Safety of the Combination of Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients [NCT04112589]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2019-12-26	Active, not recruiting
A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors [NCT03615144]	Phase 2	1 participants (Actual)	Interventional	2018-07-23	Terminated(stopped due to Participant accrual low and the study was closed)
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances [NCT05110742]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer [NCT04639245]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2021-07-19	Terminated(stopped due to Terminated due to slow accrual.)
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation [NCT03622788]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2019-08-08	Recruiting
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML) [NCT02642965]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2016-05-02	Completed
Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia [NCT01129323]		0 participants (Actual)	Interventional	2009-11-30	Withdrawn(stopped due to This study did not accrue any subjects and due to this will be closed.)
A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis [NCT02528877]	Phase 1	0 participants (Actual)	Interventional	2015-11-30	Withdrawn(stopped due to The study design was revised so a new protocol will be opened.)
Population Pharmacokinetics of the Nucleoside Analogues Clofarabine and Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation (alloHCT) [NCT03609814]		30 participants (Actual)	Observational	2016-01-26	Completed
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma [NCT01758328]	Phase 1	29 participants (Anticipated)	Interventional	2012-12-31	Active, not recruiting
A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vacci [NCT01312376]	Phase 1	18 participants (Actual)	Interventional	2011-03-31	Terminated
A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen Receptor [NCT03338972]	Phase 1	28 participants (Actual)	Interventional	2017-11-29	Completed
Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia [NCT00448019]	Phase 2	64 participants (Actual)	Interventional	2007-02-28	Completed
Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Dis [NCT04633148]	Phase 1	51 participants (Anticipated)	Interventional	2020-11-23	Recruiting
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4) [NCT04196491]	Phase 1	13 participants (Actual)	Interventional	2020-05-27	Completed
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency [NCT01176006]	Phase 2	90 participants (Anticipated)	Interventional	2010-10-05	Recruiting
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT) [NCT06028828]	Phase 2	60 participants (Anticipated)	Interventional	2023-09-11	Recruiting
Pilot Open-label Trial of Nivolumab Combined With Chemotherapy in Refractory Myelodysplastic Syndromes. [NCT03259516]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-05-25	Terminated(stopped due to Slow recruitment rate)
Genetically Engineered T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor for Treatment of Patients With B Cell Malignancies [NCT02456350]	Phase 1	36 participants (Anticipated)	Interventional	2015-04-30	Recruiting
Phase II Multicentric, Randomized Trial, Exploring Intensified Rituximab Prephase Monotherapy Before Standard Fludarabine-Cyclophosphamide-Rituximab Regimen in Previously Untreated Symptomatic B-cell Chronic Lymphocytic Leukemia [NCT01370772]	Phase 2	140 participants (Actual)	Interventional	2011-05-31	Completed
Phase I Study to Evaluate the Safety and Effectiveness of Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory Acute Myeloid Leukemia [NCT05008575]	Phase 1	27 participants (Anticipated)	Interventional	2021-12-23	Recruiting
Single Center Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells (NRTs) Combined With Programmed Cell Death-1（PD-1） Inhibitor in the Treatment of Chinese Patients With Advanced Refractory Solid Tumors [NCT03171220]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2017-06-01	Recruiting
Phase I/II Clinical Study to Evaluate the Safety and Efficacy of IM19 Chimeric Antigen Receptor T Cells(CAR-T) in the Treatment of Recurrent or Refractory (R/R) CD19 Positive Aggressive Non-Hodgkin's Lymphoma [NCT04440436]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2020-06-04	Recruiting
Phase I Dose-Escalation Study of BCMA/CS1 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for Relapsed/Refractory Multiple Myeloma [NCT05950113]	Phase 1	30 participants (Anticipated)	Interventional	2024-03-28	Not yet recruiting
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR [NCT05714345]	Phase 2	70 participants (Anticipated)	Interventional	2023-03-31	Recruiting
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations [NCT05624554]	Phase 3	300 participants (Anticipated)	Interventional	2023-03-16	Recruiting
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory H [NCT05400122]	Phase 1	12 participants (Anticipated)	Interventional	2022-09-09	Suspended(stopped due to Insufficient staff)
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML [NCT05183035]	Phase 3	98 participants (Anticipated)	Interventional	2022-10-01	Recruiting
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma [NCT04880434]	Phase 2	90 participants (Anticipated)	Interventional	2021-04-27	Active, not recruiting
TCRαβ+ T-cell/CD19+ B-cell Depleted Hematopoietic Grafts and a Reduced Intensity Preparative Conditioning Regimen Containing JSP191 (Briquilimab) to Achieve Engraftment and Blood Reconstitution in Patients With Fanconi Anemia [NCT04784052]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2021-12-07	Recruiting
A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [NCT04545762]	Phase 1	36 participants (Anticipated)	Interventional	2020-09-11	Recruiting
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors [NCT04526509]	Phase 1	11 participants (Actual)	Interventional	2020-12-21	Active, not recruiting
Allogeneic Hematopoietic Cell Transplantation With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings [NCT00603954]	Phase 2	107 participants (Actual)	Interventional	2008-01-31	Completed
Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma [NCT03706547]	Phase 1	20 participants (Anticipated)	Interventional	2018-10-30	Not yet recruiting
A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors [NCT04319757]	Phase 1	36 participants (Anticipated)	Interventional	2020-05-19	Recruiting
Open-Label Phase 1b/2a Clinical Trial to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells (GSK3377794) in Combination With Anti-Cancer Agents Including Pembrolizumab in HLA-A2+ Participants [NCT03697824]	Phase 2	0 participants (Actual)	Interventional	2019-02-25	Withdrawn(stopped due to Internal decision, study will be replaced with a larger monotherapy trial)
Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease [NCT04224558]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2020-12-15	Recruiting
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes [NCT02224872]	Phase 2	18 participants (Actual)	Interventional	2014-08-31	Completed
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma [NCT03318861]	Phase 1	17 participants (Actual)	Interventional	2017-10-20	Terminated(stopped due to The study was terminated due to lack of efficacy)
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901) [NCT01339910]	Phase 3	272 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Accrual terminated as recommended by the data and safety monitoring board.)
Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC [NCT01303887]	Phase 3	680 participants (Anticipated)	Interventional	2009-10-31	Recruiting
Multi-center, Phase II Study to Assess the Safety and Efficacy of Haploidentical Bone Marrow Transplantation Using Reduced Intensity Conditioning(RIC)Regimen and Post-transplant Cyclophosphamide,in Patients With Poor Prognosis Lymphomas [NCT02049580]	Phase 2	47 participants (Anticipated)	Interventional	2013-07-31	Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (RHIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid [NCT02781467]	Phase 1	10 participants (Actual)	Interventional	2016-07-11	Terminated(stopped due to Business Decision)
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML [NCT02057770]	Phase 1	25 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Low accrual rate)
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade [NCT02070406]	Phase 1	4 participants (Actual)	Interventional	2014-07-17	Terminated(stopped due to low accrual)
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors [NCT04596033]	Phase 1	49 participants (Actual)	Interventional	2020-11-11	Terminated(stopped due to Business reasons)
Multi-center, Investigator Initiated Phase 1 Study of MAGE-A4 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors [NCT02096614]	Phase 1	18 participants (Actual)	Interventional	2014-04-30	Completed
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms [NCT06034470]	Phase 1	30 participants (Anticipated)	Interventional	2024-01-13	Recruiting
An Open-label, Phase II, Two-stage, Study of Bisantrene(Xantrene) in Combination With Fludarabine and Clofarabine as Salvage Therapy for Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT04989335]	Phase 2	29 participants (Anticipated)	Interventional	2021-08-02	Recruiting
A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia [NCT04881240]	Phase 1	60 participants (Anticipated)	Interventional	2023-12-31	Recruiting
Phase 1 Study of the Administration of T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [NCT04223765]	Phase 1	20 participants (Anticipated)	Interventional	2020-11-12	Recruiting
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT03813147]	Phase 1	12 participants (Actual)	Interventional	2019-05-17	Active, not recruiting
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [NCT03204188]	Phase 2	15 participants (Actual)	Interventional	2017-09-22	Active, not recruiting
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [NCT01145209]	Phase 2	32 participants (Actual)	Interventional	2010-07-01	Completed
Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in Refractory/Relapsed Acute Lymphoblastic Leukemia [NCT05578378]	Phase 2/Phase 3	32 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Population Pharmacokinetics of Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation [NCT01316549]		67 participants (Actual)	Observational	2011-01-01	Completed
Shortened-duration Tacrolimus Following Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide [NCT01342289]	Phase 1	127 participants (Actual)	Interventional	2011-08-31	Completed
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease [NCT02061800]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2013-06-03	Recruiting
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN 1302) [NCT02440464]	Phase 2	57 participants (Actual)	Interventional	2015-08-31	Completed
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units [NCT00547196]		10 participants (Actual)	Interventional	2005-08-16	Active, not recruiting
A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation [NCT03602898]	Phase 2	0 participants (Actual)	Interventional	2021-06-01	Withdrawn(stopped due to Insufficient funding)
A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL Patients [NCT05370547]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2022-05-25	Recruiting
Phase I Trial of Escalated Doses of Targeted Marrow Irradiation (TMI) Combined With Fludarabine and Busulfan as Conditioning Regimen for Allogeneic Hematopoietic Progenitor Cell Transplantation [NCT02129582]	Phase 1	14 participants (Actual)	Interventional	2014-11-05	Completed
Donor-Derived Very-Rapid Manufactured CD19-Specific T Cells for Lymphoid Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation [NCT03579888]	Phase 1	4 participants (Actual)	Interventional	2020-06-26	Terminated(stopped due to Study halted prematurely)
A Multicenter, Open-label, Expanded Access Study of KTE-X19 for the Treatment of Subjects With Relapsed/Refractory B-Cell Malignancies [NCT04162756]		0 participants	Expanded Access		Approved for marketing
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma [NCT01343043]	Phase 1	50 participants (Actual)	Interventional	2012-09-27	Completed
A Phase I/II Clinical Trial of NK Cells Administration to Prevent Disease Relapse for Patient With High-Risk Myeloid Malignancies Undergoing Haploidentical Stem-Cell Transplantation [NCT01904136]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2014-04-22	Completed
Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With S [NCT05949125]	Phase 1	37 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial [NCT05020392]	Phase 3	24 participants (Anticipated)	Interventional	2021-09-14	Recruiting
Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study [NCT05598593]	Phase 2	70 participants (Anticipated)	Interventional	2022-10-23	Recruiting
Observational Study of Low Dose FCR in the Treatment of Elderly/Comorbid Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: The Q-lite Project [NCT02156726]		200 participants (Anticipated)	Observational	2011-03-31	Active, not recruiting
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source [NCT02167958]	Phase 1	28 participants (Actual)	Interventional	2015-02-11	Completed
A Safety and Efficacy Study of Autologous Chimeric Antigen Receptor Engineered T Cells Redirected to EGFRvIII in Patients With Recurrent Glioblastoma Multiforme [NCT02844062]	Phase 1	20 participants (Anticipated)	Interventional	2016-07-31	Recruiting
A Phase I Clinical Trial of Human CD19/BCMA Bispecific CAR-T Cell Therapy for Subjects With Relapsed and Refractory POMES Syndrome. [NCT03879382]	Phase 1	10 participants (Anticipated)	Interventional	2019-02-27	Active, not recruiting
Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia [NCT05665114]	Phase 1	18 participants (Anticipated)	Interventional	2022-12-24	Recruiting
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies [NCT00145626]	Phase 2	40 participants (Actual)	Interventional	2004-05-31	Completed
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas [NCT04848064]	Phase 1	12 participants (Anticipated)	Interventional	2022-05-06	Recruiting
Safety and Efficacy of Ex-vivo Expanded Allogeneic γδ T-lymphocytes (OmnImmune®) in Patients With Active Relapsed or Refractory Acute Myeloid Leukaemia (AML) Who Are Not Eligible for or do Not Consent to High Dose Salvage Chemotherapy and/or Allogeneic Ha [NCT03790072]	Phase 1	10 participants (Actual)	Interventional	2018-11-27	Completed
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source [NCT01028716]	Phase 2	46 participants (Actual)	Interventional	2010-05-19	Terminated(stopped due to The study experienced lower accrual rates after the onset of COVID. Upon review of the collected data it was deemed that an adequate amount of subjects has been enrolled to date to assess study aims.)
A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma [NCT00117156]	Phase 2	26 participants (Actual)	Interventional	2003-12-31	Completed
A Phase I/II Study of Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients With Chronic Lymphocytic Leukemia [NCT00096018]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2002-05-31	Completed
Phase 1 and 2 Study of Combination Treatment of Bortezomib, Fludarabine and Cyclophosphamide in Patients With Recurrent Mantle Cell Lymphoma [NCT01322776]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2011-03-31	Recruiting
Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis [NCT01087398]	Phase 2/Phase 3	10 participants (Anticipated)	Interventional	2009-09-30	Recruiting
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes [NCT00393029]	Phase 2	12 participants (Actual)	Interventional	2006-10-31	Completed
Randomized Trial of Unmanipulated Versus Expanded Cord Blood [NCT00067002]	Phase 2	110 participants (Actual)	Interventional	2003-04-30	Completed
HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial [NCT05586074]	Phase 3	324 participants (Anticipated)	Interventional	2023-03-03	Recruiting
Total Body Irradiation/ Fludarabine/ Busulfan/ Cyclophosphamide (TFBC) Combined With Umbilical Cord Blood Transplantation (UCBT) in the Treatment of High-risk Malignant Hematological Diseases [NCT05929092]		40 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [NCT05631912]	Phase 1/Phase 2	38 participants (Anticipated)	Interventional	2023-06-30	Recruiting
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma [NCT03391466]	Phase 3	359 participants (Actual)	Interventional	2018-01-25	Active, not recruiting
A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes [NCT03121014]	Phase 2	38 participants (Anticipated)	Interventional	2017-04-24	Recruiting
A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in [NCT02950051]	Phase 3	926 participants (Actual)	Interventional	2016-12-13	Active, not recruiting
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen [NCT00719888]	Phase 2	135 participants (Actual)	Interventional	2005-11-18	Active, not recruiting
Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphoh [NCT00027560]	Phase 2	51 participants (Actual)	Interventional	2001-07-31	Completed
Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF [NCT04339101]	Phase 2	59 participants (Actual)	Interventional	2020-11-11	Active, not recruiting
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types [NCT03610490]	Phase 2	27 participants (Actual)	Interventional	2018-08-17	Active, not recruiting
Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan,Cladribine, and Fludarabine Conditioning in Patients With AML and MDS [NCT02250937]	Phase 2	116 participants (Anticipated)	Interventional	2014-10-27	Active, not recruiting
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies [NCT04282174]	Phase 2	0 participants (Actual)	Interventional	2022-09-30	Withdrawn(stopped due to Study was split into two new studies before the first participant was enrolled.)
A Phase I Study to Examine the Toxicity of Allogeneneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewings [NCT02472392]	Phase 1	10 participants (Anticipated)	Interventional	2013-04-30	Completed
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma [NCT04706936]	Phase 1	25 participants (Anticipated)	Interventional	2021-04-01	Recruiting
A Phase I Safety and Feasibility Study of Cellular Immunotherapy for Extensive Stage Small Cell Neuroendocrine Prostate Cancer Using Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptor [NCT06094842]	Phase 1	20 participants (Anticipated)	Interventional	2024-03-01	Not yet recruiting
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies [NCT05327023]	Phase 1/Phase 2	430 participants (Anticipated)	Interventional	2022-05-23	Recruiting
Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells [NCT05088356]	Phase 1	40 participants (Anticipated)	Interventional	2021-09-07	Recruiting
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases [NCT04965597]	Phase 2	40 participants (Anticipated)	Interventional	2022-04-19	Recruiting
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies [NCT04088864]	Phase 1	52 participants (Anticipated)	Interventional	2020-01-10	Suspended(stopped due to Business decision)
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [NCT02514083]	Phase 2	29 participants (Actual)	Interventional	2015-12-09	Active, not recruiting
Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose IL-2 in Patients With Metastatic Melanoma [NCT02500576]	Phase 2	18 participants (Actual)	Interventional	2015-08-07	Completed
Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Bone Marrow (or Mobilized Peripheral Blood) Transplantation in Severe Aplastic Anemia [NCT00737685]	Phase 2	30 participants (Anticipated)	Interventional	2006-01-31	Active, not recruiting
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia [NCT00924170]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2008-10-31	Completed
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML [NCT03384212]	Phase 3	120 participants (Anticipated)	Interventional	2016-08-01	Recruiting
Phase I Study of Malignancies That Express NY-ESO-1 With T Cell Receptor-transduced T Cells Targeting NY-ESO-1 [NCT02457650]	Phase 1	36 participants (Anticipated)	Interventional	2015-04-30	Recruiting
Pilot Study of Autologous Anti-CD19 4-1BB CAR T Cells With Cell-intrinsic PD1 Inhibition in Relapsed or Refractory B-cell Lymphoma [NCT03208556]	Phase 1	20 participants (Anticipated)	Interventional	2017-06-21	Recruiting
Decitabine+ Fludarabine+Busulfan Conditioning Regimen for Elderly Acute Myeloid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT03530085]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2018-06-15	Recruiting
3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS TO TREAT CHILDREN WITH NEUROBLASTOMA (GINAKIT) [NCT02439788]	Phase 1	0 participants (Actual)	Interventional	2017-08-31	Withdrawn(stopped due to Based on newly available preclinical data we changed the CAR construct to a more effective version and will now study that product on a different protocol.)
An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A [NCT02406092]	Phase 3	122 participants (Actual)	Interventional	2015-10-13	Completed
A PHASE III, MULTICENTRE, RANDOMIZED, OPEN LABEL CLINICAL TRIAL OF AZACYTIDINE (VIDAZA®) VERSUS FLUDARABINE AND CYTARABINE (FLUGA SCHEME) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. [NCT02319135]	Phase 3	289 participants (Actual)	Interventional	2014-10-31	Completed
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies [NCT01652092]		30 participants (Anticipated)	Interventional	2012-09-04	Recruiting
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS [NCT01898793]	Phase 1/Phase 2	89 participants (Actual)	Interventional	2014-08-11	Terminated(stopped due to Insufficient funding/staff)
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy [NCT03674411]	Phase 2	22 participants (Actual)	Interventional	2019-01-02	Active, not recruiting
The Safety,Tolerance and Efficacy of Neoantigen Targeting T Cells Suspension for Intravenous Infusion(Neo-T) to Advanced Solid Tumor [NCT05798546]	Phase 1	21 participants (Anticipated)	Interventional	2022-09-28	Recruiting
Prospective, Single-center, Single-arm, Open-label Study of Obinutuzumab, Zanubrutinib and Lenalidomide Sequential CD19/CD22 CAR-T in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [NCT05797948]		20 participants (Anticipated)	Interventional	2022-07-01	Enrolling by invitation
Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma [NCT05703854]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2023-03-29	Recruiting
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML [NCT04354025]	Phase 2	0 participants (Actual)	Interventional	2023-06-30	Withdrawn(stopped due to Principal investigator decided not to move forward with the study.)
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]	Phase 2	66 participants (Actual)	Interventional	2010-12-14	Completed
Multi-center, Investigator Initiated Phase 1 Study of NY-ESO-1 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors [NCT02366546]	Phase 1	9 participants (Actual)	Interventional	2015-03-31	Active, not recruiting
A Pilot Study of EBV-TCR-T(YT-E001) in NPC Patients [NCT03648697]	Phase 2	20 participants (Anticipated)	Interventional	2018-10-10	Recruiting
CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies [NCT02529813]	Phase 1	26 participants (Actual)	Interventional	2015-12-16	Completed
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis [NCT03426969]	Early Phase 1	3 participants (Actual)	Interventional	2018-01-31	Completed
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome [NCT02328950]		50 participants (Anticipated)	Observational	2014-12-31	Recruiting
Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients [NCT03142646]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2016-08-30	Recruiting
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058) [NCT05849662]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRαβ+ T-cell/CD19+ B-cell Depletion for Patients Who Will Receive a Kidney Transplant (KT) From the Same HSCT/KT [NCT05508009]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2023-01-10	Recruiting
Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission. [NCT01191957]	Phase 3	252 participants (Actual)	Interventional	2008-01-31	Completed
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [NCT05092451]	Phase 1/Phase 2	94 participants (Anticipated)	Interventional	2022-11-01	Recruiting
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutate [NCT03591510]	Phase 2	23 participants (Anticipated)	Interventional	2019-03-13	Recruiting
Co-stimulation With Ipilimumab to Enhance Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma [NCT01701674]		13 participants (Actual)	Interventional	2012-10-09	Active, not recruiting
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia [NCT05519384]	Early Phase 1	12 participants (Anticipated)	Interventional	2022-09-14	Recruiting
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell [NCT01773395]	Phase 2	123 participants (Actual)	Interventional	2013-01-08	Terminated(stopped due to Recommendation by the Data and Safety Monitoring Board due to efficacy concerns)
Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome [NCT00357565]	Phase 2	20 participants (Anticipated)	Interventional	2005-11-30	Recruiting
An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML [NCT03661515]	Phase 1	16 participants (Actual)	Interventional	2018-07-17	Completed
Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Solid Tumor [NCT03658785]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2018-12-10	Not yet recruiting
A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer [NCT05225363]	Phase 1	33 participants (Anticipated)	Interventional	2022-05-05	Recruiting
A Phase 2 Clinical Trial to Evaluate the Efficacy of Zanubrutinib Followed Zanubrutinib Plus FCR (Fludarabine Cyclophosphamide and Rituximab) / BR(Bendamustine and Rituximab) in Newly Diagnosed Symptomatic CLL/SLL (STOP Trial) [NCT05287984]	Phase 2	63 participants (Anticipated)	Interventional	2022-03-22	Not yet recruiting
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) o [NCT04030195]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2020-03-24	Completed
High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation [NCT02294552]	Phase 2	200 participants (Actual)	Interventional	2014-10-31	Completed
A Single Center, Open Label, Single Arm Exploratory Clinical Study of CD19-Directed Allogeneic Chimeric Antigen Receptor CART-cell Immunotherapy Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia [NCT04173988]	Early Phase 1	6 participants (Anticipated)	Interventional	2020-01-09	Recruiting
Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells as Immunotherapy for Patients With Pediatric Solid Tumors [NCT02932956]	Phase 1	10 participants (Actual)	Interventional	2018-12-17	Active, not recruiting
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Relapse and Refractory Patients With CD19+/CD20+ Non-Hodgkin's Lymphoma (NHL) [NCT06160362]		20 participants (Anticipated)	Interventional	2023-10-31	Recruiting
A Study to Infuse ROR1-Specific Autologous T Cells for Patients With Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) [NCT02194374]	Phase 1	0 participants (Actual)	Interventional	2015-01-31	Withdrawn(stopped due to Study closed with no enrollment due to unavailability of reagent.)
Fludarabine-Based Conditioning for Matched Related Donor Bone Marrow Transplantation in Patients With Bone Marrow Failure Syndromes [NCT02928991]	Early Phase 1	75 participants (Anticipated)	Interventional	2015-04-30	Recruiting
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells as Immunotherapy for Patients With Hepatocellular Carcinoma [NCT02905188]	Phase 1	9 participants (Actual)	Interventional	2019-03-28	Completed
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies [NCT01664910]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2012-10-29	Completed
Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation [NCT01338987]	Phase 2	76 participants (Actual)	Interventional	2011-04-19	Completed
Phase I Clinical Trial of Human AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) [NCT04732845]	Phase 1	36 participants (Anticipated)	Interventional	2021-04-26	Recruiting
Phase I Clinical Trial of AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non Hodgkin Lymphoma [NCT03434769]	Phase 1	31 participants (Actual)	Interventional	2018-07-09	Active, not recruiting
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease [NCT01659606]	Phase 2	40 participants (Anticipated)	Interventional	2012-07-31	Active, not recruiting
A Phase 1/2 Trial of Uproleselan Combined With High Dose Busulfan Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for Patients With Chemotherapy Resistant Acute Myeloid Leukemia [NCT05569512]	Phase 1/Phase 2	28 participants (Anticipated)	Interventional	2022-10-06	Recruiting
PNOC018 A Phase 1 Clinical Trial of Autologous T Cells Expressing a TCR Specific for H3.3K27M With Inhibition of Endogenous TCR (KIND T Cells) in HLA-A*0201-positive Participants With Newly Diagnosed H3.3K27M-positive Diffuse Midline Gliomas [NCT05478837]	Phase 1	12 participants (Anticipated)	Interventional	2023-07-20	Recruiting
Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study [NCT04205240]	Phase 2	1 participants (Actual)	Interventional	2020-12-22	Terminated(stopped due to Poor accrual)
Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) [NCT03326921]	Phase 1	24 participants (Anticipated)	Interventional	2018-02-23	Suspended(stopped due to Pause in funding)
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) [NCT06066424]	Phase 1	54 participants (Anticipated)	Interventional	2023-10-24	Recruiting
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 [NCT03643276]	Phase 3	5,000 participants (Anticipated)	Interventional	2018-07-15	Recruiting
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia [NCT01085617]	Phase 3	1,033 participants (Actual)	Interventional	2010-12-31	Active, not recruiting
Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients [NCT04697940]	Phase 1/Phase 2	33 participants (Anticipated)	Interventional	2020-12-15	Recruiting
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation [NCT04024761]	Phase 1	50 participants (Anticipated)	Interventional	2019-08-31	Active, not recruiting
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian [NCT03412526]	Phase 2	15 participants (Anticipated)	Interventional	2018-01-21	Recruiting
Indoleamine-2,3-dioxygenase (IDO) Inhibition With INCB024360 and Intraperitoneal Delivery of Allogeneic Natural Killer Cells for Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer [NCT02118285]	Phase 1	2 participants (Actual)	Interventional	2014-07-28	Completed
Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study [NCT02181478]	Early Phase 1	6 participants (Actual)	Interventional	2015-07-22	Completed
Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia [NCT00931645]	Phase 3	241 participants (Actual)	Interventional	2001-04-30	Completed
A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies [NCT00051311]	Phase 2	62 participants (Actual)	Interventional	2003-01-03	Completed
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas [NCT00043979]	Phase 2	60 participants (Actual)	Interventional	2002-09-19	Completed
Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer [NCT00074269]	Phase 2	5 participants (Actual)	Interventional	2003-07-31	Terminated(stopped due to Terminated early due to poor enrollment)
HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia After Conditioning of Fludarabine, Cyclophosphamide and Antithymocyte Globulin [NCT01105273]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2009-07-31	Completed
An Open-Label Phase I/II Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer [NCT05981014]	Phase 1/Phase 2	196 participants (Anticipated)	Interventional	2023-08-01	Recruiting
An Open-Label Phase I/II Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer [NCT05981001]	Phase 1/Phase 2	170 participants (Anticipated)	Interventional	2023-08-01	Recruiting
Allogeneic Hematopoietic Cell Transplantation With Cyclophosphamide, Fludarabine, and Antithymocyte Globulin in Lower Risk Myelodysplastic Syndrome Phase 2 Extension Study [NCT06098326]	Phase 2	30 participants (Anticipated)	Interventional	2018-03-06	Active, not recruiting
Clinical Study of Universal Off-the-shelf Cell Products in Patients With CD19-positive Relapsed/Refractory B-cell Hematolymphatic Malignancies. [NCT06092047]	Early Phase 1	10 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
A Dose-escalation Clinical Study of QH103 Cell Injection (CD19 CAR-γδT Cell Injection) in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL). [NCT06056752]	Phase 1	10 participants (Anticipated)	Interventional	2023-09-27	Recruiting
Multiple-center Randomized Study to Compare Fludarabine and Busulfan Versus Fludarabine, Busulfan and Melphalan in Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplasia Syndrome (MDS) [NCT05991908]	Phase 3	222 participants (Anticipated)	Interventional	2023-10-19	Recruiting
A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord Transplantation [NCT04395222]	Phase 2	21 participants (Actual)	Interventional	2020-10-07	Active, not recruiting
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) [NCT04897321]	Phase 1	32 participants (Anticipated)	Interventional	2022-07-06	Recruiting
Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG) [NCT04196413]	Phase 1	54 participants (Anticipated)	Interventional	2020-06-04	Recruiting
Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia [NCT02083250]	Phase 1	70 participants (Actual)	Interventional	2014-03-06	Completed
Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) With Pembrolizumab, in Subjects Who Have Failed Cisplatin-Based Chemotherapy With Locally Advanced (Unresectable) or Metastatic Transitional Cell Cancer (TCC) of the Urothelium [NCT03935347]	Phase 2	0 participants (Actual)	Interventional	2019-06-20	Withdrawn(stopped due to no accrual)
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With R/R MM Who Received Three or More Lines of Therapy [NCT05998928]	Phase 2	10 participants (Anticipated)	Interventional	2023-07-27	Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) [NCT04637763]	Phase 1	72 participants (Anticipated)	Interventional	2021-05-26	Recruiting
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap S [NCT03613532]	Phase 1	78 participants (Anticipated)	Interventional	2018-10-24	Recruiting
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies [NCT05665062]	Phase 1	36 participants (Anticipated)	Interventional	2022-06-24	Recruiting
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic [NCT05457556]	Phase 3	435 participants (Anticipated)	Interventional	2023-03-15	Recruiting
Itacitinib to Prevent Graft Versus Host Disease [NCT04859946]	Phase 1	30 participants (Anticipated)	Interventional	2022-01-11	Recruiting
Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection [NCT02880293]		44 participants (Actual)	Interventional	2016-08-23	Completed
An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-Cell Lymphoma [NCT00924326]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2009-02-17	Completed
Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers [NCT02876510]	Phase 1	38 participants (Actual)	Interventional	2017-06-30	Completed
Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma [NCT03716856]	Phase 1	11 participants (Actual)	Interventional	2018-03-23	Active, not recruiting
A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab [NCT00850499]	Phase 2	12 participants (Actual)	Interventional	2009-09-30	Terminated
A Phase II Study of Fludarabine Induction With Sequential High Dose Cyclophosphamide and Rituximab as Consolidation Therapy for Previously Untreated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia [NCT00003659]	Phase 2	39 participants (Actual)	Interventional	1998-09-30	Completed
Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis [NCT02529839]		20 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid Tumors [NCT06027983]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Umbilical Cord Blood Transplant for Congenital Pediatric Disorders [NCT00950846]		40 participants (Actual)	Interventional	2009-09-30	Completed
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan [NCT00577278]	Phase 2	41 participants (Actual)	Interventional	2007-10-03	Active, not recruiting
A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma [NCT01585415]	Phase 1	12 participants (Actual)	Interventional	2012-04-09	Terminated
A Cancer Research UK Phase I Trial of Adoptive Transfer of Autologous Tumor Antigen-Specific T Cells With Preconditioning Chemotherapy and Intravenous IL2 in Patients With Advanced CEA Positive Tumors [NCT01212887]	Phase 1	14 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to due to safety concerns and lack of efficacy)
A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT01471444]	Phase 3	256 participants (Actual)	Interventional	2011-11-02	Completed
Safety and Efficacy of Anti-CD7 CAR-Engineered T Cells for Relapsed/Refractory T Lymphoid Malignancies: a Single-center, Open-label, Non-randomized, Single-arm Clinical Study [NCT04823091]	Phase 1	24 participants (Anticipated)	Interventional	2021-04-15	Recruiting
Clinical Study on the Safety and Efficacy of QN-023a Targeting CD33 in Acute Myeloid Leukemia [NCT05665075]	Phase 1	19 participants (Anticipated)	Interventional	2022-12-24	Recruiting
The Clinical Research of Fourth Generation CART-cell Therapy in Refractory-Relapsed Ovarian Cancer [NCT03814447]	Early Phase 1	10 participants (Anticipated)	Interventional	2019-08-16	Recruiting
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study [NCT02251821]	Phase 2	99 participants (Actual)	Interventional	2014-10-20	Active, not recruiting
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Antifungal Prophylaxis With Posaconazole. [NCT03434704]	Phase 2	10 participants (Actual)	Interventional	2018-06-18	Completed
Safety and Effectiveness of MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer [NCT03916679]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2019-04-20	Recruiting
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS [NCT04893915]	Phase 2	0 participants (Actual)	Interventional	2022-06-30	Withdrawn(stopped due to No funding support)
Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells) [NCT03399448]	Phase 1	3 participants (Actual)	Interventional	2018-09-05	Terminated(stopped due to Sponsor has terminated trial to pursue other targets.)
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome [NCT03071276]	Phase 2	37 participants (Actual)	Interventional	2016-01-14	Terminated(stopped due to Due to slow enrollment)
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia [NCT02162420]		50 participants (Anticipated)	Interventional	2015-01-10	Recruiting
Phase I Study of Valproic Acid Expanded Cord Blood Stem Cells as an Allogeneic Donor Source for Adults With Hematological Malignancies [NCT03885947]	Phase 1	7 participants (Actual)	Interventional	2019-02-21	Completed
Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies [NCT01163201]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to Replaced by a new study)
A Pilot Study to Assess Engraftment Using CliniMACS TCR-α/β and CD19 Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Progenitor Cell Transplantation (HSCT) in Patients With Relapsed Lymphoma [NCT02652468]		11 participants (Actual)	Interventional	2016-03-10	Completed
Clinical Research of Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Children With Stage 4/M Neuroblastoma: A Prospective, Single-arm, Phase II, Multi-center Trial [NCT05303727]	Phase 2	64 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies [NCT05705570]	Phase 1	30 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies [NCT00423826]		0 participants	Expanded Access	2007-01-31	No longer available
A Clinical Trial of MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer [NCT03799913]	Early Phase 1	20 participants (Anticipated)	Interventional	2019-04-10	Recruiting
A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured With a Pharmacologic Inhibitor of AKT in Patients With Metastatic Melanoma [NCT02489266]	Phase 1	0 participants (Actual)	Interventional	2015-06-24	Withdrawn
Multi-center, Open-label, Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy With MG4101 Plus Rituximab in Patient With Relapsed/Refractory Non-Hodgkin's Lymphoma of B-cell Origin [NCT03778619]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2018-11-28	Active, not recruiting
T Cell Therapy for Patients With Metastatic Ovarian Cancer [NCT02482090]	Phase 1	6 participants (Actual)	Interventional	2015-07-31	Completed
A Phase 1 Study of Obatoclax Mesylate (GX15-070MS) in Combination With Fludarabine-Based Chemoimmunotherapy in Previously Treated Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL) [NCT00612612]	Phase 1	28 participants (Actual)	Interventional	2008-01-31	Terminated
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant [NCT00909948]	Phase 1	7 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Slow Accrual)
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies [NCT05735717]	Phase 2	150 participants (Anticipated)	Interventional	2023-05-11	Recruiting
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure [NCT04539366]	Phase 1	67 participants (Anticipated)	Interventional	2022-01-25	Suspended(stopped due to Interim Monitoring)
Open-Label Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1a Positive Relapsed and R [NCT03168438]	Phase 1	6 participants (Actual)	Interventional	2017-08-18	Terminated(stopped due to The study was terminated following an internal review of the company's research and development portfolio)
Feasibility Study on Allogeneic Hematopoietic Stem Cell Transplantation Following Fludarabine-Busulfan-ALS-based Reduced-intensity Conditioning in Children With Hematological Malignancy or Solid Tumor Not Responding to Standard Therapy or for Which the In [NCT00750126]	Phase 2	30 participants (Anticipated)	Interventional	2007-04-30	Recruiting
A Phase I-II Study of Allogeneic CMV Specific Cytotoxic T Lymphocytes (CTL) for Patients With Refractory Glioblastoma Multiforme (GBM) [NCT00990496]	Phase 1	25 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Accrual goals not met)
A Phase II Study of Twice Daily Cytarabine and Fludarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [NCT01019317]	Phase 2	151 participants (Actual)	Interventional	2009-11-30	Completed
A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) [NCT01300572]	Phase 1	16 participants (Actual)	Interventional	2012-01-31	Completed
Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12 [NCT01236573]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.)
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes [NCT01218867]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2010-11-10	Terminated(stopped due to No objective responses were observed.)
Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders [NCT00636909]	Phase 2	25 participants (Actual)	Interventional	1999-07-31	Completed
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma [NCT00577993]	Phase 3	210 participants (Actual)	Interventional	1998-03-16	Completed
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer [NCT04093648]	Phase 1	0 participants (Actual)	Interventional	2020-01-31	Withdrawn(stopped due to The key elements of this study were incorporated into another study.)
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy. [NCT00738829]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2008-10-31	Completed
Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation [NCT00740467]	Phase 2	50 participants (Anticipated)	Interventional	2008-01-31	Recruiting
Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma [NCT05077527]	Phase 1	20 participants (Anticipated)	Interventional	2024-01-15	Not yet recruiting
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies [NCT02566304]	Phase 2	35 participants (Anticipated)	Interventional	2015-11-13	Active, not recruiting
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation [NCT00691015]	Phase 2	48 participants (Actual)	Interventional	2008-05-31	Completed
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903) [NCT01410344]	Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
Trial of the Efficacy and Safety of High-dose Immunosuppressive Therapy Based on Fludarabine and Cyclophosphamide-containing Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis. [NCT05832515]	Phase 1	200 participants (Anticipated)	Interventional	2020-10-01	Recruiting
Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies [NCT00806767]	Phase 2	82 participants (Anticipated)	Interventional	2007-03-31	Completed
Hematopoietic Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia [NCT00623935]	Phase 2	56 participants (Actual)	Interventional	2007-03-31	Completed
Phase II Study of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed PTCL [NCT00840385]	Phase 2	30 participants (Anticipated)	Interventional	2007-11-30	Recruiting
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan [NCT00619645]	Phase 2	8 participants (Actual)	Interventional	2007-06-30	Completed
Reduced Intensity Conditioning Regimen for Low- and Intermediate-risk Myelodysplastic Syndrome Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation [NCT03412266]	Phase 2	50 participants (Anticipated)	Interventional	2018-02-01	Recruiting
A Multicenter Pilot Study of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation With In-vivo T-cell Depletion to Evaluate the Role of NK Cells and KIR Mis-matches in Relapsed or Refractory High-risk Neuroblastoma. [NCT00874315]	Phase 2	0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to lack of accrual)
Phase I/II Clinical Trial of HER2 Targeted HypoSti.CAR-T Cells in Treating Patients With HER2 Positive Local Advanced or Metastatic Solid Tumors [NCT05681650]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2023-10-11	Recruiting
A Phase 1/2a, Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors [NCT05672459]	Phase 1/Phase 2	117 participants (Anticipated)	Interventional	2023-06-21	Recruiting
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractor [NCT04416984]	Phase 1/Phase 2	160 participants (Anticipated)	Interventional	2020-05-21	Recruiting
Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis [NCT04022239]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2020-03-13	Recruiting
Pilot Open-Label Study of Safety and Efficacy of Ruxolitinib Given Peri-Transplant During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelofibrosis [NCT02917096]	Phase 1	18 participants (Actual)	Interventional	2016-11-13	Completed
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult P [NCT02153580]	Phase 1	37 participants (Actual)	Interventional	2014-09-24	Active, not recruiting
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma [NCT01131169]	Phase 2	66 participants (Actual)	Interventional	2010-05-31	Completed
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02 [NCT00258427]	Phase 2	14 participants (Actual)	Interventional	2002-03-26	Completed
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies [NCT01175785]	Phase 2	15 participants (Actual)	Interventional	2010-08-31	Completed
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients With Thyroglobulin Expressing Thyroid Cancer [NCT02390739]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2015-03-02	Withdrawn
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer [NCT03907852]	Phase 1/Phase 2	175 participants (Anticipated)	Interventional	2019-04-15	Recruiting
A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia [NCT03324243]	Phase 2	0 participants (Actual)	Interventional	2018-01-31	Withdrawn(stopped due to Withdrawn: Study halted prior to enrollment of first participant)
An Open-label, Randomised Phase II Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer [NCT03335241]	Phase 2	140 participants (Anticipated)	Interventional	2017-03-01	Recruiting
Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases [NCT02483325]	Phase 2	33 participants (Actual)	Interventional	2014-09-30	Completed
Pilot Study of Adoptive Cell Transfer for the Treatment of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes [NCT02774291]	Early Phase 1	3 participants (Actual)	Interventional	2017-04-20	Terminated(stopped due to Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and Study Completion Dates have been revised based accordingly based on respective definitions)
Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study [NCT02926586]	Phase 4	200 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors [NCT03302403]		18 participants (Actual)	Interventional	2017-12-29	Active, not recruiting
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT03263936]	Phase 1	37 participants (Actual)	Interventional	2017-07-11	Completed
A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT06128044]	Phase 1	70 participants (Anticipated)	Interventional	2023-12-05	Not yet recruiting
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies [NCT05579769]	Phase 2	32 participants (Anticipated)	Interventional	2022-11-04	Recruiting
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H [NCT00047060]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2002-07-30	Completed
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML [NCT03384225]	Phase 3	120 participants (Anticipated)	Interventional	2016-08-01	Recruiting
Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies [NCT02128945]	Phase 1	10 participants (Actual)	Interventional	2014-04-30	Completed
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old [NCT03257241]	Phase 3	582 participants (Anticipated)	Interventional	2017-07-03	Recruiting
T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias [NCT03653338]	Phase 1/Phase 2	5 participants (Anticipated)	Interventional	2018-08-02	Recruiting
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma: a Pilot Feasibility Study Using a Novel Protocol [NCT02447055]	Early Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn
Phase II Study Testing Prophylaxis Feasibility of Graft Versus Host Disease With Only High Dose Cyclophosphamide Post-transplantation for Patients Eligible to a Reduced-intensity Conditioning Regiment Prior to Allogenic Transplantation With a Compatible F [NCT03263767]	Phase 2	47 participants (Actual)	Interventional	2018-01-15	Terminated(stopped due to Security criteria (MTD))
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study [NCT06093841]	Phase 2	46 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease in Recipients of a Non-Myeloablative Umbilical Cord Blood Transplantation for Treatment of Hematological Malignancies [NCT02118311]	Phase 2	0 participants (Actual)	Interventional	2016-06-30	Withdrawn(stopped due to Changing study design. Will replace with a different protocol.)
Tumor Infiltrating Lymphocytes in Pediatric Malignant Solid Tumors: A Prospective Biobanking Study and Phase I Clinical Trial [NCT06047977]	Phase 1	30 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma [NCT06026319]	Phase 1	24 participants (Anticipated)	Interventional	2023-10-26	Recruiting
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies [NCT05653271]	Phase 1	42 participants (Anticipated)	Interventional	2023-01-21	Recruiting
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting [NCT05459571]	Phase 2	40 participants (Anticipated)	Interventional	2022-08-09	Recruiting
Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies [NCT01359254]	Phase 2	1 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to did not accrue enough patients.)
A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma [NCT02706405]	Phase 1	30 participants (Actual)	Interventional	2016-11-15	Terminated(stopped due to Terminated due to slow accrual.)
A Cancer Research UK Phase I Trial of Anti-GD2 Chimeric Antigen Receptor (CAR) Transduced T-cells (1RG-CART) in Patients With Relapsed or Refractory Neuroblastoma [NCT02761915]	Phase 1	17 participants (Actual)	Interventional	2016-02-29	Completed
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT02588612]	Phase 1	10 participants (Actual)	Interventional	2016-02-01	Completed
A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies [NCT05797233]	Phase 1	58 participants (Anticipated)	Interventional	2023-08-28	Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial) [NCT05722418]	Phase 1	50 participants (Anticipated)	Interventional	2023-02-06	Recruiting
A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [NCT05400109]	Phase 1	10 participants (Anticipated)	Interventional	2023-04-26	Recruiting
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma [NCT04696731]	Phase 1	120 participants (Anticipated)	Interventional	2021-02-24	Recruiting
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major [NCT03171831]	Phase 4	30 participants (Anticipated)	Interventional	2017-04-01	Recruiting
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia [NCT05955261]	Phase 2	70 participants (Anticipated)	Interventional	2023-07-25	Recruiting
Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT05681780]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2022-12-23	Recruiting
A Phase I Study to Evaluate PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer [NCT03873805]	Phase 1	14 participants (Actual)	Interventional	2019-08-20	Active, not recruiting
Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression [NCT03480360]	Phase 3	20 participants (Anticipated)	Interventional	2018-03-28	Active, not recruiting
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine [NCT02916979]	Phase 1	20 participants (Actual)	Interventional	2016-09-06	Completed
A Phase I/II Open-Label Study of ECT-001-Expanded Cord Blood Transplantation in Pediatric and Young Adult (<21year) Patients With High-Risk and Very High-Risk Myeloid Malignancies [NCT04990323]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2021-12-01	Recruiting
A Randomized Study of Once Daily IV Busulfan With Fludarabine With Hemopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT00469144]	Phase 3	233 participants (Actual)	Interventional	2005-06-30	Completed
A Phase I Clinical Trial of T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma [NCT03958656]	Phase 1	13 participants (Actual)	Interventional	2019-06-13	Completed
Allogeneic Hematopoietic Cell Transplantation to Correct the Biochemical Defect and Create Tolerance to Donor Tissue in Subjects With Epidermolysis Bullosa [NCT00478244]		7 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to Competing studies)
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers [NCT06119685]	Phase 1/Phase 2	128 participants (Anticipated)	Interventional	2023-10-25	Recruiting
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma [NCT06043323]	Phase 2	20 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
"A Pilot Window-3 Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma" [NCT05495464]	Early Phase 1	20 participants (Anticipated)	Interventional	2022-11-18	Recruiting
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [NCT05476770]	Phase 1	54 participants (Anticipated)	Interventional	2022-11-11	Recruiting
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies [NCT04959175]	Phase 1/Phase 2	320 participants (Anticipated)	Interventional	2021-09-23	Recruiting
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma [NCT04083495]	Phase 2	20 participants (Anticipated)	Interventional	2019-09-17	Recruiting
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Tr [NCT03970096]	Phase 2	120 participants (Anticipated)	Interventional	2019-11-19	Recruiting
Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-A [NCT03666000]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2019-03-11	Recruiting
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [NCT03624036]	Phase 1	16 participants (Actual)	Interventional	2018-11-15	Terminated(stopped due to Development program terminated)
A Phase I Clinical Trial of T Cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma [NCT03602612]	Phase 1	35 participants (Actual)	Interventional	2018-09-14	Active, not recruiting
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers [NCT02830724]	Phase 1/Phase 2	124 participants (Anticipated)	Interventional	2017-04-06	Recruiting
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) [NCT02614066]	Phase 1/Phase 2	125 participants (Actual)	Interventional	2016-03-07	Completed
A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation [NCT00566696]	Phase 2	73 participants (Actual)	Interventional	2007-12-14	Completed
Study to Infuse Haploidentical Natural Killer Cells in Patients With Relapsed or Refractory Neuroblastoma [NCT00698009]	Phase 2	1 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Slow accrual.)
Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571) [NCT00416884]	Phase 2	1 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Low enrollment)
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study [NCT00968162]	Phase 1	8 participants (Actual)	Interventional	2009-02-28	Completed
Phase II Open Lable Clinical Study Efficacy and Safety of the Holistic Treatment for Young Patients With High-Risk Multiple Myeloma [NCT04008888]		50 participants (Anticipated)	Interventional	2018-01-05	Recruiting
Multicentre, Non-Randomised, Open-Label Phase II Study to Evaluate the Efficacy and Safety of Induction Treatment With Rituximab, Fludarabine, Cyclophosphamide, Followed by Rituximab Maintenance Therapy (R-Fc-Rm) in the First Line Treatment of Chronic Lym [NCT00545714]	Phase 2	86 participants (Actual)	Interventional	2007-11-21	Completed
Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501) [NCT00412360]	Phase 3	224 participants (Actual)	Interventional	2006-12-31	Completed
T-Cell or Natural Killer (NK) Cell Adback in Patients With Lymphoid Malignancies Receiving Allogeneic Stem Cell Transplantation With Campath-IH Containing Conditioning Regimens [NCT00536978]	Phase 2	22 participants (Actual)	Interventional	2007-09-30	Completed
Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome [NCT00774527]	Phase 3	82 participants (Actual)	Interventional	2003-03-31	Completed
Phase Ib Study To Assess The Feasibility And Safety Of Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes In Advanced Solid Tumors [NCT03992326]	Phase 1	6 participants (Actual)	Interventional	2019-09-01	Terminated(stopped due to Internal competitive study that is open)
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H [NCT00058825]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2000-08-31	Terminated(stopped due to Slow accrual due to practice changes meant study would take too long to finish)
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease [NCT01049854]	Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) [NCT00206726]	Phase 2	60 participants (Actual)	Interventional	2005-05-31	Completed
Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation [NCT00006184]	Phase 2	20 participants (Actual)	Interventional	2001-02-08	Completed
A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia [NCT00230282]	Phase 2	25 participants (Actual)	Interventional	2004-07-31	Completed
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies [NCT00075478]	Phase 3	87 participants (Actual)	Interventional	2003-10-31	Completed
Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS) [NCT01953900]	Phase 1	26 participants (Anticipated)	Interventional	2014-04-30	Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cell Therapy in Patients With Relapsed or Refractory CD19-positive Non-Hodgkin's Lymphoma [NCT03528421]	Phase 1	30 participants (Anticipated)	Interventional	2018-05-22	Recruiting
Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure [NCT03500731]	Phase 1/Phase 2	8 participants (Anticipated)	Interventional	2018-04-19	Recruiting
A Phase I-II Study of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies [NCT00943319]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2012-03-31	Completed
Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation [NCT00602693]	Phase 1	41 participants (Actual)	Interventional	2007-07-23	Completed
Total Body Irradiation With Fludarabine Conditioning Followed by Transplantation With Combined Umbilical Cord Blood Grafts [NCT00606437]	Phase 1	40 participants (Actual)	Interventional	2005-09-30	Completed
QN-019a as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies in Subjects With B-Cell Malignancies [NCT05379647]	Phase 1	24 participants (Anticipated)	Interventional	2021-11-04	Recruiting
Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine [NCT05379569]	Phase 4	142 participants (Anticipated)	Interventional	2022-05-15	Recruiting
Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial) [NCT05787574]	Phase 2	39 participants (Anticipated)	Interventional	2023-03-15	Recruiting
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of HRYZ-T101 TCR-T Cell for HPV18 Positive Advanced Solid Tumor [NCT05787535]	Phase 1	17 participants (Anticipated)	Interventional	2023-03-21	Recruiting
A Randomized Study of Fludarabine in Part of Induction and Postremission Treatment for de Novo Acute Myeloid Leukaemia in Elderly Patients [NCT00925873]	Phase 3	303 participants (Actual)	Interventional	1996-06-30	Completed
Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies (UCALL) [NCT01247688]		0 participants (Actual)	Interventional	2010-11-30	Withdrawn(stopped due to This study was withdrawn due to low accrual.)
Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [NCT03615105]	Phase 2	9 participants (Actual)	Interventional	2018-07-25	Active, not recruiting
Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines [NCT00923195]	Phase 2	4 participants (Actual)	Interventional	2008-12-31	Completed
HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen [NCT02776202]	Phase 2	15 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Phase I/II Study of Metastatic Cancer That Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes [NCT00924287]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to This study was terminated after the first patient treated on study died as a result of the treatment.)
A Myeloablative Conditioning Regimen Consisting of Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients With Hematological Malignancy. [NCT00597519]	Phase 2	28 participants (Actual)	Interventional	2006-03-31	Completed
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC) Including Fibrolamellar HCC [NCT02702960]	Phase 2	0 participants (Actual)	Interventional	2016-03-31	Withdrawn(stopped due to This study was withdrawn due to lack of necessary resources from the liver transplant surgical group.)
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma [NCT03704298]	Phase 1	15 participants (Actual)	Interventional	2018-11-20	Terminated(stopped due to Development program terminated)
"Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup" [NCT02666898]	Phase 2	135 participants (Actual)	Interventional	2015-10-31	Completed
Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC) [NCT06096038]	Phase 1/Phase 2	33 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolid [NCT04167696]	Phase 1	27 participants (Anticipated)	Interventional	2019-11-25	Recruiting
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy [NCT02638428]	Phase 2	90 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors [NCT00640796]	Phase 1	22 participants (Actual)	Interventional	2008-09-30	Completed
A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma [NCT00875667]	Phase 2	254 participants (Actual)	Interventional	2009-04-30	Completed
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study [NCT04009525]	Phase 4	800 participants (Anticipated)	Interventional	2019-06-01	Recruiting
A Phase 1 Trial of the Wee1 Kinase Inhibitor AZD1775 in Combination With Flag Chemotherapy in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia [NCT02791919]	Phase 1	0 participants (Actual)	Interventional	2017-05-25	Withdrawn(stopped due to Other - Protocol moved to Disapproved)
Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Phase II Trial [NCT00693927]	Phase 2	54 participants (Actual)	Interventional	2002-03-31	Completed
A Pilot Study of Sequential Autologous Stem Cell Transplantation and Immunotherapy With Reduced Intensity Allogeneic Stem Cell Transplant for High Risk Neuroblastoma [NCT00670410]	Phase 1	15 participants (Actual)	Interventional	2003-11-30	Terminated(stopped due to Poor accrual)
[NCT02577094]	Phase 1/Phase 2	0 participants (Actual)	Interventional		Withdrawn
Clinical Study of Natural Killer Cell Infusion in Patients With Acute Myeloid Leukemia [NCT04221971]	Phase 1	10 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors [NCT02653196]	Early Phase 1	1 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to The Principal Investigator left the institution.)
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Using Fludarabine, Busulfan, 400 cGy Total Body Irradiation, and Thymoglobulin [NCT00679536]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2008-05-31	Recruiting
An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma [NCT00825149]	Phase 1	137 participants (Actual)	Interventional	2009-02-28	Completed
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen [NCT00796068]	Phase 2	130 participants (Actual)	Interventional	2009-02-24	Completed
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in Patients With R/R B-Cell Acute Lymphoblastic Leukemia [NCT05225831]	Early Phase 1	100 participants (Anticipated)	Interventional	2021-08-15	Recruiting
A Phase I/II Clinical Study of TC-N201 Injection for the Treatment of Advanced Solid Tumors With HLA-A2 Expression and Positive NY-ESO-1. [NCT05881525]	Phase 1	18 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics [NCT06013423]	Phase 2	54 participants (Anticipated)	Interventional	2024-02-06	Not yet recruiting
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors [NCT06013111]	Phase 1	9 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Phase I/II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome [NCT00885833]	Phase 1/Phase 2	5 participants (Anticipated)	Interventional	2007-02-28	Completed
Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia [NCT00882323]	Phase 2	33 participants (Anticipated)	Interventional	2008-11-30	Recruiting
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treat [NCT00520130]	Phase 1/Phase 2	92 participants (Actual)	Interventional	2007-10-30	Completed
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma [NCT04989803]	Phase 1	114 participants (Anticipated)	Interventional	2021-10-27	Recruiting
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT02421939]	Phase 3	371 participants (Actual)	Interventional	2015-10-20	Active, not recruiting
A Proof of Concept Study of TBio-4101 (an Autologous Selected and Expanded Tumor Infiltrating Lymphocyte [TIL] Therapy) Using Short-Term Cultured, Selected Autologous TIL Following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients W [NCT05628883]	Phase 1	25 participants (Anticipated)	Interventional	2022-11-22	Recruiting
Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors [NCT04643574]	Phase 1	42 participants (Anticipated)	Interventional	2021-03-09	Active, not recruiting
Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells [NCT00354172]	Phase 2	16 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Competing study was started.)
A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With JSMD194, a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple Myeloma [NCT03502577]	Phase 1	18 participants (Anticipated)	Interventional	2018-05-23	Suspended(stopped due to Waiting on confirmation of additional funding)
Rasburicase to Prevent Graft -Versus-Host Disease [NCT00513474]	Phase 1	46 participants (Actual)	Interventional	2008-01-31	Completed
T-cell Based Immunotherapy for Treatment of Patients With Disseminated Melanoma. [NCT00937625]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2009-06-30	Completed
Busulfan-Fludarabine-Clofarabine With Allogeneic Stem Cell Transplantation for Advanced Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Advanced, Gleevec Refractory Chronic Myeloid Leukemia. A Randomized Phase II Study. [NCT00469014]	Phase 2	72 participants (Actual)	Interventional	2006-09-30	Completed
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia [NCT00301834]	Phase 2	35 participants (Actual)	Interventional	2005-01-31	Completed
An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With Fludarabine and Cyclophosphamide, in Patients With Previously Untreated B-cell CLL [NCT00410163]	Phase 2	61 participants (Actual)	Interventional	2007-01-31	Completed
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Haematological Diseases Using a Reduced Intensity Conditioning Regimen [NCT00959231]	Phase 2	60 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Infusion of Expanded Cord Blood T Cells Following Cord Blood Transplantation [NCT00972101]	Phase 1	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to Development of other studies led to termination without recruitment.)
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate [NCT00988715]	Phase 1	17 participants (Actual)	Interventional	2010-04-21	Completed
Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism [NCT00282412]	Phase 1	4 participants (Actual)	Interventional	2002-09-30	Terminated(stopped due to No participant enrolled for three years. No plan to continue study.)
A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis [NCT00001422]	Phase 2	20 participants	Interventional	1995-06-30	Completed
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases [NCT01019876]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2002-06-30	Recruiting
Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study [NCT01020734]	Phase 2	263 participants (Actual)	Interventional	2011-05-31	Completed
Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia [NCT01186640]	Phase 2	16 participants (Actual)	Interventional	2010-06-30	Completed
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine [NCT03600909]	Phase 2	3 participants (Actual)	Interventional	2018-05-15	Terminated(stopped due to Accrual has been slow)
IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL [NCT03524235]	Phase 1	30 participants (Anticipated)	Interventional	2018-07-18	Active, not recruiting
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer [NCT03412877]	Phase 2	270 participants (Anticipated)	Interventional	2018-09-06	Recruiting
A Phase II Clinical Trial of Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma [NCT01659151]	Phase 2	17 participants (Actual)	Interventional	2012-08-03	Active, not recruiting
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma [NCT02548468]	Phase 1	0 participants (Actual)	Interventional	2015-11-20	Withdrawn(stopped due to Slow accrual)
A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia [NCT00860574]	Phase 2	96 participants (Actual)	Interventional	2009-02-28	Completed
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT02676323]	Phase 1	19 participants (Actual)	Interventional	2016-05-03	Terminated(stopped due to Slow accrual)
A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation [NCT00856388]		62 participants (Actual)	Interventional	2009-01-14	Completed
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma [NCT04160195]	Phase 1	2 participants (Actual)	Interventional	2019-12-20	Terminated(stopped due to The original principal investigator left the National Institutes of Health (NCI) and the decision was made to close the study to enrollment.)
Autologous Hematopoietic Stem Cell Transplant for Crohn's Disease [NCT04154735]	Phase 2	0 participants (Actual)	Interventional	2019-11-30	Withdrawn(stopped due to Discontinued by Investigator)
A Pilot Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine [NCT00595127]		21 participants (Actual)	Interventional	2001-06-30	Completed
Randomized Trial of GVHD Prophylasxis With Post-transplantation Cyclophocphomide (PTCy) or Thymoglobulin in Unrelated SCT Recepients With Chronic Myeloproliferative Neoplasms and Myelodisplatic Syndrome [NCT02627573]	Phase 2	32 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Poor recruitment)
A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer [NCT03215810]	Phase 1	20 participants (Actual)	Interventional	2017-10-11	Completed
Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome [NCT00774280]	Phase 3	130 participants (Actual)	Interventional	2002-05-31	Completed
A Multicenter, Open Study to Assess the Antitumor Effect and Safety of Oral Fludarabine Phosphate (Fludara (SH T 586): 40 mg/m2/Day) Administered in 3 - 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by a Observation Period of 2 [NCT00688883]	Phase 2	52 participants (Actual)	Interventional	2003-02-28	Completed
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia [NCT00769522]	Phase 3	564 participants (Actual)	Interventional	2008-10-02	Completed
Allogeneic γ9δ2 T Cells for the Treatment of Recurrent Hematologic Tumors After Allogeneic Hematopoietic Stem Cell Transplantation [NCT05755854]	Phase 1	10 participants (Anticipated)	Interventional	2023-05-03	Recruiting
Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study [NCT05674539]	Phase 3	200 participants (Anticipated)	Interventional	2022-12-28	Recruiting
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related o [NCT00582933]	Phase 2	96 participants (Actual)	Interventional	2001-05-31	Completed
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies [NCT01760655]	Phase 2	62 participants (Actual)	Interventional	2012-12-24	Completed
G-CSF and Plerixafor With Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias [NCT00822770]	Phase 1/Phase 2	47 participants (Actual)	Interventional	2009-01-31	Completed
HLA Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease [NCT00578643]	Phase 2	15 participants (Actual)	Interventional	2004-03-31	Completed
Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma [NCT00807196]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2008-09-30	Recruiting
Reduced Intensity Conditioning Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation [NCT00795132]	Phase 2	47 participants (Actual)	Interventional	2004-04-30	Completed
Fludarabine, Cyclophosphamide, and Multiple Dose Rituximab as Frontline Therapy in Chronic Lymphocytic Leukemia (CLL) [NCT00794820]	Phase 2	66 participants (Actual)	Interventional	2003-12-31	Completed
NK Cells Infusion as Consolidation Treatment of Acute Myeloid Leukemia in Children and Adolescents [NCT02763475]	Phase 2	7 participants (Actual)	Interventional	2016-05-31	Completed
Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclopho [NCT01010217]	Phase 2	176 participants (Actual)	Interventional	2009-11-05	Completed
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cell for HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers [NCT05122221]	Phase 1	12 participants (Anticipated)	Interventional	2022-07-17	Recruiting
Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases [NCT00613561]	Phase 2	25 participants (Anticipated)	Interventional	2007-12-31	Recruiting
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies [NCT01349101]	Phase 2	80 participants (Actual)	Interventional	2011-02-10	Completed
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401) [NCT02680951]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Withdrawn due to lack of participants.)
Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma [NCT00641095]	Phase 2/Phase 3	370 participants (Actual)	Interventional	2006-12-07	Completed
A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes [NCT00608374]	Phase 3	400 participants (Anticipated)	Interventional	2006-06-30	Completed
High-dose MIBG With Subsequent Transplantation of Haploidentical Stem Cells in Children With Therapy Resistant Neuroblastoma [NCT00790413]	Early Phase 1	15 participants (Anticipated)	Interventional	2005-08-31	Active, not recruiting
Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia [NCT00003764]	Phase 3	280 participants (Anticipated)	Interventional	2000-03-09	Completed
A Phase II Study of Fludarabine (F), Rituxan (R) and Avastin (A) Followed by RA Maintenance in Patients With Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL) [NCT00845104]	Phase 2	0 participants (Actual)	Interventional	2009-01-31	Withdrawn(stopped due to No patients enrolled.)
A Phase II Trial of Transplants From HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies and Other Lethal H [NCT01119066]	Phase 2	422 participants (Actual)	Interventional	2010-05-03	Completed
A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN 1503) [NCT02766465]	Phase 2	138 participants (Actual)	Interventional	2016-11-30	Completed
Pilot Study of Allogeneic Stem Cell Transplantation From Unrelated Donors for Patients With Severe Homozygous Beta 0/+ Thalassemia or Severe Variants of Beta 0/+ Thalassemia [NCT00578292]		10 participants (Actual)	Interventional	2004-02-29	Terminated(stopped due to Stem cell transplant was determined SOC for this disease (study is not relevant))
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies [NCT05589896]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2023-11-30	Recruiting
A Phase I/II Clinical Trail of TC-E202 Targeting HPV16 E6 for Relapsed/Refractory to Standard Treatment or Metastatic Cervical Carcinoma [NCT05357027]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2022-08-10	Recruiting
Study of FT538 in Combination With Daratumumab in Acute Myeloid Leukemia [NCT04714372]	Phase 1	11 participants (Actual)	Interventional	2021-11-03	Active, not recruiting
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen [NCT02133196]	Phase 2	85 participants (Anticipated)	Interventional	2014-10-23	Recruiting
A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies. [NCT04037566]	Phase 1	40 participants (Anticipated)	Interventional	2019-08-31	Recruiting
A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies. [NCT00890500]	Phase 1	12 participants (Actual)	Interventional	2011-01-31	Completed
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies [NCT02793544]	Phase 2	80 participants (Actual)	Interventional	2016-12-31	Completed
A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma [NCT01144403]	Phase 2	8 participants (Actual)	Interventional	2010-06-30	Terminated
A Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET-positive Hodgkin Lymphoma [NCT00907036]	Phase 2	49 participants (Anticipated)	Interventional	2009-07-31	Not yet recruiting
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation [NCT02750254]	Phase 1	5 participants (Actual)	Interventional	2016-06-27	Terminated(stopped due to Toxicity. Only enrolled patients in phase I portion of trial.)
T-cell Based Immunotherapy for Treatment of Patients Squamous Cell Carcinoma in the Oral Cavity. A Pilot Study. [NCT00937300]	Phase 1	0 participants (Actual)	Interventional	2009-06-30	Withdrawn(stopped due to The patients eligible for this trial do not exist anymore due to change in procedures.)
A Pilot Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed CNS Involvement by Lymphoma [NCT02724904]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2017-05-31	Withdrawn(stopped due to Drug logistics)
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors [NCT01804634]	Phase 2	60 participants (Anticipated)	Interventional	2013-03-27	Recruiting
An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Children With Relapsed and Refractory Acute Lymphoblastic Leukemia [NCT04626765]	Early Phase 1	50 participants (Anticipated)	Interventional	2020-04-01	Recruiting
A Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of CAR-T Cell in the Treatment of Adult Relapsed Refractory (R/R) Acute Lymphoblastic Leukemia Bridging Allogeneic Hematopoietic Stem Cell Transplantation [NCT04626726]	Early Phase 1	50 participants (Anticipated)	Interventional	2020-04-01	Recruiting
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer [NCT04611126]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2021-04-22	Recruiting
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia [NCT00868413]	Phase 1	32 participants (Actual)	Interventional	2009-11-30	Completed
Fludarabine, Bendamustine, and Rituximab (FBR) Non-Myeloablative Allogeneic Conditioning for Patients With Lymphoid Malignancies [NCT00880815]	Phase 1	60 participants (Actual)	Interventional	2009-02-17	Completed
Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation [NCT03856216]	Phase 2	44 participants (Anticipated)	Interventional	2019-10-28	Recruiting
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity [NCT04339777]	Phase 2	66 participants (Anticipated)	Interventional	2020-09-22	Recruiting
A Phase I Study to Evaluate the Safety of Escalating Doses of Lymphodepleting Conditioning Chemotherapy Prior to CD19 Chimeric Antigen Receptor T Cells in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma [NCT05052528]	Phase 1	36 participants (Anticipated)	Interventional	2021-09-17	Recruiting
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) With Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malign [NCT03696537]	Phase 1	6 participants (Actual)	Interventional	2018-08-29	Terminated(stopped due to Extreme toxicity)
Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV [NCT01423032]	Phase 2/Phase 3	96 participants (Actual)	Interventional	2001-09-30	Completed
The Treatment of Hematologic Malignancies With Single or Double Umbilical Cord Blood Unit Transplantation Followed by Graft-versus-Host Prophylaxis With Tacrolimus and Mycophenolate Mofetil [NCT00608517]		6 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to slow accrual)
A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma [NCT00513604]	Phase 2	158 participants (Actual)	Interventional	2007-06-30	Completed
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor [NCT00923390]	Phase 1	5 participants (Actual)	Interventional	2009-03-02	Terminated
Adoptive Transfer of Haploidentical NK Cells in Combination With Epratuzumab for the Treatment of Relapsed Acute Lymphoblastic Leukemia [NCT00941928]	Phase 2	2 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Slow accrual)
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies [NCT00593554]	Phase 2	9 participants (Actual)	Interventional	2007-08-07	Terminated(stopped due to Slow accrual)
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations [NCT00923364]	Phase 2	19 participants (Actual)	Interventional	2009-05-07	Completed
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation [NCT00053196]	Phase 2	82 participants (Actual)	Interventional	2002-12-31	Completed
Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin [NCT00915811]	Phase 2	20 participants (Anticipated)	Interventional	2007-06-30	Terminated(stopped due to FB ATG is now a standard for sib allo MDS patients)
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD [NCT00914940]	Phase 2	41 participants (Actual)	Interventional	2009-12-17	Terminated(stopped due to Did not reach one of the primary endpoints of decreased total acute GVHD)
Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies [NCT00916045]	Phase 2	40 participants (Anticipated)	Interventional	2009-09-30	Terminated(stopped due to Recruitment issues)
Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting GPC3 for the Treatment of Recurrent or Refractory Lung Squamous Cell Carcinoma [NCT02876978]	Phase 1	20 participants (Anticipated)	Interventional	2016-03-31	Recruiting
A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia [NCT04303520]	Phase 1	20 participants (Anticipated)	Interventional	2018-05-03	Recruiting
A Randomized, Multi-Center Phase III Trial Comparing Two Conditioning Regimens (CloFluBu and BuCyMel) in Children With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. [NCT05477589]	Phase 3	170 participants (Anticipated)	Interventional	2022-06-07	Recruiting
Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant [NCT02512497]	Phase 1	10 participants (Anticipated)	Interventional	2017-12-08	Recruiting
Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation [NCT02784561]	Phase 4	80 participants (Anticipated)	Interventional	2016-07-31	Not yet recruiting
An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgk [NCT00562965]	Phase 3	29 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to See termination reason in detailed description.)
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma [NCT06151847]	Phase 2	12 participants (Anticipated)	Interventional	2024-01-27	Recruiting
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) [NCT05600426]	Phase 3	234 participants (Anticipated)	Interventional	2023-01-25	Recruiting
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) [NCT05040568]	Phase 1	15 participants (Anticipated)	Interventional	2022-02-28	Recruiting
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies [NCT00943293]	Phase 1	1 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Poor accrual; did not enter phase 2)
Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer [NCT04146298]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2021-10-21	Recruiting
Prospective Phase II Clinical Trial of Myeloablative Conditioning Regimen With Fludarabine and Busulfan Plus 400 cGy Total Body Irradiation for Hematologic Malignancies [NCT00815568]	Phase 2	114 participants (Anticipated)	Interventional	2008-08-31	Recruiting
Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML) [NCT00813124]	Phase 2	24 participants (Actual)	Interventional	2008-12-31	Completed
Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation [NCT00303667]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2005-01-31	Completed
SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia [NCT03573700]	Phase 1/Phase 2	26 participants (Actual)	Interventional	2018-07-24	Active, not recruiting
A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia [NCT00602459]	Phase 2	418 participants (Actual)	Interventional	2008-01-15	Completed
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab [NCT01174121]	Phase 2	332 participants (Anticipated)	Interventional	2010-08-26	Recruiting
Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen for Advanced/Recurrent Mantle Cell Lymphoma [NCT00525876]		49 participants (Actual)	Interventional	2005-01-31	Completed
Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation [NCT06056102]	Phase 1	20 participants (Anticipated)	Interventional	2024-01-05	Not yet recruiting
Delayed Tolerance Through Mixed Chimerism [NCT05900401]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2023-10-01	Recruiting
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myelodysplastic Syndrome [NCT05617625]	Phase 2	50 participants (Anticipated)	Interventional	2024-03-31	Suspended(stopped due to The study has been put on hold while pending CMS approval)
An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT05534620]	Phase 1	36 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Non-Myeloablative Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Using Haploidentical Donors: A Phase I Trial of Pre-Transplant Cyclophosphamide [NCT00006042]	Phase 1	0 participants	Interventional	1999-12-31	Completed
Allogeneic Peripheral Blood Progenitor Cell Transplantation in Patients With Incurable Solid Tumors: A Phase I Study [NCT00006126]	Phase 1	0 participants (Actual)	Interventional	1999-09-30	Withdrawn(stopped due to Unable to accrue subjects.)
Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells [NCT00006252]	Phase 2	47 participants (Actual)	Interventional	2001-02-28	Completed
Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia [NCT00006379]	Phase 2	58 participants (Actual)	Interventional	2000-06-30	Completed
Gemtuzumab Ozogamicin (GO), Fludarabine, And Low-Dose TBI Followed By Donor Stem Cell Transplantation For Patients With Advanced Acute Myeloid Leukemia Or Myelodysplastic Syndrome [NCT00008151]	Phase 2	0 participants	Interventional	2000-10-31	Completed
Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation [NCT00008307]	Phase 2	52 participants (Anticipated)	Interventional	1998-04-30	Active, not recruiting
A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide [NCT00389506]		0 participants (Actual)	Interventional	2006-09-30	Withdrawn
A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Subjects With BCMA-positive Multiple Myeloma [NCT03093168]	Phase 1	10 participants (Anticipated)	Interventional	2017-02-15	Recruiting
Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning in Treating Patients With Multiple Myeloma [NCT00802568]	Phase 2	48 participants (Anticipated)	Interventional	2007-04-30	Completed
A Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Chronic Myeloid Leukemia (CML) and Adoptive Cellular Immunotherapy Only in Patients With Persistent Disease and Matched Family Donors [NCT00531310]	Phase 2	5 participants (Actual)	Interventional	2003-01-31	Terminated(stopped due to Poor accrual)
A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB) [NCT00881556]	Early Phase 1	3 participants (Actual)	Interventional	2009-08-20	Terminated
Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With Advanced and [NCT00800150]	Phase 1	6 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Protocol objective could not be met. A new study with amended eligibility criteria will be developed.)
A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme [NCT02937844]	Phase 1	20 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Phase II Study of Early Allogeneic Blood Stem Cell Transplantation During Induction-chemotherapy Induced Aplasia in High-risk Acute Myeloid Leukemia [NCT00188136]	Phase 2	32 participants (Actual)	Interventional	2002-08-31	Completed
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders [NCT00533923]	Phase 2	25 participants (Anticipated)	Interventional	2002-12-31	Completed
A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic [NCT00629798]	Phase 2	64 participants (Actual)	Interventional	2008-02-12	Completed
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen [NCT00719849]	Phase 2	13 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to A new protocol was developed to replace this protocol in 2008, with removal of ATG and extension of MMF duration.)
Haploidentical Hematopoietic Stem Cell Transplantation for Pediatric Patients With Wiskott-Aldrich Syndrome: A Pilot Study [NCT00160355]	Phase 1	4 participants (Actual)	Interventional	2005-05-31	Completed
Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia [NCT00455312]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2007-08-31	Completed
High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome [NCT00278512]	Phase 1	7 participants (Actual)	Interventional	2003-08-31	Terminated(stopped due to No participant enrolled over five years. No plan to continue the study.)
Allogeneic Natural Killer Cells in Patients With Relapsed Acute Myelogenous Leukemia [NCT00274846]	Phase 2	21 participants (Actual)	Interventional	2005-03-31	Completed
A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features [NCT00290511]	Phase 2	49 participants (Actual)	Interventional	2004-06-29	Completed
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer [NCT00429572]	Phase 2	19 participants (Actual)	Interventional	1998-01-31	Completed
A Phase I/II Study of Llme Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies [NCT00429416]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2004-03-31	Completed
Adaptive Randomization of Fludarabine-Melphalan Versus Fludarabine-Cyclophosphamide Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor for Metastatic Renal Cell Carcinoma [NCT00429026]	Phase 2	40 participants (Actual)	Interventional	2004-01-31	Terminated(stopped due to Slow accrual, study terminated.)
Phase II Clinical Trial of Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis [NCT01047072]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back [NCT00378534]	Phase 2	116 participants (Actual)	Interventional	2006-09-30	Completed
Pilot Study Of Haplo-Identical Natural Killer Cell Transplantation For Acute Myeloid Leukemia [NCT00187096]		49 participants (Actual)	Interventional	2005-09-30	Completed
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy [NCT06154252]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2023-11-17	Recruiting
A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell Lymphoma [NCT06079164]	Phase 1	39 participants (Anticipated)	Interventional	2023-11-09	Recruiting
A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [NCT04789408]	Phase 1	40 participants (Anticipated)	Interventional	2021-07-19	Recruiting
Phase Ib Study of Fludarabine, Cytarabine (Ara-C) and Pegylated Erwinase (Pegcrisantaspase) in Patients With Relapsed or Refractory Leukemia [NCT04526795]	Phase 1	62 participants (Anticipated)	Interventional	2021-04-09	Recruiting
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) P [NCT04240002]	Phase 1/Phase 2	97 participants (Anticipated)	Interventional	2020-09-04	Recruiting
Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation [NCT02861417]	Phase 2	204 participants (Actual)	Interventional	2016-08-05	Active, not recruiting
A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia [NCT00254163]	Phase 3	184 participants (Actual)	Interventional	2003-12-31	Completed
Treatment of Patients With Metastatic Melanoma Using a Transplant of Autologous Lymphocytes Reactive With Tumor Following a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy, Total Body Irradiation and Reconstitution With CD34+ Cells [NCT00096382]	Phase 2	34 participants (Actual)	Interventional	2004-09-30	Completed
A Phase II Study of Bortezomib in Combination With Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (VR-FND) for Relapsed or Refractory Follicular Lymphoma [NCT00510887]	Phase 2	14 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Low accrual.)
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL) [NCT00506129]	Phase 2	33 participants (Actual)	Interventional	2003-09-30	Completed
Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies [NCT01056614]	Phase 2	23 participants (Actual)	Interventional	2004-09-30	Completed
Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen [NCT00309842]	Phase 2	213 participants (Actual)	Interventional	2005-07-28	Completed
Imatinib Mesylate, Busulfan, Fludarabine, Antithymocyte Globulin and Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia [NCT00499889]	Phase 2	42 participants (Actual)	Interventional	2003-02-28	Terminated(stopped due to Support issue.)
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML) [NCT01020539]	Phase 1	18 participants (Actual)	Interventional	2002-09-11	Completed
Phase II Trial of Rituximab/Fludarabine Followed by CAMPATH-1H in the First-Line Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [NCT00193466]	Phase 2	40 participants	Interventional	2002-01-31	Completed
Phase II Study Evaluating The Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients Wi [NCT01883323]	Phase 2	12 participants (Actual)	Interventional	2013-06-30	Completed
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies [NCT03849651]	Phase 2	140 participants (Anticipated)	Interventional	2019-01-31	Recruiting
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia [NCT02251548]	Phase 2	85 participants (Actual)	Interventional	2014-10-31	Active, not recruiting
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation [NCT01962415]	Phase 2	100 participants (Anticipated)	Interventional	2014-02-04	Recruiting
Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies Using a Preparative Regimen of Busulfan, Cyclophosphamide, and Fludarabine [NCT00208923]	Phase 2	55 participants (Anticipated)	Interventional	1998-07-31	Completed
Phase I/II Trial of De-Escalation of Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency [NCT00228852]	Phase 1/Phase 2	0 participants	Interventional		Completed
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia [NCT01949129]	Phase 2/Phase 3	1,000 participants (Anticipated)	Interventional	2013-04-30	Recruiting
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma [NCT04666168]		200 participants (Anticipated)	Interventional	2020-10-22	Recruiting
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors [NCT04665076]		60 participants (Anticipated)	Interventional	2020-10-22	Recruiting
Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma [NCT00243009]	Phase 2	1 participants (Actual)	Interventional	2005-06-30	Terminated(stopped due to Due to a lack of a referal base, study was terminated.)
A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma [NCT01954784]	Phase 1	8 participants (Actual)	Interventional	2013-10-07	Terminated(stopped due to Funding unavailable)
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE) [NCT05869955]	Phase 1	43 participants (Anticipated)	Interventional	2023-09-13	Recruiting
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes [NCT01967823]	Phase 2	11 participants (Actual)	Interventional	2013-10-24	Completed
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types [NCT03449108]	Phase 2	30 participants (Actual)	Interventional	2018-04-27	Active, not recruiting
Personalized NK Cell Therapy in CBT [NCT02727803]	Phase 2	100 participants (Anticipated)	Interventional	2016-05-19	Recruiting
A Phase I/IIa, Open-label, Non-randomized, Study of ASC-101 in Patients With Hematologic Malignancies or Myelodysplastic Syndrome (MDS) Who Are Candidates for Dual-cord Umbilical Cord Blood Transplantation (UCBT) [NCT01983761]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2013-11-30	Active, not recruiting
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [NCT02626338]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2016-02-29	Completed
HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers [NCT02379520]	Phase 1	32 participants (Anticipated)	Interventional	2015-09-30	Active, not recruiting
Subcutaneous MabCampath® (Alemtuzumab) and Oral Fludara® (Fludarabinephosphate) for the Treatment of Refractory or Relapsed Chronic Lymphocytic Leukemia in 2nd or 3rd Line of Treatment: A Pilot Trial (FLUSALEM) for the Determination of Safety, Efficacy an [NCT00565981]	Phase 2	10 participants (Actual)	Interventional	2004-03-31	Completed
Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma [NCT00566332]	Phase 3	414 participants (Actual)	Interventional	2001-06-30	Completed
The VICTORY Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation [NCT05005299]	Phase 1	18 participants (Anticipated)	Interventional	2022-06-08	Recruiting
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas [NCT01181271]	Phase 2	42 participants (Actual)	Interventional	2010-08-31	Completed
MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions [NCT02582775]	Phase 2	17 participants (Actual)	Interventional	2016-03-31	Completed
An Adaptive, Comparative, Randomized, Parallel-group, Multi Center, Phase Ib Study of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With Chemotherapy (Fludarabine and Cyclophosphamide), in Patients With Previously Untre [NCT01292603]	Phase 1	240 participants (Actual)	Interventional	2011-04-18	Completed
Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) T [NCT01163357]	Phase 1	18 participants (Actual)	Interventional	2011-01-28	Active, not recruiting
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents [NCT02014506]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2017-01-31	Recruiting
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. [NCT00739141]	Phase 2	86 participants (Actual)	Interventional	2008-08-12	Completed
A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia [NCT02024308]	Phase 4	62 participants (Anticipated)	Interventional	2010-11-30	Recruiting
Anti-CD19 Universal CAR-T Cells for CD19+ B Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial [NCT04264039]	Early Phase 1	30 participants (Anticipated)	Interventional	2020-04-01	Not yet recruiting
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders [NCT00544115]	Phase 2	260 participants (Actual)	Interventional	2001-10-16	Active, not recruiting
[NCT00005898]	Phase 1/Phase 2	30 participants	Interventional	2000-02-29	Completed
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer [NCT00006261]	Phase 2	0 participants (Actual)	Interventional	2000-05-31	Withdrawn
Phase I/II Study of HLA-Matched Non-Myeloablative Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation as Treatment for Patients With Metastatic Renal Cell Carcinoma. A Multi-Center Trial. [NCT00005851]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2000-02-29	Completed
Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML [NCT00005863]	Phase 3	0 participants	Interventional	1998-08-31	Completed
Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced [NCT00005941]	Phase 2	0 participants	Interventional	1999-11-30	Completed
A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease [NCT00006100]	Phase 1	0 participants	Interventional	2000-04-30	Active, not recruiting
Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma [NCT00006250]	Phase 3	500 participants (Anticipated)	Interventional	2000-05-31	Active, not recruiting
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma [NCT06153251]	Phase 1	130 participants (Anticipated)	Interventional	2024-01-08	Not yet recruiting
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell The [NCT05972720]	Phase 2	123 participants (Anticipated)	Interventional	2023-08-01	Recruiting
A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma [NCT05883449]	Phase 2	154 participants (Anticipated)	Interventional	2023-10-10	Recruiting
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer [NCT04102436]	Phase 2	210 participants (Anticipated)	Interventional	2024-01-03	Not yet recruiting
An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Multiple Myeloma (MM) [NCT04626752]	Early Phase 1	50 participants (Anticipated)	Interventional	2020-04-01	Recruiting
Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) vs Fludarabine and Rituximab (F-R) for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [NCT00577161]	Phase 3	0 participants (Actual)	Interventional	2007-09-30	Withdrawn(stopped due to closed to enrollment)
MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning [NCT00564200]	Phase 2	30 participants (Anticipated)	Interventional	2007-11-30	Completed
Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL) [NCT00564512]	Phase 3	178 participants (Actual)	Interventional	2007-11-30	Completed
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning [NCT00475020]	Phase 2	63 participants (Actual)	Interventional	2006-01-04	Completed
A Phase I Study Evaluating The Use Of Rft5-Dga To Deplete Alloreactive Cells For Patients With Fanconi Anemia After Haploidentical Stem Cell Transplantation [NCT00586274]	Phase 1	1 participants (Actual)	Interventional	2002-03-31	Terminated(stopped due to Poor accrual)
A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell [NCT01088048]	Phase 1	241 participants (Actual)	Interventional	2010-03-25	Completed
Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NYESO1 and LAGE1a, and Co-expressing CD8α (GSK3901961) in Participants With NYESO1 and/or LAGE1a Positive Previously Treated Advance [NCT06048705]	Phase 1	7 participants (Actual)	Interventional	2021-03-09	Terminated(stopped due to The study was terminated due to a change in GSK's R&D priorities.)
A Phase I/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of HY004 in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) [NCT06009107]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2023-10-18	Not yet recruiting
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors [NCT05395052]	Phase 1	5 participants (Actual)	Interventional	2022-05-31	Terminated(stopped due to This study was terminated by the Sponsor.)
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders [NCT05293509]	Phase 2	0 participants (Actual)	Interventional	2022-03-02	Withdrawn(stopped due to 0 accrual)
A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors [NCT05069935]	Phase 1	16 participants (Actual)	Interventional	2021-10-15	Terminated(stopped due to This study was terminated by the Sponsor.)
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT04825496]	Phase 1	18 participants (Anticipated)	Interventional	2021-04-09	Recruiting
A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma [NCT04614636]	Phase 1	42 participants (Actual)	Interventional	2020-10-17	Terminated(stopped due to This study was terminated by the Sponsor.)
A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors [NCT04551885]	Phase 1	12 participants (Actual)	Interventional	2020-09-07	Terminated(stopped due to This study was terminated by the Sponsor.)
Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma [NCT04432506]	Phase 2	20 participants (Anticipated)	Interventional	2020-07-27	Active, not recruiting
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia [NCT04220684]	Phase 1	21 participants (Anticipated)	Interventional	2020-06-01	Recruiting
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma [NCT04171843]	Phase 1	48 participants (Actual)	Interventional	2020-04-30	Terminated(stopped due to Study was terminated due to lack of sufficient therapeutic effect)
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT03164057]	Phase 2	206 participants (Actual)	Interventional	2017-06-15	Active, not recruiting
A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma [NCT05934448]	Phase 2	35 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE) [NCT04715191]	Phase 1	24 participants (Anticipated)	Interventional	2024-01-03	Not yet recruiting
Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow [NCT02757885]	Phase 2	10 participants (Actual)	Interventional	2019-07-10	Completed
A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia. [NCT02158091]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2014-06-27	Active, not recruiting
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32] [NCT02661035]	Phase 2	156 participants (Actual)	Interventional	2017-03-09	Completed
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction With [NCT01319565]	Phase 2	102 participants (Actual)	Interventional	2011-03-24	Active, not recruiting
A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin Lymphoma [NCT06014073]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2023-09-06	Recruiting
BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched (Haploidentical) Allogeneic Transplantation in Patie [NCT04187105]	Phase 2	27 participants (Anticipated)	Interventional	2020-01-27	Recruiting
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults [NCT03779854]	Phase 2	68 participants (Anticipated)	Interventional	2019-08-29	Recruiting
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia [NCT02446964]	Phase 1	24 participants (Anticipated)	Interventional	2015-06-25	Active, not recruiting
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukem [NCT02159495]	Phase 1	31 participants (Actual)	Interventional	2015-12-15	Active, not recruiting
A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA) [NCT01810588]	Phase 2	273 participants (Actual)	Interventional	2012-10-16	Active, not recruiting
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab [NCT04135092]		0 participants	Expanded Access		No longer available
Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [NCT01173679]	Phase 2	10 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to Slow accrual)
An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System [NCT04561557]	Early Phase 1	18 participants (Anticipated)	Interventional	2020-09-22	Recruiting
MT2007-19R: WCC #53 Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer [NCT00652899]	Phase 2	14 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Withdrawn due to toxicity)
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant [NCT00472329]	Phase 2	20 participants (Anticipated)	Interventional	2007-03-31	Recruiting
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Ste [NCT05436418]	Phase 1/Phase 2	240 participants (Anticipated)	Interventional	2022-11-18	Recruiting
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen [NCT04195633]	Phase 2	60 participants (Anticipated)	Interventional	2021-01-25	Recruiting
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes [NCT00670748]	Phase 2	45 participants (Actual)	Interventional	2008-05-29	Terminated(stopped due to A more highly selected protocol with ESO TCR opened for pts with melanoma)
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies [NCT03642626]		240 participants (Anticipated)	Observational	2018-12-18	Recruiting
A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients. [NCT00727415]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2008-02-29	Completed
"Phase II Study of a Reduced-toxicity Submyeloablative Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies" [NCT00841724]	Phase 2	82 participants (Actual)	Interventional	2009-01-31	Completed
Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord BloodTransplantation In Patients With Refractory Acute Leukemia [NCT00686556]	Phase 1	12 participants (Actual)	Interventional	2012-08-31	Completed
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies [NCT02718755]	Phase 2	0 participants (Actual)	Interventional	2018-05-31	Withdrawn(stopped due to Problem with drug supply)
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome [NCT03393611]	Phase 1	14 participants (Actual)	Interventional	2012-11-30	Completed
Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52 [NCT00505921]	Phase 2	27 participants (Actual)	Interventional	2003-03-31	Terminated(stopped due to Slow Accrual.)
A Phase 1, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis [NCT05938725]	Phase 1	12 participants (Anticipated)	Interventional	2023-04-28	Recruiting
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT) [NCT05878184]	Phase 1	54 participants (Anticipated)	Interventional	2023-05-02	Recruiting
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia [NCT05761171]	Phase 2	78 participants (Anticipated)	Interventional	2023-11-20	Recruiting
A Phase 1b Dose Escalation Study of Metabolically Fit CD19 Chimeric Antigen Receptor (CAR) T Cells With CD34 Selection Markers in Adult Patients With Relapsed or Refractory CD19 B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocyti [NCT05702853]	Phase 1/Phase 2	27 participants (Anticipated)	Interventional	2023-11-06	Recruiting
Phase I Study of In Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma [NCT00324623]	Phase 1	8 participants (Actual)	Interventional	2005-09-30	Completed
A Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma: Hoosier Oncology Group LYM08-134 [NCT01186458]	Phase 2	4 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Slow accrual)
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial [NCT02867800]	Phase 1	24 participants (Actual)	Interventional	2016-07-31	Active, not recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy [NCT02724163]	Phase 3	700 participants (Anticipated)	Interventional	2016-04-30	Recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures [NCT02707393]	Phase 2/Phase 3	13 participants (Actual)	Interventional	2009-04-30	Completed
A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of B7H3 or HBsAg Targeting CAR-T in Treating Advanced Hepatocellular Carcinoma [NCT05323201]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2022-02-10	Recruiting
Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial [NCT04264078]	Early Phase 1	30 participants (Anticipated)	Interventional	2021-03-01	Recruiting
IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome [NCT04205838]	Phase 2	36 participants (Anticipated)	Interventional	2020-03-04	Recruiting
Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS) [NCT00902044]	Phase 1	36 participants (Anticipated)	Interventional	2010-02-11	Active, not recruiting
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade [NCT02775292]	Phase 1	1 participants (Actual)	Interventional	2017-01-03	Completed
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies [NCT00627666]	Phase 2	52 participants (Anticipated)	Interventional	2003-01-31	Completed
A Phase I/II Study of Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 Chimeric Antigen Receptor T-Cells in Patients With Refractory CD19+ B-lineage Leukemia/Lymphoma [NCT02685670]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia [NCT00408447]	Phase 2	53 participants (Actual)	Interventional	2004-09-30	Active, not recruiting
A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate [NCT00625430]	Phase 1	18 participants (Anticipated)	Interventional	2008-03-31	Recruiting
Allogenic Immunotherapy Based on Natural Killer Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab : a Phase I Trial [NCT02845999]	Phase 1	9 participants (Actual)	Interventional	2009-11-30	Completed
Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294) [NCT00899431]	Phase 2	39 participants (Actual)	Interventional	2009-05-06	Terminated(stopped due to Terminated per PI's request at the time of continuing review)
Efficacy and Safety of Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (oFCG) in the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) [NCT05322733]	Phase 2	25 participants (Anticipated)	Interventional	2022-04-15	Recruiting
Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy [NCT00948922]	Phase 2	124 participants (Actual)	Interventional	2009-06-18	Completed
To Investigate the Safety and Preliminary Efficacy of EBV CAR-T Cells in the Treatment of Relapsed/Refractory EBV-positive Nasopharyngeal Carcinoma [NCT05654077]	Early Phase 1	24 participants (Anticipated)	Interventional	2022-01-18	Recruiting
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma [NCT04665063]		20 participants (Anticipated)	Interventional	2020-10-22	Recruiting
Graft-versus-host Disease Prophylaxis With Post-transplantation Cyclophosphamide and Ruxolitinib in Patients With Myelofibrosis [NCT02806375]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2016-01-31	Completed
Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study [NCT04473911]	Phase 1	25 participants (Actual)	Interventional	2020-08-14	Active, not recruiting
A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymph [NCT00551239]	Phase 3	0 participants (Actual)	Interventional	2007-08-31	Withdrawn
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia [NCT01423500]	Phase 3	405 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL [NCT00185445]	Phase 2	62 participants (Actual)	Interventional	2004-06-30	Completed
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia [NCT01423747]	Phase 3	400 participants (Anticipated)	Interventional	2003-07-31	Active, not recruiting
Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft [NCT02556931]	Phase 2	117 participants (Actual)	Interventional	2015-12-31	Completed
A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma [NCT02992743]	Phase 2	23 participants (Actual)	Interventional	2016-12-06	Completed
Treatment of Patients With Metastatic Melanoma by Lymphodepleting Conditioning Followed by Infusion of TCR-Gene Engineered Lymphocytes and Subsequent Fowlpox gp100 Vaccination [NCT00085462]	Phase 1	61 participants (Anticipated)	Interventional	2004-05-31	Completed
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation [NCT03159702]	Phase 2	43 participants (Anticipated)	Interventional	2017-12-08	Recruiting
An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma. [NCT00169208]	Phase 2	50 participants (Actual)	Interventional	2001-04-30	Completed
Phase II Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low-Dose TBI, and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil (MMF) Followed by Donor Lymphocyte Infusion [NCT00006233]	Phase 2	0 participants	Interventional	2000-01-31	Completed
Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil [NCT00006251]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2000-05-31	Completed
A Prospective Phase I/IIa, Open-label, Multicenter Trial to Evaluate the Safety and Efficacy of oNKord®, an Off-the-shelf, ex Vivo-cultured Allogeneic NK Cell Preparation, in Subjects With Acute Myeloid Leukemia Who Are in Morphologic Complete Remission W [NCT04632316]	Phase 1/Phase 2	33 participants (Anticipated)	Interventional	2020-12-08	Recruiting
Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies [NCT00202917]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2004-02-29	Completed
Phase II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric Acute Myeloid Leukemia [NCT00887042]	Phase 1/Phase 2	35 participants (Anticipated)	Interventional	2006-06-30	Active, not recruiting
Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia [NCT02799147]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2016-06-30	Completed
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [NCT05451849]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2022-06-21	Active, not recruiting
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies [NCT00714259]	Phase 2/Phase 3	5 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to Accrual goals could not be met within a timely manner)
A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System [NCT04426669]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2020-05-15	Recruiting
Phase I Clinical Trial Evaluating Safety of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL) [NCT04653493]	Phase 1	22 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) [NCT05712278]	Phase 1	12 participants (Anticipated)	Interventional	2023-06-16	Recruiting
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [NCT05442515]	Phase 1/Phase 2	116 participants (Anticipated)	Interventional	2022-12-28	Recruiting
A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia [NCT00186966]	Phase 3	394 participants (Actual)	Interventional	2002-03-31	Completed
A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16) [NCT00187083]	Phase 3	40 participants (Actual)	Interventional	1997-02-28	Completed
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507) [NCT03263559]	Phase 2	80 participants (Anticipated)	Interventional	2017-10-03	Active, not recruiting
A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia [NCT00337246]	Phase 2	56 participants (Anticipated)	Interventional	2005-07-31	Completed
A Pilot Phase II Trial of Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma [NCT00183989]	Phase 2	30 participants (Anticipated)	Interventional	2000-08-31	Terminated(stopped due to Insufficient accrual)
[NCT00186797]		28 participants	Interventional	2002-12-31	Completed
A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic L [NCT00220311]	Phase 4	10 participants (Actual)	Interventional	2000-11-30	Completed
Phase II Trial of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Primary Immune Deficiencies, Immune Dysregulatory Syndromes, and Inherited Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide [NCT04232085]	Phase 2	27 participants (Anticipated)	Interventional	2020-02-12	Recruiting
T Cell Receptor Alpha/Beta T Cell Depleted (α/β TCD) Hematopoietic Cell Transplantation in Patients With Fanconi Anemia (FA) [NCT03579875]	Phase 2	48 participants (Anticipated)	Interventional	2018-11-13	Recruiting
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases [NCT01962636]		200 participants (Anticipated)	Interventional	2016-12-31	Recruiting
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Acute Lymphoblastic Leukemia. [NCT02924753]	Phase 1	20 participants (Anticipated)	Interventional	2016-07-18	Recruiting
A Phase 1 Open-Label Dose-Escalation Study of the Safety of Adoptively Transferred Autologous CD8+ T Lymphocytes Targeting HPV-16 E6/E7, HPV-18 E6/E7 and Survivin in Patients With Relapsed or Refractory HPV-related Oropharyngeal Cancers [NCT05582590]	Phase 1	36 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies [NCT00782379]	Phase 2	20 participants (Actual)	Interventional	2008-10-31	Completed
"High Dose Interleukin-2 (IL-2) Therapy In Lymphodepleted Primed Patients With Metastatic Melanoma" [NCT00085423]	Phase 2	20 participants (Actual)	Interventional	2004-02-29	Completed
Haploidentical Donor NK Cell Adoptive Therapy and Double T Cell Depleted Umbilical Cord Blood Transplantation With Post-Transplant IL-2 Immune Therapy For Refractory Acute Myeloid Leukemia [NCT00871689]	Phase 2	2 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to Due to graft failure.)
A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [NCT00918723]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2009-06-30	Completed
Clinical Study on the Safety and Efficacy of Anti-PSMA CAR NK Cells in Metastatic Castration-resistant Prostate Cancer (mCRPC) [NCT03692663]	Early Phase 1	9 participants (Anticipated)	Interventional	2018-12-01	Recruiting
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Using Melphalan for T-Cell Tolerization [NCT01350258]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Poor accrual)
Phase I/II Pilot Study of Allogeneic Peripheral Blood Stem Cell Infusion For Patients With High Risk Chronic Lymphocytic Leukemia [NCT00002838]	Phase 1/Phase 2	13 participants (Actual)	Interventional	1995-12-31	Completed
Phase I/II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation Followed by Allogeneic T-cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Melanoma [NCT00003552]	Phase 1/Phase 2	0 participants	Interventional	1999-01-31	Terminated
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies [NCT01471067]	Phase 1	33 participants (Actual)	Interventional	2012-07-13	Completed
A Single-center Open-label Phase I Study of ALT-801 for ex Vivo Maturation and in Vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT01478074]	Phase 1	0 participants (Actual)	Interventional	2011-11-30	Withdrawn(stopped due to The treatment planned was determined to be of low feasibility as no subject was found eligible and able to enroll after screening over 30 subjects)
Observational Study for Evaluation of Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia. [NCT00344825]		300 participants (Actual)	Observational	2004-01-31	Completed
FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT00488709]	Phase 4	47 participants (Actual)	Interventional	2003-05-31	Completed
Dose Finding Study of Gelonin Purging of Autologous Stem Cells for Transplantation of Patients With AML/MDS in First or Subsequent Remission [NCT00043810]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2002-07-31	Terminated
Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia) [NCT01247493]	Phase 2	108 participants (Actual)	Interventional	2007-06-30	Completed
Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [NCT05554939]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2022-12-11	Recruiting
FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemi [NCT00487448]	Phase 4	200 participants (Anticipated)	Interventional	1998-07-31	Completed
Infusion of Allogeneic, 3rd Party CD19-specific T Cells for Patients With Refractory CD19+ B-Lineage Lymphoid Malignancies [NCT02274506]	Phase 1	0 participants (Actual)	Interventional	2014-10-20	Withdrawn(stopped due to PI's response to ePAAC, has withdrawn the protocol acknowledging the PI's action.)
Phase I/II Randomized Trial of Cord Blood-derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma [NCT06066359]	Phase 1/Phase 2	44 participants (Anticipated)	Interventional	2023-11-30	Recruiting
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency [NCT05907746]	Phase 2	32 participants (Anticipated)	Interventional	2023-11-29	Recruiting
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand [NCT05146739]	Phase 1	18 participants (Anticipated)	Interventional	2023-12-23	Recruiting
Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases [NCT04083183]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2020-06-16	Recruiting
A Phase I Trial of Lymphodepletion Plus Adoptive Cell Therapy With High-Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma [NCT04052334]	Phase 1	10 participants (Actual)	Interventional	2019-09-27	Active, not recruiting
NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING [NCT00521430]		30 participants (Anticipated)	Interventional	2004-04-30	Completed
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation [NCT00516152]	Phase 2	36 participants (Anticipated)	Interventional	2002-11-30	Completed
A Phase II Study of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Administered Subcutaneously as Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia [NCT00098670]	Phase 2	102 participants (Actual)	Interventional	2004-10-31	Completed
T Cell Therapy for Patients With Metastatic Renal Cell Carcinoma [NCT02926053]	Phase 1	6 participants (Anticipated)	Interventional	2016-12-31	Recruiting
[NCT00529880]	Phase 2	19 participants (Anticipated)	Interventional	2004-12-31	Recruiting
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias [NCT04623944]	Phase 1	90 participants (Anticipated)	Interventional	2020-09-21	Recruiting
Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma [NCT03602157]	Phase 1	59 participants (Anticipated)	Interventional	2018-12-12	Recruiting
A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors [NCT02498912]	Phase 1	18 participants (Actual)	Interventional	2015-08-31	Active, not recruiting
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma [NCT02348216]	Phase 1/Phase 2	307 participants (Actual)	Interventional	2015-04-21	Completed
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT) [NCT01044745]	Phase 2	20 participants (Actual)	Interventional	2009-12-10	Terminated(stopped due to Study was closed to accrual for safety related to the frequency of BK infections.)
Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma [NCT02933775]	Phase 1	45 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somat [NCT01283386]	Phase 4	26 participants (Actual)	Interventional	2011-04-27	Terminated
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) [NCT04942730]	Phase 2	40 participants (Anticipated)	Interventional	2021-01-21	Recruiting
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer [NCT04227275]	Phase 1	16 participants (Actual)	Interventional	2019-11-22	Terminated(stopped due to Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.)
A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine [NCT02143830]	Phase 2	70 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies [NCT02581007]	Phase 2	25 participants (Actual)	Interventional	2015-10-26	Completed
Ma-Spore ALL 2010 Study [NCT02894645]	Phase 4	500 participants (Anticipated)	Interventional	2008-10-31	Recruiting
Study to Evaluate the Efficacy and Safety of Relmacabtagene Autoleucel (Relma-cel) as First-Line Therapy in Adult Participants With High-Risk Large B-Cell Lymphoma [NCT05590221]	Phase 2	20 participants (Anticipated)	Interventional	2023-01-03	Recruiting
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin. [NCT04673617]	Phase 1/Phase 2	108 participants (Anticipated)	Interventional	2021-03-29	Recruiting
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies [NCT03983850]	Phase 1/Phase 2	400 participants (Anticipated)	Interventional	2019-07-09	Recruiting
A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL [NCT00543114]	Phase 1	9 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to lack of efficacy and tolerability)
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia [NCT05320380]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-08-01	Withdrawn(stopped due to Withdrawn per CS0150757)
Phase 2 Study of Personalized r-ATG Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (PRAISE-IR) [NCT04872595]	Phase 2	56 participants (Anticipated)	Interventional	2021-04-30	Recruiting
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients [NCT03745326]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2019-05-16	Recruiting
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients [NCT03190941]	Phase 1/Phase 2	110 participants (Anticipated)	Interventional	2017-09-21	Recruiting
Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brai [NCT04510051]	Phase 1	18 participants (Anticipated)	Interventional	2020-12-04	Recruiting
Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment [NCT03096782]	Phase 2	6 participants (Actual)	Interventional	2017-10-13	Completed
A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine [NCT00987480]	Phase 2	45 participants (Actual)	Interventional	2009-09-25	Completed
Phase I/Ib Study of Adoptive NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Reactive Against the NY-ESO-1-specific Cord Blood-derived NK Cells (NY-ESO-1 TCR/IL-15 NK) in Conjunction With Lymphodepleting Chemotherapy for the Management of Advance [NCT06083883]	Phase 1	44 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
Reduced Intensity Conditioning (RIC) and Transplantation of HLA(Human Leukocyte Antigen)-Haploidentical Related Bone Marrow (Haplo-BM) For Patients With Hematologic Diseases [NCT02145039]		2 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Replaced by another study.)
Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors [NCT00787761]	Phase 2	24 participants (Actual)	Interventional	2007-04-30	Completed
Sequential Myeloablative Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease [NCT00802113]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2003-06-30	Completed
Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies [NCT00818961]	Phase 2	36 participants (Actual)	Interventional	2005-05-31	Terminated(stopped due to terminated early due to meeting end point with fewer patients than anticipated)
Lenalidomide Following Rituximab and Fludarabine in Untreated Chronic Lymphocytic Leukemia [NCT00860457]	Phase 2	22 participants (Actual)	Interventional	2008-02-29	Completed
Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen [NCT00919503]	Phase 2	98 participants (Actual)	Interventional	2009-07-31	Completed
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas [NCT05583149]	Phase 2	27 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Nonmyeloablative BMT With Post-transplant Cyclophosphamide, Rituximab and Optimized Donor Selection for B-cell Lymphomas [NCT00946023]	Phase 2	135 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Funding was unavailable to complete the study as originally planned.)
Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy [NCT00003204]	Phase 3	515 participants (Actual)	Interventional	1998-03-31	Completed
A Phase I-II Study for the Treatment of Steroid Resistant GVHD With Fludarabine [NCT00004194]	Phase 1/Phase 2	0 participants	Interventional		Active, not recruiting
Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide [NCT00004218]	Phase 3	0 participants	Interventional	1999-10-31	Completed
A Study to Determine the Safety and Efficacy of Using CD8-High Density Microparticles (CD8-HDM) to Deplete CD8+ Cells From Donor Lymphocyte Infusion in Order to Reduce Graft-versus-Host Disease (GvHD) Without Compromising an Anti-Leukemia Effect in Patien [NCT00004878]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to study never opened)
Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma [NCT00005580]	Phase 1	54 participants (Actual)	Interventional	1998-09-30	Completed
Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant [NCT00005802]	Phase 1/Phase 2	0 participants	Interventional	1999-06-30	Completed
Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status [NCT01271010]	Phase 4	89 participants (Actual)	Interventional	2011-06-17	Terminated
A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refrac [NCT03467256]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2018-05-14	Active, not recruiting
Haploidentical Stem Cell Transplant Using Post Transplant Cyclophosphamide for GvHD Prophylaxis: A Pilot Study [NCT02248597]	Phase 2	27 participants (Actual)	Interventional	2015-02-25	Completed
Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation [NCT01472055]	Phase 2	46 participants (Anticipated)	Interventional	2011-10-31	Recruiting
A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation [NCT03342196]	Phase 2	40 participants (Actual)	Interventional	2018-03-21	Active, not recruiting
A Randomized Phase II Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) [NCT01894477]	Phase 2	102 participants (Actual)	Interventional	2013-11-30	Active, not recruiting
Natural Killer Cells in Allogeneic Cord Blood Transplantation [NCT01619761]	Phase 1	13 participants (Actual)	Interventional	2013-05-03	Active, not recruiting
A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia [NCT00068315]	Phase 1	18 participants (Actual)	Interventional	2003-07-31	Completed
Safety And Efficacy of Sub-Myeloablative Allogeneic Stem Cell Transplantation For Patients With Myeloproliferative Disorder (MPD), Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia [NCT00069992]	Phase 2	7 participants (Actual)	Interventional	2001-12-31	Terminated(stopped due to Closed due to competing protocols)
Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia [NCT00262795]	Phase 3	206 participants (Actual)	Interventional	2003-09-30	Completed
A Multi-Center Phase II Study of Nonmyeloablative Conditioning With TBI and Fludarabine for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Chronic Myeloid Leukemia in Chronic and Accelerated Phase [NCT00110058]	Phase 2	40 participants (Anticipated)	Interventional	2005-02-28	Completed
Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia [NCT00281983]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2000-06-30	Completed
A Phase I Trial Of Sequential Administration Of Triapine (3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone) Followed By Fludarabine In Adults With Relapsed And Refractory Leukemias And Myelodysplasias [NCT00077558]	Phase 1	0 participants	Interventional	2004-01-31	Completed
A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation [NCT00290641]		68 participants (Actual)	Interventional	2001-04-30	Completed
Fludarabine and Low-Dose TBI Dose Escalation to Determine the Optimal Regimen for Achieving High Rates Engraftment of Unrelated Donor Peripheral Blood Stem Cell in Patients With Chronic Myeloid Leukemia - A Multi-Center Trial [NCT00119340]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2005-04-30	Completed
Abbreviated Fludarabine / Mitoxantrone / Rituximab Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma [NCT00119730]	Phase 2	30 participants (Actual)	Interventional	2005-02-28	Completed
Phase II Trial Comparing Combination Treatment With Fludarabine and Alemtuzumab to Fludarabine and Rituximab in Patients With B-Cell Chronic Lymphocytic Leukemia Requiring Treatment After First Line Therapy [NCT00086775]	Phase 2	0 participants	Interventional	2003-07-31	Completed
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation [NCT00301912]	Phase 2	0 participants (Actual)	Interventional	2002-01-31	Withdrawn(stopped due to Withdrawn because study never opened to accrual)
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies [NCT00301951]	Phase 1	7 participants (Actual)	Interventional	2004-09-30	Completed
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies [NCT00304018]	Phase 1	5 participants (Actual)	Interventional	2002-10-31	Completed
Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies [NCT00296023]		25 participants (Actual)	Interventional	1999-01-31	Completed
Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Anti Cluster of Differentiation Antigen 19 (Anti-CD19) Chimeric Antigen Receptor T (CAR T) Cell Therapy With Kymriah/tIsagenlecleucel (LOKI) [NCT06003179]	Phase 1	40 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Phase I/IIa Multicenter Study Evaluating the Safety and Efficacy of CAR20(NAP)-T in Patients With Relapsed/Refractory B Cell Lymphoma (CARMA-01 Study) [NCT06002659]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia [NCT06001788]	Phase 1	171 participants (Anticipated)	Interventional	2023-12-31	Recruiting
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [NCT06001385]	Phase 2	170 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers [NCT05035407]	Phase 1	100 participants (Anticipated)	Interventional	2022-03-08	Recruiting
Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia [NCT04558736]	Phase 2	21 participants (Anticipated)	Interventional	2021-01-21	Active, not recruiting
Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With CD123 Target Module (TM123) for the Treatment of Patients With Hematologic and Lymphati [NCT04230265]	Phase 1	90 participants (Anticipated)	Interventional	2020-01-28	Recruiting
Phase I/II Study of Dual CD19-CD22 Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced CD19+ CD22+ Lymphoid Malignancies [NCT04029038]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-05-15	Withdrawn(stopped due to 0 participant accrual)
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia [NCT03766126]	Phase 1	12 participants (Anticipated)	Interventional	2018-12-06	Active, not recruiting
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis [NCT03118492]	Phase 1	16 participants (Anticipated)	Interventional	2017-05-24	Recruiting
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome [NCT01861106]	Phase 2	144 participants (Anticipated)	Interventional	2013-07-24	Recruiting
A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes and Subsequent Peptide Immunization [NCT00091104]	Phase 1	136 participants (Anticipated)	Interventional	2004-07-31	Completed
A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma [NCT00091143]	Phase 1	20 participants (Anticipated)	Interventional	2004-07-31	Completed
Phase II Study in Metastatic Renal Cell Cancer Using Cultured, Tumor-Reactive Lymphocytes and Interleukin-2 [NCT00091611]	Phase 1	3 participants (Actual)	Interventional	2004-09-30	Terminated(stopped due to This study was terminated due to low accrual.)
The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells [NCT00084695]	Phase 2	25 participants (Anticipated)	Interventional	2003-09-30	Recruiting
A Phase II Pilot Study of Tumor-Loaded Dendritic Cells Alone or Following a Non-Myeloablative Conditioning Regimen in Patients With Metastatic Renal Cell Carcinoma [NCT00093522]	Phase 2	28 participants (Anticipated)	Interventional	2004-08-31	Active, not recruiting
A Phase I Study to Assess the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors [NCT05141474]	Early Phase 1	10 participants (Anticipated)	Interventional	2021-10-28	Recruiting
A Multicenter, Single Arm, Open Label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of HRYZ-T101 Injection for HPV18 Positive Solid Tumor [NCT05952947]	Phase 1	32 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage [NCT01701323]	Phase 1	7 participants (Actual)	Interventional	2012-12-10	Terminated
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Pati [NCT04285567]	Phase 3	166 participants (Actual)	Interventional	2020-05-28	Active, not recruiting
UARK 2003-18, A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma [NCT00089453]	Phase 1	10 participants (Actual)	Interventional	2003-09-30	Completed
A Pilot Study to Evaluate the Co-infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies [NCT00343798]	Phase 1	23 participants (Actual)	Interventional	2006-04-30	Completed
Alloreactive NK Cells With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for AML and MDS [NCT00402558]	Phase 1	15 participants (Actual)	Interventional	2006-05-31	Completed
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial [NCT00093743]	Phase 1	2 participants (Actual)	Interventional	2000-01-31	Completed
Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells [NCT00104975]	Phase 1	20 participants (Anticipated)	Interventional	2005-02-28	Completed
A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT00454480]	Phase 2/Phase 3	2,000 participants (Anticipated)	Interventional	2006-08-31	Completed
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Treatment of Indolent Lymphoid Malignancies [NCT00473551]	Phase 1	4 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Terminated due to slow accrual.)
A Phase IB Study to Assess the Safety and Efficacy of Neoadjuvant Administration of Autologous Tumor Infiltrating Lymphocytes (LN144/Lifileucel) and Pembrolizumab for Treatment of Patients With Locally Advanced (Stage IIIB-D)/Metastatic (Stage IV) Melanom [NCT05176470]	Phase 1	15 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Cord Blood Expansion on Mesenchymal Stem Cells [NCT00498316]	Phase 1	98 participants (Actual)	Interventional	2007-07-03	Completed
Phase II Study of Sequential Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis [NCT00133367]	Phase 2	32 participants (Anticipated)	Interventional	2005-08-31	Completed
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers [NCT02858310]	Phase 1/Phase 2	180 participants (Anticipated)	Interventional	2017-01-27	Recruiting
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML) [NCT01247701]		16 participants (Actual)	Interventional	2010-11-30	Completed
Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML [NCT02275663]	Phase 2	37 participants (Anticipated)	Interventional	2014-12-31	Recruiting
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-NKT in the Treatment of Relapsed or Metastatic Advanced Renal Cell Carcinoma. [NCT06182735]	Phase 1	9 participants (Anticipated)	Interventional	2023-07-17	Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma [NCT05371093]	Phase 3	230 participants (Anticipated)	Interventional	2022-09-12	Recruiting
Phase I/II First-in-Human Trial With CAR19 Regulatory T Cells (CAR19-tTreg) in Adults With Relapsed/Refractory CD19+ B Acute Lymphocytic Leukemia [NCT05114837]	Phase 1/Phase 2	31 participants (Anticipated)	Interventional	2024-05-31	Not yet recruiting
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS [NCT04708054]	Phase 2	100 participants (Anticipated)	Interventional	2021-10-21	Recruiting
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers [NCT03912831]	Phase 1	8 participants (Actual)	Interventional	2019-04-30	Terminated(stopped due to Development program terminated)
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p) [NCT02629809]	Phase 2	81 participants (Actual)	Interventional	2016-03-18	Active, not recruiting
Administration Of TGF-beta Resistant Cytotoxic T-Lymphocytes to Patients With EBV-positive Nasopharyngeal Carcinoma (RESIST-NPC) [NCT02065362]	Phase 1	14 participants (Anticipated)	Interventional	2015-02-28	Active, not recruiting
A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-Beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma [NCT01955460]	Phase 1	15 participants (Anticipated)	Interventional	2014-10-15	Recruiting
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia [NCT00801489]	Phase 2	270 participants (Anticipated)	Interventional	2007-04-04	Recruiting
Allogeneic Stem Cell Transplantation Followed By Adoptive Immunotherapy for Patients With Relapsed and Refractory Hodgkin's Disease [NCT00385788]	Phase 2	52 participants (Actual)	Interventional	2005-07-31	Completed
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-Compatible Related or Unrelated Donors in Patients With B Cell Lymphoid Malignancies [NCT00425802]	Phase 2	61 participants (Actual)	Interventional	2006-11-28	Completed
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes [NCT00509496]	Phase 2	21 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to Low accrual)
Hematopoietic Cell Transplantation for Treatment of Patients With Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine With or Without Campath® [NCT00553098]	Phase 2	29 participants (Actual)	Interventional	2006-06-30	Completed
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization [NCT00612222]	Phase 2	4 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to The study was terminated due to low accrual.)
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis [NCT00618540]	Phase 2	1 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Slow accrual)
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML [NCT01168219]	Phase 2	68 participants (Actual)	Interventional	2010-07-15	Completed
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults With B Cell Malignancies [NCT04735471]	Phase 1	78 participants (Anticipated)	Interventional	2021-03-04	Recruiting
CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome, Acute Leukemia, and Chronic Myelogenous Leukemia [NCT04151706]	Phase 2	20 participants (Anticipated)	Interventional	2020-02-27	Suspended(stopped due to Interim analysis)
Umbilical Cord Blood Transplantation From Unrelated Donors [NCT03016806]	Phase 1	30 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases [NCT00582894]		17 participants (Actual)	Interventional	2005-02-28	Completed
Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia [NCT00590460]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2001-07-31	Terminated(stopped due to slow accrual)
HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide [NCT00358657]	Phase 2	14 participants (Actual)	Interventional	2006-05-24	Terminated(stopped due to Low accrual)
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies [NCT00683046]	Phase 2	204 participants (Actual)	Interventional	2001-11-30	Completed
Prospective Identification of Significant Prognostic Factors in Patients Treated With Fludarabine, Cyclophosphamide, and Rituximab (FCR) as Initial Therapy for Chronic Lymphocytic Leukemia. [NCT00759798]	Phase 2	289 participants (Actual)	Interventional	2008-08-13	Completed
Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma [NCT00793572]	Phase 2	32 participants (Actual)	Interventional	2008-10-31	Completed
Combined Haploidentical-Cord Blood Transplantation for Adults and Children [NCT00943800]		87 participants (Actual)	Interventional	2006-10-09	Completed
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial) [NCT01005576]	Phase 2	21 participants (Actual)	Interventional	2010-01-31	Completed
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [NCT01008462]	Phase 2	16 participants (Actual)	Interventional	2010-03-18	Completed
A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy With Tumour Infiltrating Lymphocytes (TIL) and Assessment of High Versus Low Dose Interleukin-2 [NCT01995344]	Phase 2	2 participants (Actual)	Interventional	2014-03-01	Terminated(stopped due to Withdrawal of funding)
A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL) [NCT01096992]	Phase 1/Phase 2	51 participants (Actual)	Interventional	2010-04-19	Completed
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30) [NCT01105650]	Phase 2	13 participants (Actual)	Interventional	2010-07-31	Completed
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin [NCT01495572]	Phase 2	5 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Due to slow accrual, the investigator decided to close the study.)
A Phase I Study of FT819 in Subjects With B-cell Malignancies [NCT04629729]	Phase 1	396 participants (Anticipated)	Interventional	2021-07-26	Recruiting
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12) [NCT03761056]	Phase 2	42 participants (Actual)	Interventional	2019-01-29	Completed
A Phase II Study of Hematopoietic Stem Cell Therapy for Young Adults With Severe Sickle Cell Disease [NCT01565616]	Phase 2	22 participants (Actual)	Interventional	2012-03-31	Completed
Phase I/II Study of CD40 Ligand Expressing MSLN-CAR T Cell Treatment in MSLN Positive Advanced/Metastatic Solid Tumors [NCT05693844]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2023-01-20	Recruiting
An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Non-Hodgkin Lymphoma (NHL) [NCT04626739]	Early Phase 1	100 participants (Anticipated)	Interventional	2020-04-01	Recruiting
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptima [NCT06045806]	Phase 3	618 participants (Anticipated)	Interventional	2023-10-16	Recruiting
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children [NCT04610125]		30 participants (Anticipated)	Interventional	2020-06-23	Recruiting
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia [NCT01300247]	Phase 1	41 participants (Actual)	Interventional	2011-05-31	Completed
A Phase II, Multicenter, Single Arm Study to Determine the Efficacy and Safety of Low Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab as Primary Therapy in Elderly Untreated Patients (>/=65 Years Old) With Chronic Lymphocytic L [NCT01263704]	Phase 2	42 participants (Actual)	Interventional	2011-07-17	Completed
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) [NCT01666080]		30 participants (Anticipated)	Interventional	2012-08-31	Recruiting
A Phase 1 Study to Evaluate Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Primary CNS Lymphoma [NCT05625594]	Phase 1	20 participants (Anticipated)	Interventional	2023-06-29	Recruiting
A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System [NCT05566223]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Relat [NCT01050764]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to Safety)
Dose Escalation Trial of Cloretazine (VNP40101M) and Hematopoietic Cell Transplantation for Patients With Selected, Poor-Prognosis Hematologic Malignancies [NCT00521859]	Phase 1	5 participants (Actual)	Interventional	2007-08-31	Completed
HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia [NCT00524667]	Phase 2	6 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Terminated due to poor accrual.)
Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN) [NCT02410551]	Phase 2	4 participants (Actual)	Interventional	2015-06-15	Terminated
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [NCT03277729]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2017-12-05	Recruiting
Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia [NCT04262843]	Phase 2	70 participants (Anticipated)	Interventional	2020-02-07	Recruiting
Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas [NCT04074746]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2020-07-18	Active, not recruiting
A Phase 1 Safety Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia [NCT03126864]	Phase 1	11 participants (Actual)	Interventional	2017-08-04	Terminated(stopped due to Terminated per the PI's request.)
A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma [NCT01434472]	Phase 2	20 participants (Actual)	Interventional	2011-11-16	Terminated(stopped due to Terminated due to insufficient funding)
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning [NCT05031897]	Phase 2	67 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Non-Myeloablative Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Disorders [NCT00053989]	Phase 2	41 participants (Actual)	Interventional	2002-01-29	Completed
[NCT01540812]		418 participants (Actual)	Observational	2012-02-29	Completed
Phase II Study of Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia in First Remission [NCT00101140]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic A [NCT00003619]	Phase 1/Phase 2	0 participants	Interventional	1998-02-28	Completed
A Clinical Trial Evaluating I131-Tositumomab (Anti-CD20) With Escalating Doses of Fludarabine Followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma in Patients 60 Years of Age and Older [NCT00110071]	Phase 1	38 participants (Actual)	Interventional	2005-01-31	Completed
A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants [NCT00112567]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2003-04-30	Completed
A Phase I Study Combining Escalating Doses of Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to Establish Mixed or Full Donor Chimerism [NCT00008177]	Phase 1	79 participants (Actual)	Interventional	1999-07-27	Completed
Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer [NCT00020176]	Phase 2	0 participants	Interventional	2000-06-30	Completed
Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine [NCT00009984]	Phase 2	70 participants (Actual)	Interventional	2002-03-31	Terminated
Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) [NCT00020800]	Phase 2	7 participants (Actual)	Interventional	2001-09-30	Completed
Submyeloablative Allogeneic Blood Stem Cell Transplantation With HLA Identical Donor Lymphocyte Infusions From Matched Related and Matched Unrelated Donors for Treatment of Metastatic Renal Cell Carcinoma [NCT00025519]	Phase 2	0 participants (Actual)	Interventional	2001-06-30	Withdrawn
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Sibling Donors For Treatment Of Patients With High Risk Acute Lymphocytic Leukemia In Complete Remission [NCT00027547]	Phase 1/Phase 2	0 participants	Interventional	2001-07-31	Completed
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial [NCT00027820]	Phase 1/Phase 2	106 participants (Actual)	Interventional	2001-08-31	Completed
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma [NCT00028600]	Phase 2	60 participants (Actual)	Interventional	2001-11-30	Completed
Allogeneic Stem Cell Transplantation Following Nonmyeloablative Chemotherapy in Patients With Hemoglobinopathies [NCT00034528]	Phase 2	2 participants (Actual)	Interventional	2001-09-30	Terminated(stopped due to Due to slow recruitment)
Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine and/or Low Dose TBI With Disease-Risk Based Immunosuppression [NCT00014235]		160 participants (Anticipated)	Interventional	2000-12-31	Completed
Allo SCT From HLA Haploidentical Related Donors Using Sub-Myeloablative Conditioning For Patients With High Risk Hemoglobinopathies: Hemo SS, Hemo SC, Hemo SB0/+ Thalassemia, Homozygous B0/+ Thalassemia or Severe B0/+ Thalassemia Variants [NCT00040417]	Phase 2	15 participants	Interventional	2000-08-31	Terminated(stopped due to unable to accrue patients)
Transplantation With T-Cell Depleted Autologous Peripheral Stem Cells for Severe Systemic Sclerosis: A Phase I Dose Escalation Study [NCT00040651]	Phase 1	15 participants	Interventional	2002-07-31	Terminated
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis [NCT00001586]	Phase 2	105 participants (Actual)	Interventional	1997-09-30	Completed
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancy, Using MHC Identical or Near Identical Donors and Sub-Myeloablative Conditioning With CAMPATH 1H (DIMSUM) [NCT00048412]	Phase 1/Phase 2	40 participants	Interventional	2000-06-30	Completed
A Phase II Study of Oral Fludarabine Phosphate in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia [NCT00049075]	Phase 2	128 participants (Actual)	Interventional	2002-08-08	Completed
A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia [NCT05576181]	Phase 1	19 participants (Anticipated)	Interventional	2022-10-15	Not yet recruiting
A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 (ThisCART19A) in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy [NCT05640713]	Phase 1	12 participants (Anticipated)	Interventional	2022-12-01	Not yet recruiting
National Mantle Cell Lymphoma Trial - Phase II Randomized Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma [NCT00053092]	Phase 2	82 participants (Anticipated)	Interventional	2002-10-31	Completed
Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes [NCT00053287]	Phase 2	42 participants (Actual)	Interventional	2002-09-30	Completed
A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma [NCT04093596]	Phase 1	132 participants (Anticipated)	Interventional	2019-09-23	Active, not recruiting
Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer [NCT00056095]	Phase 2	57 participants (Actual)	Interventional	2002-11-04	Completed
A Study of Allogeneic Blood Stem Cell Transplantation With Purine Analog-Based Conditioning For Patients With Advanced Hodgkin's Disease [NCT00423709]		46 participants (Actual)	Interventional	1998-01-31	Completed
Allogeneic Adoptive Immunochemotherapy For Treatment Of Renal Cell Carcinoma [NCT00073879]		0 participants	Interventional	2003-04-30	Completed
Clinical Study of the Safety and Initial Efficacy of BGT007 Cells in the Treatment of Patients With Relapsed /Metastatic Nasopharyngeal Carcinoma [NCT05616468]	Early Phase 1	23 participants (Anticipated)	Interventional	2022-12-30	Recruiting
Treatment Of Patients With Metastatic Melanoma Using Nonmyeloablative But Lymphocyte Depleting Regimen Followed By The Administration Of In Vitro Sensitized Lymphocytes Reactive With ESO-1 Antigen [NCT00079144]	Phase 2	0 participants	Interventional	2004-01-31	Completed
Phase II Trial Using Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma [NCT00138229]	Phase 2	6 participants (Actual)	Interventional	2005-07-31	Terminated
Randomized Study for Patients With Follicular Lymphoma Needing Treatment [NCT00140569]	Phase 3	400 participants	Interventional	1994-01-31	Completed
Feasibility/Phase II Trial of Fludarabine, Rituximab, and Alemtuzumab for Previously Treated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [NCT00143065]	Phase 2	8 participants (Actual)	Interventional	2005-08-31	Completed
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance [NCT01723839]	Phase 2	21 participants (Actual)	Interventional	2012-02-22	Completed
Treatment of Patients With Metastatic Melanoma Using Cloned Lymphocytes Following the Administration of a Non-Myeloablative But Lymphocyte Depleting Regimen [NCT00001832]	Phase 2	170 participants (Actual)	Interventional	1999-08-31	Completed
[NCT00010361]		20 participants	Interventional	2000-11-30	Completed
Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) [NCT00017108]	Phase 3	0 participants	Interventional	2001-03-31	Active, not recruiting
Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia [NCT00025038]	Phase 2	100 participants (Actual)	Interventional	2001-06-30	Completed
Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A Phase II Study [NCT00027573]	Phase 2	36 participants (Actual)	Interventional	2001-10-31	Completed
Fludarabine And Busulfan As Conditioning For Patients With Chronic Myeloid Leukemia Or Myelodysplastic Syndrome Transplanted With Hematopoietic Stem Cells From HLA-Compatible Related Or Unrelated Donors [NCT00027924]	Phase 2	0 participants	Interventional	2001-10-31	Completed
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS) [NCT03852407]	Phase 2	114 participants (Anticipated)	Interventional	2019-02-04	Recruiting
Phase II Study of Rituximab in Combination With Fludarabine and Cyclophosphamide for the Treatment of Relapsed Follicular Lymphoma [NCT00393107]	Phase 2	54 participants	Interventional	2000-03-31	Completed
Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen [NCT00615589]	Phase 2	22 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Low accrual)
Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) [NCT00276848]	Phase 3	375 participants (Actual)	Interventional	1999-07-31	Completed
Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia [NCT00276809]	Phase 2	30 participants (Anticipated)	Interventional	2001-06-30	Completed
Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression [NCT00275054]	Phase 3	825 participants (Actual)	Interventional	2005-10-31	Completed
Pivotal Study for High Dose Therapy and Autologous Stem Cell Transplantation in Early Stages of CLL [NCT00275015]	Phase 2	169 participants (Actual)	Interventional	1998-01-31	Completed
A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma [NCT05020444]	Phase 1	18 participants (Anticipated)	Interventional	2021-10-05	Recruiting
Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL) [NCT04323657]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2020-03-27	Completed
Safety and Efficacy of Campath in Nonmyeloablative Transplantation [NCT00038844]		65 participants (Actual)	Interventional	2001-06-30	Completed
Phase I and Pharmacokinetic Study of UCN-01 and Fludarabine in Relapsed or Refractory Low-Grade Lymphoid Malignancies [NCT00019838]	Phase 1	0 participants	Interventional	1999-07-31	Completed
Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed [NCT00397800]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2005-06-30	Active, not recruiting
Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia [NCT00024440]	Phase 3	0 participants	Interventional	2001-07-31	Completed
Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation [NCT00055653]	Phase 2	0 participants	Interventional	2003-01-31	Completed
Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment [NCT00028730]	Phase 2	25 participants (Actual)	Interventional	2001-08-31	Completed
Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases [NCT00056979]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2002-06-30	Terminated
A Phase I Study of Flavopiridol, Fludarabine and Rituximab in Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma [NCT00058227]	Phase 1	37 participants (Actual)	Interventional	2003-04-30	Completed
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Unrelated Donors for Treatment of Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission - A Multicenter Trial [NCT00031655]	Phase 2	30 participants (Anticipated)	Interventional	2001-09-30	Completed
A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [NCT00060684]	Phase 1	30 participants	Interventional	2001-12-31	Completed
Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia [NCT00066417]	Phase 2	51 participants (Anticipated)	Interventional		Terminated(stopped due to Trial was withdrawn for drug availability issues.)
Phase I/II Evaluation of Safety and Activity of Mylotarg Plus Melphalan and Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation [NCT00038831]	Phase 1/Phase 2	47 participants (Actual)	Interventional	2001-05-31	Completed
Immunomodulation by Ultraviolet B-Irradiation (UVB) to Facilitate Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies [NCT00068523]		10 participants (Actual)	Interventional	2003-06-30	Completed
Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation [NCT00209209]	Phase 3	570 participants (Anticipated)	Interventional	2004-01-14	Active, not recruiting
Protocol for the Treatment of Adults Aged NCT00209833]	Phase 2/Phase 3	200 participants	Interventional	1999-01-31	Active, not recruiting
A Phase II Multicenter Randomized Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And Chronic Lymphocytic Leukemia (CLL) [NCT00041288]	Phase 2	10 participants (Actual)	Interventional	2001-10-31	Terminated(stopped due to Poor accrual and difficulty with multicenter logistics)
A Pilot Study of Genasense® (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia [NCT00078234]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2003-11-30	Completed
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Maligna [NCT00078858]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2003-09-30	Completed
Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study [NCT00044954]	Phase 2	0 participants	Interventional	1999-11-30	Completed
A Phase II Study of Single Agent Depsipeptide (NSC 630176) Followed by a Phase I Study of Rituximab/Fludarabine Combination With an Escalating Dose of Depsipeptide in Relapsed or Refractory Low Grade B Cell Lymphomas [NCT00079443]	Phase 2	60 participants (Actual)	Interventional	2004-01-31	Terminated
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies [NCT00080925]	Phase 1	20 participants (Anticipated)	Interventional	2004-02-29	Completed
Multicenter Phase II Trial of Fludarabine and Cyclophosphamide in Combination With Alemtuzumab (FC-Cam) for Patients With Relapsed Chronic Lymphocytic Leukemia - CLL-2L Protocol of the German CLL-Study Group (GCLLSG) [NCT00147901]	Phase 2	61 participants (Actual)	Interventional	2005-01-31	Completed
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia [NCT00054236]	Phase 1	55 participants (Actual)	Interventional	2002-05-31	Completed
Phase I/II Study Of UCN-01 In Combination With Fludarabine In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma [NCT00045513]	Phase 1/Phase 2	0 participants	Interventional	2002-06-30	Completed
Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases [NCT00056966]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2002-11-30	Completed
Pilot/Feasibility Study To Evaluate The Safety Of Cellular Immunotherapy For CD19+ Follicular Lymphoma Using Autologous Cytolytic T Cells Genetically-Modified To Be CD19-Specific And Co-Express HyTK [NCT00182650]	Phase 1	5 participants (Anticipated)	Interventional	2004-06-30	Completed
Phase I/II Study of Allogeneic Stem Cell Transplantation For Patients With Graft Failure Following Allogeneic Transplantation Using MHC Identical or Near Identical Donors and Submyeloablative Conditioning With CAMPATH 1H (CAMGRAFT) [NCT00048399]	Phase 1/Phase 2	40 participants	Interventional	2000-12-31	Terminated(stopped due to accrual was slow)
Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem C [NCT00199147]	Phase 4	250 participants	Interventional	2000-01-31	Recruiting
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells [NCT00085449]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2006-05-31	Withdrawn(stopped due to Funding cut, no patients enrolled)
Tumor Infiltrating Lymphocytes (TIL Cells) Transduced With An Interleukin-2 (SBIL-2) Gene Following The Administration Of A Nonmyeloablative But Lymphocyte Depleting Regimen in Metastatic Melanoma [NCT00062036]	Phase 1/Phase 2	33 participants (Anticipated)	Interventional	2003-06-30	Completed
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Cen [NCT00397813]	Phase 2	77 participants (Actual)	Interventional	2006-01-31	Completed
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen [NCT02111863]	Phase 2	6 participants (Actual)	Interventional	2014-02-21	Terminated(stopped due to Study terminated due to low accrual and change in research focus.)
Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen [NCT00448201]	Phase 2	71 participants (Actual)	Interventional	2011-01-07	Completed
Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer [NCT00376805]	Phase 2	6 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to Withdrawn due to toxicity)
Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen [NCT00448357]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2005-10-31	Completed
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies [NCT03241940]	Phase 1	50 participants (Anticipated)	Interventional	2017-10-20	Recruiting
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies [NCT03233854]	Phase 1	60 participants (Anticipated)	Interventional	2017-09-01	Recruiting
A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia [NCT00472849]	Phase 1/Phase 2	92 participants (Actual)	Interventional	2007-05-31	Completed
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With B Cell Lymphoid Malignancies [NCT00387959]	Phase 2	17 participants (Actual)	Interventional	2006-07-31	Completed
A Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated and Untreated Patients With Chronic Lymphocytic Leukemia [NCT00536341]	Phase 1/Phase 2	64 participants (Actual)	Interventional	2008-01-31	Completed
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism [NCT00427661]		8 participants (Actual)	Interventional	2002-06-30	Completed
Phase I/II Trial of Fludarabine in Combination With Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients With Hematologic Malignancies [NCT00506857]	Phase 1/Phase 2	82 participants (Actual)	Interventional	2003-11-30	Completed
Transplantation of Haploidentical CD34+ Purified Peripheral Blood Stem Cells With NK-Cell Add-Back Following Conditioning With Total Body Irradiation, Thiotepa, Fludarabine and OKT3 [NCT00450983]	Phase 2	1 participants (Actual)	Interventional	2006-12-31	Terminated
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies [NCT00489281]	Phase 2	43 participants (Actual)	Interventional	2008-06-23	Terminated(stopped due to Initiation of CMS BMT study for sickle-cell disease operating under NCT01166009 made further accrual to this study impossible.)
A Randomized Phase II Trial of Fludarabine/Melphalan 140 VS. Fludarabine/Melphalan 100 Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation for Patients With Multiple Myeloma [NCT00505895]	Phase 2	52 participants (Actual)	Interventional	2002-01-31	Completed
A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia [NCT00630253]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2000-02-17	Completed
Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer [NCT04877613]	Phase 1	18 participants (Anticipated)	Interventional	2021-08-19	Recruiting
A Phase II Study of High-Dose Intravenous Busulfan and Fludarabine With Allogeneic Marrow and Peripheral Blood Progenitor Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes [NCT00502905]	Phase 2	200 participants (Actual)	Interventional	2003-10-31	Completed
CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders [NCT00579137]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to slow accrual)
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis [NCT00622895]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2006-09-01	Completed
Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases [NCT00579111]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to slow accrual)
Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies [NCT00741455]		18 participants (Actual)	Interventional	2004-06-30	Completed
Phase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes [NCT01273181]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2010-12-31	Terminated
Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies. [NCT00800839]	Phase 2	56 participants (Actual)	Interventional	2008-09-30	Completed
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma [NCT02062359]	Phase 2	2 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Study was closed due to poor accrual.)
T Cell Therapy in Combination With Peginterferon for Patients With Metastatic Melanoma [NCT02379195]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2014-11-30	Completed
Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis [NCT00775931]	Phase 2/Phase 3	7 participants (Actual)	Interventional	2008-08-31	Completed
Exploratory Study Evaluating the Interest of PET to 18F-Fludarabine for the Initial Assessment and End-treatment Evaluation of Patients With Symptomatic Multiple Myeloma in the First Line of Treatment, Not Candidates for Marrow Autograft [NCT03832127]	Phase 1	35 participants (Anticipated)	Interventional	2022-04-01	Not yet recruiting
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma [NCT05207722]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2022-04-14	Active, not recruiting
Transplantation of Two Partially Matched Umbilical Cord Blood Units Following Reduced Intensity Conditioning to Enhance Engraftment and Limit Transplant-Related Mortality in Adults With Hematologic Malignancies [NCT00827099]	Phase 2	5 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Unacceptable morbidity & mortality)
"A Feasibility Study of Early Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms" [NCT02756572]	Phase 2	30 participants (Actual)	Interventional	2016-09-22	Completed
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome [NCT05027945]	Phase 2	37 participants (Anticipated)	Interventional	2023-02-23	Recruiting
Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease [NCT04613557]	Phase 1	18 participants (Actual)	Interventional	2020-11-16	Active, not recruiting
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis [NCT04384692]	Phase 2	45 participants (Anticipated)	Interventional	2020-12-18	Recruiting
Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer [NCT03754933]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2019-02-11	Recruiting
A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With T -Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma [NCT01740557]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2015-01-28	Completed
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML [NCT01861002]	Phase 1	15 participants (Actual)	Interventional	2013-05-22	Completed
An Multicenter, Randomized, Controlled, Prospective Clinical Study of Mitoxantrone Liposome Combined With PTCy as Conditioning Regimen in Allo-HSCT in Acute Leukemia [NCT05739630]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH [NCT04540380]	Phase 1	6 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Hematopoietic Stem Cell Transplant for Sickle Cell Disease [NCT02065596]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2015-10-19	Completed
MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis [NCT00625729]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to No patients exhibited natural killer cell expansion (primary endpoint).)
Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Post-Transplant Cyclophosphamide [NCT02282904]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2014-10-23	Terminated
Clinical Study of the Efficacy and Safety of XPO-1 Inhibitors in Combination With CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma [NCT05322330]	Phase 2	20 participants (Anticipated)	Interventional	2022-02-10	Recruiting
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis [NCT00572897]	Phase 2	66 participants (Actual)	Interventional	2007-08-31	Completed
Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation [NCT02960646]	Phase 1	11 participants (Actual)	Interventional	2017-01-18	Completed
Phase I Trial of Anti-GPC3 Chimeric T Cells for Subjects With GPC3-Positive Advanced Hepatocellular Carcinoma [NCT03084380]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2017-06-01	Not yet recruiting
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblast [NCT03860844]	Phase 2	67 participants (Actual)	Interventional	2019-08-06	Terminated(stopped due to Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.)
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome [NCT02212561]	Phase 1	19 participants (Actual)	Interventional	2014-08-31	Completed
Single Patient Protocol: A Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab [NCT04536922]	Phase 2	0 participants (Actual)	Interventional	2021-01-27	Withdrawn(stopped due to Subject no longer able to participate in this single pt study.)
Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia [NCT00262782]	Phase 3	877 participants (Actual)	Interventional	1997-04-30	Completed
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime [NCT01821781]	Phase 2	20 participants (Anticipated)	Interventional	2013-03-31	Recruiting
A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma [NCT00119392]	Phase 2	42 participants (Actual)	Interventional	2004-06-30	Completed
First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL) [NCT00278265]	Phase 2	12 participants (Actual)	Interventional	2005-06-30	Terminated(stopped due to slow recruitment)
Treatment of Advanced Chronic Lymphocytic Leukemia (CLL) Fludarabine, Mitoxantrone and Cyclophosphamide With or Without G-CSF [NCT00416910]	Phase 3	83 participants (Actual)	Interventional	1999-07-31	Terminated(stopped due to low recruitment)
Purine Analog-Based Conditioning for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia [NCT00427336]		9 participants (Actual)	Interventional	2000-12-31	Completed
Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity [NCT00281892]	Phase 3	97 participants (Actual)	Interventional	2004-09-30	Completed
Phase II Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients With B-PLL [NCT00281931]	Phase 2	21 participants (Anticipated)	Interventional	1999-09-30	Terminated
Nonmyeloablative Bone Marrow Transplants in Hematologic Malignancies: Dose Finding Study for Post-Transplant Immunosuppression [NCT00255710]	Phase 1	60 participants (Anticipated)	Interventional	2002-07-31	Completed
Non-Myeloablative HLA-Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma [NCT00262886]	Phase 2	35 participants (Anticipated)	Interventional	2001-08-31	Completed
Stem Cell Enriched, T Cell Depleted Haplocompatible Peripheral Blood Transplantation for Children With Myelodysplastic Disease, Leukemia, Marrow Failure Syndromes, or Severe Immunodeficiency Diseases [NCT00295971]	Phase 1	21 participants (Actual)	Interventional	2005-04-30	Completed
Feasibility of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions for Children at High Risk for Complications With Conventional Transplantation [NCT00301860]		8 participants (Actual)	Interventional	2003-01-31	Terminated(stopped due to lack of efficacy)
Study of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CD20 - Cluster of Differentiation Antigen 20) [NCT04007029]	Phase 1	24 participants (Anticipated)	Interventional	2019-10-04	Recruiting
Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia [NCT00278213]	Phase 2	17 participants (Anticipated)	Interventional	2002-09-30	Completed
A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) [NCT05359211]	Phase 1	24 participants (Anticipated)	Interventional	2022-12-08	Recruiting
Evaluation of Safety and Efficacy of Treosulfan-cytarabine-fludarabine (FLAT) Combination Prior to Autologous Stem Cell Transplant (HSCT) in Elderly Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [NCT03961919]	Phase 2	15 participants (Actual)	Interventional	2009-02-10	Completed
BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Recovery From Focal Radiotherapy Alone or Focal Radiotherapy and Dose-intensified Temozolomide (Phase I) [NCT03396575]	Phase 1	21 participants (Anticipated)	Interventional	2018-07-17	Active, not recruiting
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4) [NCT02625480]	Phase 1/Phase 2	116 participants (Anticipated)	Interventional	2016-02-01	Recruiting
Non-myeloablative Allogeneic Stem Cell Transplantation With Match Unrelated Donors for Treatment of Hematologic Malignancies and Renal Cell Carcinoma and Aplastic Anemia [NCT00295997]		35 participants (Anticipated)	Interventional	2005-05-31	Active, not recruiting
A Phase II Study Using a Peptide Vaccine With or Without Aldesleukin Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma [NCT00303836]	Phase 2	58 participants (Actual)	Interventional	2005-11-30	Terminated
Bone Marrow Stem Cell Transplantation for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myeloid Leukemia in 1Remission [NCT00305708]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2000-08-31	Completed
A Multicenter Study to Assess the Antitumor Effect and Safety of Fludarabine Phosphate Tablet (SH T 586) in Combination With Rituximab Administered in 6 Treatment Cycles (1 Treatment Cycle: Rituximab 375 mg/m2 iv on Day 1 Along With 5-Consecutive Day Oral [NCT00311129]	Phase 2	41 participants (Actual)	Interventional	2005-12-31	Completed
A Dose Ranging Trial of MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Using Cytokines With Autologous Lymphocyte Infusion With or Without Escalating Doses of Fludarabine for Patients With Chemotherapy-naive Metastatic Melanoma [NCT00313508]	Phase 1	18 participants (Actual)	Interventional	2006-02-28	Completed
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) [NCT05537766]	Phase 2	90 participants (Anticipated)	Interventional	2022-11-01	Recruiting
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic [NCT05201183]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-10-31	Withdrawn(stopped due to insufficient staff and updates in standard practice have made it difficult to recruit participants)
A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood (UCB) Transplant For Patients With Hematologic Malignancies Needing Allogeneic Stem Cell Transplant But Do Not Have A Related HLA-Matched Donor [NCT01500161]	Phase 2	1 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to Insufficient accruals)
A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma [NCT01503242]	Phase 1	15 participants (Actual)	Interventional	2012-01-09	Completed
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders [NCT04644016]	Phase 2	31 participants (Anticipated)	Interventional	2020-11-20	Recruiting
Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors [NCT02869217]	Phase 1	22 participants (Anticipated)	Interventional	2016-09-30	Active, not recruiting
HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3 Depletion for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors After Conditioning of TBI, Fludarabine, Cyclophosphamide and Antithymocyte Glo [NCT01509300]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Phase II Trial of Reduced Intensity Conditioning (RIC) and Allogeneic Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies [NCT01622556]	Phase 2	6 participants (Actual)	Interventional	2012-01-31	Terminated
A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas [NCT01625351]	Phase 1	23 participants (Actual)	Interventional	2012-08-20	Completed
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy in Older Adults With Acute Myelogenous Leukemia in First Complete Remission [NCT01639456]	Phase 2	0 participants (Actual)	Interventional	2013-10-31	Withdrawn(stopped due to study was abandoned and a new study was written to replace this one)
Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options [NCT01652014]	Phase 2	0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to Funding unavailable)
Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL) [NCT01653717]	Phase 1	30 participants (Anticipated)	Interventional	2013-06-11	Completed
Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies [NCT01658319]	Phase 1	20 participants (Actual)	Interventional	2011-05-31	Completed
Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT00427557]	Phase 2	31 participants (Actual)	Interventional	2006-10-31	Completed
A Phase II Study of High Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Transplant for Multiple Sclerosis That Failed at Least Two Lines of Therapy [NCT01679041]	Phase 2	1 participants (Actual)	Interventional	2012-11-30	Terminated(stopped due to Insufficient accruals; PI leaving site)
A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid Leukemia [NCT05317403]	Phase 1	40 participants (Anticipated)	Interventional	2023-03-31	Recruiting
Dose Escalation Study of CD19 Chimeric Antigen Receptor (CAR) T Cells With a CD34 Selection Marker in Adults With Recurrent or Refractory B Cell Malignancies [NCT04214886]	Phase 1	24 participants (Anticipated)	Interventional	2019-12-31	Active, not recruiting
Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant [NCT00526292]	Phase 2	12 participants (Actual)	Interventional	2007-08-31	Completed
Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies [NCT03056339]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2017-06-21	Completed
An Open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide and Rituximab in Patients With Chronic Lymphocytic Leukaemia Who Are Newly Diagnosed, Have Relapsed or Are Resistant to First-Line Treatment [NCT00812669]	Phase 2	52 participants (Actual)	Interventional	2008-08-18	Completed
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial [NCT00789776]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2008-10-13	Completed
Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission [NCT02497404]	Phase 2	40 participants (Actual)	Interventional	2015-02-13	Completed
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022) [NCT06175702]		150 participants (Anticipated)	Observational	2023-12-25	Not yet recruiting
CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101) [NCT06152172]	Phase 1	24 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer [NCT05922930]	Phase 1/Phase 2	51 participants (Anticipated)	Interventional	2023-10-11	Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23) [NCT05605899]	Phase 3	300 participants (Anticipated)	Interventional	2023-02-10	Recruiting
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (AS [NCT05257083]	Phase 3	750 participants (Anticipated)	Interventional	2023-10-10	Recruiting
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) [NCT05003895]	Phase 1	38 participants (Anticipated)	Interventional	2021-12-08	Recruiting
A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children and Young Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT02626715]	Phase 2	22 participants (Actual)	Interventional	2015-09-04	Completed
Haploidentical Stem Cell Transplantation With Fixed Dose of T Cells After in Vitro T Cell Depletion Using CD3 Monoclonal Antibody for Children With Acquired Severe Aplastic Anemia [NCT01759732]	Phase 2	10 participants (Anticipated)	Interventional	2012-09-30	Recruiting
Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL). [NCT01762202]	Phase 2	80 participants (Actual)	Interventional	2013-11-05	Completed
A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21-Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia [NCT01787474]	Phase 1	30 participants (Actual)	Interventional	2014-05-19	Completed
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD [NCT02220985]	Phase 2	84 participants (Actual)	Interventional	2015-02-03	Active, not recruiting
A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies [NCT01810926]	Phase 2	130 participants (Anticipated)	Interventional	2011-09-30	Recruiting
Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis [NCT01814475]	Phase 2	62 participants (Actual)	Interventional	2011-07-31	Completed
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14) [NCT04002401]	Phase 2	27 participants (Actual)	Interventional	2019-11-05	Completed
Lymphodepleting Chemotherapy With Rituximab and Allogeneic Natural Killer Cells for Patients With Refractory Lymphoid Malignancies (MT2009-15) [NCT01181258]	Phase 2	16 participants (Actual)	Interventional	2010-08-31	Completed
Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML) [NCT04250051]	Phase 1	25 participants (Anticipated)	Interventional	2020-12-21	Recruiting
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancie [NCT01231412]	Phase 3	174 participants (Actual)	Interventional	2010-11-30	Completed
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies [NCT01749293]	Phase 2	3 participants (Actual)	Interventional	2012-08-30	Terminated(stopped due to The protocol design is being reconfigured in order to open a new study.)
Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis After Allogeneic Non-myeloablative Peripheral Blood Stem Cell Transplantation [NCT00282282]	Phase 2	31 participants (Actual)	Interventional	2006-01-31	Completed
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With Secondary Acute Myeloid Leukemia Evolving From MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT05449899]	Phase 2/Phase 3	232 participants (Anticipated)	Interventional	2022-07-31	Recruiting
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies [NCT01850108]		21 participants (Actual)	Interventional	2013-05-31	Active, not recruiting
Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN) [NCT01822652]	Phase 1	11 participants (Actual)	Interventional	2013-08-31	Active, not recruiting
Pilot Study of Affinity-enhanced Anti-NY-ESO-1 TCR Engineered Autologous T Cells in NSCLC Patients [NCT03029273]	Phase 1	20 participants (Anticipated)	Interventional	2017-03-21	Recruiting
Safety and Efficiency of Anti-CD19/CD22 Tandem Fully Human Chimeric Antigen Receptor (CAR)-Transduced T-cell Therapy for Pediatric and Young Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: a Single Centre, Non-randomised, Open [NCT04499573]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2020-07-27	Active, not recruiting
Treatment Protocol: Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Using Conditioning Regimen Without Radiation [NCT02007863]		2 participants (Actual)	Interventional	2008-08-31	Completed
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers [NCT01585428]	Phase 2	29 participants (Actual)	Interventional	2012-04-13	Completed
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation [NCT01118013]	Phase 2	6 participants (Actual)	Interventional	2010-12-31	Terminated
Reduced Intensity Conditioning And Allogeneic Stem Cell Transplantation in Patients With Medically Refractory Systemic Lupus Erythematosus and Medically Refractory Systemic Sclerosis (SSc) [NCT00684255]	Phase 1	1 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to inactive)
A Randomized Study of Combined Haplo-identical Umbilical Cord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies [NCT01745913]	Phase 2	2 participants (Actual)	Interventional	2012-10-26	Terminated(stopped due to Slow accrual)
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor [NCT01598025]		3 participants (Actual)	Interventional	2012-05-02	Terminated(stopped due to Closed due to poor accrual)
A Pilot Study Using High Dose Busulfan and Bortezomib as Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients. [NCT01534143]	Phase 2	1 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Data was not collected, because funding was unavailable to continue study.)
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor [NCT00523809]	Phase 2	5 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Slow accrual.)
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies [NCT01807611]	Phase 2	82 participants (Actual)	Interventional	2013-05-16	Completed
Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy [NCT00001677]	Phase 2	40 participants	Interventional	1998-06-30	Completed
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [NCT03448393]	Phase 1	140 participants (Anticipated)	Interventional	2018-03-26	Recruiting
A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT04898894]	Phase 1	42 participants (Anticipated)	Interventional	2021-11-15	Recruiting
NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies [NCT01823198]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2013-06-11	Completed
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation [NCT03192397]	Phase 1/Phase 2	35 participants (Actual)	Interventional	2017-08-09	Active, not recruiting
Compassionate Use Administration of Autologous CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch [NCT03594162]		0 participants	Expanded Access		No longer available
Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML [NCT01435343]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2012-07-31	Completed
Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia) [NCT05418088]	Phase 1	36 participants (Anticipated)	Interventional	2022-06-30	Recruiting
Reduced Intensity Matched Sibling Bone Marrow Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old [NCT01877837]	Phase 3	30 participants (Actual)	Interventional	2011-06-30	Completed
Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) [NCT05963217]	Phase 1	19 participants (Anticipated)	Interventional	2023-07-26	Recruiting
Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma [NCT04809766]	Phase 1	15 participants (Anticipated)	Interventional	2021-12-14	Recruiting
A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [NCT04268706]	Phase 2	97 participants (Anticipated)	Interventional	2021-02-01	Active, not recruiting
T-cell Therapy in Combination With Checkpoint Inhibitors for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer [NCT03287674]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2017-10-09	Completed
Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia [NCT00376480]	Phase 1	19 participants (Actual)	Interventional	2005-06-30	Completed
Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction [NCT03593902]	Phase 2/Phase 3	9 participants (Actual)	Interventional	2018-05-17	Terminated(stopped due to PI Sabbatical)
Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen [NCT02310997]	Phase 2	11 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to Trial closed early due to poor recruitment)
Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia With Minimal Residual Disease [NCT05601830]	Phase 1	18 participants (Anticipated)	Interventional	2022-10-28	Recruiting
PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies [NCT01455506]	Phase 1	20 participants (Actual)	Interventional	2009-05-31	Completed
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia [NCT01187017]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2010-08-31	Completed
Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors [NCT01350232]		2 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Poor accrual)
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells [NCT03333486]	Phase 2	31 participants (Actual)	Interventional	2017-12-07	Active, not recruiting
Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors [NCT05334329]	Phase 1	21 participants (Anticipated)	Interventional	2022-07-20	Recruiting
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation [NCT01572662]	Phase 2	201 participants (Actual)	Interventional	2012-04-11	Completed
Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study [NCT00004114]	Phase 1	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study never opened)
A Single Dose-escalation and Dose-expansion Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma. [NCT05776407]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) [NCT00199056]	Phase 4	225 participants	Interventional	1999-10-31	Completed
A Phase I Study of Fludarabine With Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck [NCT00004246]	Phase 1	16 participants (Actual)	Interventional	1995-06-07	Completed
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial [NCT00104858]	Phase 2	66 participants (Actual)	Interventional	2004-12-31	Completed
Phase I, Open-label Study Evaluating the Safety of Escalating Doses of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally With Co-administration of Fludarabine Phosphate Intravenously) in Subjects With Advanced Solid Tumors [NCT01310179]	Phase 1	12 participants (Actual)	Interventional	2011-02-28	Completed
Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial [NCT00118352]	Phase 2	12 participants (Actual)	Interventional	2005-03-31	Completed
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation [NCT01427881]	Phase 2	43 participants (Actual)	Interventional	2011-09-30	Completed
Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism [NCT00176852]	Phase 2/Phase 3	22 participants (Actual)	Interventional	2002-06-30	Completed
A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL) [NCT01082939]	Phase 2	80 participants (Actual)	Interventional	2002-12-31	Completed
An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation. [NCT04217278]	Phase 2/Phase 3	333 participants (Actual)	Interventional	2020-01-27	Active, not recruiting
Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies [NCT00544466]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2006-07-31	Active, not recruiting
Reduced-intensity, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies [NCT01135329]	Phase 2	15 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to The stopping rule was met and hence the study was closed)
Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [NCT01289457]	Phase 1/Phase 2	282 participants (Actual)	Interventional	2011-02-02	Completed
A Phase II Study of EL625 in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [NCT00636155]	Phase 2	20 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to funding)
Phase II Study of Metastatic Melanoma Using a Nonmyeloablative Lymphodepleting Regimen Followed by Melanoma-Reactive T-Cells Sensitized in Vitro With Peptide-Pulsed Drosophila Cells [NCT01271907]	Phase 2	3 participants (Actual)	Interventional	2011-04-15	Terminated(stopped due to Study was terminated due to withdrawal of CRADA partner.)
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies [NCT00392782]	Phase 2	24 participants (Actual)	Interventional	2005-07-31	Terminated
Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (C [NCT00381550]	Phase 2	35 participants (Actual)	Interventional	2006-08-31	Completed
Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas [NCT01456351]	Phase 3	230 participants (Actual)	Interventional	2003-09-30	Completed
Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study [NCT01203020]	Phase 2	22 participants (Actual)	Interventional	2010-10-12	Completed
Phase I/II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Gene Engineered Lymphocytes Cotransduced With Genes Encoding IL-12 and Anti-NY ESO-1 TCR [NCT01457131]	Phase 1	2 participants (Actual)	Interventional	2011-10-06	Terminated
Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion [NCT01369875]	Phase 2	2 participants (Actual)	Interventional	2011-06-17	Terminated(stopped due to Premature closure. Protocol did not meet its primary objective.)
CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma [NCT05767359]	Phase 2	20 participants (Anticipated)	Interventional	2023-04-19	Recruiting
Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT) [NCT05634785]	Phase 2	18 participants (Anticipated)	Interventional	2022-12-09	Recruiting
A Phase 1 Study of Autologous Activated T-cells Targeting the B7-H3 Antigen in Subjects With Recurrent Epithelial Ovarian Cancer [NCT04670068]	Phase 1	21 participants (Anticipated)	Interventional	2021-01-27	Recruiting
Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA [NCT03821987]		55 participants (Anticipated)	Interventional	2018-12-17	Recruiting
A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT02614560]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2015-11-30	Terminated
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) [NCT00198991]	Phase 4	1,883 participants (Actual)	Interventional	2003-04-30	Completed
Multi-Center Study Using Allogeneic Stem Cell Transplantation Following Reduced Intensity Chemotherapy in Patients With Hemoglobinopathies [NCT00153985]	Phase 2	2 participants (Actual)	Interventional	2004-03-31	Completed
A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen [NCT00070135]	Phase 2	121 participants (Actual)	Interventional	2004-01-31	Completed
A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation [NCT01596699]	Phase 2	16 participants (Actual)	Interventional	2012-05-24	Terminated(stopped due to Triggering of futility rule; Interim analysis suggested no statistical superiority over historic controls)
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation [NCT01527045]	Phase 2	47 participants (Actual)	Interventional	2012-09-25	Completed
Safety and Efficacy of Universal Chimeric Antigen Receptor-modified AT19 Cells in Patients With CD19+ Relapsed/Refractory Hematological Malignancies: a Single-center, Open-label, Single-arm Clinical Study [NCT04796688]	Phase 1	27 participants (Anticipated)	Interventional	2021-03-10	Recruiting
A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate M [NCT00089011]	Phase 2	150 participants (Actual)	Interventional	2004-04-30	Completed
A Phase I Study to Evaluate Safety, Feasibility and Immunologic Response of Adoptive T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Metastatic Melanoma [NCT01946373]	Phase 1	20 participants (Anticipated)	Interventional	2013-10-31	Recruiting
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies [NCT00048737]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2002-10-31	Completed
A Multicenter Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion [NCT00048893]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2002-11-30	Terminated(stopped due to The study was closed to accrual due to very poor enrollment.)
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning fo [NCT00105001]	Phase 2	210 participants (Actual)	Interventional	2004-11-30	Completed
Reduced-Intensity Allogeneic HSC Transplantation From HLA-Matched Related and Unrelated Donors for Patients With Multiple Myeloma - A Multi-Center Trial [NCT00054353]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2002-10-31	Completed
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability [NCT00208975]	Phase 2	15 participants (Actual)	Interventional	2002-07-31	Terminated(stopped due to slow accrual)
Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission [NCT00045435]	Phase 2	17 participants (Actual)	Interventional	2002-04-30	Completed
Phase I Clinical Trial of TSA-CTL (Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) In the Treatment of Advanced Solid Tumors [NCT02959905]	Phase 1	11 participants (Actual)	Interventional	2016-12-22	Completed
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [NCT02926833]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2016-09-29	Completed
A Study of a Reduced-Intensity Conditioning Regimen With Treosulfan and Fludarabine for Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Leukemia [NCT00253513]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2005-06-30	Completed
Protocol Title: An Open Label, Multi-centre Phase 1/2a Study of Modified and Unmodified Autologous Tumour Infiltrating Lymphocytes (TIL) in Patients With Platinum-resistant Ovarian Cancer [NCT04389229]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2020-07-01	Withdrawn(stopped due to Sponsor decision)
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases [NCT00038857]	Phase 2	29 participants (Actual)	Interventional	2001-09-30	Completed
AML Therapy With Irradiated Allogeneic Cells [NCT02105116]		6 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to No patients were eligible to receive the experimental component of the protocol therapy.)
Allogeneic Hematopoietic Cell Transplantation for Patients With Treatment-Refractory Crohn's Disease: A Phase 2 Study [NCT01570348]	Phase 2	2 participants (Actual)	Interventional	2012-07-17	Terminated(stopped due to Annual accrual goal not met)
A Single-center, Single-arm Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-CD5 Chimeric Antigen Receptor T Cells (CT125A Cells) for the Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies [NCT04767308]	Early Phase 1	18 participants (Anticipated)	Interventional	2021-03-31	Not yet recruiting
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia [NCT00280241]	Phase 2	65 participants (Actual)	Interventional	2004-06-30	Completed
Phase II Study in Metastatic Melanoma or Kidney Cancer Using Autologous Natural Killer Cells Plus Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy [NCT00328861]	Phase 2	8 participants (Actual)	Interventional	2006-05-31	Completed
A Phase II Trial of Fludarabine in Combination With Daunorubicin and Cytarabine Liposome for Adults With Newly-diagnosed Acute Myeloid Leukemia: University of California Hematologic Malignancies Consortium Protocol 1914 [NCT04425655]	Phase 2	2 participants (Actual)	Interventional	2020-08-05	Terminated(stopped due to Original investigator for the trial has left)
Adoptive Transfer of ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) in Combination With Lymphodepletion and Anti-PD-1 to Patients With Metastatic Melanoma [NCT04904185]	Phase 1	12 participants (Anticipated)	Interventional	2021-08-17	Recruiting
A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies [NCT03044743]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2017-04-07	Recruiting
Safety and Efficacy Study of Chimeric Antigen Receptor T (CAR-T) Cells in the Treatment of Relapsed/Refractory Hematological Malignancies [NCT05528887]	Phase 1	10 participants (Anticipated)	Interventional	2021-09-16	Recruiting
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [NCT02790515]	Phase 2	52 participants (Anticipated)	Interventional	2016-07-14	Recruiting
Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma [NCT00924001]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to study was stopped due to low accrual)
Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine. [NCT00373594]	Phase 2	30 participants (Anticipated)	Interventional	2005-06-30	Completed
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies [NCT01384513]	Phase 2	40 participants (Actual)	Interventional	2011-08-04	Completed
A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for [NCT03128359]	Phase 2	38 participants (Actual)	Interventional	2017-05-30	Active, not recruiting
Reduced Intensity, Partially HLA Mismatched Allogeneic BMT for Hematologic Malignancies Using Donors Other Than First-degree Relatives [NCT01203722]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2010-09-30	Recruiting
A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft [NCT04982354]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2022-07-05	Recruiting
Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens [NCT01572181]	Phase 2	50 participants (Actual)	Interventional	2012-04-30	Completed
A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma [NCT01578343]	Phase 2	20 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to we collected data of a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients.)
Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstrőm's Macroglobulinaemia (WM): a Randomized Phase II Trial [NCT01592981]	Phase 2	60 participants (Actual)	Interventional	2013-01-31	Completed
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1) [NCT03841110]	Phase 1	37 participants (Actual)	Interventional	2019-02-15	Completed
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma [NCT02652455]	Early Phase 1	11 participants (Actual)	Interventional	2016-03-08	Completed
Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas [NCT02859402]	Phase 2	34 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? A Multi-center Trial [NCT00036738]	Phase 2	28 participants (Actual)	Interventional	2001-07-13	Completed
Non-Myeloablative Conditioning and Unrelated Umbilical Cord Blood Transplantation for Children and Adults With Serious Oncohematologic Diseases [NCT00255684]		16 participants (Actual)	Interventional	2003-12-31	Terminated(stopped due to low accrual)
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies [NCT00134004]	Phase 2	210 participants (Actual)	Interventional	2004-10-31	Completed
Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) [NCT00361140]	Phase 4	72 participants (Actual)	Interventional	2005-08-31	Completed
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen [NCT00305682]	Phase 2	295 participants (Actual)	Interventional	2005-06-30	Completed
Phase II Study Using a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution With CD34+ Stem Cells in Metastatic Melanoma [NCT00314106]	Phase 2	26 participants (Actual)	Interventional	2006-04-30	Completed
An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients. [NCT03466320]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2018-09-18	Completed
Adoptive Transfer of Haploidentical Natural Killer Cells to Treat Refractory or Relapsed AML MT2010-02 [NCT01106950]	Phase 2	15 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to study drug (Ontak) no longer available)
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patie [NCT04029688]	Phase 1/Phase 2	183 participants (Anticipated)	Interventional	2020-01-27	Recruiting
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination With Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Re [NCT03793478]	Phase 1/Phase 2	65 participants (Anticipated)	Interventional	2018-08-15	Recruiting
Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT03182244]	Phase 3	276 participants (Actual)	Interventional	2018-01-15	Active, not recruiting
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies [NCT01697527]	Phase 2	6 participants (Actual)	Interventional	2012-11-02	Active, not recruiting
Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Fludarabine Lymphodepletion for Patients With Metastatic Melanoma [NCT00317759]	Phase 1	12 participants (Anticipated)	Interventional	2003-05-31	Completed
Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies [NCT00346359]	Phase 2	40 participants (Anticipated)	Interventional	2006-03-31	Completed
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies [NCT04083170]	Phase 2	10 participants (Anticipated)	Interventional	2022-10-06	Recruiting
A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory L [NCT03939026]	Phase 1	74 participants (Anticipated)	Interventional	2019-05-01	Active, not recruiting
A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma [NCT01369888]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Closed this protocol due to autoimmune toxicity.)
Combination of Cyclophosphamide and Fludarabine for Lupus Nephritis: Tolerance, Toxicity, Efficacy and Effects on B and T Lymphocyte Regeneration [NCT00001676]	Phase 1	15 participants	Interventional	1998-01-31	Completed
Safety and Efficacy Study of Novel Mesothelin CAR-T Cell Therapy in Patients With Mesothelin-positive Advanced Refractory Solid Tumors [NCT05531708]	Phase 1	0 participants (Actual)	Interventional	2021-04-02	Withdrawn(stopped due to The study is not initiated and we want it to be withdrawn.)
Safety and Efficacy Study of Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies [NCT05513612]	Phase 1	0 participants (Actual)	Interventional	2020-08-01	Withdrawn(stopped due to The study is not initiated and we want it to be withdrawn.)
Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders [NCT00801931]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2007-09-06	Terminated(stopped due to Poor accrual)
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML [NCT01640301]	Phase 1/Phase 2	47 participants (Actual)	Interventional	2012-12-06	Terminated(stopped due to Terminated due to slow accrual.)
A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) [NCT00002798]	Phase 3	880 participants (Actual)	Interventional	1996-08-31	Completed
A Randomized Phase II Study of Concurrent Fludarabine + Chimeric Anti-CD20 Monoclonal Antibody IDEC-C2B8 (Rituximab) [NSC# 687451] Induction Followed By Rituximab Consolidation In Untreated Patients With B-Cell Chronic Lymphocytic Leukemia [NCT00003248]	Phase 2	104 participants (Actual)	Interventional	1998-03-31	Completed
PHASE II TRIAL OF FLUDARABINE AND SANDOSTATIN FOR RELAPSED LOW-GRADE NON-HODGKIN'S LYMPHOMA [NCT00002779]	Phase 2	34 participants (Actual)	Interventional	1998-02-28	Completed
A Phase I Study of G3139 (NSC 683428) in Combination With Salvage Chemotherapy for Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT00004862]	Phase 1	24 participants (Actual)	Interventional	1999-10-31	Completed
A Phase I-II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin [NCT02153905]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2014-07-03	Terminated(stopped due to Slow, insufficient accrual.)
Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis [NCT00002833]	Phase 2	53 participants (Actual)	Interventional	1994-10-31	Completed
Induction of Mixed Hematopoietic Chimerism Using Fludarabine, Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion In Patients With Chronic Myeloid Leuke [NCT00003145]	Phase 2	18 participants (Actual)	Interventional	1997-08-31	Completed
Allogeneic Stem Cell Transplantation of Renal Cell Cancer and Metastatic Melanoma After Non-Myeloablative Chemotherapy [NCT00004135]	Phase 2	19 participants (Actual)	Interventional	1999-02-28	Completed
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL [NCT00003829]	Phase 2	34 participants (Actual)	Interventional	1999-08-31	Completed
A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia [NCT00004255]	Phase 2/Phase 3	0 participants	Interventional	2000-03-31	Completed
Phase I Study of Fludarabine, Carboplatin, and Topotecan for Patients With Relapsed/Refractory Acute Leukemia and Advanced Myelodysplastic Syndromes [NCT00005593]	Phase 1	31 participants (Actual)	Interventional	1998-09-30	Completed
A Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin [NCT02111850]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2014-02-07	Completed
Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST) [NCT02029638]	Phase 2	4 participants (Actual)	Interventional	2014-01-07	Terminated(stopped due to Slow accrual)
Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies [NCT00281879]	Phase 2	200 participants (Actual)	Interventional	2006-02-28	Terminated
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) [NCT03967223]	Phase 2	103 participants (Actual)	Interventional	2019-12-31	Active, not recruiting
Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations [NCT06043713]	Phase 1	24 participants (Anticipated)	Interventional	2024-01-01	Recruiting
A Single-center, Open-label Clinical Study of TIL Cells for the Treatment of the Recurrent/Metastatic Solid Tumors Patients Who Had Failed Standard Therapy [NCT05649618]	Early Phase 1	42 participants (Anticipated)	Interventional	2022-12-05	Not yet recruiting
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers [NCT02280811]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2014-10-14	Completed
A Single-arm, Open-label, Dose-finding Clinical Study of TCR-T Cells in Patients With HLA-A2-expressing and NY-ESO-1-positive Recurrent or Metastatic Solid Tumors [NCT05648994]	Early Phase 1	30 participants (Anticipated)	Interventional	2022-12-31	Not yet recruiting
Safety and Efficacy of Anti-FLT3 CAR- T Cell (TAA05 Cell Injection) in the Treatment of Relapsed/ Refractory Acute Myeloid Leukemia [NCT05445011]	Phase 1	12 participants (Anticipated)	Interventional	2022-06-14	Recruiting
A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia [NCT02833805]	Phase 2	21 participants (Actual)	Interventional	2016-09-30	Completed
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma [NCT05993299]	Phase 2	7 participants (Actual)	Interventional	2019-12-31	Active, not recruiting
Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML). [NCT05987696]	Phase 1	102 participants (Anticipated)	Interventional	2023-08-10	Not yet recruiting
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma [NCT05470283]	Phase 1	30 participants (Anticipated)	Interventional	2022-09-07	Recruiting
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma [NCT05000450]	Phase 1/Phase 2	136 participants (Anticipated)	Interventional	2021-06-06	Active, not recruiting
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma [NCT00338377]	Phase 2	1,230 participants (Actual)	Interventional	2006-02-01	Active, not recruiting
Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic Melanoma [NCT03475134]	Phase 1	18 participants (Actual)	Interventional	2018-02-21	Active, not recruiting
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory and Ultra-High-risk AML/MDS [NCT04678401]	Phase 1	20 participants (Anticipated)	Interventional	2021-01-12	Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers [NCT03935893]	Phase 2	240 participants (Anticipated)	Interventional	2019-12-03	Recruiting
CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [NCT02259348]	Phase 2	12 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Investigator's decision.)
Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma [NCT03994705]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2019-08-06	Active, not recruiting
A Phase 1/2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL). [NCT03743246]	Phase 1/Phase 2	121 participants (Anticipated)	Interventional	2018-10-17	Recruiting
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML [NCT03504410]	Phase 3	200 participants (Actual)	Interventional	2018-11-12	Terminated(stopped due to Futile)
Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Co [NCT00589316]	Phase 1	26 participants (Actual)	Interventional	2007-10-05	Terminated(stopped due to Terminated due to loss of funding)
A Phase II Study of Fludarabine Induction Followed by CAMPATH-1H Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia [NCT00004857]	Phase 2	86 participants (Actual)	Interventional	2000-01-31	Completed
Phase II Study of Fludarabine + Idarubicin + Aracytine in Refractory or Relapsed ALL in Children [NCT00003729]	Phase 2	13 participants (Actual)	Interventional	1998-12-31	Terminated(stopped due to low accrual)
Phase I/II Study of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation From HLA-Identical Donors in Children With Sickle Cell Disease [NCT00004485]	Phase 1/Phase 2	50 participants	Interventional	1999-12-31	Completed
Low-Dose TBI and Fludarabine Followed by Unrelated Donor Stem Cell Transplantation for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial [NCT00005799]		55 participants (Actual)	Interventional	1999-11-30	Completed
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation [NCT01408563]	Phase 2	33 participants (Actual)	Interventional	2011-12-31	Completed
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, [NCT03926624]	Phase 3	450 participants (Anticipated)	Interventional	2019-11-22	Recruiting
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen [NCT00365287]	Phase 1/Phase 2	148 participants (Actual)	Interventional	2000-06-30	Completed
Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia [NCT00961142]	Phase 2	23 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to slow recruitment)
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With High-risk MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT05453552]	Phase 2/Phase 3	242 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation [NCT03018223]	Phase 1	32 participants (Actual)	Interventional	2017-01-31	Completed
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT04713956]	Phase 2/Phase 3	242 participants (Anticipated)	Interventional	2021-01-15	Recruiting
Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells [NCT00376519]	Phase 1	3 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Slow accrual)
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Ne [NCT02881086]	Phase 3	1,000 participants (Actual)	Interventional	2016-08-31	Active, not recruiting
A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia [NCT00322101]	Phase 3	25 participants (Actual)	Interventional	2006-01-31	Completed
Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies [NCT02333838]	Phase 2	31 participants (Actual)	Interventional	2015-05-31	Active, not recruiting
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia [NCT04245722]	Phase 1	98 participants (Actual)	Interventional	2020-03-19	Terminated(stopped due to The study was terminated by the Sponsor.)
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma [NCT04023071]	Phase 1	72 participants (Actual)	Interventional	2019-10-04	Terminated(stopped due to The study was terminated by the Sponsor.)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) [NCT03105336]	Phase 2	159 participants (Actual)	Interventional	2017-06-20	Active, not recruiting
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia [NCT02845596]		40 participants (Anticipated)	Interventional	2016-08-31	Active, not recruiting
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma [NCT02601313]	Phase 2	105 participants (Actual)	Interventional	2015-11-09	Completed
AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATOR'S CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) [NCT01564784]	Phase 3	326 participants (Actual)	Interventional	2012-08-02	Completed
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies [NCT01690520]	Phase 2	163 participants (Actual)	Interventional	2012-12-11	Completed
A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse With Complete Remission Duration < 1 Year [NCT00480987]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to Lack of support.)
Phase I Study to Evaluate the Safety and Effectiveness of Dual CD33-CLL1 CAR-T Therapy in Relapsed/Refractory Acute Myeloid Leukemia [NCT05016063]	Early Phase 1	32 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
A Phase I Open, Single-arm Study of JWCAR029 (CD19-targeted Chimeric Antigen Receptor T Cells) for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia [NCT05727683]	Phase 1	33 participants (Anticipated)	Interventional	2022-04-28	Recruiting
Compare the Safety and Effective of HLA-mismatched Microtransplantation With HLA-matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-risk [NCT02461121]	Phase 3	156 participants (Actual)	Interventional	2004-05-31	Completed
Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes [NCT03235973]	Phase 1	29 participants (Anticipated)	Interventional	2018-04-28	Recruiting
An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma [NCT04836507]	Phase 1/Phase 2	91 participants (Anticipated)	Interventional	2021-03-02	Recruiting
Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients: A Randomised, Placebo Controlled, Double Blind Phase II Trial: NMSG #13/03 [NCT00382694]	Phase 2	80 participants	Interventional	2005-05-31	Active, not recruiting
A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19) [NCT04314843]	Phase 1	6 participants (Actual)	Interventional	2020-05-26	Terminated(stopped due to Development program terminated.)
A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation [NCT03190733]	Phase 4	192 participants (Anticipated)	Interventional	2017-08-30	Not yet recruiting
Pilot Study of Infusion of Fucosylated Regulatory T Cells to Prevent Graft Versus Host Disease [NCT02423915]	Phase 1	5 participants (Actual)	Interventional	2015-07-30	Completed
Phase I/II Study Evaluating the Infusion of Tumor-Infiltrating Lymphocytes (TILs) & Low-Dose Interleukin-2 (IL-2) Therapy Following a Preparative Regimen of Non-myeloablative Lymphodepletion Using Cyclophosphamide & Fludarabine in Patients With Malignant [NCT02414945]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2015-05-15	Completed
An Open, Single-arm Clinical Study of Autologous T Cells (CAR-T) Targeting B7-H3 Chimeric Antigen Receptor Gene in the Treatment of Patients With Advanced Gastrointestinal Tumors [NCT05515185]	Early Phase 1	30 participants (Anticipated)	Interventional	2022-09-09	Not yet recruiting
Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients [NCT03173417]	Phase 1/Phase 2	177 participants (Actual)	Interventional	2017-05-23	Completed
Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations [NCT02400281]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2015-09-30	Completed
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients [NCT03166397]	Phase 2	30 participants (Anticipated)	Interventional	2017-06-05	Recruiting
A Multicenter, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Rituximab Plus Fludarabine and Cyclophosphamide (FCR) as First-Line Treatment in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) [NCT02533401]	Phase 2	34 participants (Actual)	Interventional	2006-02-28	Completed
Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy [NCT02441803]	Phase 2	11 participants (Actual)	Interventional	2015-09-14	Active, not recruiting
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT02412475]	Phase 1	3 participants (Actual)	Interventional	2015-02-21	Terminated(stopped due to We opened a competing study with the TACL consortium)
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Hematologic Malignancies [NCT05084027]	Phase 2	50 participants (Anticipated)	Interventional	2021-10-07	Recruiting
T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies [NCT02659943]	Phase 1	27 participants (Actual)	Interventional	2016-01-21	Completed
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab [NCT02621021]	Phase 2	20 participants (Actual)	Interventional	2015-12-04	Suspended(stopped due to The team is revising the protocol design and has chosen to put the study on hold until those changes are approved.)
A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS) [NCT03670966]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2019-07-10	Recruiting
A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndr [NCT03128034]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2017-10-24	Suspended(stopped due to Administrative - FDA Comments)
A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma [NCT04121507]	Phase 2	60 participants (Actual)	Interventional	2019-06-24	Completed
Phase I/II Study of CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. [NCT03146533]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2017-05-31	Recruiting
FLUCLORIC: Randomized Multicentric Phase III Study Comparing the Efficacy of 2 Reduced Intensity Conditioning Regimens (Clofarabine/Busulfan vs Fludarabine/Busulfan) in Adults With AML and Eligible to Allogeneic Stem Cell Transplantation [NCT05917405]	Phase 2	302 participants (Anticipated)	Interventional	2023-09-14	Recruiting
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma [NCT05633615]	Phase 2	396 participants (Anticipated)	Interventional	2023-06-12	Recruiting
Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple Myeloma [NCT05442580]	Phase 1	36 participants (Anticipated)	Interventional	2023-05-30	Recruiting
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm [NCT04109482]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2020-02-17	Terminated(stopped due to Business reasons.)
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers [NCT03139370]	Phase 1	16 participants (Actual)	Interventional	2017-12-27	Terminated(stopped due to The study was terminated due to the sponsor's decision to discontinue the clinical trial.)
Phase I Study of CART-PSMA-TGFβRDN Cells in Patients With Advanced Castrate Resistant Prostate Cancer [NCT03089203]	Phase 1	19 participants (Anticipated)	Interventional	2017-03-08	Recruiting
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial [NCT03676504]	Phase 1/Phase 2	68 participants (Anticipated)	Interventional	2018-09-07	Recruiting
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma [NCT00014508]	Phase 2	0 participants	Interventional	2001-11-19	Completed
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndro [NCT03494569]	Phase 1	36 participants (Anticipated)	Interventional	2018-07-06	Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer [NCT06121570]	Phase 1	24 participants (Anticipated)	Interventional	2023-11-01	Recruiting
A Phase III Intergroup CLL Study of Asymptomatic Patients With Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation With Later Treatment in the High Risk Genetic Subset With IGVH Unmutated Disease [NCT00513747]	Phase 3	84 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Insufficient accrual)
A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) in High-Risk Previously Untreated Patients With CLL [NCT00525603]	Phase 2	60 participants (Actual)	Interventional	2005-06-30	Completed
A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer [NCT01795976]	Phase 2	2 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Withdrawal of funding)
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization [NCT00610311]	Phase 2	3 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to The study was terminated due to low accrual.)
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation [NCT00589563]	Phase 2	32 participants (Actual)	Interventional	2007-05-31	Completed
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) [NCT03821610]	Phase 2	242 participants (Anticipated)	Interventional	2018-11-22	Active, not recruiting
A Phase I Study of Administrating CD19 Chimeric Antigen Receptor Expressing T Cells Followed by Allogeneic Stem Cell Transplantation in Patients With Refractory CD19+ B-linage Leukemia/Lymphoma [NCT03110640]	Phase 1	20 participants (Anticipated)	Interventional	2016-10-01	Recruiting
Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb) [NCT01445821]	Phase 3	44 participants (Actual)	Interventional	2011-09-15	Terminated(stopped due to Developed a better regimen: DIAD. Cast. 2018 NCT03593902)
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia [NCT00281918]	Phase 3	817 participants (Actual)	Interventional	2003-07-31	Completed
Total Body Irradiation Dose De-escalation Study in Patients With Fanconi Anemia Undergoing Alternate Donor Hematopoietic Cell Transplantation [NCT00352976]	Phase 2/Phase 3	83 participants (Actual)	Interventional	2006-05-18	Completed
T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia [NCT01464359]	Phase 2	3 participants (Actual)	Interventional	2011-10-31	Terminated(stopped due to Slow accrual)
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies [NCT01499147]		100 participants (Actual)	Interventional	2000-02-29	Completed
Bortezomib Combined With Fludarabine and Cytarabine for Mantle Cell Lymphoma Patients：a Single Arm, Open-labelled, Phase 2 Study [NCT03016988]	Phase 2	50 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a) [NCT00963872]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2010-03-31	Terminated(stopped due to Lack of efficacy after interim analysis)
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN [NCT02435901]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2008-12-31	Completed
A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Hematologic Malignancies [NCT02280525]	Phase 1	8 participants (Actual)	Interventional	2015-03-05	Completed
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies [NCT01875237]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2013-12-27	Terminated
Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Trans [NCT05139004]	Phase 1	12 participants (Anticipated)	Interventional	2022-07-19	Recruiting
A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas [NCT04049513]	Phase 1	30 participants (Anticipated)	Interventional	2019-10-11	Recruiting
A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia [NCT03103971]	Phase 1	55 participants (Actual)	Interventional	2017-11-03	Active, not recruiting
Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation [NCT01518153]	Phase 2	16 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Objectives not met.)
A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia [NCT01905943]	Phase 3	979 participants (Actual)	Interventional	2013-11-04	Completed
Clinical Study on QN-023a Targeting CD33 in Relapsed/Refractory Acute Myeloid Leukemia [NCT05601466]	Phase 1	18 participants (Anticipated)	Interventional	2022-10-28	Recruiting
Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial [NCT00060424]	Phase 2	21 participants (Actual)	Interventional	2003-03-31	Completed
A Study of Thymic Shielding in Recipients of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia [NCT00167206]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2004-03-31	Terminated(stopped due to Treatment with thymic shielding found safe, another study started.)
Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders [NCT00176878]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2000-06-30	Completed
Autologous Versus Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Chemosensitive Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response or First Partial Response (BMT CTN #0202) [NCT00096460]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2004-08-31	Terminated(stopped due to lower than anticipated accrual)
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial [NCT00040846]	Phase 2	60 participants (Actual)	Interventional	2001-11-30	Completed
Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation [NCT00049504]	Phase 2	53 participants (Actual)	Interventional	2002-01-31	Completed
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma [NCT04025216]	Phase 1	16 participants (Actual)	Interventional	2019-10-10	Terminated(stopped due to The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.)
A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome [NCT05873712]	Phase 2	24 participants (Anticipated)	Interventional	2023-07-28	Recruiting
A Phase 1b Clinical Trial of Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma [NCT05577000]	Phase 1	24 participants (Anticipated)	Interventional	2021-10-18	Recruiting
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors [NCT04530487]	Phase 2	40 participants (Anticipated)	Interventional	2020-08-19	Recruiting
A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma [NCT03721068]	Phase 1	18 participants (Anticipated)	Interventional	2019-02-19	Recruiting
Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic Melanoma [NCT02278887]	Phase 3	168 participants (Actual)	Interventional	2014-09-23	Active, not recruiting
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) [NCT04318678]	Phase 1	32 participants (Anticipated)	Interventional	2020-07-29	Active, not recruiting
A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children [NCT01858740]	Phase 2	20 participants (Actual)	Interventional	2013-12-17	Completed
A Phase I Study of Adoptive Transfer of Autologous Tumour Antigen-Specific T Cells With Pre-conditioning Chemotherapy and Intravenous IL2 in Patients With CD19 Positive Malignancy [NCT01493453]	Phase 1	17 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Investigation into serious breach)
Nonmyeloablative Allogeneic Stem Cell Transplantation For Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation ( A BMT Study) [NCT00121186]	Phase 2	1 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to poor accrual)
S0125, A Phase II Study Of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation In Older Patients With Acute Myeloid Leukemia (AML) In First Complete Remission (A BMT Study) [NCT00053014]	Phase 2	5 participants (Actual)	Interventional	2003-04-30	Terminated(stopped due to Poor accrual)
Phase 2 Study of the Activity and Safety of Fludarabine, Cyclophosphamide, and Mitoxantrone Plus Rituximab (FCM-R) With Pegfilgrastim (Neulasta) as Frontline Therapy for Patients < 70 Years With Chronic Lymphocytic Leukemia [NCT00254410]	Phase 2	30 participants (Actual)	Interventional	2005-03-14	Completed
Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia [NCT00381004]	Phase 2	60 participants (Actual)	Interventional	2006-09-30	Completed
A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia [NCT00452374]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2004-11-30	Completed
Nonmyeloablative Hematopoietic Cell Transplantation for Patients With Fanconi Anemia Using Alternative Marrow Donors: A Phase II Dose-Finding Study [NCT00453388]	Phase 2	6 participants (Actual)	Interventional	2007-02-28	Completed
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction [NCT05909059]	Phase 2	20 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. [NCT05618925]	Phase 1	20 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes With Excess Blasts (MDS-EB), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Tra [NCT04994808]	Phase 2	80 participants (Anticipated)	Interventional	2023-08-11	Recruiting
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation [NCT02771197]	Phase 2	20 participants (Actual)	Interventional	2016-09-28	Completed
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma [NCT00574496]	Phase 2	25 participants (Actual)	Interventional	2007-11-13	Completed
Phase I/II Study of Sorafenib Added to Busulfan and Fludarabine Conditioning Regimen in Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation [NCT03247088]	Phase 1/Phase 2	74 participants (Anticipated)	Interventional	2017-07-30	Recruiting
"MT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and Off-the-shelf Mesenchymal Stem Cells" [NCT01033552]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2010-01-31	Completed
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination [NCT00704938]	Phase 2	3 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Terminated due to withdrawal of support from our collaborator.)
A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma [NCT03696784]	Phase 1	30 participants (Anticipated)	Interventional	2019-03-12	Recruiting
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies [NCT04088890]	Phase 1	92 participants (Anticipated)	Interventional	2019-09-12	Recruiting
ADMINISTRATION OF MOST CLOSELY MATCHED THIRD PARTY RAPIDLY GENERATED LMP, BARF1 and EBNA1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH EBV-POSITIVE LYMPHOMA AND OTHER EBV-POSITIVE MALIGNANCIES [NCT02287311]	Phase 1	42 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Anti-CD30 CAR T Cells With Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas [NCT03049449]	Phase 1	26 participants (Actual)	Interventional	2017-03-17	Completed
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 With the Administration of Pembrolizumab in the Retreatment Arm [NCT01993719]	Phase 2	33 participants (Actual)	Interventional	2013-12-12	Completed
Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia [NCT00003816]	Phase 2/Phase 3	361 participants (Actual)	Interventional	1998-10-19	Completed
A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT [NCT06125483]		38 participants (Anticipated)	Interventional	2023-11-01	Recruiting
A Phase I Trial Evaluating Escalating Doses of ²¹¹At-Labeled Anti-CD38 Monoclonal Antibody Followed by HLA-Matched or Haploidentical Donor Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma [NCT04579523]	Phase 1	30 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia [NCT01117441]	Phase 3	6,136 participants (Actual)	Interventional	2010-06-30	Completed
Haploidentical Donor Hematopoietic Stem Cell Transplantation [NCT02660281]	Phase 1	74 participants (Actual)	Interventional	2015-10-31	Completed
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma [NCT05565105]	Phase 2	100 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR)-T Cell Therapy for Subjects With Measurable Residual Disease(MRD)-Positive B Cell Acute Lymphoblastic Leukemia [NCT03919526]	Phase 1	19 participants (Actual)	Interventional	2019-08-11	Completed
Safety and Efficacy of Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for Relapsed/Refractory B Lymphoid Malignancies: a Single-center, Open-label, Single-arm Clinical Study [NCT04796675]	Phase 1	27 participants (Anticipated)	Interventional	2021-04-10	Recruiting
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma [NCT01807182]	Phase 2	11 participants (Actual)	Interventional	2013-08-20	Completed
Allogeneic Peripheral Blood Stem Cell Transplantation Using a Non-Myeloablative Preparative Regimen for Patients With Hematologic Malignancies [NCT00004145]	Phase 2	16 participants (Actual)	Interventional	1998-11-30	Completed
A Phase I Study of Anti-CD19 CAR T-cell Therapy With Axicabtagene Ciloleucel (Axi-cel) in Patients With Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphoma [NCT04608487]	Phase 1	18 participants (Actual)	Interventional	2020-12-04	Active, not recruiting
Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis [NCT04370301]	Phase 2	10 participants (Anticipated)	Interventional	2021-02-09	Recruiting
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) [NCT03597594]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2021-09-02	Active, not recruiting
A Pilot Study of CD19-Specific Car T Cells as Consolidation for Older Adults With Acute Lymphoblastic Leukemia in First Remission [NCT05707273]	Phase 1	21 participants (Anticipated)	Interventional	2023-04-26	Recruiting
Phase 2 Study of the Combination of Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib in Richter's Transformation [NCT05672173]	Phase 2	20 participants (Anticipated)	Interventional	2023-06-02	Recruiting
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant [NCT01366612]	Phase 3	53 participants (Actual)	Interventional	2010-06-16	Terminated(stopped due to Lack of Accrual)
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma [NCT01468818]	Phase 2	18 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to Study was closed prematurely due to slow and insufficient accrual.)
A Prospective Multicenter Observational Study to Assess Long-term Outcome of Participants Who Have Received oNKord® [NCT05290662]		50 participants (Anticipated)	Observational [Patient Registry]	2022-06-14	Recruiting
Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features [NCT00462332]	Phase 2	86 participants (Actual)	Interventional	2007-05-31	Completed
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes [NCT00509288]	Phase 2	24 participants (Actual)	Interventional	2007-06-30	Completed
Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Participants With Multiple Myeloma or Myelofibrosis [NCT03303950]	Phase 2	6 participants (Actual)	Interventional	2018-03-30	Terminated(stopped due to Slow accrual)
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation [NCT01529827]	Phase 2	94 participants (Actual)	Interventional	2012-02-28	Completed
In-Vivo Activated T-Cell Depletion to Prevent GVHD [NCT00594308]		10 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Treatment ineffective)
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation [NCT00744692]	Phase 1	22 participants (Actual)	Interventional	2008-10-31	Completed
A Pilot Study of an Immunosuppressive and Myeloablative Preparative Regimen for Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Severe Sickle Cell Disease [NCT01279616]	Phase 2	8 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to PI moving to a different institution.)
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Mult [NCT01251575]	Phase 2	77 participants (Actual)	Interventional	2010-12-01	Completed
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen [NCT02199041]	Phase 2	24 participants (Actual)	Interventional	2014-07-11	Terminated(stopped due to The study was halted early due to slow accrual.)
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide [NCT00809276]	Phase 1/Phase 2	92 participants (Actual)	Interventional	2009-05-31	Completed
Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies [NCT01490723]	Phase 2	20 participants (Actual)	Interventional	2013-01-31	Completed
Natural Killer (NK) Cells and Nonmyeloablative Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML) [NCT01390402]	Phase 2	6 participants (Actual)	Interventional	2012-01-31	Completed
A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [NCT05244070]	Phase 1	5 participants (Actual)	Interventional	2022-09-14	Terminated(stopped due to Business objectives have changed.)
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes [NCT01583686]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2012-05-04	Terminated(stopped due to Study terminated due to slow/insufficient accrual.)
Clofarabine Pre-conditioning Followed by Hematopoietic Stem Cell Transplant With Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia [NCT04002115]	Phase 2	2 participants (Actual)	Interventional	2020-06-03	Terminated(stopped due to terminated due to low accrual)
Itacitinib to Prevent Graft Versus Host Disease [NCT04127721]	Phase 2	0 participants (Actual)	Interventional	2020-09-22	Withdrawn(stopped due to 0 ACTUAL Enrollment must have Overall Recruitment Status)
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib [NCT01453101]	Phase 2	54 participants (Actual)	Interventional	2010-06-09	Completed
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen [NCT01991457]	Phase 2	19 participants (Actual)	Interventional	2013-08-27	Completed
Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe Hemoglobinopathies [NCT04776850]	Early Phase 1	0 participants (Actual)	Interventional	2020-12-29	Withdrawn(stopped due to Competing protocol opened in Adult SCT that will include pediatric patients and is now multi-center. No patients enrolled on study.)
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia [NCT04678336]	Phase 1	12 participants (Anticipated)	Interventional	2021-02-15	Active, not recruiting
A Study of CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-cell Acute Lymphoblastic Leukemia [NCT03263208]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2017-08-16	Recruiting
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With HER2+ Locally Advanced and/ or Metastatic Solid Tumors [NCT06101082]	Phase 1	9 participants (Anticipated)	Interventional	2023-10-25	Not yet recruiting
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma [NCT05950334]	Phase 1	322 participants (Anticipated)	Interventional	2023-11-01	Recruiting
PRESERVE: A Multi-Center Trial Using Banked, Cryopreserved HLA-Mismatched Unrelated Donor Bone Marrow and Post-Transplantation Cyclophosphamide in Allogeneic Transplantation for Patients With Hematologic Malignancies [NCT05170828]	Phase 1	0 participants (Actual)	Interventional	2022-09-30	Withdrawn(stopped due to Change in Study Design)
A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma [NCT04674813]	Phase 1	180 participants (Anticipated)	Interventional	2021-02-24	Recruiting
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma [NCT04119024]	Phase 1	24 participants (Anticipated)	Interventional	2019-11-27	Recruiting
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies [NCT03240861]	Phase 1	5 participants (Actual)	Interventional	2017-07-26	Terminated(stopped due to slow accrual)
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myelo [NCT03250338]	Phase 3	322 participants (Anticipated)	Interventional	2018-06-05	Recruiting
Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin [NCT01814046]	Phase 2	24 participants (Actual)	Interventional	2013-03-01	Terminated(stopped due to Investigator left the National Institutes of Health (NIH))
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies [NCT03399773]	Phase 2	15 participants (Anticipated)	Interventional	2022-05-10	Recruiting
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation [NCT02161783]		50 participants (Anticipated)	Observational	2014-10-06	Recruiting
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine [NCT01071239]	Phase 2	1 participants (Actual)	Interventional	2009-04-30	Completed
Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies [NCT02443831]	Phase 1	33 participants (Anticipated)	Interventional	2016-04-30	Active, not recruiting
Pre-Transplant Immune Suppression With Hematopoietic Cell Transplantation From Haploidentical Donors for Adults and Children With Sickle Cell Disease or ß-Thalassemia (Haplo PTCy) [NCT05736419]	Phase 2	24 participants (Anticipated)	Interventional	2023-02-09	Recruiting
Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NY ESO 1 and LAGE 1a, and Co-expressing the dnTGF-βRII (GSK3845097) in Participants With NY ESO 1 and/or LAGE 1a Positive Previously [NCT05943990]	Phase 1	5 participants (Actual)	Interventional	2020-12-21	Terminated(stopped due to The study was terminated due to a change in GSK's R&D priorities.)
Compassionate Use Re-Infusion of ATLCAR.CD30 [NCT03914885]		0 participants	Expanded Access		No longer available
Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation [NCT03412409]	Phase 2	50 participants (Anticipated)	Interventional	2018-02-01	Recruiting
A Pilot Study of Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease [NCT02678143]	Phase 1	1 participants (Actual)	Interventional	2016-04-26	Terminated(stopped due to Closed early due to competing studies)
Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma [NCT03380039]		6 participants (Actual)	Interventional	2017-10-13	Active, not recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer [NCT06121557]	Phase 1	24 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed/Refractory Locally Advanced or Metastatic NY-ESO-1-Expressing Triple Negative Breast Cancer [NCT05989828]	Phase 1	20 participants (Anticipated)	Interventional	2023-11-27	Not yet recruiting
A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies [NCT05417971]		20 participants (Anticipated)	Observational	2022-08-29	Recruiting
"A Phase I/II Clinical Trial of Off-the-shelf NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrel [NCT05115630]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2022-04-08	Recruiting
Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies [NCT04892277]	Phase 1	25 participants (Anticipated)	Interventional	2022-07-14	Recruiting
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies [NCT04191187]	Phase 2	37 participants (Anticipated)	Interventional	2019-12-06	Active, not recruiting
Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Advocacy and Research Alliance (STAR) Trial [NCT04018937]	Phase 2	58 participants (Anticipated)	Interventional	2019-03-22	Recruiting
A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease [NCT03121001]	Phase 2	50 participants (Anticipated)	Interventional	2017-03-20	Recruiting
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor [NCT02828592]	Phase 2	20 participants (Anticipated)	Interventional	2016-09-09	Recruiting
A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE [NCT02080195]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2016-09-13	Terminated(stopped due to Study was unable to accrue subjects)
A Phase 3, Open-Label, Multicenter, Randomized Study of SKLB1028 Versus Salvage Chemotherapy in Patients With FLT3-mutated Acute Myeloid Leukemia Refractory to or Relapsed After First-line Treatment（ALIVE） [NCT04716114]	Phase 3	315 participants (Anticipated)	Interventional	2021-03-24	Recruiting
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC) [NCT00723099]	Phase 2	73 participants (Actual)	Interventional	2008-06-25	Completed
Phase Ib Trial of Pembrolizumab Administered in Combination With or Following Adoptive Cell Therapy- A Multiple Cohort Study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial [NCT03158935]	Phase 1	8 participants (Actual)	Interventional	2017-07-07	Completed
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial [NCT00005803]	Phase 1/Phase 2	76 participants (Actual)	Interventional	1999-09-30	Completed
A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation [NCT00245037]	Phase 1/Phase 2	147 participants (Actual)	Interventional	2005-06-30	Completed
Phase I Study to Evaluate the Safety and Effectiveness of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma [NCT05008536]	Early Phase 1	27 participants (Anticipated)	Interventional	2021-10-01	Recruiting
A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII [NCT01454596]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2012-05-16	Completed
A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma [NCT02215967]	Phase 1	30 participants (Actual)	Interventional	2014-08-12	Completed
A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML) [NCT01824693]	Phase 2	30 participants (Actual)	Interventional	2013-06-24	Completed
CHAIROS - Effect of Early Brief Intensification by Chemoimmunotherapy With FCR Followed by FR and Rituximab Maintenance on Clinical Response in Chemo-naïve Patients With B-CLL [NCT02013817]	Phase 2	43 participants (Actual)	Interventional	2005-10-11	Completed
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) [NCT04245839]	Phase 2	213 participants (Anticipated)	Interventional	2020-07-14	Active, not recruiting
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in [NCT03710421]	Phase 1	30 participants (Anticipated)	Interventional	2019-04-23	Recruiting
Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia [NCT03531736]	Phase 1	17 participants (Actual)	Interventional	2018-05-09	Active, not recruiting
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML [NCT03214562]	Phase 1/Phase 2	116 participants (Anticipated)	Interventional	2017-09-26	Recruiting
Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia [NCT03016377]	Phase 1/Phase 2	54 participants (Anticipated)	Interventional	2012-03-22	Recruiting
A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma [NCT03322735]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2017-12-08	Recruiting
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma [NCT03101709]	Phase 1	30 participants (Anticipated)	Interventional	2016-08-31	Recruiting
T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma [NCT02354690]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2014-11-30	Completed
Safety and Efficacy Evaluation of IM19 Chimeric Antigen Receptor-modified T Cells (IM19CAR-T) In CD19+ B Cell Malignancies [NCT03344705]	Phase 1	20 participants (Anticipated)	Interventional	2017-08-21	Recruiting
A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies [NCT04521946]	Phase 1	0 participants (Actual)	Interventional	2021-01-14	Withdrawn(stopped due to No participants enrolled.)
A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation [NCT04098393]	Phase 1	45 participants (Anticipated)	Interventional	2019-09-18	Recruiting
Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) [NCT02649764]	Phase 1	15 participants (Actual)	Interventional	2016-05-04	Completed
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism [NCT00176865]	Phase 2	19 participants (Actual)	Interventional	2002-08-31	Completed
Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL [NCT00090051]	Phase 3	552 participants (Actual)	Interventional	2003-07-31	Completed
Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination Wi [NCT00112593]		5 participants (Actual)	Interventional	1999-11-30	Completed
Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms [NCT01707004]	Phase 2	20 participants (Actual)	Interventional	2013-05-16	Completed
A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome [NCT00119366]	Phase 2	18 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Funding ended before target accrual was reached; participants are no longer being examined or receiving intervention.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00001586 (2) [back to overview]	Change in Gene Expression Post Chemo
NCT00001586 (2) [back to overview]	Number of Participants With Adverse Events
NCT00001832 (2) [back to overview]	Number of Participants With Adverse Events
NCT00001832 (2) [back to overview]	Clinical Response
NCT00003659 (3) [back to overview]	Utilize Flow Cytometry and Polymerase Chain Reaction as Sensitive Measures of Minimal Residual Disease
NCT00003659 (3) [back to overview]	Overall Response Rate
NCT00003659 (3) [back to overview]	Overall Survival Status
NCT00003816 (4) [back to overview]	4 yr OS
NCT00003816 (4) [back to overview]	4 Year PFS
NCT00003816 (4) [back to overview]	Toxicity/TRM at Day 100
NCT00003816 (4) [back to overview]	CR Rate
NCT00005803 (4) [back to overview]	Progression Free-survival (PFS)
NCT00005803 (4) [back to overview]	Overall Survival (OS)
NCT00005803 (4) [back to overview]	Non-Relapse Mortality
NCT00005803 (4) [back to overview]	Engraftment of HLA Identical PBSC Allografts
NCT00006184 (2) [back to overview]	Number of Participants With Adverse Events
NCT00006184 (2) [back to overview]	Immune Response
NCT00027560 (6) [back to overview]	Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients
NCT00027560 (6) [back to overview]	Extensive Chronic Graft-versus-Host Disease Matched Related Patients
NCT00027560 (6) [back to overview]	Overall Survival
NCT00027560 (6) [back to overview]	Overall Survival
NCT00027560 (6) [back to overview]	Acute Graft-versus-Host Disease Matched Related Patients
NCT00027560 (6) [back to overview]	Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients
NCT00036738 (5) [back to overview]	Relapse Free Survival
NCT00036738 (5) [back to overview]	Transplant-related Mortality
NCT00036738 (5) [back to overview]	Overall Survival
NCT00036738 (5) [back to overview]	Leukemia-free Survival
NCT00036738 (5) [back to overview]	Transplant-related Mortality
NCT00038857 (1) [back to overview]	Number of Participants With Absolute Neutrophil Count Engraftment
NCT00040846 (5) [back to overview]	Evaluate the Risk for Disease Progression and Relapse
NCT00040846 (5) [back to overview]	Evaluate the Risk of Transplant Related Mortality.
NCT00040846 (5) [back to overview]	Evaluate the Risk/Incidence of Infections
NCT00040846 (5) [back to overview]	Determine Whether Engraftment Can be Maintained With a Single Dose Fludarabine, DLI and Continued MMF/CSP, Defined as Rejection Rate < 20%.
NCT00040846 (5) [back to overview]	Evaluate the Risk of Occurrence of Acute and Chronic GVHD
NCT00043979 (14) [back to overview]	Number of Participants With Engraftment
NCT00043979 (14) [back to overview]	Toxicity
NCT00043979 (14) [back to overview]	Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)
NCT00043979 (14) [back to overview]	Median Survival From Date of Progression
NCT00043979 (14) [back to overview]	Number of Participants to Complete Conversion to >95% Donor Chimerism
NCT00043979 (14) [back to overview]	Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy
NCT00043979 (14) [back to overview]	Median Time to Reach Absolute Neutrophil Count of 500/mm(3)
NCT00043979 (14) [back to overview]	Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant
NCT00043979 (14) [back to overview]	Number of Participants With Acute and Chronic GVHD
NCT00043979 (14) [back to overview]	Median Time to Reach a Platelet Count of 50,000/mm(3)
NCT00043979 (14) [back to overview]	Median Progression Free Survival
NCT00043979 (14) [back to overview]	Cluster of Differentiation 4 (CD4) Reconstitution
NCT00043979 (14) [back to overview]	Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)
NCT00043979 (14) [back to overview]	Early Post Transplantation Relapse
NCT00045435 (6) [back to overview]	Disease-free Survival-incidence of Survival Without Relapse
NCT00045435 (6) [back to overview]	Incidence of Rejection
NCT00045435 (6) [back to overview]	Incidence of Acute and Chronic GVHD
NCT00045435 (6) [back to overview]	Overall Survival
NCT00045435 (6) [back to overview]	Nonrelapse Mortality (NRM)-Incidence of Nonrelapse Death
NCT00045435 (6) [back to overview]	Incidence of Relapse
NCT00047060 (11) [back to overview]	Number of Participants Who Experienced Transplant Related Mortality
NCT00047060 (11) [back to overview]	Number of Participants That Remained Disease-free
NCT00047060 (11) [back to overview]	Number of Participants That Experienced Red Blood Cell Recovery
NCT00047060 (11) [back to overview]	Efficacy of Nonmyeloablative Preparative Regimen
NCT00047060 (11) [back to overview]	Number of Participants That Experienced Platelet Recovery
NCT00047060 (11) [back to overview]	Number of Participants That Experienced Graft Failure
NCT00047060 (11) [back to overview]	Number of Participants That Experienced Engraftment
NCT00047060 (11) [back to overview]	Number of Participants Overall Survival
NCT00047060 (11) [back to overview]	Number of Participants Who Experienced Acute GVHD Grades II-IV
NCT00047060 (11) [back to overview]	Number of Participant Who Experienced Chronic Graft Versus Host Disease
NCT00047060 (11) [back to overview]	Median Time in Months to Achieve Full Myeloid and Full Donor T-cell Chimerism
NCT00048737 (1) [back to overview]	Number of Participants With Graft Failure
NCT00048893 (1) [back to overview]	Number of Participants With Adverse Events
NCT00049504 (3) [back to overview]	Donor Engraftment (Chimerism)
NCT00049504 (3) [back to overview]	Non-relapse-related Mortality
NCT00049504 (3) [back to overview]	Incidence of Grades III-IV Acute GVHD
NCT00051311 (9) [back to overview]	Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis
NCT00051311 (9) [back to overview]	Percentage of Recipients Who Achieved Donor Chimerism at Day +14
NCT00051311 (9) [back to overview]	Number of Recipients With Non-serious Adverse Events
NCT00051311 (9) [back to overview]	Median Time to Neutrophil Recovery
NCT00051311 (9) [back to overview]	Median Time to Platelet Recovery
NCT00051311 (9) [back to overview]	Number of Recipients Evaluable Who Achieved Full Donor Chimerism at Day+100
NCT00051311 (9) [back to overview]	Median Cycles of Induction Chemotherapy With Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, and Prednisone Given to Recipients
NCT00051311 (9) [back to overview]	Number of Recipients Who Developed Chronic Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis
NCT00051311 (9) [back to overview]	Number of Recipients With a Response to Reduced-intensity Stem Cell Transplantation (RIST)
NCT00053014 (2) [back to overview]	Serious Adverse Events
NCT00053014 (2) [back to overview]	Overall Survival
NCT00053989 (4) [back to overview]	Acute GvHD
NCT00053989 (4) [back to overview]	OS
NCT00053989 (4) [back to overview]	PFS
NCT00053989 (4) [back to overview]	Day 100 TRM
NCT00054353 (8) [back to overview]	PFS
NCT00054353 (8) [back to overview]	Relapse Rate
NCT00054353 (8) [back to overview]	Response Rate
NCT00054353 (8) [back to overview]	Engraftment
NCT00054353 (8) [back to overview]	Incidence of Acute GVHD (Grades III-IV)
NCT00054353 (8) [back to overview]	OS
NCT00054353 (8) [back to overview]	Non-relapse Mortality
NCT00054353 (8) [back to overview]	Incidence of Chronic (Extensive) GVHD
NCT00058825 (9) [back to overview]	Median Time to Engraftment With the Isolex/CLINIMACs System
NCT00058825 (9) [back to overview]	2-year Overall Survival
NCT00058825 (9) [back to overview]	Donor Chimerism Engraftment of Greater Than 50%
NCT00058825 (9) [back to overview]	Transplant Related Mortality (TRM)
NCT00058825 (9) [back to overview]	Number of Patients Who Engrafted With the Isolex/CLINIMACs System
NCT00058825 (9) [back to overview]	Time in Days to ANC Engraftment
NCT00058825 (9) [back to overview]	Acute Graft Versus Host Disease
NCT00058825 (9) [back to overview]	Chronic Graft Versus Host Disease
NCT00058825 (9) [back to overview]	2-year Relapse-free Survival
NCT00060424 (5) [back to overview]	Transplant-related Mortality
NCT00060424 (5) [back to overview]	Rate of Relapse
NCT00060424 (5) [back to overview]	Acute Grade II-IV GVHD and Chronic (Extensive) GVHD
NCT00060424 (5) [back to overview]	Rate and Types of Infections
NCT00060424 (5) [back to overview]	Overall Survival
NCT00067002 (5) [back to overview]	Number of Participants Severity of Acute GVHD by Treatment Arm
NCT00067002 (5) [back to overview]	Rate of Chronic GVHD
NCT00067002 (5) [back to overview]	Number of Participants With Engraftment
NCT00067002 (5) [back to overview]	Rate of Acute Graft Versus Host Disease (GVHD)
NCT00067002 (5) [back to overview]	Time To Neutrophil Engraftment
NCT00070135 (3) [back to overview]	Non-relapse Mortality (NRM)
NCT00070135 (3) [back to overview]	2 Year Disease Free Survival In Unrelated Donor Recipient Group
NCT00070135 (3) [back to overview]	2 Year DFS for All Patients
NCT00074269 (7) [back to overview]	Response as Measured at 12 Months Post Allografting
NCT00074269 (7) [back to overview]	Progression-free Survival
NCT00074269 (7) [back to overview]	Overall Survival
NCT00074269 (7) [back to overview]	Number of Participants With Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes
NCT00074269 (7) [back to overview]	Number of Participants With Adverse Events
NCT00074269 (7) [back to overview]	Number of Participants With Acute and Chronic Graft-versus-host Disease (GVHD)
NCT00074269 (7) [back to overview]	Frequency of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1 Month Post Allografting
NCT00074490 (4) [back to overview]	Percentage of Patients With Opportunistic Infection
NCT00074490 (4) [back to overview]	Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD)
NCT00074490 (4) [back to overview]	Percentage of Patients to Receive T Cell Infusion
NCT00074490 (4) [back to overview]	Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)
NCT00075478 (8) [back to overview]	Incidence of Graft Rejection
NCT00075478 (8) [back to overview]	Incidence of Relapse-related Mortality
NCT00075478 (8) [back to overview]	Incidence of Relapse/Progression
NCT00075478 (8) [back to overview]	Incidence of Non-relapse Mortality
NCT00075478 (8) [back to overview]	Incidence of Grades II-IV Acute GVHD
NCT00075478 (8) [back to overview]	Incidence of Chronic Extensive GVHD
NCT00075478 (8) [back to overview]	Progression-free Survival
NCT00075478 (8) [back to overview]	Overall Survival
NCT00076752 (16) [back to overview]	Anti-Nuclear Antibody
NCT00076752 (16) [back to overview]	Anti-Smith-Ribonuclear Protein Antibody
NCT00076752 (16) [back to overview]	Cluster of Differentiation 19 (CD19) + Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 3 (CD3) + Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 4 (CD4) + Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 8 (CD8) + Cells
NCT00076752 (16) [back to overview]	Extractable Nuclear Antigen (ENA)
NCT00076752 (16) [back to overview]	Natural Killer Cells
NCT00076752 (16) [back to overview]	Platelet Count
NCT00076752 (16) [back to overview]	Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
NCT00076752 (16) [back to overview]	Number of Participants With Adverse Events
NCT00076752 (16) [back to overview]	White Blood Cells
NCT00076752 (16) [back to overview]	Relapse-free Complete Clinical Response
NCT00076752 (16) [back to overview]	Absolute Lymphocyte Count
NCT00076752 (16) [back to overview]	Absolute Neutrophil Count
NCT00076752 (16) [back to overview]	Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody
NCT00085423 (3) [back to overview]	Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST
NCT00085423 (3) [back to overview]	Number of Participants With Lymphocyte Recovery as Measured by Blood Count
NCT00085423 (3) [back to overview]	Time to Progression as Measured by RECIST
NCT00086580 (20) [back to overview]	Mean EQ-5D™ Index Scores to Measure Quality of Life at End of Treatment
NCT00086580 (20) [back to overview]	Participant Best Response to Treatment Assessed by the Independent Response Review Panel (IRRP)
NCT00086580 (20) [back to overview]	Total Volume of Distribution (Vss) of Fludarabine
NCT00086580 (20) [back to overview]	Participants With Minimal Residual Disease (MRD)
NCT00086580 (20) [back to overview]	Mean Systemic Clearance (CL) of Fludarabine
NCT00086580 (20) [back to overview]	Mean EuroQol Visual Analogue Scale (EQ-VAS) Scores to Measure Quality of Life at End of Treatment
NCT00086580 (20) [back to overview]	Mean EuroQol Visual Analogue Scale (EQ-VAS) Scores to Measure Quality of Life at Baseline
NCT00086580 (20) [back to overview]	Area Under the Curve (AUC) of Fludarabine From (AUC 0-tau)
NCT00086580 (20) [back to overview]	Mean EQ-5D™ Index Scores to Measure Quality of Life at Baseline
NCT00086580 (20) [back to overview]	Maximum Plasma Concentration (Cmax) of Fludarabine
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates of Overall Survival Time for Participants With Rai Stage I-II
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates of Overall Survival Time
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates for Time to Alternative Therapy
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) for Participants With Rai Stage III-IV
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates for Duration of Response Assessed by the Independent Response Review Panel (IRRP)
NCT00086580 (20) [back to overview]	Kaplan Meier Estimates for Time to Disease Progression Assessed by the Independent Response Review Panel (IRRP)
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates of Overall Survival Time for Participants With Rai Stage III-IV
NCT00086580 (20) [back to overview]	Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) for Participants With Rai Stage I-II
NCT00086580 (20) [back to overview]	Summary of Participants With Adverse Experiences (AEs)
NCT00089011 (8) [back to overview]	Incidences of Grades II-IV Acute GVHD
NCT00089011 (8) [back to overview]	Incidence of Grade III/IV GVHD
NCT00089011 (8) [back to overview]	Incidences of Graft Rejection
NCT00089011 (8) [back to overview]	Overall Survival
NCT00089011 (8) [back to overview]	Incidence of Chronic Extensive GVHD
NCT00089011 (8) [back to overview]	Rates of Relapse-related Mortality
NCT00089011 (8) [back to overview]	Rates of Disease Progression
NCT00089011 (8) [back to overview]	Rate and Duration of Steroid Use for the Treatment of Chronic GVHD
NCT00090051 (15) [back to overview]	Final Analysis: Time to New Chronic Lymphocytic Leukemia (CLL) Treatment
NCT00090051 (15) [back to overview]	Final Analysis: Time to Overall Survival Event
NCT00090051 (15) [back to overview]	Final Analysis: Percentage of Participants With Complete Response
NCT00090051 (15) [back to overview]	Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
NCT00090051 (15) [back to overview]	Number of Participants With Disease-free Survival (DFS) Events
NCT00090051 (15) [back to overview]	Number of Participants With Event-free Survival (EFS) Events
NCT00090051 (15) [back to overview]	Number of Participants With Overall Survival (OS) Events
NCT00090051 (15) [back to overview]	Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC)
NCT00090051 (15) [back to overview]	Final Analysis: Time to Disease-Free Survival Event
NCT00090051 (15) [back to overview]	Overall Survival (OS)
NCT00090051 (15) [back to overview]	Disease-free Survival (DFS)
NCT00090051 (15) [back to overview]	Final Analysis: Time to Progression-Free Survival Event
NCT00090051 (15) [back to overview]	Final Analysis: Duration of Response
NCT00090051 (15) [back to overview]	Final Analysis: Time to Event-Free Survival Event
NCT00090051 (15) [back to overview]	Event-free Survival (EFS)
NCT00096018 (2) [back to overview]	Duration of Response
NCT00096018 (2) [back to overview]	Overall Responders (Complete and Partial Response)
NCT00096382 (2) [back to overview]	Clinical Tumor Regression
NCT00096382 (2) [back to overview]	Safety
NCT00096460 (1) [back to overview]	Lymphoma Progression-free Survival
NCT00098670 (5) [back to overview]	Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab
NCT00098670 (5) [back to overview]	Number of Participants With Severe Non-Hematologic Adverse Events During Treatment With Alemtuzumab
NCT00098670 (5) [back to overview]	2 Year Survival
NCT00098670 (5) [back to overview]	2 Year Progression Free Survival
NCT00098670 (5) [back to overview]	Number of Participants With a Complete or Partial Response After Induction Therapy With Fludarabine & Rituximab
NCT00104858 (8) [back to overview]	Number of Participants With Regimen-related Toxicity and Infections
NCT00104858 (8) [back to overview]	Number of Participants With Grade II-III and III-IV Acute GVHD and Chronic GVHD
NCT00104858 (8) [back to overview]	Rituxan Concentration
NCT00104858 (8) [back to overview]	Donor and Host Polymorphisms of the FCgammaRIIIa Receptor and CD32 and Their Impact on Disease Response and Relapse
NCT00104858 (8) [back to overview]	Overall Survival
NCT00104858 (8) [back to overview]	Number of Patients Achieving Complete Response and Partial Response (Overall Response Rate)
NCT00104858 (8) [back to overview]	Number of Participants With Treatment-related Mortality
NCT00104858 (8) [back to overview]	Number of Participants With Relapse/Progression
NCT00105001 (5) [back to overview]	Number of Participants Surviving Without Progression
NCT00105001 (5) [back to overview]	Number of Participants Utilizing High-Dose Corticosteroids
NCT00105001 (5) [back to overview]	Number of Non-Relapse Mortalities
NCT00105001 (5) [back to overview]	Number of Participants Surviving Overall
NCT00105001 (5) [back to overview]	Number of Participants With Grades II-IV Acute GVHD
NCT00112593 (6) [back to overview]	Progression of HIV
NCT00112593 (6) [back to overview]	Death From Regimen Toxicity or Opportunistic Infection
NCT00112593 (6) [back to overview]	Death From GVHD
NCT00112593 (6) [back to overview]	Successful Induction of Mixed Hematopoietic Chimerism as Assessed by the Percentage of Peripheral Blood T Cells That Are of Donor Origin
NCT00112593 (6) [back to overview]	Reconstitution of HIV-specific Immunity
NCT00112593 (6) [back to overview]	Overall Survival
NCT00117156 (5) [back to overview]	Delayed Pneumonia Toxicity Rate
NCT00117156 (5) [back to overview]	Objective Response Rate
NCT00117156 (5) [back to overview]	Delayed Bone Marrow Toxicity Rate
NCT00117156 (5) [back to overview]	3.1-Year Progression-Free Survival
NCT00117156 (5) [back to overview]	3.1-Year Overall Survival
NCT00118352 (6) [back to overview]	Incidence of Non-relapse Mortality
NCT00118352 (6) [back to overview]	Disease Progression/Relapse
NCT00118352 (6) [back to overview]	Incidence of Infection
NCT00118352 (6) [back to overview]	Incidence of Grade III-IV Acute GVHD
NCT00118352 (6) [back to overview]	Incidence of High-dose Corticosteroid Utilization.
NCT00118352 (6) [back to overview]	Incidence of Graft Rejection
NCT00119366 (3) [back to overview]	Participant Disease Response Within 4 Weeks After Transplant
NCT00119366 (3) [back to overview]	Number of Participants With 100% Donor Chimerism at Day 28 and Day 84
NCT00119366 (3) [back to overview]	Two-year Disease-free Survival of Study Participants Who Completed the Study Regimen
NCT00119392 (5) [back to overview]	Overall and Progression-free Survival
NCT00119392 (5) [back to overview]	Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.
NCT00119392 (5) [back to overview]	Engraftment and Hematopoietic Toxicity
NCT00119392 (5) [back to overview]	Treatment Related Mortality (TRM)
NCT00119392 (5) [back to overview]	Response Rates
NCT00121186 (2) [back to overview]	Overall Survival
NCT00121186 (2) [back to overview]	Progression-free Survival
NCT00134004 (5) [back to overview]	Progression-free Survival
NCT00134004 (5) [back to overview]	Graft Failure Rate
NCT00134004 (5) [back to overview]	Hematologic and Non-hematologic Toxicities as Measured by NCI Common Toxicity Criteria for Adverse Events, v 3.0 Weekly Until 1 Year After Transplantation
NCT00134004 (5) [back to overview]	Relapse Rate
NCT00134004 (5) [back to overview]	Transplant-related Mortality
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Engraftment Failure
NCT00145626 (13) [back to overview]	Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation
NCT00145626 (13) [back to overview]	Kinetics of Lymphohematopoietic Reconstitution
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Minimal Residual Disease (MRD)
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Dose of NK Cells
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Donor Type
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Disease Status at HSCT
NCT00145626 (13) [back to overview]	One-year Survival
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Dose of CD34
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Age of Donor at HSCT
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Match N/6 HLA Loci
NCT00153985 (3) [back to overview]	The Incidence of Grade II-IV Acute Graft vs. Host Disease.
NCT00153985 (3) [back to overview]	Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy.
NCT00153985 (3) [back to overview]	Solid Organ Toxicity Related to the Conditioning Regimen.
NCT00167206 (9) [back to overview]	Immune Reconstitution - Mean Value (1 Year)
NCT00167206 (9) [back to overview]	Number of Patients Who Exhibited Regimen-related Toxicity (RRT)
NCT00167206 (9) [back to overview]	Number of Patients Who Exhibited Secondary Graft Failure
NCT00167206 (9) [back to overview]	Number of Patients With Acute Graft Versus-Host Disease (aGVHD)
NCT00167206 (9) [back to overview]	Number of Patients With Chronic Graft Versus-Host Disease (GVHD)
NCT00167206 (9) [back to overview]	Immune Reconstitution - Mean Value (2 Years)
NCT00167206 (9) [back to overview]	Number of Patients Alive at 1 Year
NCT00167206 (9) [back to overview]	Number of Patients Alive at 2 Years
NCT00167206 (9) [back to overview]	Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment
NCT00176852 (15) [back to overview]	Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
NCT00176852 (15) [back to overview]	The Incidence of Chimerism at 6 Months
NCT00176852 (15) [back to overview]	The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)
NCT00176852 (15) [back to overview]	The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)
NCT00176852 (15) [back to overview]	Disease Free Survival
NCT00176852 (15) [back to overview]	Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
NCT00176852 (15) [back to overview]	Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity
NCT00176852 (15) [back to overview]	Overall Survival
NCT00176852 (15) [back to overview]	Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
NCT00176852 (15) [back to overview]	The Incidence of Grade 2-4 Acute Graft Versus Host Disease (Acute GVHD)
NCT00176852 (15) [back to overview]	The Incidence of Chimerism at 1 Year
NCT00176852 (15) [back to overview]	Overall Survival
NCT00176852 (15) [back to overview]	The Incidence of Grade 3-4 Acute Graft Versus Host Disease (Acute GVHD)
NCT00176852 (15) [back to overview]	Disease Free Survival
NCT00176852 (15) [back to overview]	The Incidence of Chimerism at 100 Days
NCT00176865 (9) [back to overview]	Percentage of Donor Chimerism at 100 Days
NCT00176865 (9) [back to overview]	Number of Subjects With Mixed Chimerism
NCT00176865 (9) [back to overview]	Incidence of Chronic Graft Versus Host Disease (cGVHD)
NCT00176865 (9) [back to overview]	Incidence of Grade 2-4 Acute Graft Versus Host Disease (aGVHD)
NCT00176865 (9) [back to overview]	Incidence of Grade 3-4 Acute Graft Versus Host Disease (aGVHD)
NCT00176865 (9) [back to overview]	Number of Subjects Alive at One Year
NCT00176865 (9) [back to overview]	Number of Subjects Alive at 100 Days
NCT00176865 (9) [back to overview]	Percentage of Donor Chimerism at 365 Days
NCT00176865 (9) [back to overview]	Percentage of Donor Chimerism at 180 Days
NCT00176878 (6) [back to overview]	Number of Patients With Disease Recurrence
NCT00176878 (6) [back to overview]	Number of Patients With Grade 2-4 Acute Graft Versus Host Disease
NCT00176878 (6) [back to overview]	Number of Patients With Succcessful Engraftment After Transplantation
NCT00176878 (6) [back to overview]	Number of Patients Alive at Three Years (Survival)
NCT00176878 (6) [back to overview]	Number of Patients With Chronic Graft Versus Host Disease
NCT00176878 (6) [back to overview]	Number of Patients Alive (Survival) at 2 Years
NCT00187096 (10) [back to overview]	Duration of Engraftment of Natural Killer (NK) Cells
NCT00187096 (10) [back to overview]	Overall Survival
NCT00187096 (10) [back to overview]	Number of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant
NCT00187096 (10) [back to overview]	Percent of Peak NK Cell Chimerism
NCT00187096 (10) [back to overview]	Proportion of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant
NCT00187096 (10) [back to overview]	Relapse-free Survival
NCT00187096 (10) [back to overview]	Number of KIR-mismatched NK Cells
NCT00187096 (10) [back to overview]	Number of Participants With Evidence of NK Cells Lysing a Target Cell Line (K562)
NCT00187096 (10) [back to overview]	Percent of Detectable Donor NK Cells at Day 28
NCT00187096 (10) [back to overview]	Day That Maximum NK Cell Engraftment Was Reached
NCT00206726 (6) [back to overview]	Percentage of Participants With Overall Response at Different Observation Times
NCT00206726 (6) [back to overview]	Complete Response (CR)
NCT00206726 (6) [back to overview]	Overall Survival (OS)
NCT00206726 (6) [back to overview]	Overall Response (OR)
NCT00206726 (6) [back to overview]	Progression-free Survival (PFS)
NCT00206726 (6) [back to overview]	Number of Participants With Minimal Residual Disease (MRD)
NCT00208975 (1) [back to overview]	Number of Patients's Who Had Complete Response and Partial Response to the Treatment of Fludarabine and Cyclophosphamide Followed by GM-CSF and Rituximab.
NCT00230282 (2) [back to overview]	Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR)
NCT00230282 (2) [back to overview]	Duration of Response
NCT00245037 (7) [back to overview]	Progression-Free Survival
NCT00245037 (7) [back to overview]	Acute Graft-Versus-Host Disease (aGVHD) Outcome
NCT00245037 (7) [back to overview]	Chronic Graft-Versus-Host Disease (cGVHD) Outcome
NCT00245037 (7) [back to overview]	Non-relapse Mortality
NCT00245037 (7) [back to overview]	Overall Survival
NCT00245037 (7) [back to overview]	Relapse Mortality
NCT00245037 (7) [back to overview]	Regimen-Related Toxicities
NCT00253513 (4) [back to overview]	Number of Patients Experiencing Regimen-related Toxicity Events in Study Population
NCT00253513 (4) [back to overview]	Number of Patients Experiencing Graft Failure
NCT00253513 (4) [back to overview]	Number of Subjects Who Are Without Disease at One Year as Indicator of Disease Free Survival.
NCT00253513 (4) [back to overview]	Incidence (Percent of Participants) With Nonrelapse Mortality (NRM) by Day 200 (Secondary Phase Only)
NCT00254163 (9) [back to overview]	Infective Event Rate
NCT00254163 (9) [back to overview]	Hematologic Recovery
NCT00254163 (9) [back to overview]	Infection Rate
NCT00254163 (9) [back to overview]	Mean Absolute Neutrophil Count (ANC) at Post-treatment
NCT00254163 (9) [back to overview]	Objective Remission Rate (ORR)
NCT00254163 (9) [back to overview]	Percentage of Patients Hospitalized
NCT00254163 (9) [back to overview]	Progression-free Survival (PFS) Rate at 1-year
NCT00254163 (9) [back to overview]	Progression-free Survival (PFS) Rate at 2-year
NCT00254163 (9) [back to overview]	Complete Remission (CR)
NCT00254410 (4) [back to overview]	Clinical Response Rate at 6 Months
NCT00254410 (4) [back to overview]	Clinical Response Rate at 3 Months
NCT00254410 (4) [back to overview]	Molecular Response Rate at 3 Months
NCT00254410 (4) [back to overview]	Molecular Response Rate at 6 Months
NCT00255684 (2) [back to overview]	Number of Participants Who Survived 100 Days or Longer
NCT00255684 (2) [back to overview]	Number of Participants Who Developed Acute Graft Versus Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Major Infections
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Acute Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Acute Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Chronic Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Chronic Graft-Versus-Host Disease
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Graft Failure
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Overall Survival
NCT00258427 (8) [back to overview]	Number of Participants Experiencing Relapse
NCT00274846 (4) [back to overview]	Median Time to Disease Relapse (Months)
NCT00274846 (4) [back to overview]	Overall Survival Time of Patients With Complete Remission
NCT00274846 (4) [back to overview]	Number of Patients With Natural Killer (NK) Cell Expansion
NCT00274846 (4) [back to overview]	Number of Patients With Complete Remission
NCT00278512 (1) [back to overview]	Survival
NCT00280241 (4) [back to overview]	Overall Survival Rate
NCT00280241 (4) [back to overview]	Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL
NCT00280241 (4) [back to overview]	Duration of Response
NCT00280241 (4) [back to overview]	Efficacy of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL
NCT00281918 (11) [back to overview]	Final Analysis: Time to Overall Survival Event
NCT00281918 (11) [back to overview]	Final Analysis: Time to Progression-free Survival Event
NCT00281918 (11) [back to overview]	Event-free Survival (EFS)
NCT00281918 (11) [back to overview]	Final Analysis: Duration of Response
NCT00281918 (11) [back to overview]	Final Analysis: Time to Disease-free Survival (DFS) Event in Participants With Complete Response (CR)
NCT00281918 (11) [back to overview]	Overall Survival (OS)
NCT00281918 (11) [back to overview]	Final Analysis: Percentage of Participants With Complete Response (CR) and Partial Response
NCT00281918 (11) [back to overview]	Final Analysis: Time to Event-free Survival Event
NCT00281918 (11) [back to overview]	Final Analysis: Time to New Treatment for Chronic Lymphocytic Leukemia(CLL)
NCT00281918 (11) [back to overview]	Disease-free Survival (DFS) of Patients With Confirmed Complete Response (CR).
NCT00281918 (11) [back to overview]	Progression-free Survival (PFS)
NCT00282282 (3) [back to overview]	Percentage of Participants With ≥90 Percent Donor-derived Hematopoeisis Around 100 Days Post Transplantation
NCT00282282 (3) [back to overview]	Incidence of Grade II-IV Acute GVHD (aGVHD) Developing by Day 100 Following Non-myeloablative PBSC Transplantation Using Tacrolimus and Sirolimus.
NCT00282282 (3) [back to overview]	Disease Response.
NCT00282412 (1) [back to overview]	Survival
NCT00290511 (7) [back to overview]	Median Progression Free Survival
NCT00290511 (7) [back to overview]	Overall Survival
NCT00290511 (7) [back to overview]	Percentage of Participants With Overall Survival Rate at 10 Years
NCT00290511 (7) [back to overview]	Number of Participants With Time to Progression (TTP)
NCT00290511 (7) [back to overview]	Tolerance and Efficacy of Maintenance Therapy With Rituximab
NCT00290511 (7) [back to overview]	Tolerance and Efficacy of Maintenance Therapy With Yttrium-90 Ibritumomab Tiuxetan (YIT)
NCT00290511 (7) [back to overview]	Progression Free Survival at 10 Years
NCT00301834 (5) [back to overview]	Disease-free Survival With Correction of Disease at One Year Post Transplantation
NCT00301834 (5) [back to overview]	Number of Participants Achieving Durable Engraftment (Presence of Donor Cells) at 6 Weeks Post Transplantation
NCT00301834 (5) [back to overview]	Cytomegalovirus (CMV) Viral Infection and Disease Symptoms
NCT00301834 (5) [back to overview]	Toxicity Grade ≥ 3 From Start of Conditioning Through the First Year Post Transplantation
NCT00301834 (5) [back to overview]	Treatment-related Mortality at 100 Days and 1 Year Post Transplantation
NCT00303667 (9) [back to overview]	Number of Patients With Treatment-Related Mortality
NCT00303667 (9) [back to overview]	Number of Patients With Graft Failure
NCT00303667 (9) [back to overview]	Disease-free Survival at 1 Year
NCT00303667 (9) [back to overview]	Disease-free Survival at 6 Months
NCT00303667 (9) [back to overview]	In Vivo Expansion of a Donor NK Cells NK Cell Product
NCT00303667 (9) [back to overview]	Incidence of Chronic Graft Versus Host Disease
NCT00303667 (9) [back to overview]	Incidence of Grade III-IV Acute Graft Versus Host Disease
NCT00303667 (9) [back to overview]	Incidence of Post-transplant Lymphoproliferative Disorder (PTLD)
NCT00303667 (9) [back to overview]	Number of Patients With Disease Relapse
NCT00303719 (5) [back to overview]	Overall Survival
NCT00303719 (5) [back to overview]	Neutrophil and Donor Cell Engraftment
NCT00303719 (5) [back to overview]	Acute Graft-Versus-Host Disease
NCT00303719 (5) [back to overview]	Transplant Related Mortality
NCT00303719 (5) [back to overview]	Serious Adverse Events
NCT00305682 (15) [back to overview]	Number of Participants With Chronic Graft-Versus-Host Disease
NCT00305682 (15) [back to overview]	Number of Participants Experiencing Relapse (Incidence of Relapse)
NCT00305682 (15) [back to overview]	Number of Participants Experiencing Relapse (Incidence of Relapse) at 2 Years
NCT00305682 (15) [back to overview]	Number of Participants Who Were Alive at 1 Year Post Transplant
NCT00305682 (15) [back to overview]	Number of Participants Who Were Dead at 6 Months After Study Completion
NCT00305682 (15) [back to overview]	Number of Participants With Acute Graft-versus-host Disease (GVHD)
NCT00305682 (15) [back to overview]	Number of Participants Who Were Alive at 2 Years Post Transplant
NCT00305682 (15) [back to overview]	Percentage of Donor Chimerism at 180 Days
NCT00305682 (15) [back to overview]	Percentage of Donor Chimerism at 21 Days
NCT00305682 (15) [back to overview]	Percentage of Donor Chimerism at 365 Days
NCT00305682 (15) [back to overview]	Number of Participants Experiencing Progression-free Survival
NCT00305682 (15) [back to overview]	Number of Participants Experiencing Progression-free Survival at 2 Years
NCT00305682 (15) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT00305682 (15) [back to overview]	Number of Participants With Platelet Engraftment
NCT00305682 (15) [back to overview]	Percentage of Donor Chimerism at 100 Days
NCT00309842 (11) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT00309842 (11) [back to overview]	Number of Participants With Chronic Graft-Versus-Host Disease
NCT00309842 (11) [back to overview]	Number of Participants Who Were Alive at 1 Year Transplant Overall Survival
NCT00309842 (11) [back to overview]	Number of Participants Who Died Due to Transplant
NCT00309842 (11) [back to overview]	Number of Participants With Platelet Engraftment
NCT00309842 (11) [back to overview]	Percentage Chimerism at 1 Year
NCT00309842 (11) [back to overview]	Number of Participants With Acute Graft-Versus-Host Disease
NCT00309842 (11) [back to overview]	Percentage Chimerism on Day 21
NCT00309842 (11) [back to overview]	Percentage Chimerism on Day 100
NCT00309842 (11) [back to overview]	Percentage Chimerism at 6 Months
NCT00309842 (11) [back to overview]	Percentage Chimerism at 2 Years
NCT00314106 (2) [back to overview]	Number of Participants With Adverse Events
NCT00314106 (2) [back to overview]	Complete Response
NCT00322101 (6) [back to overview]	Incidence and Severity of Acute and Chronic Graft-vs-host Disease
NCT00322101 (6) [back to overview]	Progression-free Survival
NCT00322101 (6) [back to overview]	Non-relapse Mortality
NCT00322101 (6) [back to overview]	Donor Cell Engraftment
NCT00322101 (6) [back to overview]	Overall Survival
NCT00322101 (6) [back to overview]	Incidence of Disease Progression/Relapse
NCT00326417 (5) [back to overview]	Chronic GVHD
NCT00326417 (5) [back to overview]	Overall Survival (OS)
NCT00326417 (5) [back to overview]	Disease-free Survival (DFS)
NCT00326417 (5) [back to overview]	Cumulative Incidence of Graft Failure
NCT00326417 (5) [back to overview]	Acute Graft vs Host Disease (GVHD)
NCT00328861 (2) [back to overview]	Safety
NCT00328861 (2) [back to overview]	Objective Response
NCT00352976 (18) [back to overview]	Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 365 Days
NCT00352976 (18) [back to overview]	Average IgG Levels as a Measure of Immune Reconstitution After Transplant by 365 Days
NCT00352976 (18) [back to overview]	Number of Participants With Secondary Graft Failure at 100 Days
NCT00352976 (18) [back to overview]	Number of Participant With Neutrophil Recovery
NCT00352976 (18) [back to overview]	Number of Participants Experiencing Overall Survival
NCT00352976 (18) [back to overview]	Number of Participants Experiencing Infections by Day 365
NCT00352976 (18) [back to overview]	Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 365 Days
NCT00352976 (18) [back to overview]	Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 180 Days
NCT00352976 (18) [back to overview]	Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 100 Days
NCT00352976 (18) [back to overview]	Average IgG Levels as a Measure of Immune Reconstitution After Transplant, by 180 Days
NCT00352976 (18) [back to overview]	Number of Participants Experiencing Infections by Day 180
NCT00352976 (18) [back to overview]	Number of Participants Experiencing Infections by Day 100
NCT00352976 (18) [back to overview]	Number of Participants Experiencing Grade ≥3 Regimen Related Toxicity
NCT00352976 (18) [back to overview]	Number of Participants Experiencing Chronic GVHD
NCT00352976 (18) [back to overview]	Average Immunoglobulin G (IgG) Levels as a Measure of Immune Reconstitution After Transplant, by 100 Days
NCT00352976 (18) [back to overview]	Number of Participants Experiencing Acute Graft-versus-host Disease (GVHD)
NCT00352976 (18) [back to overview]	Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 100 Days
NCT00352976 (18) [back to overview]	Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 180 Days
NCT00354172 (15) [back to overview]	Chimerism After Double Umbilical Cord Blood Transplant (UCBT)
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died Due to Transplant.
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Attained Neutrophil Engraftment
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Attained Platelet Engraftment
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died by 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died by 24 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Experienced Relapse by 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Experienced Relapse by 24 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Were Disease-free and Alive at 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Were Disease-free and Alive at 6 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Acute Graft-versus-host Disease (GVHD) Grade II-IV
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Acute Graft-versus-Host Disease at Grade III-IV
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Chronic Graft-Versus-Host Disease
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Successful Natural Killer Cell Expansion
NCT00354172 (15) [back to overview]	Number of Patients Who Were Disease-free and Alive at 24 Months
NCT00358657 (9) [back to overview]	Incidence of Grade I/II Acute Graft Versus Host Disease (GVHD)
NCT00358657 (9) [back to overview]	Incidence of Chronic GVHD
NCT00358657 (9) [back to overview]	Proportion of Patients Who Achieve Greater Than 5% Donor T-cell Chimerism
NCT00358657 (9) [back to overview]	Number of Patients With Transplant Related Mortality
NCT00358657 (9) [back to overview]	Number of Patients With Infections
NCT00358657 (9) [back to overview]	Graft Rejection
NCT00358657 (9) [back to overview]	Immune Reconstitution
NCT00358657 (9) [back to overview]	Graft Failure
NCT00358657 (9) [back to overview]	Incidence of Grade III/IV Acute Graft Versus Host Disease (GVHD)
NCT00361140 (2) [back to overview]	Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)
NCT00361140 (2) [back to overview]	Non-relapse Mortality
NCT00376805 (4) [back to overview]	Overall Median Number of Days Patients Alive After Treatment
NCT00376805 (4) [back to overview]	Number of Patients Who Had Expansion of Natural Killer Cells
NCT00376805 (4) [back to overview]	Number of Patients by Disease Response
NCT00376805 (4) [back to overview]	Number of Patients Who Died While on Study
NCT00378534 (5) [back to overview]	Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System
NCT00378534 (5) [back to overview]	Number of Participants Who Developed Limited Chronic GVHD
NCT00378534 (5) [back to overview]	Number of Participants With Relapse of Disease
NCT00378534 (5) [back to overview]	Number of Participants Who Develop Extensive GVHD
NCT00378534 (5) [back to overview]	Number of Participants Who Developed Acute GVHD Grades I, II, III, IV
NCT00381004 (3) [back to overview]	Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.
NCT00381004 (3) [back to overview]	Number of Participants With Overall Response Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.
NCT00381004 (3) [back to overview]	Number of Participants Progression-free
NCT00381550 (2) [back to overview]	Incidence of Grade 3 or 4 Drug-related Non-hematologic Toxicity as Assessed by NCI CTCAE v3.0
NCT00381550 (2) [back to overview]	Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical Evaluation
NCT00385788 (1) [back to overview]	Transplant Related Mortality Rate
NCT00387959 (1) [back to overview]	Survival at 1 Year After Transplantation
NCT00392782 (7) [back to overview]	Incidence of Chronic Graft-versus-host Disease (GVHD)
NCT00392782 (7) [back to overview]	Incidence of Disease Relapse
NCT00392782 (7) [back to overview]	Incidence of Disease-free Survival
NCT00392782 (7) [back to overview]	Incidence of Grade II-IV Acute Graft-vs-host Disease (GVHD)
NCT00392782 (7) [back to overview]	Incidence of Graft Failure
NCT00392782 (7) [back to overview]	Overall Survival
NCT00392782 (7) [back to overview]	Transplant-related Mortality
NCT00393029 (3) [back to overview]	Clinical Tumor Regression
NCT00393029 (3) [back to overview]	In Vivo Survival of T-cell Receptor (TCR) Gene-engineered Cells in Participants
NCT00393029 (3) [back to overview]	The Number of Participants With Adverse Events
NCT00397813 (5) [back to overview]	Number of Patients Who Engrafted
NCT00397813 (5) [back to overview]	Number of Patients Who Had Infections
NCT00397813 (5) [back to overview]	Number of Patients With HCT Failure.
NCT00397813 (5) [back to overview]	Number of Patients With Relapse/Progression
NCT00397813 (5) [back to overview]	Number of Patients With Progression-free Survival
NCT00410163 (18) [back to overview]	AUC(0-inf) and AUC(0-672) After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)
NCT00410163 (18) [back to overview]	Percent Change From Screening (Visit 1) in Complement (CH50) Levels at Visit 9 (Week 4)
NCT00410163 (18) [back to overview]	Progression-Free Survival
NCT00410163 (18) [back to overview]	Time to Next Anti-chronic Lymphocytic Leukemia (CLL) Therapy or Death
NCT00410163 (18) [back to overview]	Median Percent Change in CD5+CD19+ and CD5+CD20+ Cells in Peripheral Blood From Onset of Course 3 Throughout Follow-up (FU) Compared to Screening
NCT00410163 (18) [back to overview]	Median Percent Change in Tumor Size From Baseline (Visit 2, Wk 0) at Visits 9, 21, 25, 29, 33, 34, 35, and 37
NCT00410163 (18) [back to overview]	Number of Participants (Par.) Who Were Classified as Responders and Non-responders
NCT00410163 (18) [back to overview]	Vss After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)
NCT00410163 (18) [back to overview]	CL After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)
NCT00410163 (18) [back to overview]	Duration of Response
NCT00410163 (18) [back to overview]	t1/2 After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)
NCT00410163 (18) [back to overview]	Number of Participants With Positive Human Anti-human Anti Bodies (HAHA) at Visits 1, 21, 35, and 39
NCT00410163 (18) [back to overview]	Number of Participants (Par.) With Complete Remission (CR), Measured From Start of Treatment Until 3 Months After Last Infusion
NCT00410163 (18) [back to overview]	Number of Participants Classified as Responders Having CR Who Tested Negative for Minimal Residual Disease (MRD)
NCT00410163 (18) [back to overview]	Number of Participants Who Experienced Any Adverse Event From First Treatment (Visit 2) to Visit 43 (Month 60)
NCT00410163 (18) [back to overview]	Ctrough and Cmax at the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)
NCT00410163 (18) [back to overview]	Number of Participants Who Reported Myelosuppression (Anemia, Leukopenia, Neutropenia, and Thrombocytopenia)
NCT00410163 (18) [back to overview]	Number of Participants With Progression or Death
NCT00412360 (9) [back to overview]	Percentage of Participants With Treatment-related Mortality
NCT00412360 (9) [back to overview]	Percentage of Participants With Acute Graft-versus-host Disease (GVHD)
NCT00412360 (9) [back to overview]	Percentage of Participants With Chronic GVHD
NCT00412360 (9) [back to overview]	Percentage of Participants With Neutrophil and Platelet Engraftment
NCT00412360 (9) [back to overview]	Time to Neutrophil and Platelet Engraftment
NCT00412360 (9) [back to overview]	Percentage of Participants With Disease-free Survival
NCT00412360 (9) [back to overview]	Number of Participants With Engraftment Syndrome
NCT00412360 (9) [back to overview]	Percentage of Participants With Overall Survival
NCT00412360 (9) [back to overview]	Percentage of Participants With Relapse
NCT00416884 (1) [back to overview]	Number of Participants With Treatment-related Mortality
NCT00425802 (8) [back to overview]	Incidence of Chronic GVHD at 1 Year
NCT00425802 (8) [back to overview]	Incidence of Moderate to Severe Grades II to IV Graft Versus Host Disease (GVHD) at 100 Days
NCT00425802 (8) [back to overview]	Overall Survival at 1 Year
NCT00425802 (8) [back to overview]	Time to Neutrophil Engraftment
NCT00425802 (8) [back to overview]	Immune Reconstruction/CD4+ Count at 3 Months
NCT00425802 (8) [back to overview]	Time to Platelet Engraftment
NCT00425802 (8) [back to overview]	Immune Reconstruction/CD4+ Count at 6 Months
NCT00425802 (8) [back to overview]	Immune Reconstruction/CD4+ Count at 1 Year
NCT00427336 (1) [back to overview]	Number of Patients With Engraftment Response
NCT00427557 (1) [back to overview]	Number of Participants With Engraftment
NCT00427661 (3) [back to overview]	Engraftment at 1 Year Post BMT.
NCT00427661 (3) [back to overview]	Development of GVHD Within 1 Year of BMT
NCT00427661 (3) [back to overview]	Incidence of Grade 2-4 Acute GVHD.
NCT00429416 (5) [back to overview]	Number of Patients Who Achieve a CD4 Count > 200/Micro-liters
NCT00429416 (5) [back to overview]	Incidence of Grade II-IV Acute Graft-Versus-Host-Disease (GVHD)
NCT00429416 (5) [back to overview]	Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality
NCT00429416 (5) [back to overview]	Rate of Serious Infectious Complications
NCT00429416 (5) [back to overview]	Rate of Engraftment of Non-Myeloablative Transplants
NCT00429572 (5) [back to overview]	Grade II-IV Toxicity
NCT00429572 (5) [back to overview]	Time to Progressive Disease
NCT00429572 (5) [back to overview]	Overall Survival
NCT00429572 (5) [back to overview]	Number of Participants With Tumor Response
NCT00429572 (5) [back to overview]	Number of Participants With Acute or Chronic GVHD And Response to Therapy
NCT00448019 (3) [back to overview]	Overall Response Rate (ORR) to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated CLL
NCT00448019 (3) [back to overview]	Progression Free Survival (PFS) Rate
NCT00448019 (3) [back to overview]	Number of Participants With Complete or Partial Response to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated Chronic Lymphocytic Leukemia (CLL)
NCT00448201 (4) [back to overview]	Complete or Mixed Donor Chimerism at 30, 60, and 90 Days Post-transplant
NCT00448201 (4) [back to overview]	Graft-vs-host Disease at 6 Months Post-transplant
NCT00448201 (4) [back to overview]	Treatment-related Mortality
NCT00448201 (4) [back to overview]	5-year Disease-free Survival
NCT00448357 (6) [back to overview]	Incidence of DNA Chimerism in Patients Between One Month Post Transplant
NCT00448357 (6) [back to overview]	Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912)
NCT00448357 (6) [back to overview]	Overall Survival
NCT00448357 (6) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs)
NCT00448357 (6) [back to overview]	Capacity of Test Dosing of Busulfan That Would Result in the Desired Area Under the Curve Concentration Exposure of Patients Receiving a Full-dose Busulfan Regimen
NCT00448357 (6) [back to overview]	Incidence of Graft vs Host Disease in Patients Between One Month and Two Years Post Transplant
NCT00450983 (4) [back to overview]	Risk for Graft Failure
NCT00450983 (4) [back to overview]	Risk for Mortality From Infection Before Day 180
NCT00450983 (4) [back to overview]	Risk of Developing Grades III-IV Acute Graft-vs-host Disease (GVHD)
NCT00450983 (4) [back to overview]	Risk for Life-threatening Infections
NCT00452374 (2) [back to overview]	Number of Participants With a Complete Response or Partial Response
NCT00452374 (2) [back to overview]	Maximum Tolerated Dose (MTD) Oxaliplatin
NCT00453388 (4) [back to overview]	Number of Patients Who Engraft at Each Dose of TBI Used
NCT00453388 (4) [back to overview]	Incidence of Transplant-related Mortality
NCT00453388 (4) [back to overview]	Incidence of Grades III-IV Acute GVHD
NCT00453388 (4) [back to overview]	Incidence of Adverse Events
NCT00455312 (10) [back to overview]	Overall Survival
NCT00455312 (10) [back to overview]	Overall Survival
NCT00455312 (10) [back to overview]	Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD)
NCT00455312 (10) [back to overview]	Incidence of Chronic GVHD
NCT00455312 (10) [back to overview]	Incidence of Chronic GVHD
NCT00455312 (10) [back to overview]	Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD)
NCT00455312 (10) [back to overview]	Incidence of Late Secondary Malignancies
NCT00455312 (10) [back to overview]	Incidence of Regimen Related Mortality at 100 Days
NCT00455312 (10) [back to overview]	Neutrophil Engraftment
NCT00455312 (10) [back to overview]	Incidence of Pulmonary Complications
NCT00462332 (2) [back to overview]	Length of Survival
NCT00462332 (2) [back to overview]	Number of Patients With Complete Response
NCT00469014 (1) [back to overview]	Treatment Related Mortality
NCT00469144 (2) [back to overview]	3 Year Progression Free Survival
NCT00469144 (2) [back to overview]	Treatment-related Mortality (TRM)
NCT00472849 (2) [back to overview]	Maximum Total Tolerated Dose (MTD) of Daily Combination Fludarabine 30 mg/m^2 and Cytarabine 500 mg/m^2 Among 3 Dose Levels (Dose Level 1: 2 Days, Dose Level 2: 3 Days or Dose Level 3: 4 Days)
NCT00472849 (2) [back to overview]	Overall Response: Number of Participants With Complete Remission, Nodular Partial Remission, and Partial Remission
NCT00475020 (2) [back to overview]	Rate of Non-relapse Mortality at 100 Days Post-transplant
NCT00475020 (2) [back to overview]	Efficacy of This Therapy 3 Years Post-transplant
NCT00478244 (10) [back to overview]	Number of Patients With Acute Graft-Versus-Host Disease (GVHD)
NCT00478244 (10) [back to overview]	Number of Patients With Chronic Graft-Versus-Host Disease (cGVHD)
NCT00478244 (10) [back to overview]	Number of Patients With Detectable Collagen Type VII
NCT00478244 (10) [back to overview]	Number of Patients With Donor Derived Cells in Skin
NCT00478244 (10) [back to overview]	Number of Patients With Neutrophil Engraftment
NCT00478244 (10) [back to overview]	Number of Patients With Platelet Engraftment
NCT00478244 (10) [back to overview]	Number of Patients With Resistance to Blister Formation
NCT00478244 (10) [back to overview]	Number of Patients With Transplant-Related Mortality
NCT00478244 (10) [back to overview]	Number of Patients With >70% Donor Chimerism
NCT00478244 (10) [back to overview]	Overall Survival
NCT00480987 (1) [back to overview]	Number of Participants With Objective Response
NCT00489281 (3) [back to overview]	Transplant-related Mortality
NCT00489281 (3) [back to overview]	Donor Chimerism at 1 Year
NCT00489281 (3) [back to overview]	Donor Chimerism at 30 Days
NCT00499889 (3) [back to overview]	Number of Participants in Complete Molecular Remission at 1 Year
NCT00499889 (3) [back to overview]	Participants' With mCR Response to Post Transplant DLI
NCT00499889 (3) [back to overview]	Participants' With mCR Response to Post Transplant Imatinib Mesylate Therapy
NCT00502905 (1) [back to overview]	Number of Participants With Successful Engraftment
NCT00505895 (2) [back to overview]	Number of Participants With Successful Engraftment at Day 100
NCT00505895 (2) [back to overview]	Acute Grade II-IV Graft Versus Host Disease (GVHD)
NCT00505921 (1) [back to overview]	Participant Progression Free Survival at 2 Years
NCT00506129 (2) [back to overview]	Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA)
NCT00506129 (2) [back to overview]	Average Overall Survival (OS) Length
NCT00506857 (2) [back to overview]	Maximum Tolerated Dose (MTD)
NCT00506857 (2) [back to overview]	Number of Participants With Graft Versus Host Disease (GVHD)
NCT00509288 (2) [back to overview]	Toxicity
NCT00509288 (2) [back to overview]	Clinical Tumor Regression.
NCT00509496 (2) [back to overview]	Clinical Tumor Regression.
NCT00509496 (2) [back to overview]	Toxicity
NCT00510887 (6) [back to overview]	Number of Participants With Neuropathy, Any Grade
NCT00510887 (6) [back to overview]	Percentage of Subjects Experiencing Progression Free Survival
NCT00510887 (6) [back to overview]	Percentage of Subjects Experiencing Overall Survival
NCT00510887 (6) [back to overview]	Number of Participants With a Grade 3-4 Hematologic Toxicity.
NCT00510887 (6) [back to overview]	Duration of Response
NCT00510887 (6) [back to overview]	Complete and Partial Response
NCT00513474 (3) [back to overview]	Number of Participant With Adverse Events (AE)
NCT00513474 (3) [back to overview]	Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD)
NCT00513474 (3) [back to overview]	Uric Acid Levels
NCT00513604 (2) [back to overview]	Clinical Response
NCT00513604 (2) [back to overview]	Toxicity
NCT00513747 (5) [back to overview]	Overall Survival (OS) for High Risk Patients
NCT00513747 (5) [back to overview]	Disease-Free Survival in High Risk Patients
NCT00513747 (5) [back to overview]	Time to Second Treatment in High Risk Patients
NCT00513747 (5) [back to overview]	Time to First Treatment Survival in Low Risk Patients
NCT00513747 (5) [back to overview]	Overall Survival in Low Risk Patients
NCT00520130 (17) [back to overview]	Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)
NCT00520130 (17) [back to overview]	Days to Engraftment of Platelets
NCT00520130 (17) [back to overview]	Early Treatment Related Mortality
NCT00520130 (17) [back to overview]	Overall Survival
NCT00520130 (17) [back to overview]	Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)
NCT00520130 (17) [back to overview]	Days to Engraftment of Neutrophils
NCT00520130 (17) [back to overview]	Percentage of Participants With Late Treatment Related Mortality
NCT00520130 (17) [back to overview]	Toxicities
NCT00520130 (17) [back to overview]	Changes in CD8 T Cell Receptor Vbeta Repertoire
NCT00520130 (17) [back to overview]	Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations
NCT00520130 (17) [back to overview]	Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations
NCT00520130 (17) [back to overview]	Immune Reconstitution of Normal Killer (NK) Cells
NCT00520130 (17) [back to overview]	Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT00520130 (17) [back to overview]	Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells
NCT00520130 (17) [back to overview]	Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells
NCT00520130 (17) [back to overview]	Days to Engraftment of Lymphocytes
NCT00520130 (17) [back to overview]	Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire
NCT00525603 (1) [back to overview]	Overall Participant Response
NCT00525876 (1) [back to overview]	Overall Survival at 100 Days Post Transplant (Number of Surviving Participants)
NCT00526292 (1) [back to overview]	Treatment Efficacy as Defined by Complete or Partial Remission
NCT00536341 (4) [back to overview]	Complete Response Rate
NCT00536341 (4) [back to overview]	Overall Survival
NCT00536341 (4) [back to overview]	Number of Adverse Events as a Measure of Safety and Tolerability
NCT00536341 (4) [back to overview]	Progression-Free Survival
NCT00544115 (2) [back to overview]	Two-year Overall Survival
NCT00544115 (2) [back to overview]	Neutrophil Engraftment - The Days Till ANC Recovery
NCT00544466 (2) [back to overview]	Overall Survival on Day 180 Days Post-transplant
NCT00544466 (2) [back to overview]	Number of Grade 3 and Above Toxicities of Helical Tomotherapy (HT) in Combination With Fludarabine and Melphalan Followed by Allogeneic Stem Cell Transplantation.
NCT00545714 (14) [back to overview]	Percentage of Participants With Immunoglobulin Heavy Locus (IgH) Rearrangement
NCT00545714 (14) [back to overview]	Overall Survival (OS)
NCT00545714 (14) [back to overview]	Duration of Response (DOR)
NCT00545714 (14) [back to overview]	Percentage of Participants With Positive and Negative Zeta-Chain-Associated Protein Kinase 70 (ZAP-70) Expression
NCT00545714 (14) [back to overview]	Percentage of Participants With Genetic Abnormalities
NCT00545714 (14) [back to overview]	Percentage of Participants With Cluster of Differentiation (CD) 38 Cells >/=30% in Peripheral Blood
NCT00545714 (14) [back to overview]	Percentage of Participants With Clinical Response of CR or PR as Assessed by Multiparameter Flow Cytometry
NCT00545714 (14) [back to overview]	Percentage of Participants With Clinical Response of CR or PR Among Participants With Negative Minimal Residual Disease (MRD) as Assessed by Multiparameter Flow Cytometry
NCT00545714 (14) [back to overview]	Treatment-Free Survival (TFS)
NCT00545714 (14) [back to overview]	Progression-Free Survival (PFS)
NCT00545714 (14) [back to overview]	Percentage of Participants With CR With Incomplete Bone Marrow Recovery (CRi)
NCT00545714 (14) [back to overview]	Percentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen
NCT00545714 (14) [back to overview]	Percentage of Participants Who Died
NCT00545714 (14) [back to overview]	Percentage of Participants With PD or Death
NCT00547196 (2) [back to overview]	Survival Rate at Day 100 After Allogeneic Transplant From Umbilical Cord Blood (UCB)
NCT00547196 (2) [back to overview]	Survival Rate at Day 180 After Allogeneic Transplant From Umbilical Cord Blood (UCB)
NCT00553098 (11) [back to overview]	Overall Survival
NCT00553098 (11) [back to overview]	Number of Patients Who Achieve Greater Than 50% Donor T-cell Chimerism
NCT00553098 (11) [back to overview]	Clinical Significant Infection, Requiring Treatment, Within 100 Days Post Transplant
NCT00553098 (11) [back to overview]	Immune Reconstitution by 1 Year Post Transplant
NCT00553098 (11) [back to overview]	Number of Patients Diagnosed With Overall Grade 1 or Grade 2 Acute GVHD
NCT00553098 (11) [back to overview]	Number of Patients Diagnosed With Acute GVHD
NCT00553098 (11) [back to overview]	Number of Patients Diagnosed With Overall Grade III or Grade IV Acute GVHD
NCT00553098 (11) [back to overview]	Greater Than 50% CD33+ Donor Chimerisms at 1 Year Post Transplant
NCT00553098 (11) [back to overview]	Greater Than 50% CD19+ Donor Chimerisms at 1 Year Post Transplant
NCT00553098 (11) [back to overview]	Disease Response by 1 Year Post Transplant
NCT00553098 (11) [back to overview]	Number of Patients Diagnosed With Chronic GVHD
NCT00562965 (7) [back to overview]	Percentage of Participants With Objective Response (OR)
NCT00562965 (7) [back to overview]	Number of Participants With Grade 3 or 4 Treatment Emergent Adverse Events (TEAEs)
NCT00562965 (7) [back to overview]	Overall Survival Probability at Months 6, 12 and 24
NCT00562965 (7) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Laboratory Findings
NCT00562965 (7) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT00562965 (7) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in QT Interval Findings
NCT00562965 (7) [back to overview]	Progression-Free Survival (PFS)
NCT00566696 (7) [back to overview]	To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.
NCT00566696 (7) [back to overview]	To Estimate the Rate of Overall Grade III-IV Acute GVHD, and the Rate and Severity of Chronic GVHD in Research Participants.
NCT00566696 (7) [back to overview]	Disease-Free Survival (DFS)
NCT00566696 (7) [back to overview]	Event-free Survival (EFS)
NCT00566696 (7) [back to overview]	Incidence of Regimen-related Mortality
NCT00566696 (7) [back to overview]	Overall Survival (OS)
NCT00566696 (7) [back to overview]	Incidence of Non-hematologic Regimen-related Toxicities
NCT00572897 (6) [back to overview]	Response Outcomes
NCT00572897 (6) [back to overview]	Transplant-related Mortality
NCT00572897 (6) [back to overview]	The Primary Endpoint is Progression-free Survival.
NCT00572897 (6) [back to overview]	PLT
NCT00572897 (6) [back to overview]	Absolute Neutrophil Count (ANC)
NCT00572897 (6) [back to overview]	Overall Survival
NCT00574496 (3) [back to overview]	Disease Relapse or Progression as Measured by CT Scan or PET
NCT00574496 (3) [back to overview]	Overall Survival
NCT00574496 (3) [back to overview]	Progression-free Survival at 1 Year
NCT00577278 (3) [back to overview]	Overall Survival at Two Years
NCT00577278 (3) [back to overview]	Relapse/Progression Rate at Two Years
NCT00577278 (3) [back to overview]	Progression-free Survival at Two Years
NCT00577993 (2) [back to overview]	Number of Participants With Overall Survival (10 Years) by Treatment
NCT00577993 (2) [back to overview]	Number of Participants With Progression Free Survival (10 Years) by Treatment
NCT00578292 (8) [back to overview]	Immune Reconstitution
NCT00578292 (8) [back to overview]	Hematopoietic Reconstitution
NCT00578292 (8) [back to overview]	Event-free Survival
NCT00578292 (8) [back to overview]	Engraftment Rate After Transplant
NCT00578292 (8) [back to overview]	Number of Participants With CHRONIC GVHD
NCT00578292 (8) [back to overview]	Number of Participants With Infectious Complications
NCT00578292 (8) [back to overview]	Number of Participants With Stable Mixed Hematopoietic Chimerism (HC)
NCT00578292 (8) [back to overview]	Number of Participants With Transient Mixed Hematopoietic Chimerism (HC)
NCT00578643 (2) [back to overview]	Percentage of Participants With Engraftment
NCT00578643 (2) [back to overview]	Number of Patients That Have Complete Donor Chimerism After Transplant.
NCT00579111 (2) [back to overview]	Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity
NCT00579111 (2) [back to overview]	Number of Patients With Successful Donor Engraftment
NCT00579137 (4) [back to overview]	Patients Alive at 1 Year
NCT00579137 (4) [back to overview]	Number of Patients With Grade III to IV Acute GVHD
NCT00579137 (4) [back to overview]	Number of Patients With Grade III or IV Toxicity
NCT00579137 (4) [back to overview]	Number of Patients With Donor Engraftment
NCT00582894 (4) [back to overview]	Number of Participants Experiencing Engraftment Donor Chimerism (EDC)
NCT00582894 (4) [back to overview]	Number of Participants Relapse-Free
NCT00582894 (4) [back to overview]	Number of Participants Overall Survival as a Function of Time.
NCT00582894 (4) [back to overview]	Number of Participants Experiencing Transplant Related Mortality (TRM)
NCT00582933 (1) [back to overview]	Death From GVHD
NCT00589316 (1) [back to overview]	Two-Year Disease-free Survival of Study Participants Who Completed the Study Regimen
NCT00589563 (14) [back to overview]	Overall Survival at Two Years Post HSCT
NCT00589563 (14) [back to overview]	Occurrence of Thrombotic Microangiopathy
NCT00589563 (14) [back to overview]	Occurence of Sinusoidal Obstructive Syndrome (SOS)
NCT00589563 (14) [back to overview]	Non-relapse Mortality at Two Years Post HSCT
NCT00589563 (14) [back to overview]	Incidence of Disease Relapse/Progression at 2 Years Post HSCT
NCT00589563 (14) [back to overview]	Event Free Survival at Two Years Post HSCT
NCT00589563 (14) [back to overview]	Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100
NCT00589563 (14) [back to overview]	Cumulative Incidence of Chronic GVHD
NCT00589563 (14) [back to overview]	Non-relapse Mortality at 100 Days Post HSCT
NCT00589563 (14) [back to overview]	Severity of Chronic GVHD
NCT00589563 (14) [back to overview]	Severity of Acute GVHD
NCT00589563 (14) [back to overview]	Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation
NCT00589563 (14) [back to overview]	Time to Platelet Count Recovery (Engraftment)
NCT00589563 (14) [back to overview]	Time to Absolute Neutrophil Count Recovery (Engraftment)
NCT00590460 (10) [back to overview]	Patients With Treated Related Death
NCT00590460 (10) [back to overview]	Patients With Limited Chronic GVHD From Day 100 to 365
NCT00590460 (10) [back to overview]	Patients With Grade III - IV Acute GVHD
NCT00590460 (10) [back to overview]	Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)
NCT00590460 (10) [back to overview]	Days to Absolute Neutrophil Count (ANC) of 500/mm3
NCT00590460 (10) [back to overview]	Patients With Extensive Chronic GVHD From Day 100 to 365
NCT00590460 (10) [back to overview]	Number of Patients With Donor Engraftment
NCT00590460 (10) [back to overview]	Number of Patients Alive at 1 Year Post Transplant
NCT00590460 (10) [back to overview]	Number of Patients With Graft Failure
NCT00590460 (10) [back to overview]	Days to Platelet Count of 20,000/mm3 Without Transfusions
NCT00593554 (7) [back to overview]	Treatment-related Mortality (TRM) Rate at 6 Months After Transplantation
NCT00593554 (7) [back to overview]	Time to Platelet Engraftment
NCT00593554 (7) [back to overview]	Acute Graft vs. Host Disease (GvHD)
NCT00593554 (7) [back to overview]	Chronic Graft vs. Host Disease (GvHD)
NCT00593554 (7) [back to overview]	Frequency of Infection
NCT00593554 (7) [back to overview]	Regimen-related Toxicity
NCT00593554 (7) [back to overview]	Time to Neutrophil Engraftment
NCT00594308 (5) [back to overview]	Number of Patients With Acute Grade II-IV GVHD
NCT00594308 (5) [back to overview]	Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.
NCT00594308 (5) [back to overview]	Number of Days for Absolute Neutrophil Count to Recover
NCT00594308 (5) [back to overview]	Number of Patients Engrafting at Day +30 by Short Tandem Repeat (STR) on Peripheral Blood Mononuclear Cells (PBMC's).
NCT00594308 (5) [back to overview]	Time to Resolution of Cytopenias: Platelet Transfusion Independence
NCT00595127 (1) [back to overview]	Incidence & Quality of Engraftment & Hematopoietic Reconstitution
NCT00597519 (1) [back to overview]	Overall Response
NCT00602459 (6) [back to overview]	Time-to-progression in Patients With Del(11q22.3)
NCT00602459 (6) [back to overview]	Time-to-progression in Patients Without Del(11q22.3)
NCT00602459 (6) [back to overview]	Overall Response Rates in Patients With Del(11q22.3)
NCT00602459 (6) [back to overview]	PFS Rate of Patients With Del(11q22.3)
NCT00602459 (6) [back to overview]	Overall Response Rate in Patients Without Del(11q22.3)
NCT00602459 (6) [back to overview]	2-Year Progression Free Survival (PFS) Rate
NCT00603954 (11) [back to overview]	Quality and Timing of Immunologic Reconstitution: Concentration of ATG Levels
NCT00603954 (11) [back to overview]	Percentage of 4-year Progression Free Survival in the 2 Groups
NCT00603954 (11) [back to overview]	Percentage of 5-year Overall Survival in the 2 Groups
NCT00603954 (11) [back to overview]	Percentage of Participants With Chronic GVHD in the 2 Groups
NCT00603954 (11) [back to overview]	Percentage of 5-year Progression Free Survival in the 2 Groups
NCT00603954 (11) [back to overview]	Number of Participants With Graft Rejection as Defined by Whole Blood and T Cell Chimerism
NCT00603954 (11) [back to overview]	Percentage of 4-year Overall Survival in the 2 Groups
NCT00603954 (11) [back to overview]	Incidences of Bacterial, Fungal and Viral Infections in the 2 Groups.
NCT00603954 (11) [back to overview]	Percentage of Non Relapse Mortality in the 2 Groups
NCT00603954 (11) [back to overview]	Percentage of Participants With Grade II-IV Acute GVHD Between the 2 Groups
NCT00603954 (11) [back to overview]	Percentage of Relapse Rate in the 2 Groups
NCT00608517 (7) [back to overview]	Number of Participants With 100-day Non-relapse Mortality
NCT00608517 (7) [back to overview]	Number of Participants With Chronic Graft Versus Host Disease (GVHD)
NCT00608517 (7) [back to overview]	Number of Subjects With All-cause Mortality
NCT00608517 (7) [back to overview]	Number of Participants With Sustained Donor Engraftment of Umbilical Cord Blood Stem Cells
NCT00608517 (7) [back to overview]	Overall Survival
NCT00608517 (7) [back to overview]	Number of Participants Who Relapsed at 1 Year
NCT00608517 (7) [back to overview]	Number of Participants With Acute Graft-versus-host Disease (GVHD)
NCT00610311 (2) [back to overview]	Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR)
NCT00610311 (2) [back to overview]	Number of Participants With Adverse Events
NCT00612222 (2) [back to overview]	Number of Participants With Adverse Events
NCT00612222 (2) [back to overview]	Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR)
NCT00615589 (5) [back to overview]	The Percentage of Patients Free From Progression at 1 Year
NCT00615589 (5) [back to overview]	Non Relapse Mortality (NRM) at 1 Year and 3 yearsThe Percentage of Deaths Not Attributable to Disease Relapse or Progression
NCT00615589 (5) [back to overview]	The Percentage of Patients Alive 1 Year Post Transplant
NCT00615589 (5) [back to overview]	Percentage of Patients With Treatment Related Mortality (TRM)
NCT00615589 (5) [back to overview]	Percentage of Patients With Acute and Chronic Graft Versus Host Disease (GVHD)
NCT00618540 (8) [back to overview]	Overall Survival
NCT00618540 (8) [back to overview]	Platelet Engraftment
NCT00618540 (8) [back to overview]	Incidence of Chronic GVHD
NCT00618540 (8) [back to overview]	Transplantation-related Death
NCT00618540 (8) [back to overview]	Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD)
NCT00618540 (8) [back to overview]	Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD)
NCT00618540 (8) [back to overview]	Neutrophil Engraftment
NCT00618540 (8) [back to overview]	Disease-free Survival at 12 Months Post Transplantation
NCT00619645 (2) [back to overview]	Number of Patients With Day 100 Transplant-related Mortality
NCT00619645 (2) [back to overview]	Number of Patients Alive 24 Months Post Day 100 Transplant
NCT00622895 (10) [back to overview]	Skin Score
NCT00622895 (10) [back to overview]	Event-free Survival (EFS)
NCT00622895 (10) [back to overview]	EFS
NCT00622895 (10) [back to overview]	Incidence of Graft Rejection
NCT00622895 (10) [back to overview]	Overall Survival
NCT00622895 (10) [back to overview]	The Percent of Participants With Definite and Probable Viral, Fungal, and Bacterial Infections
NCT00622895 (10) [back to overview]	Treatment-related Mortality
NCT00622895 (10) [back to overview]	Incidence and Severity of Graft-versus-host Disease (GVHD)
NCT00622895 (10) [back to overview]	Quality of Life as Assessed by the Medical Outcome Short Form (36) Health Survey Instrument (SF-36)
NCT00622895 (10) [back to overview]	Quality of Life as Assessed by the Modified Scleroderma Health Assessment Questionnaire (SHAQ)
NCT00623935 (2) [back to overview]	Percentage of Participants Alive at 1 Year
NCT00623935 (2) [back to overview]	Percentage of Participants With Relapse Free Survival at 1 Year
NCT00625729 (6) [back to overview]	Number of Patients Whose Disease Progressed After Treatment
NCT00625729 (6) [back to overview]	Number of Patients Exhibiting Natural Killer Cell Expansion
NCT00625729 (6) [back to overview]	Number of Patients With Adequate Natural Killer Cells Infused
NCT00625729 (6) [back to overview]	Number of Patients With Interleukin-15 Production and NK Cell Expansion
NCT00625729 (6) [back to overview]	Number of Patients With Overall Survival
NCT00625729 (6) [back to overview]	Number of Patients With Overall Response
NCT00630253 (5) [back to overview]	Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)
NCT00630253 (5) [back to overview]	Number of Participants With Transplant Related Deaths
NCT00630253 (5) [back to overview]	Number of Participants Experiencing Overall Survival
NCT00630253 (5) [back to overview]	Number of Participants With Acute Graft-Versus-Host Disease (GVHD)
NCT00630253 (5) [back to overview]	Number of Participants Experiencing Graft Failure
NCT00636155 (3) [back to overview]	Progression Free Survival
NCT00636155 (3) [back to overview]	Overall Survival
NCT00636155 (3) [back to overview]	Number of Patients With an Overall Response (Complete Response + Partial Response)
NCT00652899 (4) [back to overview]	Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product
NCT00652899 (4) [back to overview]	Median Overall Survival Number of Days Patients Alive After Treatment
NCT00652899 (4) [back to overview]	Median Number of Days to Progression
NCT00652899 (4) [back to overview]	Number of Patients Per Disease Response
NCT00670748 (3) [back to overview]	Number of Participants With Serious and Non-Serious Adverse Events
NCT00670748 (3) [back to overview]	Clinical Response Per the Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00670748 (3) [back to overview]	Number of Participants With In Vivo Survival of T-Cell Receptor (TCR)-Engineered Cells
NCT00683046 (2) [back to overview]	Median Disease-free Survival
NCT00683046 (2) [back to overview]	Median Overall Survival
NCT00691015 (8) [back to overview]	Severity of Acute Graft-versus-host Disease (GVHD)
NCT00691015 (8) [back to overview]	Incidence of Acute Graft-versus-host Disease (GVHD)
NCT00691015 (8) [back to overview]	Time to Engraftment (i.e., Absolute Neutrophil Recovery [ANC > 500/mm³] )
NCT00691015 (8) [back to overview]	Safety, as Defined by Serious Adverse Events and Adverse Events Related to Study Treatment.
NCT00691015 (8) [back to overview]	Incidence of Chronic GVHD.
NCT00691015 (8) [back to overview]	Incidence of Infections, Including Bacterial, Fungal, and Viral Infections (i.e., CMV and EBV Reactivation, Including Post-transplant Lymphoproliferative Disorders)
NCT00691015 (8) [back to overview]	Karnofsky Performance Status Performance Status
NCT00691015 (8) [back to overview]	Overall Survival.
NCT00704938 (2) [back to overview]	Clinical Response (Complete Response + Partial Response)
NCT00704938 (2) [back to overview]	Number of Participants With Adverse Events
NCT00714259 (7) [back to overview]	Composite Incidence of Acute and Chronic Graft Versus Host Disease
NCT00714259 (7) [back to overview]	Number of Participants With Detectable Donor Chimerism at up to 100 Days Post Transplant
NCT00714259 (7) [back to overview]	Progression Free Survival Post Transplant
NCT00714259 (7) [back to overview]	Progressive Free Survival Post Transplant
NCT00714259 (7) [back to overview]	Progressive Free Survival Post Transplant
NCT00714259 (7) [back to overview]	Progressive Free Survival Post Transplant
NCT00714259 (7) [back to overview]	Non-relapse Treatment Related Mortality
NCT00719849 (16) [back to overview]	Probability of Progression-free Survival at 1 Year
NCT00719849 (16) [back to overview]	Probability of Progression-free Survival at 2 Years
NCT00719849 (16) [back to overview]	Probability of Survival at 1 Year
NCT00719849 (16) [back to overview]	Probability of Survival at 2 Years
NCT00719849 (16) [back to overview]	Incidence of Neutrophil Engraftment at Day 42
NCT00719849 (16) [back to overview]	Chimerism
NCT00719849 (16) [back to overview]	Incidence of Chronic Graft-versus-host-disease (GVHD) at 1 Year
NCT00719849 (16) [back to overview]	Incidence of Clinically Significant Infections at 1 Year
NCT00719849 (16) [back to overview]	Incidence of Clinically Significant Infections at 6 Months
NCT00719849 (16) [back to overview]	Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD) at Day 100
NCT00719849 (16) [back to overview]	Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD) at Day 100
NCT00719849 (16) [back to overview]	Incidence of Clinically Significant Infections at 2 Years
NCT00719849 (16) [back to overview]	Incidence of Non-relapse Mortality at 6 Months
NCT00719849 (16) [back to overview]	Incidence of Platelet Engraftment at 6 Months
NCT00719849 (16) [back to overview]	Incidence of Relapse at 1 Year
NCT00719849 (16) [back to overview]	Incidence of Relapse at 2 Years
NCT00723099 (9) [back to overview]	Number of Participants With Graft Failure/Rejection
NCT00723099 (9) [back to overview]	Time to Platelet Engraftment of > 20,000 Cells Per mm3
NCT00723099 (9) [back to overview]	Percent of Patients With Non-relapse Mortality
NCT00723099 (9) [back to overview]	Percent of Patients With Non-relapse Mortality
NCT00723099 (9) [back to overview]	Percent of Patients With Grade II-IV Acute Graft Versus Host Disease
NCT00723099 (9) [back to overview]	Percent of Patients With Chronic GVHD
NCT00723099 (9) [back to overview]	Percent of Patients With Acute GVHD Grades III-IV
NCT00723099 (9) [back to overview]	Overall Survival
NCT00723099 (9) [back to overview]	Median Time to ANC > 500
NCT00727415 (6) [back to overview]	Number of Patients Reaching Disease-free Survival (DSF) Overall
NCT00727415 (6) [back to overview]	Maximum Tolerated Dose of Lenalidomide (Phase I)
NCT00727415 (6) [back to overview]	Number of Patients With Severe Infections
NCT00727415 (6) [back to overview]	Correlation Between Complete Response (CR) and Baseline Biologic Parameters (i.e., IgHV, CD38, Etc.).
NCT00727415 (6) [back to overview]	Toxicity as Assessed by NCI CTCAE v3.0
NCT00727415 (6) [back to overview]	Overall Complete Response (CR) Rate (Phase II)
NCT00739141 (4) [back to overview]	Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients
NCT00739141 (4) [back to overview]	Progression Free Survival/PFS at 1 Year Post UCBT.
NCT00739141 (4) [back to overview]	Percentage of Participants With Sustained CB-derived Platelet Engraftment
NCT00739141 (4) [back to overview]	Percentage of Participants With Sustained CB-derived Neutrophil Engraftment
NCT00741455 (3) [back to overview]	Number of Participants With Successful Bone Marrow Engraftment
NCT00741455 (3) [back to overview]	Number of Participants Who Achieve Complete Donor Chimerism
NCT00741455 (3) [back to overview]	Overall Survival Measured in Participants
NCT00744692 (9) [back to overview]	To Describe the Incidence of Grade 3-4 Organ Toxicity
NCT00744692 (9) [back to overview]	To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant
NCT00744692 (9) [back to overview]	To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure
NCT00744692 (9) [back to overview]	To Evaluate the Pace of Immune Reconstitution.
NCT00744692 (9) [back to overview]	To Describe the Pace of Neutrophil Recovery
NCT00744692 (9) [back to overview]	Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving UCBT for Non-malignant Disorders.
NCT00744692 (9) [back to overview]	To Describe the Pace of Platelet Recovery
NCT00744692 (9) [back to overview]	To Determine the Overall Survival at day180 Post-transplant
NCT00744692 (9) [back to overview]	To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV)
NCT00759798 (1) [back to overview]	Number of Participants With Complete Remission (CR)
NCT00775931 (4) [back to overview]	Transplant Related Mortality at 100 Days
NCT00775931 (4) [back to overview]	Number of Patients Who Achieved Donor Cell Engraftment
NCT00775931 (4) [back to overview]	Incidence of Grade II - IV Acute Graft-versus-host Disease
NCT00775931 (4) [back to overview]	Transplant Related Toxicity
NCT00782379 (11) [back to overview]	Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)
NCT00782379 (11) [back to overview]	Non-relapse Mortality at Day 100 After Peripheral Blood Stem Cell Transplantation (PBSCT)
NCT00782379 (11) [back to overview]	Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation
NCT00782379 (11) [back to overview]	Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 90 Post-transplantation
NCT00782379 (11) [back to overview]	Disease Free Survival at Day 100
NCT00782379 (11) [back to overview]	Overall Survival at 12 Months
NCT00782379 (11) [back to overview]	Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 30 Post-transplantation
NCT00782379 (11) [back to overview]	Disease Free Survival at 12 Months
NCT00782379 (11) [back to overview]	Non-relapse Mortality at 1 Year After Peripheral Blood Stem Cell Transplantation (PBSCT)
NCT00782379 (11) [back to overview]	Overall Survival at Day 100
NCT00782379 (11) [back to overview]	Incidence of Graft Rejection for Patients at Day 100
NCT00787761 (8) [back to overview]	Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation
NCT00787761 (8) [back to overview]	T-cell and Myeloid Chimerism at Days 90 Post-transplantation (>90% Chimerism)
NCT00787761 (8) [back to overview]	Disease-free Survival (DFS) at 24 Months
NCT00787761 (8) [back to overview]	Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)
NCT00787761 (8) [back to overview]	Non-relapse Mortality (NRM) at Day 180 Post-transplantation
NCT00787761 (8) [back to overview]	Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease
NCT00787761 (8) [back to overview]	Overall Survival (OS) at 24 Months
NCT00787761 (8) [back to overview]	T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)
NCT00789776 (7) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT00789776 (7) [back to overview]	Number of Participants With Grades III-IV Acute GVHD
NCT00789776 (7) [back to overview]	Number of Participants With Relapsed Disease
NCT00789776 (7) [back to overview]	Number of Subjects Surviving Post-transplant.
NCT00789776 (7) [back to overview]	Number of Participants Who Experienced Chronic Extensive GVHD
NCT00789776 (7) [back to overview]	Number of Non-relapse Participant Mortalities
NCT00789776 (7) [back to overview]	Number of Participants Who Experienced Graft Failure
NCT00793572 (6) [back to overview]	Number of Patients Surviving Overall
NCT00793572 (6) [back to overview]	Number of Patients Surviving Progression-free
NCT00793572 (6) [back to overview]	Number of Patients With Chronic GVHD
NCT00793572 (6) [back to overview]	Number of Patients With Grade II-IV Acute GVHD
NCT00793572 (6) [back to overview]	Number of Patients With Toxicities Related to Bortezomib Maintenance Therapy
NCT00793572 (6) [back to overview]	Number of Patients With Non-relapse Mortality
NCT00794820 (3) [back to overview]	Complete Remission (CR) Rate of FCR3 in Treatment-naïve Participants With Chronic Lymphocytic Leukemia (CLL) at 6 Months
NCT00794820 (3) [back to overview]	Overall Survival (OS) Rate
NCT00794820 (3) [back to overview]	Remission Duration/Time to Progression (TTP)
NCT00795132 (3) [back to overview]	Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments
NCT00795132 (3) [back to overview]	Two Year Overall Survival
NCT00795132 (3) [back to overview]	Number of Participants Who Experienced Transplantation-related Mortality (TRM)
NCT00796068 (12) [back to overview]	Non-relapse Mortality
NCT00796068 (12) [back to overview]	Incidence of Clinically Significant Infections
NCT00796068 (12) [back to overview]	Incidence of Acute or Chronic Graft-versus-host Disease (GVHD)
NCT00796068 (12) [back to overview]	Duration (Days) Until Participants Obtained Platelet Engraftment
NCT00796068 (12) [back to overview]	The Number of Participants Alive at Two-years Follow up.
NCT00796068 (12) [back to overview]	Number of Patients With Non-relapse Mortality (NRM)
NCT00796068 (12) [back to overview]	Number of Participants With Secondary Graft Failure
NCT00796068 (12) [back to overview]	Number of Participants With Graft Failure/Rejection
NCT00796068 (12) [back to overview]	Number of Participants With Acute Graft-versus-host Disease (GVHD) Grade II-IV by Day 100
NCT00796068 (12) [back to overview]	Number of Participants Surviving up to 2 Years Without Disease Progression
NCT00796068 (12) [back to overview]	Incidence of Relapse or Disease Progression
NCT00796068 (12) [back to overview]	Number of Participants Surviving by 1 Year
NCT00800839 (6) [back to overview]	2-year Progression-Free Survival
NCT00800839 (6) [back to overview]	Cumulative Incidence of Grade II to IV Acute GVHD
NCT00800839 (6) [back to overview]	Day-100 Treatment-Related Mortality
NCT00800839 (6) [back to overview]	Rate of Engraftment
NCT00800839 (6) [back to overview]	Cumulative Incidence of Grade III to IV Acute GVHD
NCT00800839 (6) [back to overview]	2-year Overall Survival
NCT00802113 (7) [back to overview]	Time to Neutrophil Engraftment
NCT00802113 (7) [back to overview]	Time to Platelet Engraftment
NCT00802113 (7) [back to overview]	Total Number of Subjects With a Disease Relapse or Progression Following MAC AutoSCT
NCT00802113 (7) [back to overview]	Total Number of Subjects That Experienced Transplant-related Mortality (TRM)
NCT00802113 (7) [back to overview]	Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT)
NCT00802113 (7) [back to overview]	Total Number of Subjects With Grade II-IV Acute Graft-versus-Host-Disease (GVHD)
NCT00802113 (7) [back to overview]	Total Number of Subjects With Partial Response or Stable Disease Following MAC AutoSCT
NCT00809276 (1) [back to overview]	To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow That Leads to an Acceptable Incidence of Grades III/IV Acute GVHD
NCT00813124 (1) [back to overview]	Number of Participants With Molecular Response
NCT00818961 (11) [back to overview]	Overall Survival at 1 Year
NCT00818961 (11) [back to overview]	Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant
NCT00818961 (11) [back to overview]	Platelet Engraftment
NCT00818961 (11) [back to overview]	Number of Patients Experiencing Chronic Graft Versus Host Disease
NCT00818961 (11) [back to overview]	Non-relapse Mortality at Day 100
NCT00818961 (11) [back to overview]	Complete Donor Chimerism
NCT00818961 (11) [back to overview]	Non-relapse Mortality at 1 Year Post-transplant
NCT00818961 (11) [back to overview]	Neutrophil Recovery
NCT00818961 (11) [back to overview]	Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism
NCT00818961 (11) [back to overview]	Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant
NCT00818961 (11) [back to overview]	Survival at Day 100
NCT00822770 (3) [back to overview]	Engraftment Response Rate: Number of Transplanted Participants With Complete Chimerism at Day 30
NCT00822770 (3) [back to overview]	Number of Participants Alive With no Disease Progression at Time of Allo Transplant
NCT00822770 (3) [back to overview]	Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor
NCT00827099 (2) [back to overview]	Number of Participants With 100 Day Transplant-related Mortality (TRM)
NCT00827099 (2) [back to overview]	Number of Patients That Engrafted Blood Counts by 30 Days After Transplant
NCT00850499 (2) [back to overview]	Overall Response Rate
NCT00850499 (2) [back to overview]	Complete Response Rate
NCT00856388 (8) [back to overview]	Rate of Complete Donor Chimerism - Blood
NCT00856388 (8) [back to overview]	Median Time to Platelet Engraftment
NCT00856388 (8) [back to overview]	1 yr Extenstive Chronic GVHD
NCT00856388 (8) [back to overview]	3 yr Overall Survival
NCT00856388 (8) [back to overview]	Acute GVHD Grade III-IV
NCT00856388 (8) [back to overview]	Day 100 TRM
NCT00856388 (8) [back to overview]	Median Time to ANC Engraftment
NCT00856388 (8) [back to overview]	Rate of Complete Donor Chimerism - Blood
NCT00860457 (1) [back to overview]	Complete Response Rate
NCT00860574 (8) [back to overview]	Incidence of Chronic GVHD
NCT00860574 (8) [back to overview]	Incidence of Grades II-IV Acute GVHD
NCT00860574 (8) [back to overview]	Median Donor CD3 + T Lymphocyte Chimerism in Peripheral Blood
NCT00860574 (8) [back to overview]	Non Relapse Mortality (NRM) Incidence
NCT00860574 (8) [back to overview]	Non Relapse Mortality Incidence
NCT00860574 (8) [back to overview]	Relapse-free Survival
NCT00860574 (8) [back to overview]	Overall Survival (OS)
NCT00860574 (8) [back to overview]	Relapse Incidence
NCT00871689 (8) [back to overview]	Number of Patients With Successful Natural Killer Expansion
NCT00871689 (8) [back to overview]	Number of Patients With Grade III-IV Acute Graft-Versus-Host (GVHD) Disease
NCT00871689 (8) [back to overview]	Number of Patients With Neutrophil Engraftment
NCT00871689 (8) [back to overview]	Incidence of Primary Graft Failure
NCT00871689 (8) [back to overview]	Median Overall Survival
NCT00871689 (8) [back to overview]	Number of Patients With Acute Graft-Versus-Host (GVHD) Disease
NCT00871689 (8) [back to overview]	Number of Patients With Complete Remission of Disease
NCT00871689 (8) [back to overview]	Number of Patients With Transplant-Related Death (TRD)
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Financial Problems Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Fatigue Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate of Time to Treatment Failure (TTF) as Assessed by the Investigator
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate of Time to Treatment Failure as Assessed by the Investigator at the Final Analysis
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Constipation
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Diarhoea
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Dyspnoea Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Fatigue Domain
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Financial Problems Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Global Health Status / QoL Domain
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Insomnia Domain
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Nausea / Vomiting Domain
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Pain Domain
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain
NCT00875667 (47) [back to overview]	Number of Participants With Treatment Emergent Adverse Events
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Dyspnoea Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Diarhoea Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Pain Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Constipation Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate of Time to Progression According to the IRC Central Review
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate of Time to First Response as Assessed by the Investigator at the Final Analysis
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate of Time to First Response (TTFR) According to the IRC Central Review
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate for Progression Free Survival by Investigator's Assessment at the Final Analysis
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate for Overall Survival as Assessed by the Investigator at the Final Analysis
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate for Overall Survival (OS) According to the IRC Central Review
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate for Duration of Response as Assessed by the Investigator at the Final Analysis
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate for Duration of Response (DOR) According to the IRC Central Review
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain
NCT00875667 (47) [back to overview]	Kaplan Meier Estimate of Time to Progression as Assessed by the Investigator at the Final Analysis
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Percentage of Participants With a Complete Response, Unconfirmed Complete Response, Partial Response and Stable Disease at the Final Analysis
NCT00875667 (47) [back to overview]	Percentage of Participants With a Complete Response, Unconfirmed Complete Response, Partial Response and Stable Disease According to the IRC Central Review
NCT00875667 (47) [back to overview]	Percentage of Participants Who Achieved an Overall Response as Assessed by the Investigator at the Final Analysis
NCT00875667 (47) [back to overview]	Percentage of Participants Who Achieved an Overall Response According to the IRC Central Review
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Nausea and Vomiting Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Insomnia Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Maximum Change From Baseline in the EORTC QLQ-C30 Global Health Status / QoL Domain to Treatment Discontinuation Visit
NCT00875667 (47) [back to overview]	Mean Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
NCT00899431 (1) [back to overview]	Percentage of Participants With GVHD (Graft Versus Host Disease)
NCT00914940 (4) [back to overview]	Number of Participants Who Did Not Engraft After Receiving a CD45RA+ T Cell Depleted PBSC Transplant
NCT00914940 (4) [back to overview]	Number of Participants Who Have Relapsed Within 5 Years of CD45RA+ T Cell Depleted PBSC Transplant
NCT00914940 (4) [back to overview]	Number of Participants With Chronic GVHD
NCT00914940 (4) [back to overview]	Transplant-related Mortality by Day 100
NCT00918723 (4) [back to overview]	To Estimate the Rate of Conversion of Partial Response (PR) to Complete Response (CR) After Fludarabine, Cyclophosphamide and Rituximab (FCR) Plus Vorinostat
NCT00918723 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Vorinostat That Can be Combined With Fludarabine Phosphate, Cyclophosphamide and Rituximab (FCR) (Phase I)
NCT00918723 (4) [back to overview]	Overall Survival
NCT00918723 (4) [back to overview]	Percentage of Patients With Progression-free Survival at 2 Years
NCT00919503 (10) [back to overview]	Number of Participants With Infections
NCT00919503 (10) [back to overview]	Number of Patients With Grade II-IV Acute Graft-versus-host Disease
NCT00919503 (10) [back to overview]	Number of Patients With of Chronic Graft-versus-host Disease
NCT00919503 (10) [back to overview]	Overall Survival
NCT00919503 (10) [back to overview]	Preliminary Efficacy
NCT00919503 (10) [back to overview]	Donor Chimerism CD3 at 100 Days Post Transplant
NCT00919503 (10) [back to overview]	Donor Chimerism CD33 at Day 100 Post Transplant
NCT00919503 (10) [back to overview]	Immune Reconstitution Following Hematopoietic Cell Transplantation
NCT00919503 (10) [back to overview]	Disease Response at One Year Following Hematopoietic Cell Transplantation
NCT00919503 (10) [back to overview]	Non-relapse Mortality
NCT00923195 (2) [back to overview]	Toxicity Profile
NCT00923195 (2) [back to overview]	Complete Response Rates for Patients With Metastatic Melanoma
NCT00923364 (7) [back to overview]	Overall Survival
NCT00923364 (7) [back to overview]	Incidence of Acute and Chronic Graft-versus-host Disease (GVHD)
NCT00923364 (7) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events
NCT00923364 (7) [back to overview]	Number of Participants With Disease Free Survival
NCT00923364 (7) [back to overview]	Days to Platelet Engraftment
NCT00923364 (7) [back to overview]	Days to Neutrophil Engraftment
NCT00923364 (7) [back to overview]	Percentage of Donor Cells at Last Follow Up in Patients With Mutations GATA Binding Protein 2 (GATA2)
NCT00924001 (3) [back to overview]	Number of Participiants With In-vivo Survival of Infused Cells
NCT00924001 (3) [back to overview]	Number of Participants With an Objective Clinical Tumor Regression Response According to RECIST Criteria
NCT00924001 (3) [back to overview]	Number of Participants With Adverse Events
NCT00924170 (17) [back to overview]	Area Under the Plasma Concentration (AUC) - LMB2
NCT00924170 (17) [back to overview]	Duration of Response (Complete Response + Partial Response)
NCT00924170 (17) [back to overview]	Half Life (t1/2) of LMB-2
NCT00924170 (17) [back to overview]	Number of Participants With Dose Limiting Toxicity (DLT)
NCT00924170 (17) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events
NCT00924170 (17) [back to overview]	Overall Survival (OS)
NCT00924170 (17) [back to overview]	Peak Level of LMB-2 in Adult T-Cell Lymphoma
NCT00924170 (17) [back to overview]	Percentage of Patients Who Developed Neutralizing Antibodies After One or More Cycles of LMB-2
NCT00924170 (17) [back to overview]	Plasma Clearance (CL) of LMB-2
NCT00924170 (17) [back to overview]	Progression Free Survival (PFS)
NCT00924170 (17) [back to overview]	Volume of Distribution of LMB-2
NCT00924170 (17) [back to overview]	Count of Participants With Adverse Events Attributed At Least Possibly to Patients Treated With Fludarabine and Cyclophosphamide Dose Levels 20+200, 25+250, and 30+300 mg/m^2
NCT00924170 (17) [back to overview]	Soluble Cluster of Differentiation 25 (sCD25) Between Responders and Nonresponders
NCT00924170 (17) [back to overview]	Soluble Cluster of Differentiation 25 (sCD25) Between Responders and Nonresponders
NCT00924170 (17) [back to overview]	Percentage of Participants With a Minimally Durable Clinical Response Rate
NCT00924170 (17) [back to overview]	Count of Participants With Grades 3-5 Adverse Events of > 1 Adult T-Cell Leukemia (ATL) Patients Treated With 20+200, 25+250, and 30+300 mg/m^2 LMB-2/Fludarabine and Cyclophosphamide
NCT00924170 (17) [back to overview]	Post Treatment Effects of LMB-2 + Fludarabine and Cyclophosphamide (FC) on Normal B and T Cell Subsets by Flow Cytometry
NCT00924287 (2) [back to overview]	Number of Participants With Adverse Events
NCT00924287 (2) [back to overview]	Number of Participants With In Vivo Survival of Transfused Cells
NCT00924326 (2) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0).
NCT00924326 (2) [back to overview]	Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma
NCT00943319 (3) [back to overview]	Maximum Tolerated Dose
NCT00943319 (3) [back to overview]	Overall Survival
NCT00943319 (3) [back to overview]	Disease Free Survival
NCT00943800 (3) [back to overview]	Percentage of Participants With Incidence of Acute (Grade II-IV) and Chronic Graft-vs-host Disease(GVHD)
NCT00943800 (3) [back to overview]	Overall Survival- Percentage of Participants Who Survived at 2 Years and 5 Years
NCT00943800 (3) [back to overview]	Percentage of Participants With Neutrophil Engraftment
NCT00946023 (12) [back to overview]	Relapse
NCT00946023 (12) [back to overview]	Progression-free Survival
NCT00946023 (12) [back to overview]	Graft Failure
NCT00946023 (12) [back to overview]	Incidence of Chronic GVHD
NCT00946023 (12) [back to overview]	Incidence of Grades II-IV Acute Graft-versus-Host-Disease (GVHD)
NCT00946023 (12) [back to overview]	Incidence of Grades III-IV Acute GVHD
NCT00946023 (12) [back to overview]	Non-relapse Mortality
NCT00946023 (12) [back to overview]	Engraftment
NCT00946023 (12) [back to overview]	Overall Survival
NCT00946023 (12) [back to overview]	Overall Survival
NCT00946023 (12) [back to overview]	Progression-free Survival
NCT00946023 (12) [back to overview]	Relapse
NCT00948922 (3) [back to overview]	Overall Survival (OS) Rate
NCT00948922 (3) [back to overview]	Progression Free Survival (PFS)
NCT00948922 (3) [back to overview]	Percentage of Participants With Acute or Chronic Graft-versus-host Disease (GVHD) Following Transplant
NCT00950846 (6) [back to overview]	Number of Participants With Chronic GvHD
NCT00950846 (6) [back to overview]	Overall Survival at 1 Year After Umbilical Cord Blood Transplant in Pediatric Patients.
NCT00950846 (6) [back to overview]	Overall Survival at 100 Days After Umbilical Cord Blood Transplant in Pediatric Patients.
NCT00950846 (6) [back to overview]	Overall Survival at 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients.
NCT00950846 (6) [back to overview]	Number of Participants With Donor Engraftment After Transplant.
NCT00950846 (6) [back to overview]	Incidence of Severe Grade III-IV Acute GvHD at Day 100.
NCT00963872 (20) [back to overview]	Incidence of Grades III-IV Graft-vs-host Disease
NCT00963872 (20) [back to overview]	Neutrophil Engraftment
NCT00963872 (20) [back to overview]	Non-Relapse Mortality
NCT00963872 (20) [back to overview]	Non-relapse Mortality
NCT00963872 (20) [back to overview]	Number of Patients With the Complement 3a (C3a) Unit Predominating
NCT00963872 (20) [back to overview]	Overall Survival
NCT00963872 (20) [back to overview]	Overall Survival at Day 720
NCT00963872 (20) [back to overview]	Relapse of Disease
NCT00963872 (20) [back to overview]	Relapse of Disease
NCT00963872 (20) [back to overview]	Incidence of Grades II-IV Graft-vs-host Disease
NCT00963872 (20) [back to overview]	Donor Chimerism in Blood
NCT00963872 (20) [back to overview]	Donor Chimerism in Blood
NCT00963872 (20) [back to overview]	Donor Chimerism
NCT00963872 (20) [back to overview]	Donor Chimerism
NCT00963872 (20) [back to overview]	Donor Chimerism
NCT00963872 (20) [back to overview]	Disease Progression
NCT00963872 (20) [back to overview]	Disease Progression
NCT00963872 (20) [back to overview]	Chronic Graft-Versus-Host Disease
NCT00963872 (20) [back to overview]	Bone Marrow Chimerism
NCT00963872 (20) [back to overview]	Platelet Recovery
NCT00987480 (4) [back to overview]	The Incidence of Acute GvHD
NCT00987480 (4) [back to overview]	The Incidence of Early Transplant Related Mortality
NCT00987480 (4) [back to overview]	Overall Survival at 3 Years
NCT00987480 (4) [back to overview]	Disease-free Survival at 3 Years
NCT01005576 (4) [back to overview]	Incidence of Disease Recurrence
NCT01005576 (4) [back to overview]	Median Time to ANC Engraftment
NCT01005576 (4) [back to overview]	Median Time to Platelet Engraftment
NCT01005576 (4) [back to overview]	Primary Objective: Event-free Survival at 1 Year.
NCT01008462 (7) [back to overview]	Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease
NCT01008462 (7) [back to overview]	Event-Free Survival (EFS)
NCT01008462 (7) [back to overview]	Number of Patients Who Engrafted
NCT01008462 (7) [back to overview]	Number of Patients Who Had Infections
NCT01008462 (7) [back to overview]	Number of Patients With Relapsed/Progressive Disease
NCT01008462 (7) [back to overview]	Overall Survival
NCT01008462 (7) [back to overview]	Non-relapse Mortality (NRM)
NCT01010217 (6) [back to overview]	Number of Participants With Non-relapse Mortality (NRM)
NCT01010217 (6) [back to overview]	Grade III-IV aGVHD
NCT01010217 (6) [back to overview]	Disease Free Survival
NCT01010217 (6) [back to overview]	cGVHD
NCT01010217 (6) [back to overview]	Number of Participants With Non Related Mortality (NRM)
NCT01010217 (6) [back to overview]	Engraftments
NCT01019317 (1) [back to overview]	Participants With a Complete Response
NCT01027000 (1) [back to overview]	2-year Progression-free Survival in Early Disease Participants
NCT01028716 (12) [back to overview]	Disease-free Survival
NCT01028716 (12) [back to overview]	Point Estimate of Overall Survival at 3 Years
NCT01028716 (12) [back to overview]	Percentage of Participants With Chronic Graft Versus Host Disease
NCT01028716 (12) [back to overview]	Relapse of Malignancy After Transplantation
NCT01028716 (12) [back to overview]	Incidence of Grades III/IV Acute Graft Versus Host Disease
NCT01028716 (12) [back to overview]	Time to Neutrophil Recovery
NCT01028716 (12) [back to overview]	Time to Platelet Recovery
NCT01028716 (12) [back to overview]	Toxicity of Treatment Regimen Determined by Number of Adverse Events Per Organ System
NCT01028716 (12) [back to overview]	Incidence of Primary Graft Failure
NCT01028716 (12) [back to overview]	Non-relapse Mortality at 1 Year
NCT01028716 (12) [back to overview]	Number of Platelet Transfusions
NCT01028716 (12) [back to overview]	Number of Red Blood Cell Transfusions
NCT01044745 (4) [back to overview]	Transplant-related Mortality (TRM)
NCT01044745 (4) [back to overview]	Overall Survival
NCT01044745 (4) [back to overview]	Event-free Survival
NCT01044745 (4) [back to overview]	Number of Participants With Grades II-IV Acute GVHD
NCT01050764 (6) [back to overview]	Serious Infections
NCT01050764 (6) [back to overview]	Overall Survival (OS), 1 Year
NCT01050764 (6) [back to overview]	Maximum-tolerated Dose (MTD) of Regulatory and Conventional T-cells
NCT01050764 (6) [back to overview]	To Measure the Incidence and Severity of Acute and Chronic GvHD
NCT01050764 (6) [back to overview]	Acute Graft-versus-Host-Disease (aGvHD)
NCT01050764 (6) [back to overview]	Median Overall Survival (OS)
NCT01082939 (1) [back to overview]	Number of Participants With an Overall Response
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 4)
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 6)
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 7)
NCT01088048 (15) [back to overview]	Plasma Concentration of IDELA (Cohort 1, Cohorts 2 and 3, Cohort 5)
NCT01088048 (15) [back to overview]	Overall Survival
NCT01088048 (15) [back to overview]	Progression-free Survival
NCT01088048 (15) [back to overview]	Time to Response
NCT01088048 (15) [back to overview]	Toxicity of Administration of IDELA
NCT01088048 (15) [back to overview]	Duration of Exposure to IDELA
NCT01088048 (15) [back to overview]	Plasma Concentration of Lenalidomide
NCT01088048 (15) [back to overview]	Sub-study: Plasma Concentration of IDELA (Cohorts 1-4)
NCT01088048 (15) [back to overview]	Plasma Concentration of Bendamustine
NCT01088048 (15) [back to overview]	Overall Response Rate
NCT01088048 (15) [back to overview]	Plasma Concentration of Everolimus
NCT01088048 (15) [back to overview]	Duration of Response
NCT01096992 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Bendamustine Combined With Fixed-Dose Fludarabine and Rituximab (FBR)
NCT01096992 (2) [back to overview]	Overall Response Rate of Bendamustine Combined With Fixed-Dose Fludarabine and Rituximab (FBR)
NCT01105650 (4) [back to overview]	Response Rate
NCT01105650 (4) [back to overview]	Overall Survival
NCT01105650 (4) [back to overview]	Time to Disease Progression
NCT01105650 (4) [back to overview]	Number of Participants With Progressive Disease at One Year
NCT01106950 (6) [back to overview]	Percent of Patients With Successful Expansion of Natural Killer Cells After Infusion
NCT01106950 (6) [back to overview]	Percent of Patients With Natural Killer Cell Expansion Versus KIR Genotype Versus Treg Depletion
NCT01106950 (6) [back to overview]	Percent of Patients With Incidence of Relapse
NCT01106950 (6) [back to overview]	Percent of Patients With Disease Free Survival
NCT01106950 (6) [back to overview]	Percent of Patients With Complete Remission of Disease
NCT01106950 (6) [back to overview]	Number of Patients With Treatment-Related Death
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	The Incidence of Durable Hematopoietic Engraftment for T-cell Depleted Transplants Fractionated by the CliniMACS System Administered After Each of the Four Disease Targeted Cytoreduction Regimens.
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	Number of Participants With Acute and Chronic GVHD Following T-cell Depleted, CD34+ Progenitor Cell Enriched Transplants Fractionated by the CliniMACS System.
NCT01119066 (6) [back to overview]	Incidence of Non-relapse Mortality (Transplant-related Mortality) Following Each Cytoreduction Regimen and a Transplant Fractionated by the CliniMACS System.
NCT01131169 (2) [back to overview]	Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS)
NCT01131169 (2) [back to overview]	Proportion of Participants With Relapsed Multiple Myeloma Alive at 2 Years
NCT01135329 (1) [back to overview]	Graft Failure
NCT01144403 (4) [back to overview]	Number of Participant With Adverse Event (AE)
NCT01144403 (4) [back to overview]	Progression-free Survival (PFS)
NCT01144403 (4) [back to overview]	Overall Survival (OS)
NCT01144403 (4) [back to overview]	Overall Response Rate (ORR)
NCT01145209 (6) [back to overview]	Number of Grade 3 and 4 Treatment Related Adverse Events
NCT01145209 (6) [back to overview]	Progression Free Survival Rate 2 Years After Initiation of Induction Therapy
NCT01145209 (6) [back to overview]	Participants With MRD Negativity at the Completion of Consolidation Immunotherapy Who Failed to Achieve MRD Negativity
NCT01145209 (6) [back to overview]	Participants With Minimal Residual Disease (MRD) Negativity
NCT01145209 (6) [back to overview]	Participants With Complete Response Rates Following Induction Chemoimmunotherapy.
NCT01145209 (6) [back to overview]	Median Relationship of CD20 Expression With MRD Negativity Rate
NCT01168219 (3) [back to overview]	Progression-free Survival
NCT01168219 (3) [back to overview]	Overall Survival (OS)
NCT01168219 (3) [back to overview]	100-day Mortality
NCT01173679 (2) [back to overview]	Toxicities
NCT01173679 (2) [back to overview]	Progression-Free and Overall Survival
NCT01181258 (4) [back to overview]	Number of Patients With an Objective Response
NCT01181258 (4) [back to overview]	Time to Disease Progression
NCT01181258 (4) [back to overview]	Serious Adverse Events
NCT01181258 (4) [back to overview]	Patients With Expansion of NK Cells
NCT01181271 (12) [back to overview]	Cumulative Incidence of Non-relapse Mortality
NCT01181271 (12) [back to overview]	Estimated Two Year Overall Survival Rate for All Participants
NCT01181271 (12) [back to overview]	Cumulative Incidence of Disease Relapse
NCT01181271 (12) [back to overview]	Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants
NCT01181271 (12) [back to overview]	Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant
NCT01181271 (12) [back to overview]	Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL
NCT01181271 (12) [back to overview]	Peripheral Blood All-cell Donor Chimerism
NCT01181271 (12) [back to overview]	Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant
NCT01181271 (12) [back to overview]	Estimated Two Year Progression Free Survival Rate for All Participants
NCT01181271 (12) [back to overview]	Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants
NCT01181271 (12) [back to overview]	Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD)
NCT01181271 (12) [back to overview]	Cumulative Incidence of Extensive Chronic Graft-versus-host-disease
NCT01186458 (1) [back to overview]	Toxicity
NCT01187017 (4) [back to overview]	Number of Patients Who Experienced Disease Relapse
NCT01187017 (4) [back to overview]	Participant Survival Following Fludarabine/ Cyclophosphamide in Participants With Severe Aplastic Anemia
NCT01187017 (4) [back to overview]	Response Rate at 6 Months
NCT01187017 (4) [back to overview]	Number of Participants With Clonal Evolution
NCT01203020 (9) [back to overview]	Rates of Acute and Chronic Graft Versus Host Disease (GVHD).
NCT01203020 (9) [back to overview]	Non-Relapse Mortality (NRM) Following RTC Transplantation at 1 Year.
NCT01203020 (9) [back to overview]	Non-Relapse Mortality (NRM) Following RTC Transplantation at 2 Years.
NCT01203020 (9) [back to overview]	Relapse Rate (RR) Following Transplantation at 2-year.
NCT01203020 (9) [back to overview]	Relapse Rate (RR) Following Transplantation at 1-year.
NCT01203020 (9) [back to overview]	Percentage of 1 Year Overall Survival (OS)
NCT01203020 (9) [back to overview]	Percentage of 2-year Progression Free Survival (PFS)
NCT01203020 (9) [back to overview]	Percentage of 2 Year Overall Survival (OS)
NCT01203020 (9) [back to overview]	Percentage of 1-year Progression Free Survival (PFS)
NCT01218867 (2) [back to overview]	Number of Participants With a Response to Therapy
NCT01218867 (2) [back to overview]	Number of Participants With Serious and Non-Serious Adverse Events
NCT01231412 (6) [back to overview]	Number of Non-Relapse Mortalities
NCT01231412 (6) [back to overview]	Number of of Participants Surviving Overall
NCT01231412 (6) [back to overview]	Number of Participants With Relapse/Progression
NCT01231412 (6) [back to overview]	Number of Patients With Chronic Extensive GVHD
NCT01231412 (6) [back to overview]	Number of Patients With Grades II-IV Acute GVHD
NCT01231412 (6) [back to overview]	Number of Patients With Grades III-IV Acute GVHD
NCT01236573 (3) [back to overview]	Maximum Tolerated Dose (MTD)
NCT01236573 (3) [back to overview]	Number of Participants With Adverse Events
NCT01236573 (3) [back to overview]	Response (Complete Response (CR) + Partial Response (PR)) to Therapy
NCT01247701 (7) [back to overview]	Number of Participants With Chronic GvHD
NCT01247701 (7) [back to overview]	Number of Participants With Platelet Engraftment
NCT01247701 (7) [back to overview]	Number of Participants With Severe Acute GVHD Grade III-IV
NCT01247701 (7) [back to overview]	Number of Participants With Donor Engraftment After Transplant.
NCT01247701 (7) [back to overview]	Number of Participants With Relapse Rate After Transplant
NCT01247701 (7) [back to overview]	Overall Survival at 100 Days, 1 Year, and 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients.
NCT01247701 (7) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT01251575 (3) [back to overview]	Number of Patients With Grade III-IV Acute GVHD
NCT01251575 (3) [back to overview]	Number of Non-Relapse Mortalities
NCT01251575 (3) [back to overview]	Number of Patients With Grade II-IV Acute Graft Versus Host Disease (GVHD)
NCT01256398 (6) [back to overview]	Disease Free Survival (DFS)
NCT01256398 (6) [back to overview]	Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]	Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]	Overall Survival (OS)
NCT01256398 (6) [back to overview]	Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]	Response
NCT01263704 (6) [back to overview]	Quality of Life (QoL): Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Questionnaire
NCT01263704 (6) [back to overview]	Percentage of Participants With Neutropenic Fever, Infection, >/= Grade 3 Drug-Related Neutropenia, >/= Grade 3 Drug-Related Thrombocytopenia, Hospitalizations
NCT01263704 (6) [back to overview]	Hospitalization Days
NCT01263704 (6) [back to overview]	Overall Response Rate
NCT01263704 (6) [back to overview]	Progression-free Survival (PFS)
NCT01263704 (6) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01271010 (10) [back to overview]	Event-free Survival
NCT01271010 (10) [back to overview]	Duration of Response
NCT01271010 (10) [back to overview]	Percentage of Participants With Phenotypic Remission
NCT01271010 (10) [back to overview]	Progression-free Survival
NCT01271010 (10) [back to overview]	Percentage of Participants With Partial Remission
NCT01271010 (10) [back to overview]	Percentage of Participants With Disease Progression
NCT01271010 (10) [back to overview]	Percentage of Participants With Complete Remission
NCT01271010 (10) [back to overview]	Percentage of Participants With Stable Disease
NCT01271010 (10) [back to overview]	Overall Survival
NCT01271010 (10) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious AEs
NCT01271907 (2) [back to overview]	Clinical Response
NCT01271907 (2) [back to overview]	Safety of Drosophila Generated PBL Administered in Combination With a Lymphodepleting Preparative Regimen and Supportive Systemic Aldesleukin
NCT01273181 (2) [back to overview]	Toxicity Profile
NCT01273181 (2) [back to overview]	Clinical Tumor Regression (Complete Response (CR) + Partial Response (PR)) in Patients With Metastatic Cancer
NCT01283386 (10) [back to overview]	Duration of Response
NCT01283386 (10) [back to overview]	Event-free Survival
NCT01283386 (10) [back to overview]	Overall Survival
NCT01283386 (10) [back to overview]	Percentage of Participants With Complete Remission
NCT01283386 (10) [back to overview]	Percentage of Participants With Disease Progression
NCT01283386 (10) [back to overview]	Percentage of Participants With Partial Remission
NCT01283386 (10) [back to overview]	Percentage of Participants With Phenotypic Remission
NCT01283386 (10) [back to overview]	Percentage of Participants With Stable Disease
NCT01283386 (10) [back to overview]	Progression-free Survival
NCT01283386 (10) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious AEs
NCT01289457 (4) [back to overview]	Overall Survival
NCT01289457 (4) [back to overview]	Response Rates of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI)
NCT01289457 (4) [back to overview]	Event-Free Survival (EFS) at 2 Years
NCT01289457 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Clofarabine, Idarubicin, and Cytarabine
NCT01292603 (15) [back to overview]	Part 2: Percentage of Participants With Total B-Cell Depletion by Visit
NCT01292603 (15) [back to overview]	Part 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit
NCT01292603 (15) [back to overview]	Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 6
NCT01292603 (15) [back to overview]	Part 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration
NCT01292603 (15) [back to overview]	Part 1: Percentage of Participants With Anti-Rituximab Antibodies
NCT01292603 (15) [back to overview]	Part 1: Percentage of Participants With Total B-Cell Depletion by Visit
NCT01292603 (15) [back to overview]	Part 2: Terminal Half-Life of Rituximab at Cycle 6
NCT01292603 (15) [back to overview]	Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab
NCT01292603 (15) [back to overview]	Part 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV
NCT01292603 (15) [back to overview]	Part 2: Total CD19+ B-Cell Counts by Visit
NCT01292603 (15) [back to overview]	Part 2: Percentage of Participants With Anti-Rituximab Antibodies
NCT01292603 (15) [back to overview]	Part 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV
NCT01292603 (15) [back to overview]	Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6
NCT01292603 (15) [back to overview]	Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6
NCT01292603 (15) [back to overview]	Part 2: Rituximab C Trough Levels at Cycle 5
NCT01300247 (7) [back to overview]	Number of Participants With Human Anti-Human Antibodies (HAHAs)
NCT01300247 (7) [back to overview]	Duration of Objective Response (DOR), Assessed by the Investigator According to IWCLL Guidelines
NCT01300247 (7) [back to overview]	Percentage of Participants Who Had B-Cell Recovery
NCT01300247 (7) [back to overview]	Percentage of Participants Who Had B-Cell Depletion
NCT01300247 (7) [back to overview]	Percentage of Participants With Objective Response, Assessed According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines
NCT01300247 (7) [back to overview]	Percentage of Participants Who Were Alive and Progression Free
NCT01300247 (7) [back to overview]	Percentage of Participants Who Were Alive
NCT01300572 (9) [back to overview]	Rates of Non-relapse Mortality
NCT01300572 (9) [back to overview]	Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor
NCT01300572 (9) [back to overview]	The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk MDS.
NCT01300572 (9) [back to overview]	Rates of Engraftment
NCT01300572 (9) [back to overview]	Rates of Donor Chimerism
NCT01300572 (9) [back to overview]	Achievement of Remission
NCT01300572 (9) [back to overview]	Duration of Remission
NCT01300572 (9) [back to overview]	Disease-free Survival
NCT01300572 (9) [back to overview]	Overall Survival
NCT01310179 (2) [back to overview]	Number of Participants With Side Effects After Ad/PNP-F-araAMP Treatment
NCT01310179 (2) [back to overview]	Treatment Outcome and Percent Change in Tumor Volume
NCT01338987 (4) [back to overview]	Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT)
NCT01338987 (4) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
NCT01338987 (4) [back to overview]	Number of Adverse Events Related to Study Drug Experienced by Participants After Second Bone Marrow Transplant (BMT)
NCT01338987 (4) [back to overview]	Time to Engraftment in First Transplant Recipients Only With Median Thoracic Spine Standardized Uptake Values (SUV) of 1.4 or Greater Than Those Patients With SUV's Less Than 1.4
NCT01339910 (10) [back to overview]	Number of Participants With Primary Graft Failure
NCT01339910 (10) [back to overview]	Number of Participants With Donor Cell Engraftment
NCT01339910 (10) [back to overview]	Percentage of Participants With Neutrophil and Platelet Engraftment
NCT01339910 (10) [back to overview]	Percentage of Participants With Acute Graft Versus Host Disease (GVHD)
NCT01339910 (10) [back to overview]	Number of Participants With Secondary Graft Failure
NCT01339910 (10) [back to overview]	Percentage of Participants With Relapse-Free Survival (RFS)
NCT01339910 (10) [back to overview]	Percentage of Participants With Overall Survival (OS)
NCT01339910 (10) [back to overview]	Percentage of Participants With Disease Relapse
NCT01339910 (10) [back to overview]	Percentage of Participants With Chronic GVHD
NCT01339910 (10) [back to overview]	Percentage of Participants With Treatment-related Mortality
NCT01343043 (8) [back to overview]	Time to Maximum Persistence of NY-ESO-1 Genetically Engineered T Cells
NCT01343043 (8) [back to overview]	Duration of Overall Response
NCT01343043 (8) [back to overview]	Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-infused (NY-ESO-1 Genetically Engineered T) Cell Antibody Result
NCT01343043 (8) [back to overview]	Objective Response Rate (ORR)
NCT01343043 (8) [back to overview]	Best Overall Response
NCT01343043 (8) [back to overview]	Overall Survival
NCT01343043 (8) [back to overview]	Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
NCT01343043 (8) [back to overview]	Progression Free Survival
NCT01366612 (1) [back to overview]	To Compare the Relapse Rate at 1 Year of Patients With Myeloid Malignancies Receiving Each Treatment
NCT01369875 (2) [back to overview]	Number of Participants With Clinical Tumor Regression.
NCT01369875 (2) [back to overview]	Number of Participants With Serious and Non-Serious Adverse Events
NCT01369888 (2) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD) of Intravenous Recombinant IL-15 as a Daily Intravenous Bolus for 10 Consecutive Days in Patients With Metastatic Melanoma Who Have Received a Lymphodepleting Chemotherapy and ACT TIL.
NCT01369888 (2) [back to overview]	Number of Participants With Adverse Events
NCT01390402 (1) [back to overview]	Number of Participants With Molecular Complete Remission at 3 Month Post Transplant
NCT01408563 (12) [back to overview]	Relapse-free Survival
NCT01408563 (12) [back to overview]	Rates of Grade II-IV and Grade III-IV Acute Graft Versus Host Disease (GVHD) at 100 Days
NCT01408563 (12) [back to overview]	Rate of Post-transplant Lymphoma
NCT01408563 (12) [back to overview]	Overall Survival
NCT01408563 (12) [back to overview]	Median Time to Neutrophil Engraftment
NCT01408563 (12) [back to overview]	Number of Participants With Primary Graft Failure
NCT01408563 (12) [back to overview]	Median Time to Platelet Engraftment
NCT01408563 (12) [back to overview]	Median Thrombopoietin Levels After Transplant
NCT01408563 (12) [back to overview]	Immune Reconstitution - Median CD4 Count at 12 Months
NCT01408563 (12) [back to overview]	100-day Treatment Related Mortality
NCT01408563 (12) [back to overview]	1 Year Relapse Rate
NCT01408563 (12) [back to overview]	The Rate of Chronic GVHD
NCT01410344 (7) [back to overview]	Percentage of Participants With Acute Graft-Versus-Host Disease (GVHD)
NCT01410344 (7) [back to overview]	Percentage of Participants With Relapse/Progression
NCT01410344 (7) [back to overview]	Chimerism
NCT01410344 (7) [back to overview]	Percentage of Participants Recovering Hematologic Function
NCT01410344 (7) [back to overview]	Percentage of Participants With Overall Survival
NCT01410344 (7) [back to overview]	Percentage of Participants With Chronic Graft-Versus-Host Disease (GVHD)
NCT01410344 (7) [back to overview]	Percentage of Participants With Non-Relapse Mortality
NCT01427881 (9) [back to overview]	Chronic GVHD Requiring Systemic Immunosuppressive Treatment
NCT01427881 (9) [back to overview]	Grades II-IV and III-IV Acute GVHD
NCT01427881 (9) [back to overview]	Persistent or Recurrent Malignancy After HCT
NCT01427881 (9) [back to overview]	Overall Survival
NCT01427881 (9) [back to overview]	Hematologic Recovery
NCT01427881 (9) [back to overview]	Non-relapse Mortality
NCT01427881 (9) [back to overview]	Graft Failure
NCT01427881 (9) [back to overview]	Donor Engraftment
NCT01427881 (9) [back to overview]	Disease-free Survival
NCT01434472 (7) [back to overview]	Progression-free Survival
NCT01434472 (7) [back to overview]	Overall Survival
NCT01434472 (7) [back to overview]	Hematopoietic Toxicity
NCT01434472 (7) [back to overview]	Absolute Neutrophil Count (ANC) Engraftment
NCT01434472 (7) [back to overview]	Treatment-related Mortality
NCT01434472 (7) [back to overview]	Platelet Engraftment
NCT01434472 (7) [back to overview]	Response Rates
NCT01445821 (2) [back to overview]	Number of Participants With Treatment Failure
NCT01445821 (2) [back to overview]	Survival of Treatment
NCT01453101 (3) [back to overview]	Overall Response Rate
NCT01453101 (3) [back to overview]	Overall Survival (OS)
NCT01453101 (3) [back to overview]	Progression Free Survival
NCT01454596 (5) [back to overview]	Circulating Chimeric Antigen Receptor (CAR+) Cells in Peripheral Blood at 1 Month Post Treatment
NCT01454596 (5) [back to overview]	Number of Patients With an Objective Response
NCT01454596 (5) [back to overview]	Number of Treatment Related Adverse Events
NCT01454596 (5) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
NCT01454596 (5) [back to overview]	Progression Free Survival
NCT01464359 (9) [back to overview]	Incidence of Graft Failure
NCT01464359 (9) [back to overview]	Incidence of Acute Graft-Versus-Host Disease
NCT01464359 (9) [back to overview]	Duration of Survival
NCT01464359 (9) [back to overview]	Duration of Survival
NCT01464359 (9) [back to overview]	Duration of Survival
NCT01464359 (9) [back to overview]	Disease Free Survival
NCT01464359 (9) [back to overview]	Clinical Disease Response
NCT01464359 (9) [back to overview]	Clinical Disease Response
NCT01464359 (9) [back to overview]	Transplant-Related Mortality
NCT01468818 (1) [back to overview]	Objective Response in Patients With Metastatic Melanoma
NCT01471444 (4) [back to overview]	Overall Survival (OS) Post Transplant at 1, 3 and 5 Years
NCT01471444 (4) [back to overview]	Number of Participants in the Study Who Are With no Grade 3 or 4 Acute Graft-versus-host Disease at Any Time During the First 100 Days Post Transplant.
NCT01471444 (4) [back to overview]	Number of Participants With Non Relapse Mortality at 100 Day Post Transplant
NCT01471444 (4) [back to overview]	Progression-Free Survival (PFS)
NCT01490723 (2) [back to overview]	Treatment-Related Mortality (TRM)
NCT01490723 (2) [back to overview]	Overall Survival (OS)
NCT01495572 (2) [back to overview]	Number of Participants With Adverse Events
NCT01495572 (2) [back to overview]	Clinical Tumor Response
NCT01499147 (4) [back to overview]	Participants With 100 Day Transplant-related Mortality.
NCT01499147 (4) [back to overview]	Number of Participants With Engraftment.
NCT01499147 (4) [back to overview]	Number of Participants With Moderate to Severe (Grade 2-4) Acute Graft Versus Host Disease (GVHD).
NCT01499147 (4) [back to overview]	Time to ANC and Platelet Engraftment
NCT01518153 (2) [back to overview]	Overall Survival (OS)
NCT01518153 (2) [back to overview]	Success Rate
NCT01527045 (8) [back to overview]	Number of Patients With Grades II-IV Acute Graft-versus-host-disease (GVHD)
NCT01527045 (8) [back to overview]	Number of Patients Requiring Secondary Systemic Immunosuppressive Therapy
NCT01527045 (8) [back to overview]	Number of Non-relapse Mortalities
NCT01527045 (8) [back to overview]	Number of Donors Discontinuing Atorvastatin Due to Toxicity
NCT01527045 (8) [back to overview]	Number of Patients With Recurrent or Progressive Malignancy
NCT01527045 (8) [back to overview]	Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD) Post-transplant
NCT01527045 (8) [back to overview]	Number of Patients With Chronic Extensive GVHD
NCT01527045 (8) [back to overview]	Number of Patients Surviving Overall
NCT01529827 (4) [back to overview]	Progression Free Survival (PFS) at One Year
NCT01529827 (4) [back to overview]	Median Time to Neutrophil Engraftment
NCT01529827 (4) [back to overview]	Clinical Response
NCT01529827 (4) [back to overview]	Transplant Related Mortality (TRM)
NCT01564784 (12) [back to overview]	Duration of Remission (DoR) for Participants Who Achieved CR/CRi (Per Investigator Assessment)
NCT01564784 (12) [back to overview]	Maximum Observed Inotuzumab Ozogamicin Serum Concentration (Cmax) and Pre-Dose Inotuzumab Ozogamicin Serum Concentration (Ctrough) Following Single and Multiple Dosing
NCT01564784 (12) [back to overview]	Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) Score
NCT01564784 (12) [back to overview]	Change From Baseline in EQ-5D VAS
NCT01564784 (12) [back to overview]	Progression-Free Survival (PFS)
NCT01564784 (12) [back to overview]	Percentage of Participants With Veno-Occlusive Liver Disease (VOD)/Sinusoidal Obstruction Syndrome (SOS) Following Post Study HSCT
NCT01564784 (12) [back to overview]	Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint Adjudication Committee (EAC)
NCT01564784 (12) [back to overview]	Change From Baseline in EuroQol 5 Dimension Health Questionnaire (EQ-5D) Index Score
NCT01564784 (12) [back to overview]	Overall Survival (OS)
NCT01564784 (12) [back to overview]	Percentage of Participants Who Had a Hematopoietic Stem-Cell Transplant (HSCT)
NCT01564784 (12) [back to overview]	Cytogenetic Status (Based on Local Laboratory Analysis) of Participants With CR/CRi (Per EAC Assessment)
NCT01564784 (12) [back to overview]	Percentage of Participants Achieving MRD Negativity (Based on Central Laboratory Analysis) in Participants Achieving a CR/CRi (Per EAC Assessment)
NCT01565616 (8) [back to overview]	Graft Failure
NCT01565616 (8) [back to overview]	Chronic Graft Versus Host Disease (GVHD)
NCT01565616 (8) [back to overview]	Time to Neutrophil and Platelet Engraftment
NCT01565616 (8) [back to overview]	PROMIS-57 Scores Health Related Quality of Life
NCT01565616 (8) [back to overview]	Event -Free Survival Rate
NCT01565616 (8) [back to overview]	Transplant Related Outcomes
NCT01565616 (8) [back to overview]	Acute Graft Versus Host Disease (GVHD)
NCT01565616 (8) [back to overview]	Overall Survival
NCT01570348 (11) [back to overview]	EFS
NCT01570348 (11) [back to overview]	Event-free Survival (EFS)
NCT01570348 (11) [back to overview]	Incidence and Severity of GVHD
NCT01570348 (11) [back to overview]	Incidence of Disease-modifying Drugs for CD Initiated Post-transplant
NCT01570348 (11) [back to overview]	Overall Survival
NCT01570348 (11) [back to overview]	Quality of Life Measured Using the Previously Validated Short Inflammatory Bowel Disease Questionnaire
NCT01570348 (11) [back to overview]	Regimen-related Toxicity Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4
NCT01570348 (11) [back to overview]	Treatment-related Mortality (TRM)
NCT01570348 (11) [back to overview]	Incidence of Graft Rejection
NCT01570348 (11) [back to overview]	Development of Infectious Complications
NCT01570348 (11) [back to overview]	Disease Activity
NCT01572662 (3) [back to overview]	Overall Survival
NCT01572662 (3) [back to overview]	Overall Survival
NCT01572662 (3) [back to overview]	Non-Relapse Mortality Rate (NRM)
NCT01583686 (1) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
NCT01585428 (1) [back to overview]	Number of Patients With Serious and Non-serious Adverse Events
NCT01596699 (3) [back to overview]	Number of Participants With Treatment-Related Adverse Events as a Measure of Safety and Tolerability
NCT01596699 (3) [back to overview]	Engraftment Rate of Patients With Non-malignant Diseases (Stratum A)
NCT01596699 (3) [back to overview]	Mixed-donor Chimerism Rate of Patients With High-risk Myeloid Malignancies (Stratum B)
NCT01640301 (11) [back to overview]	Treatment-related Toxicity Rate (Arm II)
NCT01640301 (11) [back to overview]	Treatment-related Toxicity Rate (Arm I)
NCT01640301 (11) [back to overview]	Maintenance of T Cell Receptor (TCR) Expression of Transduced T Cells (Arm I) i.e. Persistence
NCT01640301 (11) [back to overview]	Maintenance of Function of Transduced T Cells (Arm I)
NCT01640301 (11) [back to overview]	Incidence of Relapse After T Cell Therapy (Arm II)
NCT01640301 (11) [back to overview]	Count of Participants Who Experienced Chronic Graft Versus Host Disease (GVHD) (Arm I)
NCT01640301 (11) [back to overview]	Anti-leukemic Potential Efficacy, in Terms of Duration of Response (Arm II)
NCT01640301 (11) [back to overview]	Count of Participants Who Experienced Chronic Graft Versus Host Disease (GVHD) (Arm II)
NCT01640301 (11) [back to overview]	Count of Participants Who Experienced Grade III-IV Acute Graft Versus Host Disease (GVHD) (Arm II)
NCT01640301 (11) [back to overview]	Count of Participants Who Experienced Grade III-IV Acute Graft-versus-host Disease (GVHD) (Arm I)
NCT01640301 (11) [back to overview]	Disease-free Survival After T Cell Therapy
NCT01659151 (3) [back to overview]	Number of Participants With Progression Free Survival (PFS)
NCT01659151 (3) [back to overview]	Percentage of Participants With Overall Response (OR)
NCT01659151 (3) [back to overview]	Percentage of Participant Drop Out Rate
NCT01690520 (6) [back to overview]	Time to Platelet Engraftment (20k)
NCT01690520 (6) [back to overview]	Time to Neutrophil Engraftment
NCT01690520 (6) [back to overview]	Overall Survival
NCT01690520 (6) [back to overview]	Proportion of Patients With Severe Acute Graft Versus Host Disease
NCT01690520 (6) [back to overview]	Proportion of Participants With Chronic Graft Versus Host Disease
NCT01690520 (6) [back to overview]	Non-relapse Mortality
NCT01701674 (4) [back to overview]	Occurrence of Dose Limiting Toxicity (DLT) Events
NCT01701674 (4) [back to overview]	Rate of Meeting Feasibility Requirements
NCT01701674 (4) [back to overview]	Progression Free Survival (PFS)
NCT01701674 (4) [back to overview]	Overall Response Rate (ORR)
NCT01707004 (8) [back to overview]	Progression Free Survival
NCT01707004 (8) [back to overview]	Percentage of Participants With Platelet Recovery by Day 30
NCT01707004 (8) [back to overview]	Time to Neutrophil Recovery
NCT01707004 (8) [back to overview]	Cumulative Incidence of Chronic GVHD According to BMTCTN
NCT01707004 (8) [back to overview]	Cumulative Incidence of Grade III-IV Acute GVHD
NCT01707004 (8) [back to overview]	Number of Participants With Complete Remission After Transplantation
NCT01707004 (8) [back to overview]	Number of Participants With Primary Graft Failure
NCT01707004 (8) [back to overview]	Overall Survival (OS)
NCT01723839 (2) [back to overview]	Overall Response Rate
NCT01723839 (2) [back to overview]	Complete Response
NCT01749293 (3) [back to overview]	Number of Participants That Engrafted and the Number of Participants That Had Full Donor Chimerism at Day 60
NCT01749293 (3) [back to overview]	Number of Participants That Had an Overall Survival Rate
NCT01749293 (3) [back to overview]	Number of Participants That Had an Event Free Survival Rate
NCT01773395 (5) [back to overview]	18-Month Overall Survival
NCT01773395 (5) [back to overview]	Percentage of Participants Experiencing Grade 3 or Higher Non-Hematologic or Grade 4 or Higher Hematologic Adverse Events
NCT01773395 (5) [back to overview]	Percentage of Participants Experiencing Acute and Chronic Graft-Versus-Host Disease
NCT01773395 (5) [back to overview]	Percentage of Participants With Relapse and/or Non-Relapse Mortality
NCT01773395 (5) [back to overview]	18-Month Progression Free Survival
NCT01807182 (3) [back to overview]	Count of Participants Who Experienced Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT01807182 (3) [back to overview]	Number of Participants Who Experienced in Vivo Persistence of Adoptively Transferred T Cells Following TIL Infusion
NCT01807182 (3) [back to overview]	A Count of Participants With Biomarker Expression Above Threshold
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Successful Engraftment
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Transplant-related Mortality (TRM)
NCT01807611 (6) [back to overview]	Overall Survival
NCT01807611 (6) [back to overview]	Event-free Survival
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Acute and/or Chronic Graft Versus Host Disease (GVHD)
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Malignant Relapse
NCT01814046 (3) [back to overview]	Percentage of Participants With Ocular Melanoma Treated With Young Tumor Infiltrating Lymphocytes (TIL) With or Without High Dose Aldesleukin With an Objective Response Rate of (Complete Response (CR) + Partial Response (PR))
NCT01814046 (3) [back to overview]	Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)
NCT01814046 (3) [back to overview]	Count of Participants With Changes in Visual Symptoms
NCT01823198 (3) [back to overview]	Overall Survival
NCT01823198 (3) [back to overview]	Number of Participants With Grade 3 Toxicities
NCT01823198 (3) [back to overview]	Number of Participants Who Experienced Dose-limiting Toxicities (DLT)
NCT01824693 (4) [back to overview]	Percentage of Participants Who Experience Primary Graft Failure Event Between Arms
NCT01824693 (4) [back to overview]	Percent Probability of Event-free Survival (EFS)
NCT01824693 (4) [back to overview]	Percent Probability of 18 Months-relapse Event Between Arms
NCT01824693 (4) [back to overview]	Number of Participants Who Experience Treatment-Related Mortality (TRM) by Day 100
NCT01861002 (1) [back to overview]	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
NCT01875237 (8) [back to overview]	To Assess the Proportions of GvHD Response Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess the Proportion of Patients Developing Grade I-IV Acute GvHD
NCT01875237 (8) [back to overview]	To Assess the Incidence of GvHD Treatment Failure Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Evaluate the Safety of Donor Lymphocyte Infusion Followed by Dimerizer Drug, AP1903 by Number of Participants With Adverse Events.
NCT01875237 (8) [back to overview]	To Assess Post Donor Lymphocyte Infusion (DLI) Chimerism
NCT01875237 (8) [back to overview]	To Assess the Incidence of Acute GvHD Flare After CR/PR Requiring Additional Agent for Systemic Therapy Before Day 56 Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess the Incidence of Epstein-Barr Virus -PTLD or EBV Reactivation Requiring Therapy Post DLI.
NCT01875237 (8) [back to overview]	Number of Participants Assessed Post Donor Lymphocyte Infusion (DLI): Disease-free Survival & Non-relapse Mortality, Chimerism and GVHD.
NCT01877837 (2) [back to overview]	Overall Survival
NCT01877837 (2) [back to overview]	Number of Participants With Graft Failure
NCT01894477 (2) [back to overview]	Number of Participants With Acute GVHD, Graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT01894477 (2) [back to overview]	Number of Participants That Did Not Progress Within 6 Months
NCT01898793 (8) [back to overview]	Duration of Remission (DOR) (Phase I, Phase II, and Pediatric)
NCT01898793 (8) [back to overview]	Maximal Tolerated or Tested Dose (MT/TD) of CIML-NK Cells (Phase I)
NCT01898793 (8) [back to overview]	Time to Progression (Phase I, Phase II, and Pediatric)
NCT01898793 (8) [back to overview]	Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
NCT01898793 (8) [back to overview]	Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
NCT01898793 (8) [back to overview]	Complete Remission Rate (CR/CRi) in Participants With Relapsed or Refractory AML Following CIML NK Therapy (Phase II)
NCT01898793 (8) [back to overview]	Overall Survival (OS) (Phase I, Phase II, and Pediatric)
NCT01898793 (8) [back to overview]	Disease Free Survival (DFS) (Phase I, Phase II, and Pediatric)
NCT01905943 (12) [back to overview]	Number of Participants With Adverse Events of Special Interest (AESIs)
NCT01905943 (12) [back to overview]	Number of Participants With Adverse Events of Particular Interest (AEPIs)
NCT01905943 (12) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01905943 (12) [back to overview]	Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)
NCT01905943 (12) [back to overview]	Percentage of Participants With Best Overall Response (BOR)
NCT01905943 (12) [back to overview]	Median Time to Response (TTR)
NCT01905943 (12) [back to overview]	Median Time to Progression-Free Survival (PFS)
NCT01905943 (12) [back to overview]	Median Time to Overall Survival (OS)
NCT01905943 (12) [back to overview]	Median Time to Duration of Response (DoR)
NCT01905943 (12) [back to overview]	Median Time to New Anti-Leukemia Therapy (TTNT)
NCT01905943 (12) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry
NCT01905943 (12) [back to overview]	Median Time to Event-Free Survival (EFS)
NCT01967823 (6) [back to overview]	Percentage of Participants With a Response
NCT01967823 (6) [back to overview]	Number of Participants With Serious and Non-serious Treatment Related Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
NCT01967823 (6) [back to overview]	Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells
NCT01967823 (6) [back to overview]	Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells
NCT01967823 (6) [back to overview]	Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells
NCT01967823 (6) [back to overview]	Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells
NCT01991457 (1) [back to overview]	Number of Subjects Disease-free Survival
NCT01993719 (13) [back to overview]	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
NCT01993719 (13) [back to overview]	Overall Response Rate (ORR)
NCT01993719 (13) [back to overview]	Overall Response Rate (ORR)
NCT01993719 (13) [back to overview]	Progression-free Survival (PFS)
NCT01993719 (13) [back to overview]	Number of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression)
NCT01993719 (13) [back to overview]	Overall Response Rate (ORR)
NCT01993719 (13) [back to overview]	Number of Treatment-related Adverse Events for Participants Who Received Pembrolizumab
NCT01993719 (13) [back to overview]	Progression-free Survival (PFS)
NCT01993719 (13) [back to overview]	Progression-free Survival (PFS)
NCT01993719 (13) [back to overview]	Overall Progression Free Survival (PFS)
NCT01993719 (13) [back to overview]	Overall Survival
NCT01993719 (13) [back to overview]	Overall Survival
NCT01993719 (13) [back to overview]	Number of Participants With Treatment-related Grade 3-5 Adverse Events in Arm 1N and Arm 1P
NCT02007863 (1) [back to overview]	Number of Successful Unrelated Cord Blood (UCB) Transplants
NCT02013817 (6) [back to overview]	Percentage of Participants With the Best Clinical Response by Visit (Clinical Assessment)
NCT02013817 (6) [back to overview]	Percentage of Participants With the Best Clinical Response by Visit (Clinical + Radiological Assessment)
NCT02013817 (6) [back to overview]	Time to Next Treatment - Percentage of Participants With an Event
NCT02013817 (6) [back to overview]	Time to Next Treatment - Time to Event
NCT02013817 (6) [back to overview]	Percentage of Participants With a Best Clinical Response of Clinical Remission (CR)
NCT02013817 (6) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Engraftment Syndrome
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Chronic T Cell-Mediated or Antibody-Mediated Rejection
NCT02029638 (18) [back to overview]	Number of Adverse Events (AEs) by Severity- Including Infection, Wound Complications, Post-Transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Number of Participants Free From Return to Immunosuppression for the Duration of the Study
NCT02029638 (18) [back to overview]	Number of Adverse Events (AEs)- Including Infection, Wound Complications, Post-transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Number of Participants Experiencing an Incidence of Graft-versus-Host Disease Post-Transplant
NCT02029638 (18) [back to overview]	Number of Days Post-Transplant to the First Episode of Acute Rejection Requiring Treatment
NCT02029638 (18) [back to overview]	Number of Days From Transplant to Platelet Count Recovery
NCT02029638 (18) [back to overview]	Number of Days From Neutrophil Nadir to Absolute Neutrophil Recovery
NCT02029638 (18) [back to overview]	Duration in Days of Graft-versus-Host Disease in Transplanted Participants
NCT02029638 (18) [back to overview]	Histological Severity of Biopsies Demonstrating Acute Rejection as Defined by Banff 2007 Classification Renal Allograft Pathology
NCT02029638 (18) [back to overview]	Duration in Days of Adverse Events (AEs)- Including Infection, Wound Complications, Post-transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Acute Renal Allograft Rejection
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Died
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Developed Donor-Specific Antibody During Study Participation
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Developed Donor- Specific Antibody After Initiation of Immunosuppression Withdrawal
NCT02029638 (18) [back to overview]	Percent of Participants Who Achieved Operational Tolerance
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Remained Off Immunosuppression for at Least 52 Weeks, Including Those in Whom the 52 Week Biopsy Was Not Performed
NCT02048813 (2) [back to overview]	Overall Survival (OS) Rate at 3 Years
NCT02048813 (2) [back to overview]	Progression-free Survival (PFS) Rate at 3 Years
NCT02062359 (1) [back to overview]	Number of Participants With Adverse Events
NCT02080195 (5) [back to overview]	Acute Graft Versus Host Disease (GVHD)
NCT02080195 (5) [back to overview]	Survival
NCT02080195 (5) [back to overview]	Graft Failure
NCT02080195 (5) [back to overview]	The Feasibility of the Conditioning Regimen and Post Transplantation Cyclophosphamide in Refractory SLE Patients With Donors Having Various Degrees of Matching
NCT02080195 (5) [back to overview]	Chronic Graft Versus Host Disease (GVHD)
NCT02111850 (6) [back to overview]	Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and Aldesleukin
NCT02111850 (6) [back to overview]	Number of Engineered T Cell Receptor (TCR) Cells That Survived at 4 Weeks
NCT02111850 (6) [back to overview]	Number of Participants With Dose-limiting Toxicity (DLT)
NCT02111850 (6) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).
NCT02111850 (6) [back to overview]	Number of Adverse Events With Grades ≥1 That Are Possibly, Probably, and/or Definitely Related to Treatment
NCT02111850 (6) [back to overview]	Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression)
NCT02111863 (3) [back to overview]	Count of Participants With Serious and Non-Serious Adverse Events
NCT02111863 (3) [back to overview]	Overall Survival (OS) of Patients Receiving a Lymphocyte Depleting Preparative Regimen
NCT02111863 (3) [back to overview]	Objective Response Rate of Patients With Metastatic Melanoma
NCT02145039 (4) [back to overview]	Number of Patients With Hematopoietic Engraftment
NCT02145039 (4) [back to overview]	2 Year Survival
NCT02145039 (4) [back to overview]	Number of Patients Experiencing Acute Graft-versus-host Disease by 100 Days
NCT02145039 (4) [back to overview]	Number of Patients Experiencing Transplant Related Mortality (TRM)
NCT02153905 (4) [back to overview]	Number of Patients With Objective Tumor Regression
NCT02153905 (4) [back to overview]	Number of Treatment Related Adverse Events Related to T-Cell Receptor (TCR) Gene-Engineered Cells
NCT02153905 (4) [back to overview]	Number of Participants With Dose-Limiting Toxicity (DLT)
NCT02153905 (4) [back to overview]	Number of Participants With Serious and Non-Serious Adverse Events
NCT02158091 (2) [back to overview]	Number of Patients Who Had a Minimal Residual Disease (MRD) Negative Complete Response (CR) 2 Months After Chemotherapy
NCT02158091 (2) [back to overview]	Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) During Phase I
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Chronic Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT02199041 (9) [back to overview]	Number of Participants With Overall Survival (OS)
NCT02199041 (9) [back to overview]	Number of Participants With Secondary Graft Failure
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Morbidity
NCT02199041 (9) [back to overview]	Number of Participants With Malignant Relapse
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Mortality (TRM)
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Acute Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants With Event-free Survival (EFS)
NCT02215967 (3) [back to overview]	Number of Participants With Best Response
NCT02215967 (3) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)
NCT02215967 (3) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT02224872 (11) [back to overview]	Number of Patients With Primary or Secondary Graft Failure Following Transplant
NCT02224872 (11) [back to overview]	Number of Patients That Expired Due to Non-relapsed-related Mortality Following Transplant
NCT02224872 (11) [back to overview]	Participants With Chronic GVHD at One Year
NCT02224872 (11) [back to overview]	Length of Time Required for Patients to Recover ANC and Platelet Counts After Transplant
NCT02224872 (11) [back to overview]	Number of Participants With Grade II-IV or Grade III-IV Acute GVHD
NCT02224872 (11) [back to overview]	Participants That Were GVHD Free, Relapse Free Survival (GRFS)
NCT02224872 (11) [back to overview]	Number of Patients That Have Survived at One Year
NCT02224872 (11) [back to overview]	Number of Patients That Expired Due to Transplant Related Mortality
NCT02224872 (11) [back to overview]	Number of Patients That Have Acheived Full Donor Chimerism by Day 60 After Transplant
NCT02224872 (11) [back to overview]	Number of Participants With Major Toxicities Related to Transplant
NCT02224872 (11) [back to overview]	Is This Type of Transplantation for Severe Aplastic Anemia Feasible and Safe?
NCT02248597 (5) [back to overview]	12 Month Disease Free Survival Probability
NCT02248597 (5) [back to overview]	Progression Free Survival
NCT02248597 (5) [back to overview]	Rate of Acute GvHD
NCT02248597 (5) [back to overview]	Overall Survival
NCT02248597 (5) [back to overview]	Relapse-free Mortality
NCT02251548 (12) [back to overview]	Participants Who Convert From Bone Marrow MRD Negativity to MRD Positivity in Participants Who Discontinue Ibrutinib
NCT02251548 (12) [back to overview]	Rate of MRD Negative CR After 3 Cycles of iFCR
NCT02251548 (12) [back to overview]	Complete Response Rate (CRR)
NCT02251548 (12) [back to overview]	Overall Response Rate
NCT02251548 (12) [back to overview]	Partial Response Rate (PRR)
NCT02251548 (12) [back to overview]	1-year Combined Response With MRD From Bone Marrow
NCT02251548 (12) [back to overview]	Part I: Participants Who Achieve a Minimal Residual Disease (MRD) Negative Complete Response (CR) in the Bone Marrow at 2 Months Post FCR
NCT02251548 (12) [back to overview]	Number of Participants Who Convert From Bone Marrow MRD Negative PR to Bone Marrow MRD Negative CR After 2 Years on Treatment
NCT02251548 (12) [back to overview]	Number of Participants Who Convert From Bone Marrow MRD Negative PR to Bone Marrow MRD Negative CR After 1 Year of Ibrutinib Maintenance
NCT02251548 (12) [back to overview]	Median Overall Survival (OS)
NCT02251548 (12) [back to overview]	Median Progression-Free Survival (PFS)
NCT02251548 (12) [back to overview]	Median Time to Bone Marrow MRD Negativity
NCT02259348 (9) [back to overview]	Percentage of Participants Engrafted by Day 42 Post-transplant
NCT02259348 (9) [back to overview]	Overall Survival (OS)
NCT02259348 (9) [back to overview]	Mean of Days to Absolute Neutrophil Count (ANC) Engraftment
NCT02259348 (9) [back to overview]	Incidence of Malignant Relapse
NCT02259348 (9) [back to overview]	Median Days to Absolute Neutrophil Count (ANC) Engraftment
NCT02259348 (9) [back to overview]	Event-free Survival (EFS)
NCT02259348 (9) [back to overview]	Incidence and Severity of Chronic GvHD
NCT02259348 (9) [back to overview]	Incidence and Severity of Acute GvHD
NCT02259348 (9) [back to overview]	Rate of Transplant-related Mortality (TRM)
NCT02280811 (7) [back to overview]	Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells
NCT02280811 (7) [back to overview]	Maximum Tolerated Dose (MTD)
NCT02280811 (7) [back to overview]	Number of Participants With a Dose Limiting Toxicity (DLT)
NCT02280811 (7) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events
NCT02280811 (7) [back to overview]	Objective Tumor Response Rate (Complete or Partial Response)
NCT02280811 (7) [back to overview]	Percentage of Cluster of Differentiation 3 (CD3+) Cells That Are E6 T-Cell Receptor Memory of Circulating T-Cells in Responders and Non-responders
NCT02280811 (7) [back to overview]	Duration of Response
NCT02282904 (2) [back to overview]	To Determine the Safety of This Allogeneic HSCT Approach in Patients With CGD Including Transplant Related Toxicity, the Incidence of Acute and Chronic Graft-versus-host Disease, Immune Reconstitution, Overalland Disease-free Survival.
NCT02282904 (2) [back to overview]	To Determine the Efficacy of This Allogeneic Transplant Approach in Reconstituting Normal Hematopoiesis and Reversing the Clinical Phenotype of CGD
NCT02348216 (29) [back to overview]	Phase 2 Pivotal Study (Cohorts 1 and 2): Best Overall Response Using IRRC Per Cheson 2007
NCT02348216 (29) [back to overview]	Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood
NCT02348216 (29) [back to overview]	Phase 1 Study: Number of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs)
NCT02348216 (29) [back to overview]	Phase 1 Study: ORR as Assessed by Investigator Per Revised IWG Response Criteria for Malignant Lymphoma
NCT02348216 (29) [back to overview]	Phase 2 Pivotal Study (Cohorts 1 and 2): Duration of Response (DOR) Using IRRC Per Cheson 2007
NCT02348216 (29) [back to overview]	Pharmacodynamics: Peak Level of Cytokine (Ferritin) in Serum (Phase 1 and Phase 2 Cohorts 1 and 2)
NCT02348216 (29) [back to overview]	Pharmacodynamics: Peak Level of Cytokine (CRP) in Serum
NCT02348216 (29) [back to overview]	Phase 2 Safety Management Study (Cohort 4): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades
NCT02348216 (29) [back to overview]	Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 4 and Grade 3 or Higher Resulting From Decreased Parameter Value
NCT02348216 (29) [back to overview]	Phase 2: Progression-Free Survival (PFS) as Assessed by Investigator Per Revised IWG Response Criteria for Malignant Lymphoma
NCT02348216 (29) [back to overview]	Phase 2 Safety Management Study: Number of Participants With the European Quality of Life Five Dimension Five Level Scale (EQ-5D) Score
NCT02348216 (29) [back to overview]	Phase 2 Pivotal Study (Cohorts 1 and 2): ORR Per Independent Radiological Review Committee (IRRC)
NCT02348216 (29) [back to overview]	Pharmacodynamics: Peak Level of Cytokine (Ferritin) in Serum (Phase 2 Cohort 3)
NCT02348216 (29) [back to overview]	Phase 2 Pivotal Study (Cohorts 1 and 2): Overall Response Rate (ORR) as Assessed by Investigator Per Revised International Working Group (IWG) Response Criteria for Malignant Lymphoma
NCT02348216 (29) [back to overview]	Phase 2 Pivotal Study (Cohorts 1 and 2): PFS Using IRRC Per Cheson 2007
NCT02348216 (29) [back to overview]	Percentage of Participants With Positive Replication Competent Retrovirus (RCR)
NCT02348216 (29) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
NCT02348216 (29) [back to overview]	Percentage of Participants With Anti-Axicabtagene Ciloleucel Antibodies
NCT02348216 (29) [back to overview]	Phase 2 Safety Management Study (Cohorts 3, 4, 5, and 6): ORR as Assessed by Investigator Per the Revised IWG Response Criteria for Malignant Lymphoma
NCT02348216 (29) [back to overview]	Phase 2 Safety Management Study: EQ-5D Visual Analogue Scale (VAS) Score
NCT02348216 (29) [back to overview]	Phase 2: Duration of Response (DOR) as Assessed by Investigator Per Revised IWG Response Criteria for Malignant Lymphoma
NCT02348216 (29) [back to overview]	Phase 2: Overall Survival (OS)
NCT02348216 (29) [back to overview]	Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 4 and Grade 3 or Higher Resulting From Increased Parameter Value
NCT02348216 (29) [back to overview]	Phase 2 Safety Management Study (Cohort 3): Percentage of Participants With Treatment-Emergent Cytokine Release Syndrome (CRS) and Neurologic Toxicities by Severity Grades
NCT02348216 (29) [back to overview]	Phase 2 Safety Management Study (Cohort 5): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades
NCT02348216 (29) [back to overview]	Pharmacodynamics: Peak Level of Cytokines (Ferritin, ICAM-1, IL-2 R, Perforin, and VCAM-1) in Serum (Phase 2 Cohorts 4, 5, and 6)
NCT02348216 (29) [back to overview]	Phase 2 Safety Management Study (Cohort 6): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades
NCT02348216 (29) [back to overview]	Pharmacodynamics: Peak Level of Cytokines (IP-10, Granzyme B, IFN-gamma, IL-1 RA, IL-10, IL-15, IL-2, IL-6, IL-7, IL-8, TNF Alpha, and GM-CSF) in Serum (Phase 2 Cohorts 4, 5, and 6)
NCT02348216 (29) [back to overview]	Pharmacodynamics: Peak Level of Cytokines in Serum (Phase 1 and Phase 2 Cohorts 1, 2, and 3)
NCT02354690 (5) [back to overview]	Treatment Related Immune Responses
NCT02354690 (5) [back to overview]	Number of Reported Adverse Events
NCT02354690 (5) [back to overview]	Objective Response Rate
NCT02354690 (5) [back to overview]	Overall Survival
NCT02354690 (5) [back to overview]	Progression Free Survival
NCT02379195 (5) [back to overview]	Objective Response Rate
NCT02379195 (5) [back to overview]	Number of Participants With Adverse Events/Serious Adverse Events
NCT02379195 (5) [back to overview]	Treatment Related Immune Responses
NCT02379195 (5) [back to overview]	Progression Free Survival
NCT02379195 (5) [back to overview]	Overall Survival
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm
NCT02421939 (12) [back to overview]	Percentage of Participants Who Achieved Transfusion Conversion and Maintenance
NCT02421939 (12) [back to overview]	Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant
NCT02421939 (12) [back to overview]	Change From Baseline in Brief Fatigue Inventory (BFI)
NCT02421939 (12) [back to overview]	Percentage of Participants With Composite Complete Remission (CRc Rate)
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) Rate
NCT02421939 (12) [back to overview]	Duration of Remission
NCT02421939 (12) [back to overview]	Duration of Overall Survival (OS)
NCT02421939 (12) [back to overview]	Duration of Leukemia-Free Survival (LFS)
NCT02421939 (12) [back to overview]	Duration of Event-Free Survival (EFS)
NCT02421939 (12) [back to overview]	Number of Participants With Adverse Events
NCT02435901 (3) [back to overview]	Event Free Survival; Number of Participants Who Survived at 2 Years
NCT02435901 (3) [back to overview]	Assessment of Treatment Related Mortality and Morbidity
NCT02435901 (3) [back to overview]	Number of Participants With Sustained Cell Engraftment of Donor Cells
NCT02440464 (14) [back to overview]	Percentage of Participants With Infections Post-randomization by Infection Type
NCT02440464 (14) [back to overview]	Percentage of Participants With Disease Progression
NCT02440464 (14) [back to overview]	Percentage of Participants With Overall Survival (OS)
NCT02440464 (14) [back to overview]	Percentage of Participants With Progression-Free Survival
NCT02440464 (14) [back to overview]	Percentage of Participants With Toxicities Post-randomization by Toxicity Type
NCT02440464 (14) [back to overview]	Percentage of Participants With Treatment-Related Mortality (TRM)
NCT02440464 (14) [back to overview]	Percentage of Participants With Best Response to Treatment After Randomization
NCT02440464 (14) [back to overview]	Percentage of Participants With Response to Treatment
NCT02440464 (14) [back to overview]	Percentage of Participants With Infections Post-randomization by Time Point
NCT02440464 (14) [back to overview]	Percentage of Participants With Acute GVHD (Grades III-IV)
NCT02440464 (14) [back to overview]	Medical Outcomes Study (MOS) - Short Form 36 (SF-36) Score
NCT02440464 (14) [back to overview]	Percentage of Participants With Chronic GVHD
NCT02440464 (14) [back to overview]	Functional Assessment of Cancer Therapy (FACT) - Bone Marrow Transplant (BMT) Total Score
NCT02440464 (14) [back to overview]	Percentage of Participants With Toxicities Post-randomization by Time Point
NCT02497404 (9) [back to overview]	Acute Graft-versus-Host Disease (GVHD)
NCT02497404 (9) [back to overview]	Disease Free Survival at 1 Year Post-transplant
NCT02497404 (9) [back to overview]	Overall Survival at 6 Months Post-transplant
NCT02497404 (9) [back to overview]	Disease Free Survival at 6 Months Post-transplant
NCT02497404 (9) [back to overview]	Graft Failure
NCT02497404 (9) [back to overview]	High-Risk Extensive Chronic Graft-versus-Host-Disease
NCT02497404 (9) [back to overview]	Overall Survival at 1 Year Post-Transplant
NCT02497404 (9) [back to overview]	Overall Survival at 2 Years Post-Transplant
NCT02497404 (9) [back to overview]	Disease Free Survival at 2 Years Post-transplant
NCT02533401 (5) [back to overview]	Progression-Free Survival (PFS)
NCT02533401 (5) [back to overview]	Percentage of Participants With Death or Disease Progression
NCT02533401 (5) [back to overview]	Percentage of Participants Who Died
NCT02533401 (5) [back to overview]	Overall Survival (OS)
NCT02533401 (5) [back to overview]	Percentage of Participants With Complete Response (CR), Nodular Partial Response (nPR), or Partial Response (PR)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Disease Relapse, Days 90-180 (D90)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Non-relapse Mortality, Day 360 (D60)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Non-relapse Mortality, Day 360 (D90)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Non-relapse Mortality, Days 60-180 (D60)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Grades III-IV GVHD, Day 360 (D90)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Relapse, Day 360 (D60)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Relapse, Day 360 (D90)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Graft Failure, Days 60-180 (D60)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Graft Failure, Days 90-180 (D90)
NCT02556931 (22) [back to overview]	Percentage of Participants Who Are Able to Stop Prophylactic Tacrolimus (D90 Cohort)
NCT02556931 (22) [back to overview]	Number of Number of Participants Who Experience Graft Failure, Day 360 (D90)
NCT02556931 (22) [back to overview]	Number of Number of Participants With Severe Chronic GVHD, Day 360 (D60)
NCT02556931 (22) [back to overview]	Number of Number of Participants Who Experience Graft Failure, Day 360 (D60)
NCT02556931 (22) [back to overview]	Number of Number of Participants Who Experience Grades III-IV GVHD, Day 360 (D60)
NCT02556931 (22) [back to overview]	Number of Participants With Chronic GVHD, Days 60-180 (D60)
NCT02556931 (22) [back to overview]	Number of Participants With Chronic GVHD, Days 90-180 (D90)
NCT02556931 (22) [back to overview]	Number of Participants With Grades III-IV Acute GVHD, Days 60-180 (D60)
NCT02556931 (22) [back to overview]	Number of Participants With Grades III-IV Acute GVHD, Days 90-180 (D90)
NCT02556931 (22) [back to overview]	Percentage of Participants Who Are Able to Stop Prophylactic Tacrolimus (D60 Cohort)
NCT02556931 (22) [back to overview]	Number of Number of Participants With Severe Chronic GVHD, Day 360 (D90)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Disease Relapse, Days 60-180 (D60)
NCT02556931 (22) [back to overview]	Number of Participants Who Experience Non-relapse Mortality, Days 90-180 (D90)
NCT02581007 (4) [back to overview]	Graft Rejection
NCT02581007 (4) [back to overview]	GVHD Incidence
NCT02581007 (4) [back to overview]	Overall Survival
NCT02581007 (4) [back to overview]	Relapse Incidence
NCT02588612 (10) [back to overview]	Number of Participants With Hematology Results by Maximum Grade Increase Post-Baseline
NCT02588612 (10) [back to overview]	Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02588612 (10) [back to overview]	Disease Control Rate (DCR)
NCT02588612 (10) [back to overview]	Duration of Response
NCT02588612 (10) [back to overview]	Overall Response Rate (ORR)
NCT02588612 (10) [back to overview]	Progression-Free Survival (PFS) by Investigator Assessment
NCT02588612 (10) [back to overview]	Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings
NCT02588612 (10) [back to overview]	Time to Response
NCT02588612 (10) [back to overview]	Change From Baseline in Oxygen Saturation
NCT02588612 (10) [back to overview]	Number of Participants With Any Grade Increase in Clinical Chemistry Parameters
NCT02601313 (8) [back to overview]	Change Over Time in European Quality of Life-5 Dimensions(EQ-5D) Self-Care Scale Score
NCT02601313 (8) [back to overview]	Change Over Time in European Quality of Life-5 Dimensions(EQ-5D) Usual Activity Scale Score
NCT02601313 (8) [back to overview]	Percentage of Participants With Objective Response (OR) Per the Lugano Classification According to Independent Radiology Review Committee (IRRC) in Cohort 2
NCT02601313 (8) [back to overview]	Change Over Time in EQ-5D Visual Analogue Scale (VAS) Score
NCT02601313 (8) [back to overview]	Change Over Time in European Quality of Life-5 Dimensions(EQ-5D) Pain / Discomfort Activity Scale Score
NCT02601313 (8) [back to overview]	Change Over Time in European Quality of Life-5 Dimensions(EQ-5D) Mobility Scale Score
NCT02601313 (8) [back to overview]	Change Over Time in European Quality of Life-5 Dimensions(EQ-5D) Anxiety / Depression Activity Scale Score
NCT02601313 (8) [back to overview]	Percentage of Participants With Objective Response (OR) Per the Lugano Classification According to Independent Radiology Review Committee (IRRC) in Cohort 1
NCT02614066 (18) [back to overview]	Phase 2: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
NCT02614066 (18) [back to overview]	Phase 2: Percentage of Participants With Anti-KTE-X19 Antibodies
NCT02614066 (18) [back to overview]	Phase 2: Change From Baseline Over Time in EQ-5D: Visual Analogue Scale (VAS)
NCT02614066 (18) [back to overview]	Phase 2: Number of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Value
NCT02614066 (18) [back to overview]	Phase 2: Number of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value
NCT02614066 (18) [back to overview]	Phase 2: Number of Participants With 5-Level European Quality of Life-5 Dimensions (EQ-5D-5L): Health Utility Index Scale
NCT02614066 (18) [back to overview]	Phase 2: Relapse-free Survival (RFS)
NCT02614066 (18) [back to overview]	Phase 1: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT02614066 (18) [back to overview]	Phase 2: Complete Remission With Incomplete Hematologic Recovery (CRi) Rate Per Independent Review
NCT02614066 (18) [back to overview]	Phase 2: Duration of Remission (DOR) Per Independent Review
NCT02614066 (18) [back to overview]	Phase 2: Minimum Residual Disease (MRD) Negative Remission Rate
NCT02614066 (18) [back to overview]	Phase 2: Percentage of Participants With Allogeneic Stem Cell Transplant (Allo-SCT)
NCT02614066 (18) [back to overview]	Phase 2: MRD Negative Rate Among Complete Remission (CR) Participants
NCT02614066 (18) [back to overview]	Phase 2: Complete Remission (CR) Rate Per Independent Review
NCT02614066 (18) [back to overview]	Phase 2: MRD Negative Rate Among Complete Remission With Incomplete Hematologic Recovery (CRi) Participants
NCT02614066 (18) [back to overview]	Phase 2: OCR Rate (CR + CRi) Per Investigator Review
NCT02614066 (18) [back to overview]	Phase 2: Overall Complete Remission (OCR) Rate (Complete Remission [CR]+ Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed Per Independent Review
NCT02614066 (18) [back to overview]	Phase 2: Overall Survival (OS)
NCT02614560 (7) [back to overview]	Incidence of Laboratory Abnormalities
NCT02614560 (7) [back to overview]	Rate of MRD Negativity
NCT02614560 (7) [back to overview]	Best Response of CR or CRi
NCT02614560 (7) [back to overview]	Duration of Response
NCT02614560 (7) [back to overview]	Overall Survival
NCT02614560 (7) [back to overview]	Incidence of Adverse Events
NCT02614560 (7) [back to overview]	1-year Survival Rate
NCT02626338 (1) [back to overview]	Clinical Response to Crenolanib With Standard Salvage Chemotherapy
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Time of Maximum Concentration
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Volume of Distribution
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Area Under the Curve
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Clearance
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Volume of Distribution
NCT02642965 (11) [back to overview]	Number of Participants With a Dose-limiting Toxicity
NCT02642965 (11) [back to overview]	Percentage of Responders (Complete Response or Complete Remission With Partial or Incomplete Platelet Recovery) After First Cycle of Therapy
NCT02642965 (11) [back to overview]	Percentage of Responders (Complete Response or Complete Remission With Partial Platelet Recovery) After up to 2 Cycles
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Time of Maximum Concentration
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Area Under the Curve
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Clearance
NCT02652468 (7) [back to overview]	Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet Transfusions in the Preceding 7 Days
NCT02652468 (7) [back to overview]	Overall Survival (OS)
NCT02652468 (7) [back to overview]	Number of Participants With Severe Chronic GVHD
NCT02652468 (7) [back to overview]	Number of Participants With Graft Failure
NCT02652468 (7) [back to overview]	Number of Participants With Grade III-IV Acute GVHD as Determined by International Bone Marrow Transplant Registry (IBMTR) Severity Index Criteria
NCT02652468 (7) [back to overview]	Progression-free Survival
NCT02652468 (7) [back to overview]	Number of Participants With Treatment-related Mortality
NCT02659943 (12) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT02659943 (12) [back to overview]	Number of Participants With Evidence of Immunogenicity of the Chimeric Antigen Receptor (CAR) T-cell Product
NCT02659943 (12) [back to overview]	Number of Participants With a Dose-Limiting Toxicity (DLT)
NCT02659943 (12) [back to overview]	Number of Participants Who Had Anti-Lymphoma Activity
NCT02659943 (12) [back to overview]	MTD
NCT02659943 (12) [back to overview]	Median Peak Chimeric Antigen Receptor (CAR) T Cells Level for Participants Treated
NCT02659943 (12) [back to overview]	Maximum Feasible Dose
NCT02659943 (12) [back to overview]	Number of Participants With a Duration of Best Response in Months
NCT02659943 (12) [back to overview]	Number of Participants Who Had a Second or Third Infusion of Chimeric Antigen Receptor (CAR)+ T Cells
NCT02659943 (12) [back to overview]	Number of Participants Who Had a Best Response of Complete Remission (CR), Partial Remission (PR), Stable Disease (SD), and Progressive Disease (PD)
NCT02659943 (12) [back to overview]	Number of Participants That Had Any Grade 2, 3, 4 and 5 Adverse Events
NCT02659943 (12) [back to overview]	Percentage of Enrolled Participants Who Actually Get Treated
NCT02706405 (14) [back to overview]	Highest Treatment Dose Administered on Study
NCT02706405 (14) [back to overview]	Rate of Complete Response (CR) by Investigator Assessment Using Lugano Criteria
NCT02706405 (14) [back to overview]	Progression Free Survival
NCT02706405 (14) [back to overview]	Overall Survival
NCT02706405 (14) [back to overview]	Objective Response Rate by Investigator Assessment Using Lugano Criteria
NCT02706405 (14) [back to overview]	Maximum JCAR014 Cmax in Blood by Quantitative Polymerase Chain Reaction (qPCR) Analysis
NCT02706405 (14) [back to overview]	Maximum JCAR014 Cmax by Flow Cytometry
NCT02706405 (14) [back to overview]	Duration of Response
NCT02706405 (14) [back to overview]	Dose Limiting Toxicity (DLT) Rates
NCT02706405 (14) [back to overview]	Count of Participants Who Experienced Adverse Events
NCT02706405 (14) [back to overview]	AUC of JCAR014 Cells by qPCR Analysis
NCT02706405 (14) [back to overview]	Area Under the Curve (AUC) of JCAR014 by Flow Cytometry
NCT02706405 (14) [back to overview]	Time to Loss of JCAR014 Detection in Blood by qPCR Analysis
NCT02706405 (14) [back to overview]	Rate of Partial Response (PR) by Investigator Assessment Using Lugano Criteria
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - GENDER
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Treatment Related Mortality Among Patients Who Received Early Transplant vs Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - TREATMENT RELATED MORTALITY
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Patient-reported Outcomes for Trial Participants
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - AGE
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Relapsed-free Survival 6 Months After Transplant
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant
NCT02756572 (19) [back to overview]	Acute Graft Versus Host Disease Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 84
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 28
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Resource Utilization Data for Trial Participants
NCT02757885 (12) [back to overview]	Veno-occlusive Disease (VOD) Rate
NCT02757885 (12) [back to overview]	Rate of Disease Recurrence
NCT02757885 (12) [back to overview]	Primary Graft Rejection Rate
NCT02757885 (12) [back to overview]	Overall Survival Rate
NCT02757885 (12) [back to overview]	Late Graft Rejection Rate
NCT02757885 (12) [back to overview]	Infection Rate
NCT02757885 (12) [back to overview]	Frequency of Stroke
NCT02757885 (12) [back to overview]	Frequency of Idiopathic Pneumonia Syndrome (IPS)
NCT02757885 (12) [back to overview]	Rate of Central Nervous System (CNS) Toxicity
NCT02757885 (12) [back to overview]	Event-free Survival (EFS) Rate
NCT02757885 (12) [back to overview]	Cumulative Incidence of Neutrophil Engraftment and Platelet Engraftment.
NCT02757885 (12) [back to overview]	Chimerism Rate Following Hematopoietic Cell Transplantation for Sickle Cell Disease
NCT02761915 (7) [back to overview]	Assessment of Tumour Response From Baseline (RECIST)
NCT02761915 (7) [back to overview]	Safety and Tolerability of 1RG-CART Therapy
NCT02761915 (7) [back to overview]	To Determine Recommended Phase II Regimen by Assessing the Number of DLTs at Each Dose Level
NCT02761915 (7) [back to overview]	1RG-CART Counts in the Peripheral Blood
NCT02761915 (7) [back to overview]	To Evaluate Anti-tumour Activity (Overall Survival)
NCT02761915 (7) [back to overview]	To Evaluate Anti-tumour Activity (Progression Free Survival)
NCT02761915 (7) [back to overview]	Assessment of Tumour Response From Baseline (irRC)
NCT02771197 (2) [back to overview]	Number of Patients With 2-year Relapse Risk
NCT02771197 (2) [back to overview]	Assess Safety of Pembrolizumab by Recording the Number of Participants With Treatment-related Adverse Events
NCT02774291 (1) [back to overview]	Number of Participants With Toxicity Graded According to NCI-CTCAE Version 4.0
NCT02833805 (12) [back to overview]	Number of Participants Who Experience Primary Graft Failure
NCT02833805 (12) [back to overview]	Number of Participants Who Experience Grades III-IV Acute GVHD
NCT02833805 (12) [back to overview]	Number of Participants Who Experience Grades II-IV Acute GVHD
NCT02833805 (12) [back to overview]	Overall Survival at One Year
NCT02833805 (12) [back to overview]	GVHD-free Relapse-free Survival (GRFS)
NCT02833805 (12) [back to overview]	Probability of Neutrophil Recovery as Assessed by the Number of Participants Who Have Recovered Neutrophil Counts
NCT02833805 (12) [back to overview]	Probability of Platelet Recovery as Assessed by Number of Participants Who Have Recovered Platelet Counts
NCT02833805 (12) [back to overview]	Number of Participants Who Experience Chronic GVHD
NCT02833805 (12) [back to overview]	Overall Survival and Engraftment at One Year
NCT02833805 (12) [back to overview]	Number of Participants With Full Donor Chimerism
NCT02833805 (12) [back to overview]	Number of Participants Who Experience Secondary Graft Failure
NCT02833805 (12) [back to overview]	Transplant-related Mortality
NCT02918292 (15) [back to overview]	Percentage of Participants With Cytomegalovirus (CMV), Epstein Barr Virus (EBV) or Post-Transplant Lymphoproliferative Disease (PTLD)
NCT02918292 (15) [back to overview]	Percentage of Participants With Neutrophil Recovery
NCT02918292 (15) [back to overview]	Percentage of Participants With Acute Graft-vs-host-disease (GVHD)
NCT02918292 (15) [back to overview]	Percentage of Participants With Chronic GVHD
NCT02918292 (15) [back to overview]	Percentage of Participants With Graft-Failure-Free Survival
NCT02918292 (15) [back to overview]	Percentage of Participants With Overall Survival (OS)
NCT02918292 (15) [back to overview]	Percentage of Participants With Platelet Recovery
NCT02918292 (15) [back to overview]	Percentage of Participants With Primary Graft Failure
NCT02918292 (15) [back to overview]	Percentage of Participants With Secondary Graft Failure
NCT02918292 (15) [back to overview]	Frequencies of Infections Categorized by Infection Type
NCT02918292 (15) [back to overview]	Health Related Quality of Life (HR-QoL) - PedsQL Stem Cell Transplant Module
NCT02918292 (15) [back to overview]	Immune Reconstitution of Flow Cytometry
NCT02918292 (15) [back to overview]	Immune Reconstitution of Quantitative Immunoglobulins
NCT02918292 (15) [back to overview]	Participants With Grade 3-5 Toxicities by SOC
NCT02918292 (15) [back to overview]	Health Related Quality of Life (HR-QoL) - Medical Outcomes Study Short Form (MOS SF-36)
NCT02926833 (22) [back to overview]	Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
NCT02926833 (22) [back to overview]	Phase 1 and 2: Atezolizumab Levels in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Atezolizumab Levels in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Atezolizumab Levels in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Atezolizumab Levels in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Interferon-Gamma (IFN-γ), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin (IL)-2, IL-6, IL-8, IL-15, and Tumor Necrosis Factor-Alpha (TNF-α) in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values
NCT02926833 (22) [back to overview]	Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values
NCT02926833 (22) [back to overview]	Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values
NCT02926833 (22) [back to overview]	Phase 1 and 2: Complete Response Rate (CRR)
NCT02926833 (22) [back to overview]	Phase 1 and 2: Duration of Response (DOR)
NCT02926833 (22) [back to overview]	Phase 1 and 2: Objective Response Rate (ORR)
NCT02926833 (22) [back to overview]	Phase 1 and 2: Overall Survival (OS)
NCT02926833 (22) [back to overview]	Phase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Peak Serum Levels of Ferritin in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood
NCT02926833 (22) [back to overview]	Phase 1 and 2: Percentage of Participants Experiencing Adverse Events (AEs)
NCT02926833 (22) [back to overview]	Phase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies
NCT02926833 (22) [back to overview]	Phase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies
NCT02926833 (22) [back to overview]	Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values
NCT02926833 (22) [back to overview]	Phase 1 and 2: Progression-Free Survival (PFS)
NCT02992743 (22) [back to overview]	Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer
NCT02992743 (22) [back to overview]	Area Under the Time Curve From Zero to Time 28 Days AUC(0-28) of GSK3377794
NCT02992743 (22) [back to overview]	Change From Baseline in ECG Mean Heart Rate
NCT02992743 (22) [back to overview]	Progression Free Survival (PFS) Assessed by Investigator
NCT02992743 (22) [back to overview]	Time to Cmax (Tmax)
NCT02992743 (22) [back to overview]	Time to Response (TTR) Assessed by Independent Reviewer
NCT02992743 (22) [back to overview]	Duration of Response (DOR) Assessed by Independent Reviewer
NCT02992743 (22) [back to overview]	Number of Participants With Insertional Oncogenesis
NCT02992743 (22) [back to overview]	Duration of Response (DOR) Assessed by Investigator
NCT02992743 (22) [back to overview]	Maximum Transgene Expansion (Cmax) of GSK3377794
NCT02992743 (22) [back to overview]	Progression Free Survival (PFS) Assessed by Independent Reviewer
NCT02992743 (22) [back to overview]	Time to Response (TTR) Assessed by Investigator
NCT02992743 (22) [back to overview]	Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer Assessment
NCT02992743 (22) [back to overview]	Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
NCT02992743 (22) [back to overview]	Change From Baseline in Electrocardiogram (ECG) Parameters- PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval and RR Interval
NCT02992743 (22) [back to overview]	Number of Participants With Adverse Event of Special Interest (AESI)
NCT02992743 (22) [back to overview]	Number of Participants With Any Grade Increase in Clinical Chemistry Results at Worst-case Post-baseline
NCT02992743 (22) [back to overview]	Number of Participants With Any Grade Increase in Hematology Results at Worst-case Post-baseline
NCT02992743 (22) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
NCT02992743 (22) [back to overview]	Number of Participants With Positive Anti-drug Antibodies (ADAs)
NCT02992743 (22) [back to overview]	Number of Participants With Replication Competent Lentivirus (RCL)
NCT02992743 (22) [back to overview]	Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
NCT03018223 (4) [back to overview]	Incidence of Chronic GVHD
NCT03018223 (4) [back to overview]	Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD)
NCT03018223 (4) [back to overview]	Progression Free Survival (PFS)
NCT03018223 (4) [back to overview]	Overall Survival (OS)
NCT03049449 (10) [back to overview]	Peak Percentage and Persistence at 1 Month of Peripheral Blood Mononuclear Cells (PBMC) That Expressed the Chimeric Antigen Receptor (CAR) T-cells
NCT03049449 (10) [back to overview]	Peak Percentage and Persistence at 1 Month of Peripheral Blood Mononuclear Cells (PBMC) That Expressed the Chimeric Antigen Receptor (CAR) T-cells
NCT03049449 (10) [back to overview]	Peak Percentage and Persistence at 1 Month of Peripheral Blood Mononuclear Cells (PBMC) That Expressed the Chimeric Antigen Receptor (CAR) T-cells
NCT03049449 (10) [back to overview]	Number of Participants With a Dose Limiting Toxicity (DLT)
NCT03049449 (10) [back to overview]	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03049449 (10) [back to overview]	Peak Percentage and Persistence at 1 Month of Peripheral Blood Mononuclear Cells (PBMC) That Expressed the Chimeric Antigen Receptor (CAR) T-cells
NCT03049449 (10) [back to overview]	Peak Percentage and Persistence at 1 Month of Peripheral Blood Mononuclear Cells (PBMC) That Expressed the Chimeric Antigen Receptor (CAR) T-cells
NCT03049449 (10) [back to overview]	Peak Percentage and Persistence at 1 Month of Peripheral Blood Mononuclear Cells (PBMC) That Expressed the Chimeric Antigen Receptor (CAR) T-cells
NCT03049449 (10) [back to overview]	Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progression as Their Best Response
NCT03049449 (10) [back to overview]	Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced CD30-expressing Lymphomas
NCT03071276 (3) [back to overview]	The Overall Response (OR) Rate (Complete Response + Incomplete Count Recovery + Partial Response)
NCT03071276 (3) [back to overview]	Complete Response
NCT03071276 (3) [back to overview]	Complete Response or Complete Response With Incomplete Count Recovery
NCT03096782 (3) [back to overview]	Time to Engraftment
NCT03096782 (3) [back to overview]	Disease-free Survival
NCT03096782 (3) [back to overview]	Overall Survival
NCT03128359 (3) [back to overview]	Overall Survival (OS) at 1 Year
NCT03128359 (3) [back to overview]	Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) at 1 Year
NCT03128359 (3) [back to overview]	Acute Graft Versus Host Disease (aGVHD) of Grades 2-4 According to the Consensus Grading
NCT03168438 (13) [back to overview]	Maximum Persistence (Cmax) of GSK3377794
NCT03168438 (13) [back to overview]	Duration of Response
NCT03168438 (13) [back to overview]	Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])
NCT03168438 (13) [back to overview]	Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only
NCT03168438 (13) [back to overview]	Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline
NCT03168438 (13) [back to overview]	Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline
NCT03168438 (13) [back to overview]	Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline
NCT03168438 (13) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03168438 (13) [back to overview]	Time to Response
NCT03168438 (13) [back to overview]	Time to Maximum Persistence
NCT03168438 (13) [back to overview]	Progression-free Survival
NCT03168438 (13) [back to overview]	Overall Response Rate
NCT03168438 (13) [back to overview]	Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings
NCT03215810 (2) [back to overview]	Number of Participants With Objective Response
NCT03215810 (2) [back to overview]	Rate of Dose Limiting Toxicity (DLT)
NCT03287674 (4) [back to overview]	Progression Free Survival
NCT03287674 (4) [back to overview]	Overall Survival
NCT03287674 (4) [back to overview]	Treatment Related Immune Responses
NCT03287674 (4) [back to overview]	Number of Participants With Reported Adverse Events by Type
NCT03303950 (8) [back to overview]	Number of Participants With Minimal Residual Disease (MRD) Response
NCT03303950 (8) [back to overview]	Disease Free Survival at One Year
NCT03303950 (8) [back to overview]	Incidence of Acute Graft Versus Host Disease (GVHD)
NCT03303950 (8) [back to overview]	Incidence of Chronic GVHD
NCT03303950 (8) [back to overview]	Non-relapse Mortality (NRM) at Day 100
NCT03303950 (8) [back to overview]	Non-relapse Mortality (NRM) at Day 365
NCT03303950 (8) [back to overview]	Overall Survival at One Year
NCT03303950 (8) [back to overview]	Number of Participants With Different Clinical Responses
NCT03318861 (8) [back to overview]	Overall Survival (OS)
NCT03318861 (8) [back to overview]	Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities
NCT03318861 (8) [back to overview]	Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT03318861 (8) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT03318861 (8) [back to overview]	Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1
NCT03318861 (8) [back to overview]	Time to Next Treatment (TTNT)
NCT03318861 (8) [back to overview]	Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1
NCT03318861 (8) [back to overview]	Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria
NCT03338972 (7) [back to overview]	Count of Patients That Experienced Adverse Events
NCT03338972 (7) [back to overview]	Dose-limiting Toxicities (DLT) Rate
NCT03338972 (7) [back to overview]	Duration of Persistence of Adoptively Transferred BCMA CAR-T Cells
NCT03338972 (7) [back to overview]	Number of Participants With Detectable BCMA CART Cell Migration to Primary Disease Site (Bone Marrow) at Day 28
NCT03338972 (7) [back to overview]	Objective Response Rate (ORR)
NCT03338972 (7) [back to overview]	Overall Survival (OS)
NCT03338972 (7) [back to overview]	Progression-free Survival (PFS)
NCT03504410 (1) [back to overview]	Complete Remission (CR)
NCT03593902 (2) [back to overview]	Survival of Treatment
NCT03593902 (2) [back to overview]	Change in Skin Score by mRSS
NCT03602612 (3) [back to overview]	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).
NCT03602612 (3) [back to overview]	Number of Participants at Each Dose Level Who Experience a Dose-Limiting Toxicity (DLT)
NCT03602612 (3) [back to overview]	Maximum Tolerated Dose (MTD) of Anti-B Cell Maturation Antigen (BCMA) - Chimeric Antigen Receptor (CAR)-T Cells
NCT03624036 (4) [back to overview]	Objective Response Rate (ORR) Per Investigator Review Assessed by International Workshop on CLL (IWCLL) 2018 Criteria
NCT03624036 (4) [back to overview]	Peak Level of Anti-CD19 CAR T-Cells in Blood
NCT03624036 (4) [back to overview]	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
NCT03624036 (4) [back to overview]	Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT03761056 (15) [back to overview]	Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value
NCT03761056 (15) [back to overview]	Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Value
NCT03761056 (15) [back to overview]	Duration of Response (DOR) Per the Lugano Classification
NCT03761056 (15) [back to overview]	Event-Free Survival (EFS)
NCT03761056 (15) [back to overview]	Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators
NCT03761056 (15) [back to overview]	Objective Response Rate (ORR) Per the Lugano Classification as Determined by Study Investigators
NCT03761056 (15) [back to overview]	Time to Peak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8, CRP, and Ferritin
NCT03761056 (15) [back to overview]	Overall Survival (OS)
NCT03761056 (15) [back to overview]	Peak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8
NCT03761056 (15) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (SAE)
NCT03761056 (15) [back to overview]	Peak Serum Level of C-Reactive Protein (CRP)
NCT03761056 (15) [back to overview]	Peak Serum Level of Ferritin
NCT03761056 (15) [back to overview]	Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood
NCT03761056 (15) [back to overview]	Progression-Free Survival (PFS)
NCT03761056 (15) [back to overview]	Relapse With Central Nervous Disease (CNS) Disease
NCT03813147 (8) [back to overview]	Elimination Half-life of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Maximum Time to Concentration of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Total Plasma Clearance of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Maximum Concentration of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Number of Participants With Adverse Events Attributable to MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Number of Participants With Antitumor Activity of MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Number of Participants With Dose Limiting Toxicities of MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Area Under the Plasma Concentration Versus Time Curve of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03860844 (13) [back to overview]	AML: AUC of Isatuximab
NCT03860844 (13) [back to overview]	Percentage of Participants With Complete Response (CR) Rate
NCT03860844 (13) [back to overview]	Overall Response Rate (ORR)
NCT03860844 (13) [back to overview]	Number of Participants With Infusion Reactions (IRs)
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	Cluster of Differentiation (CD)38 Receptor Density
NCT03860844 (13) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
NCT03860844 (13) [back to overview]	AML: Ceoi of Isatuximab
NCT03873805 (2) [back to overview]	Number of Participants Experiencing a Dose-limiting Toxicity (DLT)
NCT03873805 (2) [back to overview]	Grade 3 Toxicity Profile
NCT03912831 (1) [back to overview]	Phase 1A: Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities (DLTs)
NCT03958656 (3) [back to overview]	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03958656 (3) [back to overview]	Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation Molecule F7 (SLAMF7) Chimeric Antigen Receptor (CAR)
NCT03958656 (3) [back to overview]	Number of Participants With a Response
NCT04002115 (7) [back to overview]	Severity of Chronic GVHD
NCT04002115 (7) [back to overview]	Rate of Chronic GVHD
NCT04002115 (7) [back to overview]	Severity of Acute Graft-versus-host Disease (GVHD)
NCT04002115 (7) [back to overview]	Complete Remission (CR) Rate at Day 30 Post HSCT
NCT04002115 (7) [back to overview]	Non-relapse Related Mortality
NCT04002115 (7) [back to overview]	Rate of Acute Graft-versus-host Disease (GVHD)
NCT04002115 (7) [back to overview]	Neutrophil Engraftment
NCT04030195 (4) [back to overview]	Objective Response Rate
NCT04030195 (4) [back to overview]	Maximum Tolerated Dose (MTD)
NCT04030195 (4) [back to overview]	Number of Participants With Dose-Limiting Toxicities
NCT04030195 (4) [back to overview]	Progression-free Survival (PFS)
NCT04160195 (7) [back to overview]	Last Time-Point at Which Chimeric Antigen Receptors (CAR) T Cells Were Detected in the Blood
NCT04160195 (7) [back to overview]	Maximum Tolerated Dose (MTD) of Chimeric Antigen Receptors (CAR) T Cells
NCT04160195 (7) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT04160195 (7) [back to overview]	Percentage of Peak Blood Chimeric Antigen Receptors (CAR) T Cells
NCT04160195 (7) [back to overview]	Percentage of Peripheral Blood Mononuclear Cells (PBMC) of Chimeric Antigen Receptors (CAR) T Cells
NCT04160195 (7) [back to overview]	Number of Participants Administered T Cells Expressing a Novel Fully- Human Anti-cluster of Differentiation 19 (CD19) and Anti-cluster of Differentiation 20 (CD20) Chimeric Antigen Receptors (CAR) Who Experienced a Dose-limiting Toxicity (DLT)
NCT04160195 (7) [back to overview]	Number of Participants With Clinical Response
NCT04205240 (2) [back to overview]	Number of Patients With Grade II-IV Acute Graft-versus Host Disease (GvHD (aGVHD)
NCT04205240 (2) [back to overview]	Number of Patients With a Partial Response
NCT04339101 (3) [back to overview]	Progression Free Survival (PFS)
NCT04339101 (3) [back to overview]	Cumulative Incidence of Grade II-IV Acute GVHD
NCT04339101 (3) [back to overview]	Graft-versus-host Disease Free Relapse Free (GRFS) at 1 Year
NCT04395222 (2) [back to overview]	Proportion of Failure of the Haplo-Graft
NCT04395222 (2) [back to overview]	Percentage of Subjects With Successful Haplo-derived Neutrophil Engraftment
NCT04639245 (6) [back to overview]	Participants That Displayed Transgenic T Cells in Tumor Tissue
NCT04639245 (6) [back to overview]	Overall Survival
NCT04639245 (6) [back to overview]	Count of Participants That Experienced Treatment-related Unexpected Grade 3 or Higher Adverse Events
NCT04639245 (6) [back to overview]	Peripheral Blood Concentration of Infused Transgenic T Cells Over Time
NCT04639245 (6) [back to overview]	Progression-free Survival
NCT04639245 (6) [back to overview]	Objective Response Rates
NCT05993299 (5) [back to overview]	Time to Cmax (Tmax)
NCT05993299 (5) [back to overview]	Overall Response Rate (ORR)
NCT05993299 (5) [back to overview]	Maximum Transgene Expansion (Cmax)
NCT05993299 (5) [back to overview]	Disease Control Rate (DCR)
NCT05993299 (5) [back to overview]	Area Under the Time Curve From Zero to Time 28 Days (AUC[0-28])

Change in Gene Expression Post Chemo

Changes in lymphocyte gene expression was measured by deoxyribonucleic acid (DNA) microarray analysis of circulating leukemic cells after completion of study treatment. A change in expression is defined as a >50% increase in circulating leukemic cells or a 30% decrease in circulating leukemic cells. (NCT00001586)
Timeframe: 6 hours post treatment, and 24 hours post treatment

Intervention	Percent change in cells (Number)
	6 hours post treatment (e.g. ># cells)	24 hours post treatment (e.g. > # cells)
Intermediate-high Risk B-Cell Pts	30	50

Intervention	Participants (Number)
Abl Cells IV + Cyclophosphamide 30 mg/kg	3
Abl Cells IV + Cyclophosphamide 60 mg/kg	3
Abl Cells IV+Low Dose IV IL-2 (Initial)	3
Abl Cells IV+High Dose IV IL-2 (Initial)	6
Abl Cells IV + MTD IL-2	50
Abl Cells IA + MTD (Prior Cells IV on 6)	4
Abl Cells IA + MTD IL-2	7
Abl Cells IA+MTD IL-2 (MART-1 Reactive)	8
Abl Cells IV + MTD IL-2 no GCSF	6
Abl Cells IV+MTD IL-2 no GCSF(gp100 Reactive)	1
Abl Cells IV+MTD IL-2 no GCSF (MART-1reactive)	7
Abl Cells IV + SQ IL-2 With GCSF	6
Abl Cells IV + SQ IL-2 With GCSF (MART-1 Reactive)	3
Abl Cells IV + SQ IL-2 With GCSF (no Reactivity)	2

Intervention	Participants (Number)
	Complete Response	Partial Response	Minor Response	Progressive Disease	Mixed Response	No Response	Stable Disease
Abl Cells IA + MTD (Prior Cells IV on 6)	0	0	0	0	0	4	0
Abl Cells IA + MTD IL-2	1	0	0	0	0	5	0
Abl Cells IA+MTD IL-2 (MART-1 Reactive)	1	1	0	0	1	5	0
Abl Cells IV + Cyclophosphamide 30 mg/kg	0	0	0	0	0	3	0
Abl Cells IV + Cyclophosphamide 60 mg/kg	0	0	0	0	0	3	0
Abl Cells IV + MTD IL-2	3	14	0	0	0	32	1
Abl Cells IV + MTD IL-2 no GCSF	1	1	0	0	0	4	0
Abl Cells IV + SQ IL-2 With GCSF	0	3	0	0	0	3	0
Abl Cells IV + SQ IL-2 With GCSF (MART-1 Reactive)	0	1	0	0	0	2	0
Abl Cells IV + SQ IL-2 With GCSF (no Reactivity)	0	0	0	0	0	2	0
Abl Cells IV+High Dose IV IL-2 (Initial)	0	0	0	0	0	6	0
Abl Cells IV+Low Dose IV IL-2 (Initial)	0	0	0	0	0	3	0
Abl Cells IV+MTD IL-2 no GCSF (MART-1reactive)	0	2	0	0	0	5	0
Abl Cells IV+MTD IL-2 no GCSF(gp100 Reactive)	0	0	1	0	0	0	0

Intervention	participants (Number)
	Flow cytometric complete response	Molencular (PCR) complete response
Intermediate or High Risk Chronic Lymphocytic Leukemia	20	12

Intervention	participants (Number)
	Complete Response	Nodular Partial Response	Partial Response	Failure
Intermediate or High Risk Chronic Lymphocytic Leukemia	22	2	8	4

Intervention	Participants (Count of Participants)
	6 Months	1 Year	1.5 Years	2 Years	3 Years
Chemoresistant Group	12	8	8	8	8
Chemosensitive Group	36	27	25	25	22
Unknown Chemosensitivity Group	1	0	0	0	0

Intervention	Participants (Count of Participants)
Recipient - Chemotherapy Group	10
Donor - Vaccination Generation Group	10

Intervention	percentage of participants (Number)
	CD3 - Graft rejection	CD3 - Mixed chimerism	CD3 - Full donor chimerism	CD3 - Unknown	CD33 - Graft Rejection	CD33 - Mixed chimerism	CD33 - Full donor chimerism	CD33 - Unknown
Dose Level 1 (No Campath)	3.3	18.3	70	8.33	1.7	3.3	80	15

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Progressive Disease (PD)	Partial Response (PR)	Very Good Partial Response (VGPR)
Arm 2-Recipients	2	4	4	2

Intervention	Months (Median)
	Participants who did not receive a transplant(n=7)	Participants who received a transplant (n=23)
Arm 2-Recipients	3.3	19.1

Intervention	Participants (Count of Participants)
	Chest wall; G2 skin	Abdomen; G4 GI	Pancreas; G4 LFTs, G4 pancreatitis	Pleura, mediastinum; G4 LFTs, G2 mucositis	Chest wall; G4 skin, G3 mucositis	Spine, skull; G2 nausea+vomiting, G2 fatigue	Pelvis; G4 enteritis	Pulmonary (cyberknife)	Brain; B3 mucositis	Whole lung; G3 mucositis, G3 skin, G5 lung	L arm, R shoulder, B/L femur
Arm 2-Recipients	1	1	1	1	1	1	1	1	1	1	1

Intervention	percentage of participants (Number)
BuCy	56.4
CyTBI	56.5
FluMel	38.2
VpCyTBI	39.1
Other	53.3

Intervention	percentage of participants (Number)
BuCy	49.1
CyTBI	52.2
FluMel	33.2
VpCyTBI	26.1
Other	40

Intervention	percentage of participants (Number)
	From date of enrollment	From date of transplantation
Arm 2-Recipients	39.1	34.8

Intervention	participants (Number)
	acute GVHD	chronic GVHD
Recipients -Cyclosporine GVHD Prophylaxis	12	12
Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis	5	5

Intervention	percentage of participants (Number)
	Grade II-IV aGVHD	cGVHD
Treatment (Nonmyeloablative Donor PBSC Transplant)	35.3	35.3

Intervention	Participants (Count of Participants)
	Grade II	Grade III-IV
Stem Cell Transplant Therapy With Campath-1H	0	1

Intervention	Participants (Count of Participants)
	Limited	Extensive
Stem Cell Transplant Therapy With Campath-1H	3	0

Intervention	months (Median)
	Myeloid Chimerism	Donor T-cell Chimerism
Stem Cell Transplant Therapy With Campath-1H	9	7

Intervention	Participants (Count of Participants)
	Grade I GVHD	Grade II GVHD	Grade III GVHD	Grade IV GVHD
Recipient	1	7	6	0

Intervention	Participants (Count of Participants)
	Complete Remission or Complete Remission Unconfirmed	Progressive Disease
Recipient	15	16

Intervention	participants (Number)
	Grade 0	Grade I	Grade II	Grade III	Grade IV
Stem Cell Transplant	26	0	0	1	0

Intervention	Participants (Count of Participants)
	Acute GVHD	Chronic extensive GVHD
Treatment (Enzyme Inhibitor, Transplant, GVHD Prophylaxis)	10	10

fludarabine

Cross-References

Synonyms (112)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (28)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (139)

Molecular Functions (43)

Ceullar Components (27)

Bioassays (210)

Research

Studies (3,359)

Study Types

Clinical Trials (1439)

Trial Overview

Trial Outcomes

Change in Gene Expression Post Chemo

Number of Participants With Adverse Events

Number of Participants With Adverse Events

Clinical Response

Utilize Flow Cytometry and Polymerase Chain Reaction as Sensitive Measures of Minimal Residual Disease

Overall Response Rate

Overall Survival Status

4 yr OS

4 Year PFS

Toxicity/TRM at Day 100

CR Rate

Progression Free-survival (PFS)

Overall Survival (OS)

Non-Relapse Mortality

Engraftment of HLA Identical PBSC Allografts

Number of Participants With Adverse Events

Immune Response

Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients

Extensive Chronic Graft-versus-Host Disease Matched Related Patients

Overall Survival

Overall Survival

Acute Graft-versus-Host Disease Matched Related Patients

Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients

Relapse Free Survival

Transplant-related Mortality

Overall Survival

Leukemia-free Survival

Transplant-related Mortality

Number of Participants With Absolute Neutrophil Count Engraftment

Evaluate the Risk for Disease Progression and Relapse

Evaluate the Risk of Transplant Related Mortality.

Evaluate the Risk/Incidence of Infections

Determine Whether Engraftment Can be Maintained With a Single Dose Fludarabine, DLI and Continued MMF/CSP, Defined as Rejection Rate < 20%.

Evaluate the Risk of Occurrence of Acute and Chronic GVHD

Number of Participants With Engraftment

Toxicity

Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)

Median Survival From Date of Progression

Number of Participants to Complete Conversion to >95% Donor Chimerism

Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy

Median Time to Reach Absolute Neutrophil Count of 500/mm(3)

Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant

Number of Participants With Acute and Chronic GVHD

Median Time to Reach a Platelet Count of 50,000/mm(3)

Median Progression Free Survival

Cluster of Differentiation 4 (CD4) Reconstitution

Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)

Early Post Transplantation Relapse

Disease-free Survival-incidence of Survival Without Relapse

Incidence of Rejection

Incidence of Acute and Chronic GVHD

Overall Survival

Nonrelapse Mortality (NRM)-Incidence of Nonrelapse Death

Incidence of Relapse

Number of Participants Who Experienced Transplant Related Mortality

Intervention	infections (Number)
	Viral	Fungal	Fever of unknown origin	Bacterial	Other
Treatment (Enzyme Inhibitor, Transplant, GVHD Prophylaxis)	27	13	6	53	5

Intervention	Participants (Count of Participants)
	Grade ≤ 2	Grade ≥ 3	No GVHD
Expanded CB Arm	15	2	27
Un-Manipulated CB Arm	20	6	19

Intervention	Participants (Count of Participants)
	Overall Chronic GVHD	Limited	Extensive
Expanded CB Arm	20	14	13
Un-Manipulated CB Arm	16	10	9

Intervention	percentage of participants (Number)
Arm IVD Cohort 1 (Th2 DLI)	0
Arm IVD Cohort 3 (Multiple Th2 DLI)	11.11
Arm IVA (12-day Expanded Th2 DLI)	7.50
Arm IVB (6-day Expanded Th2 DLI)	9.09
Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus)	11.90

Intervention	participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	0
Arm II (TBI, Transplant, GVHD Prophylaxis)	2

Intervention	EU (Mean)
	Day -7	Day 0	1 month	3 months	6 months	1 year	18 months	2 years	3 years 9
Autologous HSCT in SLE	5.4	4.7	3.7	3.2	2.7	2.6	2.8	2.5	2.5

Intervention	participants (Number)
	Overall Response (CR+PR)	Complete Response (CR)	Partial Response (PR)	Progressive Disease (PD)	Stable Disease (SD)	Not Evaluable (NE)
Combination Arm (FluCAM)	137	21	116	6	12	13
Fludarabine Alone	126	7	119	9	21	11

Intervention	participants (Number)
	At least 1 treatment emergent AE	At least 1 related treatment emergent AE	At least 1 treatment-emergent infection	At least 1 drug-related infection	At least 1 serious AE	At least 1 related serious AE	Discontinuation of study drug due to AE	Discontinuation of study drug due to related AE	Deaths	Patients who died due to a related AE	Patients who died within 30 days of the last dose
Combination Arm (FluCAM)	161	159	67	44	54	47	37	32	10	7	4
Fludarabine Alone	149	125	58	30	41	28	32	24	12	6	7

Intervention	Participants (Count of Participants)
Arm I (Nonmyeloablative Conditioning With Fludarabine and TBI)	26
Arm II (Nonmyeloablative Conditioning With TBI)	14

Intervention	Days (Median)
Fludarabine+Cyclophosphamide (FC)	1085.0
Fludarabine+Cyclophosphamide+Rituximab (FCR)	1625.0